Document:

Exhibit 10.1

 

Execution Copy

 

AGREEMENT AND PLAN OF MERGER

 

by and among

 

Radius Health, Inc.

MPM Acquisition Corp.

and

RHI Merger Corp.

 

April 25, 2011

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE I
    	
DEFINITIONS
    	
1
    
	
 
    	
 
    	
 
    
	
ARTICLE II
    	
MERGER
    	
6
    
	
 
    	
 
    	
 
    
	
2.1
    	
Effects   of Merger
    	
6
    
	
 
    	
 
    	
 
    
	
2.2
    	
Effect   on Radius Capital Stock and Merger Sub Capital Stock
    	
7
    
	
 
    	
 
    	
 
    
	
2.3
    	
Rights   of Holders of Certificates Evidencing Radius Capital Stock
    	
9
    
	
 
    	
 
    	
 
    
	
2.4
    	
Procedure   for Exchange of Radius Capital Stock
    	
10
    
	
 
    	
 
    	
 
    
	
2.5
    	
Dissenting   Shares
    	
12
    
	
 
    	
 
    	
 
    
	
2.6
    	
Directors   and Officers of the Surviving Corporation
    	
12
    
	
 
    	
 
    	
 
    
	
2.7
    	
Directors   and Officers of MPMAC
    	
13
    
	
 
    	
 
    	
 
    
	
ARTICLE   III
    	
REPRESENTATIONS AND WARRANTIES OF RADIUS
    	
13
    
	
 
    	
 
    	
 
    
	
3.1
    	
Organization   and Qualification
    	
13
    
	
 
    	
 
    	
 
    
	
3.2
    	
Authority   Relative to this Agreement; Non-Contravention
    	
13
    
	
 
    	
 
    	
 
    
	
3.3
    	
No   Conflicts
    	
14
    
	
 
    	
 
    	
 
    
	
3.4
    	
Capitalization
    	
14
    
	
 
    	
 
    	
 
    
	
3.5
    	
Litigation
    	
15
    
	
 
    	
 
    	
 
    
	
3.6
    	
No   Brokers or Finders
    	
15
    
	
 
    	
 
    	
 
    
	
3.7
    	
Subsidiaries
    	
15
    
	
 
    	
 
    	
 
    
	
3.8
    	
Tax   Matters
    	
15
    
	
 
    	
 
    	
 
    
	
3.9
    	
Contracts   and Commitments
    	
16
    
	
 
    	
 
    	
 
    
	
3.10
    	
Affiliate   Transactions
    	
17
    
	
 
    	
 
    	
 
    
	
3.11
    	
Compliance   with Laws; Permits
    	
17
    
	
 
    	
 
    	
 
    
	
3.12
    	
Financial   Statements
    	
18
    
	
 
    	
 
    	
 
    
	
3.13
    	
Books   and Records
    	
18
    
	
 
    	
 
    	
 
    
	
3.14
    	
Real   Property
    	
18
    
	
 
    	
 
    	
 
    
	
3.15
    	
Insurance
    	
18
    
	
 
    	
 
    	
 
    
	
3.16
    	
No   Undisclosed Liabilities
    	
18
    
	
 
    	
 
    	
 
    
	
3.17
    	
Environmental   Matters
    	
19
    
	
 
    	
 
    	
 
    
	
3.18
    	
Absence   of Certain Developments
    	
19
    
	
 
    	
 
    	
 
    
	
3.19
    	
Employee   Benefit Plans
    	
20
    
	
 
    	
 
    	
 
    
	
3.20
    	
Employees
    	
21
    
	
 
    	
 
    	
 
    
	
3.21
    	
Proprietary   Information and Inventions
    	
21
    

 

 

TABLE OF CONTENTS
 (cont.)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
3.22
    	
Intellectual   Property
    	
21
    
	
 
    	
 
    	
 
    
	
3.23
    	
Tax-Free   Reorganization
    	
22
    
	
 
    	
 
    	
 
    
	
3.24
    	
Vote   Required
    	
23
    
	
 
    	
 
    	
 
    
	
3.25
    	
Full   Disclosure
    	
23
    
	
 
    	
 
    	
 
    
	
ARTICLE   IV
    	
REPRESENTATIONS AND WARRANTIES OF MPMAC AND MERGER   SUB
    	
23
    
	
 
    	
 
    	
 
    
	
4.1
    	
Organization   and Qualification
    	
23
    
	
 
    	
 
    	
 
    
	
4.2
    	
Authority   Relative to this Agreement; Non-Contravention
    	
23
    
	
 
    	
 
    	
 
    
	
4.3
    	
No   Conflicts
    	
24
    
	
 
    	
 
    	
 
    
	
4.4
    	
Capitalization
    	
24
    
	
 
    	
 
    	
 
    
	
4.5
    	
Exchange   Act Reports; Financial Statements
    	
25
    
	
 
    	
 
    	
 
    
	
4.6
    	
Litigation
    	
26
    
	
 
    	
 
    	
 
    
	
4.7
    	
Subsidiaries
    	
26
    
	
 
    	
 
    	
 
    
	
4.8
    	
No   Brokers or Finders
    	
26
    
	
 
    	
 
    	
 
    
	
4.9
    	
Tax   Matters
    	
26
    
	
 
    	
 
    	
 
    
	
4.10
    	
Contracts   and Commitments
    	
28
    
	
 
    	
 
    	
 
    
	
4.11
    	
Affiliate   Transactions
    	
28
    
	
 
    	
 
    	
 
    
	
4.12
    	
Compliance   with Laws; Permits
    	
28
    
	
 
    	
 
    	
 
    
	
4.13
    	
Validity   of the MPMAC Capital Stock
    	
28
    
	
 
    	
 
    	
 
    
	
4.14
    	
Books   and Records
    	
29
    
	
 
    	
 
    	
 
    
	
4.15
    	
Real   Property
    	
29
    
	
 
    	
 
    	
 
    
	
4.16
    	
Insurance
    	
29
    
	
 
    	
 
    	
 
    
	
4.17
    	
No   Undisclosed Liabilities
    	
29
    
	
 
    	
 
    	
 
    
	
4.18
    	
Environmental   Matters
    	
29
    
	
 
    	
 
    	
 
    
	
4.19
    	
Absence   of Certain Developments
    	
29
    
	
 
    	
 
    	
 
    
	
4.20
    	
Employee   Benefit Plans
    	
30
    
	
 
    	
 
    	
 
    
	
4.21
    	
Employees
    	
30
    
	
 
    	
 
    	
 
    
	
4.22
    	
Proprietary   Information and Inventions
    	
30
    
	
 
    	
 
    	
 
    
	
4.23
    	
Intellectual   Property
    	
30
    
	
 
    	
 
    	
 
    
	
4.24
    	
Tax   Free Reorganization
    	
31
    

 

ii

 

TABLE OF CONTENTS
 (cont.)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
4.25
    	
Full   Disclosure
    	
31
    
	
 
    	
 
    	
 
    
	
ARTICLE   V
    	
CONDUCT OF BUSINESS PENDING THE MERGER
    	
31
    
	
 
    	
 
    	
 
    
	
5.1
    	
Conduct   of Business by MPMAC and Merger Sub
    	
31
    
	
 
    	
 
    	
 
    
	
5.2
    	
Conduct   of Business by Radius
    	
32
    
	
 
    	
 
    	
 
    
	
ARTICLE   VI
    	
ADDITIONAL COVENANTS AND AGREEMENTS
    	
32
    
	
 
    	
 
    	
 
    
	
6.1
    	
Governmental   Filings
    	
32
    
	
 
    	
 
    	
 
    
	
6.2
    	
Expenses
    	
32
    
	
 
    	
 
    	
 
    
	
6.3
    	
Due   Diligence; Access to Information; Confidentiality
    	
33
    
	
 
    	
 
    	
 
    
	
6.4
    	
Tax   Treatment
    	
34
    
	
 
    	
 
    	
 
    
	
6.5
    	
Press   Releases
    	
35
    
	
 
    	
 
    	
 
    
	
6.6
    	
Securities   Reports
    	
35
    
	
 
    	
 
    	
 
    
	
6.7
    	
Private   Placement
    	
35
    
	
 
    	
 
    	
 
    
	
6.8
    	
Radius   Stockholders’ Meeting; Materials to Stockholders
    	
35
    
	
 
    	
 
    	
 
    
	
6.9
    	
No   Solicitation
    	
36
    
	
 
    	
 
    	
 
    
	
6.10
    	
Failure   to Fulfill Conditions
    	
36
    
	
 
    	
 
    	
 
    
	
6.11
    	
Notification   of Certain Matters
    	
37
    
	
 
    	
 
    	
 
    
	
6.12
    	
Customary   Representations, Assumptions and Qualifications
    	
37
    
	
 
    	
 
    	
 
    
	
ARTICLE   VII
    	
CONDITIONS
    	
37
    
	
 
    	
 
    	
 
    
	
7.1
    	
Conditions   to Obligations of Each Party
    	
37
    
	
 
    	
 
    	
 
    
	
7.2
    	
Additional   Conditions to Obligation of MPMAC and Merger Sub
    	
38
    
	
 
    	
 
    	
 
    
	
7.3
    	
Additional   Conditions to Obligation of Radius
    	
39
    
	
 
    	
 
    	
 
    
	
ARTICLE   VIII
    	
TERMINATION
    	
41
    
	
 
    	
 
    	
 
    
	
8.1
    	
Termination
    	
41
    
	
 
    	
 
    	
 
    
	
8.2
    	
Effect   of Termination
    	
42
    
	
 
    	
 
    	
 
    
	
ARTICLE   IX
    	
GENERAL PROVISIONS
    	
42
    
	
 
    	
 
    	
 
    
	
9.1
    	
Notices
    	
42
    
	
 
    	
 
    	
 
    
	
9.2
    	
No   Survival
    	
43
    
	
 
    	
 
    	
 
    
	
9.3
    	
Interpretation
    	
43
    
	
 
    	
 
    	
 
    
	
9.4
    	
Severability
    	
43
    
	
 
    	
 
    	
 
    
	
9.5
    	
Amendment
    	
44
    

 

iii

 

TABLE OF CONTENTS
 (cont.)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
9.6
    	
Waiver
    	
44
    
	
 
    	
 
    	
 
    
	
9.7
    	
Miscellaneous
    	
44
    
	
 
    	
 
    	
 
    
	
9.8
    	
Counterparts
    	
44
    
	
 
    	
 
    	
 
    
	
9.9
    	
Third   Party Beneficiaries
    	
44
    
	
 
    	
 
    	
 
    
	
9.10
    	
Governing   Law
    	
44
    
	
 
    	
 
    	
 
    
	
9.11
    	
Jurisdiction;   Service of Process
    	
44
    
	
 
    	
 
    	
 
    
	
9.12
    	
Disclosure   in Schedules
    	
44
    

 

iv

 

EXHIBITS

 

Exhibit A — Certificate of Merger

Exhibit B — MPMAC Certificate of Designation

Exhibit C — Letter of Transmittal

Exhibit D — Redemption Agreement

Exhibit E — Indemnity Agreement

 

v

 

AGREEMENT AND PLAN OF MERGER

 

This Agreement and Plan of Merger (this “Agreement”) is entered into as of April 25, 2011, by and among Radius Health, Inc., a Delaware corporation (“Radius”), MPM Acquisition Corp., a Delaware corporation (“MPMAC”), and RHI Merger Corp., a Delaware corporation (“Merger Sub”).

 

W I T N E S S E T H

 

WHEREAS, the Boards of Directors of Radius, MPMAC and Merger Sub have determined that it is in the best interests of such corporations and their respective stockholders to consummate the merger of Merger Sub with and into Radius with Radius as the surviving corporation (the “Merger”);

 

WHEREAS, MPMAC, as the sole stockholder of Merger Sub, has approved this Agreement, the Merger and the transactions contemplated by this Agreement pursuant to action taken by written consent in accordance with the requirements of the Delaware General Corporation Law (“DGCL”) and the Bylaws of Merger Sub;

 

WHEREAS, pursuant to the Merger, among other things, the outstanding shares of capital stock of Radius shall be converted into the Merger Consideration (as hereinafter defined) upon the Effective Time (as hereinafter defined);

 

WHEREAS, the parties to this Agreement intend to adopt this Agreement as a plan of reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations promulgated thereunder, and intend that the Merger and the transactions contemplated by this Agreement be undertaken pursuant to that plan; and

 

WHEREAS, the parties to this Agreement intend that the Merger qualify as a “reorganization,” within the meaning of Section 368(a) of the Code, and that MPMAC, Merger Sub and Radius will each be a “party to a reorganization,” within the meaning of Section 368(b) of the Code, with respect to the Merger.

 

NOW, THEREFORE, in consideration of the representations, warranties and covenants contained herein, the parties hereto agree as follows:

 

ARTICLE I
 DEFINITIONS

 

As used herein, the following terms shall have the following meanings (such meaning to be equally applicable to both the singular and plural forms of the terms defined):

 

“Affiliate” has the meaning as defined in Rule 12b-2 promulgated under the Exchange Act, as such regulation is in effect on the date hereof.

 

 

“Certificate of Merger” shall mean the certificate of merger in substantially the form attached hereto as Exhibit A.

 

“Closing” shall have the meaning as set forth in Section 2.1(c) hereof.

 

“Closing Date” shall have the meaning as set forth in Section 2.1(c) hereof.

 

“Code” has the meaning ascribed thereto in the preambles to this Agreement.

 

“Common Exchange Ratio” shall mean: One (1).

 

“Convertible Securities” shall have the meaning as set forth in Section 2.2(g) hereof.

 

“Copyrights” has the meaning ascribed thereto in Section 3.22(a).

 

“Delaware General Corporation Law” or “DGCL” shall mean Title 8, Chapter 1 of the Delaware Code, as amended.

 

“Dissenting Shares” shall have the meaning as set forth in Section 2.5 hereof.

 

“Effective Date” shall have the meaning ascribed thereto in Section 2.1(c) hereof.

 

“Effective Time” shall have the meaning ascribed thereto in Section 2.1(c) hereof.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, or any successor law and the rules and regulations promulgated thereunder.

 

“Evaluation Material” shall have the meaning ascribed thereto in Section 6.3(a).

 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.

 

“GAAP” shall mean United States generally accepted accounting principles as in effect from time to time.

 

“Intellectual Property” has the meaning ascribed thereto in Section 3.22(a).

 

“Indemnity Agreement” has the meaning ascribed thereto in Section 6.13.

 

“Know-How” has the meaning ascribed thereto in Section 3.22(a).

 

“Knowledge” means, with respect to an individual, that such individual is actually aware of a particular fact or other matter, with no obligation to conduct any inquiry or other investigation to determine the accuracy of such fact or other matter. A Person other than an individual shall be deemed to have Knowledge of a particular fact or other matter if the officers,

 

2

 

directors or other management personnel of such Person had Knowledge of such fact or other matter.

 

“Letter of Transmittal” has the meaning ascribed thereto in Section 2.4(a).

 

“Material Adverse Effect” shall, with respect to an entity, mean a material adverse effect on the business, operations, results of operations or financial condition of such entity on a consolidated basis.

 

“Merger” shall have the meaning ascribed thereto in the preambles of this Agreement.

 

“Merger Consideration” means the shares of MPMAC Common Stock and MPMAC Preferred Stock issuable in connection with the Merger to the holders of Radius Common Stock and Radius Preferred Stock, respectively, based on the Common Exchange Ratio and the Preferred Exchange Ratio, respectively.

 

“MPMAC Certificate of Designation” shall mean the certificate of designation setting forth all of the rights, preferences and other terms of the MPMAC Preferred Stock in substantially the form attached hereto as Exhibit B.

 

“MPMAC Common Stock” shall mean the common stock, par value $0.0001 per share, of MPMAC.

 

“MPMAC Financial Statements” shall have the meaning ascribed thereto in Section 4.5(b).

 

“MPMAC Form 10” shall have the meaning ascribed thereto in Section 4.5(a).

 

“MPMAC Insiders” shall have the meaning ascribed thereto in Section 4.11.

 

“MPMAC Intellectual Property” shall have the meaning ascribed thereto in Section 4.23.

 

“MPMAC Latest Balance Sheet” shall have the meaning ascribed thereto in Section 4.17.

 

“MPMAC Permits” shall have the meaning ascribed thereto in Section 4.12(b).

 

“MPMAC Preferred Stock” shall mean, collectively, the MPMAC Series A-1 Stock, the MPMAC Series A-2 Stock, MPMAC Series A-3 Stock, MPMAC Series A-4 Stock. MPMAC Series A-5 Stock and MPMAC Series A-6 Stock.

 

“MPMAC Previous Filings” shall have the meaning ascribed thereto in Section 4.5(a).

 

“MPMAC Professional Fees” shall mean the aggregate amount of fees, costs and expenses of MPMAC’s attorneys, accountants and other service providers incurred by MPMAC on or prior to the Effective Date in connection with the preparation and negotiation of this

 

3

 

Agreement and the Redemption Agreement and the closing of the transactions contemplated hereby or thereby.

 

“MPMAC Returns” shall have the meaning ascribed thereto in Section 4.9(a).

 

“MPMAC SEC Filings” shall have the meaning ascribed thereto in Section 4.5(a).

 

“MPMAC Series A-1 Stock” shall mean the Series A-1 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“MPMAC Series A-2 Stock” shall mean the Series A-2 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“MPMAC Series A-3 Stock” shall mean the Series A-3 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“MPMAC Series A-4 Stock” shall mean the Series A-4 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“MPMAC Series A-5 Stock” shall mean the Series A-5 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“MPMAC Series A-6 Stock” shall mean the Series A-6 Preferred Stock, par value $0.0001 per share, of MPMAC contemplated by the MPMAC Certificate of Designations.

 

“Options” shall have the meaning as set forth in Section 2.2(f) hereof.

 

“Patents” has the meaning ascribed thereto in Section 3.22(a).

 

“Person” means any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, governmental authority or other entity.

 

“Preferred Exchange Ratio” shall mean: One-Tenth (0.1).

 

“Radius Common Stock” means the common stock, par value $0.01, of Radius.

 

“Radius Financial Statements” shall have the meaning as set forth in Section 3.12 hereof.

 

“Radius Insiders” shall have the meaning as set forth in Section 3.10 hereof.

 

“Radius Intellectual Property” shall have the meaning as set forth in Section 3.22 hereof.

 

“Radius Latest Balance Sheet” shall have the meaning as set forth in Section 3.16 hereof.

 

“Radius Permits” shall have the meaning as set forth in Section 3.11(b) hereof.

 

4

 

“Radius Plans” shall have the meaning as set forth in Section 3.19(a) hereof.

 

“Radius Preferred Stock” shall mean, collectively, the Radius Series A-1 Stock, the Radius Series A-2 Stock, Radius Series A-3 Stock, Radius Series A-4 Stock, Radius Series A-5 Stock and Radius Series A-6 Stock.

 

“Radius Returns” shall have the meaning as set forth in Section 3.8(a) hereof.

 

“Radius Series A-1 Stock” means the Series A-1 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Series A-2 Stock” means the Series A-2 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Series A-3 Stock” means the Series A-3 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Series A-4 Stock” means the Series A-4 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Series A-5 Stock” means the Series A-5 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Series A-6 Stock” means the Series A-6 Convertible Preferred Stock, par value $0.01, of Radius.

 

“Radius Stockholder Meeting” shall have the meaning ascribed thereto in Section 6.8 hereof.

 

“Redemption Agreement” shall have the meaning ascribed thereto in Section 6.12.

 

“Representatives” shall have the meaning ascribed thereto in Section 6.3(a).

 

“Requisite Radius Stockholder Vote” shall have the meaning ascribed thereto in Section 3.2.

 

“SEC” shall mean the United States Securities and Exchange Commission.

 

“Securities Act” shall mean the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.

 

“Stock Option Plan” shall have the meaning as set forth in Section 2.2(f) hereof.

 

“Stockholder Questionnaire” shall have the meaning ascribed thereto in Section 6.7.

 

5

 

“Subsidiary” shall, with respect to any Person, mean (i) each corporation in which such Person owns directly or indirectly fifty percent (50%) or more of the voting securities of such corporation and (ii) any other Person in which such Person owns at least a majority voting interest, and shall, in each case, unless otherwise indicated, be deemed to refer to both direct and indirect subsidiaries of such Person.

 

“Surviving Company” shall have the meaning ascribed thereto in Article II.

 

“Tax” or “Taxes” (and, with correlative meaning, “Taxable” and “Taxing”) shall mean any federal, state, local or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, property or windfall profits taxes, environmental taxes, customs duties, capital stock, franchise, employees’ income withholding, foreign or domestic withholding, social security, unemployment, disability, workers’ compensation, employment-related insurance, real property, personal property, sales, use, transfer, value added, alternative or add-on minimum or other governmental tax, fee, assessment or charge of any kind whatsoever including any interest, penalties or additions to any Tax or additional amounts in respect of the foregoing.

 

“Trademarks” has the meaning ascribed thereto in Section 3.22(a).

 

“Warrants” shall have the meaning as set forth in Section 2.2(h) hereof.

 

ARTICLE II
 MERGER

 

Subject to the satisfaction or waiver of the conditions set forth in Article VII, at the Effective Time, (i) Merger Sub will merge with and into Radius, and (ii) Radius will become a wholly-owned subsidiary of MPMAC. The term “Surviving Company” as used herein shall mean Radius, as a wholly-owned subsidiary of MPMAC after giving effect to the Merger. The Merger will be effected pursuant to the Certificate of Merger in accordance with the provisions of, and with the effect provided in, Section 251 of the DGCL.

 

2.1          Effects of Merger.

 

(a)           From and after the Effective Time and until further amended in accordance with law, (i) the Certificate of Incorporation of Merger Sub as in effect immediately prior to the Effective Time shall be the Certificate of Incorporation of the Surviving Company, except that all references to the name of the Merger Sub shall be changed to refer to “Radius Health, Inc.” and the identity of the incorporator shall be deleted, and (ii) the Bylaws of Merger Sub as in effect immediately prior to the Effective Time shall be the Bylaws of the Surviving Company.

 

(b)           MPMAC, Radius and Merger Sub, respectively, shall each use its best efforts to take all such action as may be necessary or appropriate to effectuate the Merger in accordance with the DGCL at the Effective Time. If at any time after the Effective Time, any further action is necessary or desirable to carry out the purposes of this Agreement and to vest

 

6

 

the Surviving Company with full right, title and possession to all properties, rights, privileges, immunities, powers and franchises of either Radius or Merger Sub, the officers of the Surviving Company are fully authorized in the name of MPMAC, Radius and Merger Sub or otherwise to take, and shall take, all such lawful and necessary action.

 

(c)           Subject to the provisions of Article VII and Article VIII hereof, the closing (the “Closing”) of the transactions contemplated hereby shall take place on or before May 13, 2011 (the “Closing Date”), at the offices of Bingham McCutchen LLP located at One Federal Street, Boston, MA 02110 or such other time and place as Radius and MPMAC mutually agree at the earliest practicable time after the satisfaction or waiver of the conditions in Article VII. On the Closing Date, or as soon thereafter as practicable, to effect the Merger, the parties hereto will cause the Certificate of Merger to be filed with the Delaware Secretary of State in accordance with the DGCL. The Merger shall be effective when the filing of the Certificate of Merger is accepted by the Delaware Secretary of State (the “Effective Time”). As used herein, the term “Effective Date” shall mean the date on which the Effective Time occurs.

 

2.2          Effect on Radius Capital Stock and Merger Sub Capital Stock.  To effectuate the Merger, and subject to the terms and conditions of this Agreement, at the Effective Time:

 

(a)           Each share of Radius Common Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for one fully paid and nonassessable share of MPMAC Common Stock;

 

(b)           (i)            Each share of Radius Series A-1 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-1 Stock equal to one multiplied by the Preferred Exchange Ratio;

 

(ii)           Each share of Radius Series A-2 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-2 Stock equal to one multiplied by the Preferred Exchange Ratio;

 

(iii)          Each share of Radius Series A-3 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-3 Stock equal to one multiplied by the Preferred Exchange Ratio;

 

(iv)          Each share of Radius Series A-4 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and

 

7

 

exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-4 Stock equal to one multiplied by the Preferred Exchange Ratio;

 

(v)           Each share of Radius Series A-5 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-5 Stock equal to one multiplied by the Preferred Exchange Ratio; and

 

(vi)          Each share of Radius Series A-6 Stock issued and outstanding immediately prior to the Effective Time (other than shares cancelled and extinguished pursuant to this Section 2.2 and Dissenting Shares) shall automatically be converted into and exchangeable for a fraction of a fully paid and nonassessable share of MPMAC Series A-6 Stock equal to one multiplied by the Preferred Exchange Ratio;

 

(c)           All shares of Radius Common Stock and Radius Preferred Stock held at the Effective Time by Radius as treasury stock will be cancelled and extinguished and no payment will be made with respect to those shares;

 

(d)           Each share of Radius Common Stock and Radius Preferred Stock issued and outstanding immediately prior to the Effective Time and owned by Merger Sub or MPMAC, if any, shall be cancelled and extinguished without any conversion thereof and no payment shall be made with respect thereto;

 

(e)           All shares of common stock, $0.0001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one validly issued, fully paid and nonassessable share of common stock of the Surviving Company;

 

(f)            MPMAC shall assume Radius’s 2003 Long-Term Incentive Plan, as amended (the “Stock Option Plan”) and all of Radius’s rights and obligations under the outstanding stock options to purchase shares of Radius Common Stock, pursuant to the Stock Option Plan, granted by Radius on or prior to the Effective Date, which stock options are disclosed in Schedule 2.2(f) hereto and have not prior to the Effective Date been exercised, cancelled or terminated nor expired (collectively the “Options”). The Options shall be assumed in accordance with the terms and conditions of the Stock Option Plan, except that, from and after the Effective Time: (i) all actions to be taken under the Stock Option Plan or the Options by the Board of Directors of Radius or a committee thereof shall be taken by the Board of Directors of MPMAC or a committee thereof, (ii) each Option shall evidence the right to purchase a number of shares of MPMAC Common Stock (rounded to the nearest whole share) equal to the number of shares of Radius Common Stock into which such Option is exercisable immediately prior to the Effective Date multiplied by the Common Exchange Ratio, (iii) the new option price for each share of MPMAC Common Stock issuable upon exercise of an Option shall be determined by dividing the option exercise price immediately prior to the Effective Date by the Common Exchange Ratio (rounded to the nearest cent) and (iv) all references in the Options and the Stock Option Plan to Radius and Radius Common Stock shall be deemed to be references to MPMAC

 

8

 

and MPMAC Common Stock, respectively, after giving effect to the adjustments pursuant to clauses (ii) and (iii). Notwithstanding the provisions set forth in clause (iii) above, with respect to each Option intended to be an “incentive stock option” under Section 422 of the Code, if the new option price calculated pursuant to clause (iii) would cause any such Option not to satisfy the requirements of Section 424(a) of the Code and Treasury Regulation § 1.425-1(a)(1)(i), the new exercise price with respect to that Option will be increased to the minimum price that it could be and still satisfy the requirements of that regulation. MPMAC agrees to use its best efforts to take such other steps as are necessary to ensure that those Options which are deemed “incentive stock options” under Section 422 of the Code remain “incentive stock options;”

 

(g)           MPMAC shall assume the rights and obligations under Radius’s outstanding warrants listed in Schedule 2.2(g) hereof (the “Warrants”), if any, to purchase shares of Radius Common Stock or Radius Preferred Stock. The Warrants shall be assumed in accordance with their terms and conditions. Each Warrant shall, from and after the Effective Time, evidence the right to purchase a number of shares of MPMAC Common Stock or MPMAC Preferred Stock (rounded to the nearest whole share) equal to the number of shares of Radius Common Stock or Radius Preferred Stock into which such Warrant is exercisable immediately prior to the Effective Date multiplied by the Common Exchange Ratio or Preferred Exchange Ratio, as applicable. The new exercise price of the Warrants shall be determined by dividing the exercise price of the Warrants immediately prior to the Effective Date by the Common Exchange Ratio or Preferred Exchange Ratio, as applicable. All references in the Warrants to Radius and Radius Common Stock or Radius Preferred Stock, as the case may be, shall be deemed to be references to MPMAC and MPMAC Common Stock or MPMAC Preferred Stock, as the case may be, respectively, after giving effect to the adjustments pursuant to this Section.

 

2.3          Rights of Holders of Certificates Evidencing Radius Capital Stock.

 

(a)           On and after the Effective Date and until surrendered for exchange, each outstanding stock certificate that immediately prior to the Effective Date represented shares of Radius Common Stock (except Dissenting Shares and shares cancelled or extinguished pursuant to Section 2.2(d)) shall be deemed for all purposes, to evidence ownership of and to represent the number of whole shares of MPMAC Common Stock into which such shares of Radius Common Stock shall have been converted pursuant to Section 2.2(a) above. The record holder of each such outstanding certificate representing shares of Radius Common Stock, shall, after the Effective Date, be entitled to vote the shares of MPMAC Common Stock into which such shares of Radius Common Stock shall have been converted on any matters on which the holders of record of MPMAC Common Stock, as of any date subsequent to the Effective Date, shall be entitled to vote. In any matters relating to such certificates of Radius Common Stock, MPMAC may rely conclusively upon the record of stockholders maintained by Radius containing the names and addresses of the holders of record of Radius Common Stock on the Effective Date.

 

(b)           On and after the Effective Date, each share of Radius Preferred Stock outstanding immediately prior to the Effective Time (except Dissenting Shares and shares cancelled or extinguished pursuant to Section 2.2(d)), each of which shall be uncertificated as of the Effective Date, as recorded on the books and records of Radius, shall be deemed for all

 

9

 

purposes, to evidence ownership of and to represent the number of whole shares of MPMAC Preferred Stock into which such shares of Radius Preferred Stock shall have been converted pursuant to Section 2.2(b) above. Shares of the MPMAC Preferred Stock shall have the terms, rights and preferences substantially set forth in the Certificate of Designation. The record holder of each such share of Radius Preferred Stock, shall, after the Effective Date, be entitled to vote the shares of MPMAC Preferred Stock into which such shares of Radius Preferred Stock shall have been converted on any matters on which the holders of record of MPMAC Preferred Stock, as of any date subsequent to the Effective Date, shall be entitled to vote. In any matters relating to the ownership of Radius Preferred Stock, MPMAC may rely conclusively upon the record of stockholders maintained by Radius containing the names and addresses of the holders of record of Radius Preferred Stock on the Effective Date.

 

2.4          Procedure for Exchange of Radius Capital Stock.

 

(a)           After the Effective Time, holders of certificates theretofore evidencing outstanding shares of Radius Common Stock (except Dissenting Shares and shares cancelled or extinguished pursuant to Section 2.2(d)), upon surrender of such certificates together with the delivery of a letter of transmittal in the form of Exhibit C hereto (the “Letter of Transmittal”) duly completed and validly executed in accordance with the instructions thereto to the Secretary of MPMAC, shall be entitled to receive certificates representing the number of shares of MPMAC Common Stock into which shares of Radius Common Stock theretofore represented by the certificates so surrendered are exchangeable as provided in Section 2.2(a) hereof. MPMAC shall not be obligated to deliver any such shares of MPMAC Common Stock to which any former holder of shares of Radius Common Stock is entitled until such holder surrenders the certificate or certificates representing such shares. Upon surrender, each certificate evidencing Radius Common Stock shall be cancelled. No certificates or scrip representing fractional shares of MPMAC Common Stock or MPMAC Preferred Stock shall be issued in the Merger, and such fractional share interests will not entitle the owner thereof to vote or to any other rights of a stockholder of the Surviving Corporation.  Upon surrender of Radius Common Stock or Radius Preferred Stock, as the case may be, each holder of a fractional MPMAC Common Stock or MPMAC Preferred Stock interest that would have been issued in the Merger but for the foregoing sentence shall be paid by MPMAC an amount in cash equal to the product obtained by multiplying (i) such fractional share interest to which such holder (after taking into account all fractional share MPMAC Common Stock or MPMAC Preferred Stock interests, as applicable, then held by such holder) would otherwise be entitled, by (ii) $8.142. If there is a transfer of Radius Common Stock ownership which is not registered in the transfer records of Radius, a certificate representing the proper number of shares of MPMAC Common Stock may be issued to a person other than the person in whose name the certificate so surrendered is registered if: (x) upon presentation to the Secretary of MPMAC, such certificate shall be properly endorsed or otherwise be in proper form for transfer, (y) the person requesting such payment shall pay any transfer or other Taxes required by reason of the issuance of shares of MPMAC Common Stock to a person other than the registered holder of such certificate or establish to the reasonable satisfaction of MPMAC that such Tax has been paid or is not applicable, and (z) the issuance of such MPMAC Common Stock shall not, in the sole discretion of MPMAC, violate the requirements of the Regulation D “safe harbor” of the Securities Act with respect to the private placement of MPMAC Common Stock that will result from the Merger.

 

10

 

(b)           For each outstanding share of Radius Preferred Stock recorded on the books and records of Radius immediately prior to Effective Time (except Dissenting Shares and shares cancelled or extinguished pursuant to Section 2.2(d)), MPMAC shall record in its books and records, immediately after the Effective Time (or as soon thereafter as reasonably practicable), in the respective name of such holder as set forth in the Radius books and records, the number of shares of MPMAC Preferred Stock into which the shares of Radius Preferred Stock are exchangeable as provided in Section 2.2(b) hereof. Upon surrender of a Letter of Transmittal duly completed and validly executed in accordance with the instructions thereto to the Secretary of MPMAC, holders of Radius Preferred Stock shall be entitled to receive certificates representing the number of shares of MPMAC Preferred Stock into which shares of Radius Preferred Stock are exchangeable as provided in Section 2.2(b) hereof. If there is a transfer of Radius Preferred Stock ownership which is not registered in the transfer records of Radius, the proper number of shares of MPMAC Preferred Stock subject to such transfer may be recorded in the name of a person other than the person in whose name the shares so surrendered are registered if: (x) upon presentation to the Secretary of MPMAC, the transfer of such shares shall be properly endorsed or otherwise be in proper form for transfer, (y) the person requesting such payment shall pay any transfer or other Taxes required by reason of the issuance of shares of MPMAC Preferred Stock to a person other than the registered holder of such shares or establish to the reasonable satisfaction of MPMAC that such Tax has been paid or is not applicable, and (z) the issuance of such MPMAC Preferred Stock shall not, in the sole discretion of MPMAC, violate the requirements of the Regulation D “safe harbor” of the Securities Act with respect to the private placement of MPMAC Preferred Stock that will result from the Merger.

 

(c)           All shares of MPMAC Common Stock and MPMAC Preferred Stock issued upon the surrender for exchange of Radius Common Stock and Radius Preferred Stock, respectively, in accordance with the above terms and conditions shall be deemed to have been issued and paid in full satisfaction of all rights pertaining to such shares of Radius Common Stock and Radius Preferred Stock, respectively.

 

(d)           Any shares of MPMAC Common Stock or MPMAC Preferred Stock issued in the Merger will not be transferable except (1) pursuant to an effective registration statement under the Securities Act or (2) upon receipt by MPMAC of a written opinion of counsel for the holder reasonably satisfactory to MPMAC to the effect that the proposed transfer is exempt from the registration requirements of the Securities Act and relevant state securities laws. Restrictive legends shall be placed on all certificates representing shares of MPMAC Common Stock and MPMAC Preferred Stock, as applicable, issued in the Merger, substantially as follows:

 

“NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS IN EFFECT THEREUNDER AND ALL APPLICABLE STATE SECURITIES OR

 

11

 

“BLUE SKY” LAWS (SUCH FEDERAL AND STATE LAWS, THE “SECURITIES LAWS”) OR (B) IF THE CORPORATION HAS BEEN FURNISHED WITH AN OPINION OF COUNSEL FOR THE HOLDER, WHICH OPINION AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE PROVISIONS OF THE SECURITIES LAWS.

 

(e)           In the event any certificate for Radius Common Stock or any certificate or similar instrument evidencing Radius Preferred Stock, Options, Warrants or Convertible Securities shall have been lost, stolen or destroyed, MPMAC shall issue and pay in exchange for such lost, stolen or destroyed certificate, promptly following its receipt of an affidavit of that fact by the holder thereof, such shares of the MPMAC Common Stock or MPMAC Preferred Stock, as applicable, as may be required pursuant to this Agreement; provided, however, that MPMAC, in its discretion and as a condition precedent to the issuance and payment thereof, may require the owner of such lost, stolen or destroyed certificate to deliver a bond in such sum as it may direct as indemnity against any claim that may be made against MPMAC or any other party with respect to the certificate alleged to have been lost, stolen or destroyed.

 

2.5          Dissenting Shares.  Shares of capital stock of Radius held by stockholders of Radius who have properly exercised and preserved appraisal rights with respect to those shares in accordance with Section 262 of the DGCL (“Dissenting Shares”) shall not be converted into or represent a right to receive shares of MPMAC Common Stock or MPMAC Preferred Stock, as applicable, pursuant to Section 2.2 above, but the holders thereof shall be entitled only to such rights as are granted by Section 262 of the DGCL. Each holder of Dissenting Shares who becomes entitled to payment for such shares pursuant to Section 262 of the DGCL shall receive payment therefor from the Surviving Company in accordance with such laws; provided, however, that if any such holder of Dissenting Shares shall have effectively withdrawn such holder’s demand for appraisal of such shares or lost such holder’s right to appraisal and payment of such shares under Section 262 of the DGCL, such holder or holders (as the case may be) shall forfeit the right to appraisal of such shares and each such share shall thereupon be deemed to have been cancelled, extinguished and exchanged, as of the Effective Time, into and represent the right to receive from MPMAC shares of MPMAC Common Stock or MPMAC Preferred Stock, as applicable, as provided in Section 2.2 above. Any payments in respect of Dissenting Shares will be deemed made by the Surviving Company.

 

2.6          Directors and Officers of the Surviving Corporation.  From and after the Effective Time, the directors and officers of the Surviving Company shall be the persons who were directors and officers of Radius immediately prior to the Effective Time, respectively. These directors and officers of the Surviving Company shall hold office for the term specified in, and subject to the provisions contained in, the Certificate of Incorporation and Bylaws of the Surviving Company and applicable law. If, at or after the Effective Time, a vacancy shall exist on the board of directors or in any of the offices of the Surviving Company, such vacancy shall be filled in the manner provided in the Certificate of Incorporation and Bylaws of the Surviving Company.

 

12

 

2.7          Directors and Officers of MPMAC.  At the Closing, the Board of Directors of MPMAC shall, subject to compliance with Section 14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder, take the following action, to be effective upon the Effective Time: (i) increase the size of the Board of Directors of MPMAC to seven (7) persons; (ii) elect to the Board of Directors of MPMAC the persons who were directors of Radius immediately prior to the Closing; and (iii) appoint as the officers of MPMAC those who were the officers of Radius immediately prior to the Closing, or, in either case with regard to clauses (ii) and (iii), such other persons designated by Radius. All of the persons serving as directors of MPMAC immediately prior to the Closing and will not continue in such capacity after the Closing shall resign immediately following the election of the new directors, all subject to compliance with Rule 14f-1 promulgated under the Exchange Act. Subject to applicable law, MPMAC shall take all action reasonably requested by Radius, but consistent with the Certificate of Incorporation and Bylaws of MPMAC, that is reasonably necessary to effect any such election or appointment of the designees of Radius to MPMAC’s Board of Directors, including promptly hereafter mailing to MPMAC’s stockholders an information statement containing the information required by Section 14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder. Radius shall supply MPMAC all information with respect to it and its nominees, officers, directors and Affiliates required by such Section 14(f) and Rule 14f-1. The provisions of this Section 2.7 are in addition to and shall not limit any rights which Radius or any of its Affiliates may have as a holder or beneficial owner of shares of capital stock of MPMAC as a matter of law with respect to the election of directors or otherwise. Immediately after the Effective Time, the newly-constituted board of directors of MPMAC will appoint the officers of Radius immediately prior to the Effective Time as the officers of MPMAC. The newly-appointed directors and officers of MPMAC shall hold office for the term specified in, and subject to the provisions contained in, the Certificate of Incorporation and Bylaws of MPMAC and applicable law.

 

ARTICLE III
 REPRESENTATIONS AND WARRANTIES OF RADIUS

 

Radius hereby represents and warrants to MPMAC and Merger Sub as follows:

 

3.1          Organization and Qualification.  Radius is, and on the Effective Date will be, a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and has the requisite corporate power to carry on its business as now conducted. The copies of the Certificate of Incorporation and Bylaws of Radius that have been made available to MPMAC prior to the date of this Agreement are correct and complete copies of such documents as in effect as of the date hereof, and shall be in effect on the Effective Date. Radius is, and on the Effective Date will be, licensed or qualified to do business in every jurisdiction in which the nature of its business or its ownership of property requires it to be licensed or qualified, except where the failure to be so licensed or qualified would not have a Material Adverse Effect on Radius or the Surviving Company.

 

3.2          Authority Relative to this Agreement; Non-Contravention.  The execution and delivery of this Agreement by Radius and the consummation by Radius of the transactions

 

13

 

contemplated hereby have been duly authorized by the Board of Directors of Radius and, except for approval of the Merger and adoption of this Agreement by the affirmative vote of a majority of votes that holders of the outstanding shares of Radius Common Stock and Radius Preferred Stock, as applicable, are entitled to cast (the “Requisite Radius Stockholder Vote”), which will be obtained prior to Closing, no other corporate proceedings on the part of Radius are necessary to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by Radius and, assuming it is a valid and binding obligation of MPMAC and Merger Sub, constitutes a valid and binding obligation of Radius enforceable in accordance with its terms except as enforcement may be limited by general principles of equity whether applied in a court of law or a court of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally. Except for (x) approvals under applicable Blue Sky laws and filing of Form D with the Securities and Exchange Commission, and (y) the filing of the Certificate of Merger with the Secretary of State of Delaware, no authorization, consent or approval of, or filing with, any public body, court or authority is necessary on the part of Radius for the consummation by Radius of the transactions contemplated by this Agreement, except for such authorizations, consents, approvals and filings as to which the failure to obtain or make the same would not, in the aggregate, reasonably be expected to have a Material Adverse Effect on Radius or the Surviving Company or adversely affect the consummation of the transactions contemplated hereby.

 

3.3          No Conflicts.  Radius is not subject to, or obligated under, any provision of (a) its Certificate of Incorporation or Bylaws, (b) any agreement, arrangement or understanding, (c) any license, franchise or permit or (d) subject to obtaining the approvals referred to in the next sentence, any law, regulation, order, judgment or decree, which would conflict with, be breached or violated, or in respect of which a right of termination or acceleration or any security interest, charge or encumbrance on any of its assets would be created, by the execution, delivery or performance of this Agreement, or the consummation of the transactions contemplated hereby, other than any such conflicts, breaches, violations, rights of termination or acceleration or security interests, charges or encumbrances which, in the aggregate, could not reasonably be expected to result in a Material Adverse Effect on Radius or the Surviving Company.

 

3.4          Capitalization.

 

(a)           The authorized, issued and outstanding shares of capital stock of Radius as of the date hereof are correctly set forth in Schedule 3.4(a). The issued and outstanding shares of capital stock of Radius are, and on the Effective Date will be, duly authorized, validly issued, fully paid and nonassessable and not issued in violation of any preemptive rights and, to Radius’s Knowledge, free from any restrictions on transfer (other than restrictions under the Securities Act or state securities laws) or any option, lien, pledge, security interest, encumbrance or charge of any kind. Other than as described in Schedule 3.4(a), Radius has no other equity securities or securities containing any equity features authorized, issued or outstanding. Except as set forth in Schedule 3.4(a), there are no agreements or other rights or arrangements existing which provide for the sale or issuance of capital stock by Radius and there are no rights, subscriptions, warrants, options, conversion rights or agreements of any kind outstanding to purchase or otherwise acquire from Radius any shares of capital stock or other securities of Radius of any kind, and

 

14

 

there will not be any such agreements prior to or on the Effective Date. There are, and on the Effective Date there will be, no agreements or other obligations (contingent or otherwise) which may require Radius to repurchase or otherwise acquire any shares of its capital stock.

 

(b)           Schedule 3.4(b) contains a list of the names of the owners of record as of the date of this Agreement of all issued and outstanding shares of Radius Common Stock and Radius Preferred Stock and the number of shares of Radius Common Stock and Radius Preferred Stock, respectively, each of them holds and the names of all holders of options, warrants, convertible securities, exchangeable securities and other rights entitling the holder thereof to purchase equity of Radius and the number of shares of Radius Common Stock, Radius Preferred Stock or other equity security underlying each such option, warrant, convertible security, exchangeable security and other right.

 

(c)           Radius does not own, and is not party to any contract to acquire, any equity securities or other securities of any Person or any direct or indirect equity or ownership interest in any other Person. Except as contemplated by this Agreement, Radius is not a party to, and, to Radius’s Knowledge, there do not exist, except as set forth in the Stockholders Agreement, any voting trusts, proxies, or other contracts with respect to the voting of shares of capital stock of Radius.

 

3.5          Litigation.  There are no actions, suits, proceedings, orders or investigations pending or, to the Knowledge of Radius, threatened against Radius or its officers, directors, employees or Affiliates, or the nominees for officer or director of MPMAC after the Effective Time, individually or in the aggregate, at law or in equity, or before or by any federal, state or other governmental department, court, commission, board, bureau, agency or instrumentality, domestic or foreign, and to the Knowledge of Radius, there is no reasonable basis for any proceeding, claim, action or governmental investigation directly or indirectly involving Radius or its officers, directors, employees or affiliates, individually or in the aggregate. Radius is not a party to any order, judgment or decree issued by any federal, state or other governmental department, court, commission, board, bureau, agency or instrumentality, domestic or foreign.

 

3.6          No Brokers or Finders.  Neither Radius nor any of its officers, directors, employees or Affiliates has employed any broker, finder, investment banker or investment advisor or Person performing similar function, or incurred any liability, for brokerage commissions, finders’ fees, investment advisory fees or similar compensation, in connection with the transactions contemplated by this Agreement.

 

3.7          Subsidiaries.  Radius does not have, and on the Effective Date will not have, any subsidiaries, nor does it have any direct or indirect interest in any other business entity.

 

3.8          Tax Matters.

 

(a)           (i) Except as set forth in Schedule 3.8, Radius has timely filed or sent (or has had timely filed or sent on its behalf) all returns, declarations, reports, estimates, information returns, and statements, including any schedules and amendments to such documents (“Radius Returns”), required to be filed or sent by it in respect of any Taxes or required to be filed or sent 

 

15

 

by it by any applicable Taxing authority; (ii) all such Radius Returns are complete and accurate in all material respects; (iii) Radius has timely paid (or has had timely paid on its behalf) all Taxes required to have been paid by it; (iv) Radius has established on the Radius Latest Balance Sheet, in accordance with GAAP, reserves that are adequate for the payment of any Taxes not yet paid; and (v) Radius has complied with all applicable laws, rules, and regulations relating to the collection or withholding of Taxes from third parties (including without limitation employees) and the payment thereof (including, without limitation, withholding of Taxes under Sections 1441 and 1442 of the Code, or similar provisions under any foreign laws).

 

(b)           To Radius’s Knowledge, there are no liens for Taxes upon any assets of Radius, except liens for Taxes not yet due.

 

(c)           No deficiency for any Taxes has been asserted, assessed or, to Radius’s Knowledge, proposed against Radius that has not been finally resolved or that is not being contested in good faith. Except as disclosed in Schedule 3.8, no waiver, extension or comparable consent given by Radius regarding the application of the statute of limitations with respect to any Taxes or Radius Returns is outstanding, nor is any request for any such waiver or consent pending. Except as disclosed in Schedule 3.8, there is no pending Tax audit or other administrative proceeding or court proceeding with regard to any Taxes or Radius Returns nor has there been any notice to Radius by any Taxing authority regarding any such Tax audit or other proceeding, or, to the Knowledge of Radius, is any such Tax audit or other proceeding threatened with regard to any Taxes or Radius Returns.

 

(d)           Except as set forth in Schedule 3.8, Radius has not requested any extension of time within which to file any Radius Return, which return has not since been filed.

 

3.9          Contracts and Commitments.

 

(a)           Schedule 3.9 hereto lists the following agreements, whether oral or written, to which Radius is a party, which are currently in effect, and which relate to the operation of Radius’s business: (i) collective bargaining agreement or contract with any labor union; (ii) bonus, pension, profit sharing, retirement or other form of deferred compensation plan; (iii) stock purchase or stock option plan; (iv) contract for the employment of any officer, individual employee or other person on a full-time or consulting basis or relating to severance pay for any such person; (v) contract, agreement or understanding relating to the voting of Radius Common Stock or Radius Preferred Stock, or the election of directors of Radius; (vi) agreement or indenture relating to the borrowing of money or to mortgaging, pledging or otherwise placing a lien on any of the assets of Radius; (vii) guaranty of any obligation for borrowed money or otherwise; (viii) lease or agreement under which Radius is lessee of, or holds or operates any property, real or personal, owned by any other party, for which the annual rental exceeds $10,000; (ix) lease or agreement under which Radius is lessor of, or permits any third party to hold or operate, any property, real or personal, for which the annual rental exceeds $10,000; (x) contract which prohibits Radius from freely engaging in business anywhere in the world; (xi) license agreement or agreement providing for the payment or receipt of royalties or other compensation by Radius in connection with the intellectual property rights listed in Schedule 3.22(b) hereto; (xii) contract or commitment for capital expenditures in excess of

 

16

 

$10,000; (xiii) agreement for the sale of any capital asset; (xiv) contracts, understandings, arrangements or commitments with respect to the acquisition and/or use by Radius of Intellectual Property of others or by others of Intellectual Property of Radius; or (xv) other agreement which is either material to Radius’s business or was not entered into in the ordinary course of business.

 

(b)           To Radius’s Knowledge, Radius has performed all material obligations required to be performed by it in connection with the contracts, understandings, arrangements or commitments required to be disclosed in Schedule 3.9 hereto and is not in receipt of any claim of default under any contract, understanding, arrangement or commitment required to be disclosed in Schedule 3.9 hereto; Radius has no present expectation or intention of not fully performing any material obligation pursuant to any contract, understanding, arrangement or commitment required to be disclosed in Schedule 3.9 hereto; and Radius has no Knowledge of any breach or anticipated breach by any other party to any contract, understanding, arrangement or commitment required to be disclosed in Schedule 3.9 hereto.

 

3.10        Affiliate Transactions.  Except as set forth in Schedule 3.10 hereto, and other than pursuant to this Agreement, no officer, director or employee of Radius, or any member of the immediate family of any such officer, director or employee, or any entity in which any of such persons owns any beneficial interest (other than any publicly-held corporation whose stock is traded on a national securities exchange, the Nasdaq Global or Capital Markets or in an over-the-counter market and less than five percent of the stock of which is beneficially owned by any of such persons) (collectively “Radius Insiders”), has any agreement with Radius (other than normal employment arrangements set forth in Schedule 3.9) or any interest in any property, real, personal or mixed, tangible or intangible, used in or pertaining to the business of Radius (other than ownership of capital stock of Radius). Except as set forth in Schedule 3.10, Radius is not indebted to any Radius Insider (except for amounts due as normal salaries and bonuses and in reimbursement of ordinary business expenses) and no Radius Insider is indebted to Radius (except for cash advances for ordinary business expenses). None of the Radius Insiders has any direct or indirect interest in any competitor, supplier or customer of Radius or in any person, firm or entity from whom or to whom Radius leases any property, or in any other person, firm or entity with whom Radius transacts business of any nature. For purposes of this Section 3.10, the members of the immediate family of an officer, director or employee shall consist of the spouse, parents, children and siblings of such officer, director or employee.

 

3.11        Compliance with Laws; Permits.

 

(a)           Except for any noncompliance that would not reasonably be expected to have a Material Adverse Effect on Radius or the Surviving Company, Radius and its officers, directors, agents and employees have complied with all applicable laws, regulations and other requirements, including, but not limited to, federal, state, local and foreign laws, ordinances, rules, regulations and other requirements pertaining to equal employment opportunity, employee retirement, affirmative action and other hiring practices, occupational safety and health, workers’ compensation, unemployment and building and zoning codes, and no claims have been filed against Radius, and Radius has not received any notice, alleging a violation of any such laws, regulations or other requirements. Radius is not relying on any exemption from or deferral of any

 

17

 

such applicable law, regulation or other requirement that would not be available to MPMAC after it acquires Radius’s properties, assets and business.

 

(b)           Radius has obtained all licenses, permits and certificates, from federal, state, local and foreign authorities (including, without limitation, federal and state agencies regulating occupational health and safety), that are necessary to the conduct of its operations and business, except where the failure to have any such license, permit or certificate would not reasonably be expected to have a Material Adverse Effect on Radius or the Surviving Company.

 

3.12        Financial Statements.  Radius has made available to MPMAC audited balance sheets of Radius as of December 31, 2008 and 2009 and an unaudited balance sheet as of December 31, 2010, and the related statements of income, changes in stockholders’ equity, and cash flows of Radius for the years then ended and from the inception of Radius to such date (the “Radius Financial Statements”) and its unaudited balance sheet as of February 28, 2011 and the related unaudited statements of income, change in stockholders’ equity and cash flows of Radius for the two-month period then ended (the “Radius Interim Statements”). The Radius Financial Statements were prepared in accordance with GAAP consistently applied with past practice (except in each case as described in the notes thereto) and on that basis present fairly, in all material respects, the financial position and the results of operations, changes in stockholders’ equity, and cash flows of Radius as of the dates of and for the periods referred to in the Radius Financial Statements and the Radius Interim Statements, respectively.

 

3.13        Books and Records.  The books of account, minute books, stock record books, and other records of Radius, complete copies of which have been made available to MPMAC, have been properly kept and contain no inaccuracies except for inaccuracies that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Radius or the Surviving Company. At the Closing, all of Radius’s records will be in the possession of Radius.

 

3.14        Real Property.  Radius does not own any real property. Schedule 3.14 contains an accurate list of all leaseholds and other interests of Radius in any real property. Radius has good and valid title to those leaseholds and other interests free and clear of all liens and encumbrances, and the real property to which those leasehold and other interests pertain constitutes the only real property used in Radius’s business.

 

3.15        Insurance.  The insurance policies owned and maintained by Radius that are material to Radius are in full force and effect, all premiums due and payable thereon have been paid (other than retroactive or retrospective premium adjustments that Radius is not currently required, but may in the future be required, to pay with respect to any period ending prior to the date of this Agreement), and Radius has received no notice of cancellation or termination with respect to any such policy that has not been replaced on substantially similar terms prior to the date of such cancellation.

 

3.16        No Undisclosed Liabilities.  Except as reflected in the unaudited balance sheet of Radius at February 28, 2011 (the “Radius Latest Balance Sheet”), Radius has no liabilities (whether accrued, absolute, contingent, unliquidated or otherwise except (i) liabilities which

 

18

 

have arisen after the date of the Radius Latest Balance Sheet in the ordinary course of business (none of which is a material uninsured liability), or (ii) liabilities under this Agreement.

 

3.17        Environmental Matters.  None of the operations of Radius involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260-270 or any state, local or foreign equivalent.

 

3.18        Absence of Certain Developments.  Except as disclosed on Schedule 3.18 or in the Radius Financial Statements or as otherwise contemplated by this Agreement, since the date of the Radius Latest Balance Sheet, Radius has conducted its business only in the ordinary course consistent with past practice and there has not occurred or been entered into, as the case may be: (i) any event having a Material Adverse Effect on Radius or the Surviving Company, (ii) any event that could reasonably be expected to prevent or materially delay the performance of Radius’s obligations pursuant to this Agreement, (iii) any material change by Radius in its accounting methods, principles or practices, (iv) any declaration, setting aside or payment of any dividend or distribution in respect of the shares of capital stock of Radius or any redemption, purchase or other acquisition of any of Radius’s securities, (v) any increase in the compensation or benefits or establishment of any bonus, insurance, severance, deferred compensation, pension, retirement, profit sharing, stock option (including, without limitation, the granting of stock options, stock appreciation rights, performance awards or restricted stock awards), stock purchase or other employee benefit plan of Radius, or any other increase in the compensation payable or to become payable to any employees, officers, consultants or directors of Radius, (vi) other than issuances of options pursuant to duly adopted option plans, any issuance, grants or sale of any stock, options, warrants, notes, bonds or other securities, or entry into any agreement with respect thereto by Radius, (vii) any amendment to the Certificate of Incorporation or Bylaws of Radius, (viii) other than in the ordinary course of business consistent with past practice, any (w) capital expenditures by Radius, (x) purchase, sale, assignment or transfer of any material assets by Radius, (y) mortgage, pledge or existence of any lien, encumbrance or charge on any material assets or properties, tangible or intangible of Radius, except for liens for Taxes not yet due and such other liens, encumbrances or charges which do not, individually or in the aggregate, have a Material Adverse Effect on Radius or the Surviving Company, or (z) cancellation, compromise, release or waiver by Radius of any rights of material value or any material debts or claims, (ix) any incurrence by Radius of any material liability (absolute or contingent), except for current liabilities and obligations incurred in the ordinary course of business consistent with past practice, (x) damage, destruction or similar loss, whether or not covered by insurance, materially affecting the business or properties of Radius, (xi) entry into any agreement, contract, lease or license other than in the ordinary course of business consistent with past practice, (xii) any acceleration, termination, modification or cancellation of any agreement, contract, lease or license to which Radius is a party or by which it is bound, (xiii) entry by Radius into any loan or other transaction with any officers, directors or employees of Radius, (xiv) any charitable or other capital contribution by Radius or pledge therefore, (xv) entry by Radius into any transaction of a material nature other than in the ordinary course of business consistent with past practice, or (xvi) any negotiation or agreement by the Radius to do any of the things described in the preceding clauses (i) through (xv).

 

19

 

3.19        Employee Benefit Plans.

 

(a)           Schedule 3.19(a) lists all (i) “employee benefit plans,” within the meaning of Section 3(3) of ERISA, of Radius, (ii) bonus, stock option, stock purchase, stock appreciation right, incentive, deferred compensation, supplemental retirement, severance, and fringe benefit plans, programs, policies or arrangements, and (iii) employment or consulting agreements, for the benefit of, or relating to, any current or former employee (or any beneficiary thereof) of Radius, in the case of a plan described in (i) or (ii) above, that is currently maintained by Radius or with respect to which Radius has an obligation to contribute, and in the case of an agreement described in (iii) above, that is currently in effect (the “Radius Plans”). Radius has heretofore made available to MPMAC true and complete copies of the Radius Plans and any amendments thereto, any related trust, insurance contract, summary plan description, and, to the extent required under ERISA or the Code, the most recent annual report on Form 5500 and summaries of material modifications.

 

(b)           No Radius Plan is (1) a “multiemployer plan” within the meaning of Sections 3(37) or 4001(a)(3) of ERISA, (2) a “multiple employer plan” within the meaning of Section 3(40) of ERISA or Section 413(c) of the Code, or (3) is subject to Title IV of ERISA or Section 412 of the Code.

 

(c)           There is no proceeding pending or, to Radius’s Knowledge, threatened against the assets of any Radius Plan or, with respect to any Radius Plan, against Radius other than proceedings that would not reasonably be expected to result in a material liability, and to Radius’s Knowledge there is no proceeding pending or threatened in writing against any fiduciary of any Radius Plan other than proceedings that would not reasonably be expected to result in a material liability.

 

(d)           Each of the Radius Plans has been operated and administered in all material respects in accordance with its terms and applicable law, including, but not limited to, ERISA and the Code.

 

(e)           Each of the Radius Plans that is intended to be “qualified” within the meaning of Section 401(a) of the Code has received a favorable determination, notification, or opinion letter from the IRS.

 

(f)            Except as set forth in Schedule 3.19(f), no director, officer, or employee of Radius will become entitled to retirement, severance or similar benefits or to enhanced or accelerated benefits (including any acceleration of vesting or lapsing of restrictions with respect to equity-based awards) under any Radius Plan solely as a result of consummation of the transactions contemplated by this Agreement. No director of officer or control person of MPMAC prior to the Effective Time has or shall have any liability, cost or expense (including reasonable attorneys fees and expenses) relating to any aspect of the Radius Plans. Such individuals and entities shall be able to rely on the representation and warranty in the foregoing sentence as a third party beneficiary hereof.

 

20

 

3.20        Employees.

 

(a)           Schedule 3.20 lists the following information for each employee and each director of Radius as of the date of this Agreement, including each employee on leave of absence or layoff status: (i) name; (ii) job title; (iii) current annual base salary or annualized wages; and (iv) cash bonus compensation earned during 2009 and 2010.

 

(b)           Except as otherwise set forth in Schedule 3.20, or as contemplated by this Agreement, to the Knowledge of Radius, (i) neither any executive employee of Radius nor any group of Radius’s employees has any plans to terminate his, her or its employment; (ii) Radius has no material labor relations problem pending and its labor relations are satisfactory; (iii) there are no workers’ compensation claims pending against Radius nor is Radius aware of any facts that would give rise to such a claim; (iv) to the Knowledge of Radius, no employee of Radius is subject to any secrecy or noncompetition agreement or any other agreement or restriction of any kind that would impede in any way the ability of such employee to carry out fully all activities of such employee in furtherance of the business of Radius; (v) no employee or former employee of Radius has any claim with respect to any intellectual property rights of Radius set forth in Schedule 3.22(b) hereto; and (vi) there is no reasonable basis for any of the events described in the preceding clauses (i) - (v).

 

3.21        Proprietary Information and Inventions.  Each current Radius employee, consultant, and advisory board member is party to either a non-disclosure agreement in the form attached as Schedule 3.21 or other agreement relating to employment with Radius and containing comparable non-disclosure provisions. To Radius’s Knowledge, no current or former Radius employee, consultant or advisory board member who is party to a non-disclosure agreement has breached that non-disclosure agreement. To Radius’s Knowledge, no current Radius employee, consultant or advisory board member who is party to an alternative employment agreement with Radius has breached the non-disclosure provisions of that agreement.

 

3.22        Intellectual Property.

 

(a)           Except as set forth in Schedule 3.22(a), to its Knowledge, Radius owns or has valid and enforceable licenses to use all of the following used in or necessary to conduct its business as currently conducted (collectively, the “Radius Intellectual Property”):

 

(i)            patents, including any registrations, continuations, continuations in part, renewals, and any applications for any of the foregoing (collectively, “Patents”);

 

(ii)           registered and unregistered copyrights and copyright applications (collectively, “Copyrights”);

 

(iii)          registered and unregistered trademarks, service marks, trade names, slogans, logos, designs and general intangibles of the like nature, together with all registrations and applications therefor (collectively, “Trademarks”);

 

21

 

(iv)          trade secrets, confidential or proprietary technical information, know-how, designs, processes, research in progress, inventions and invention disclosures (whether patentable or unpatentable) (collectively, “Know-How”);

 

(v)           software (together with Patents, Copyrights, Trademarks, and Know-How, “Intellectual Property”).

 

(b)           Set forth in Schedule 3.22(b) is a complete and accurate list of all Patents, Trademarks, registered or material Copyrights and software owned by or licensed by or to, Radius. Schedule 3.22(b), including a complete and accurate list of all Persons from which or to which Radius licenses any material Intellectual Property.

 

(c)           To its Knowledge, Radius has exclusive rights to the Radius Intellectual Property (with the exception of any such rights retained by governmental organizations and licensors), free and clear of all liens and encumbrances and free of all licenses except those set forth in Schedule 3.22(c) and licenses relating to off-the-shelf software having a per-application acquisition price of less than $5,000. No Copyright registration, Trademark registration, or Patent set forth in Schedule 3.22(b) has lapsed, expired or been abandoned or cancelled, or is subject to any pending or, to Radius’s Knowledge, threatened opposition or cancellation proceeding in any country.

 

(d)           Except as set forth in Schedule 3.22(d), to Radius’s Knowledge (1) neither the conduct of Radius’s business nor the manufacture, marketing, licensing, sale, distribution or use of its products or services infringes upon the proprietary rights of any Person, and (2) there are no infringements of the Radius Intellectual Property by any Person. Except as set forth in Schedule 3.22(a) and Schedule 3.22(c), there are no claims pending or, to Radius’s Knowledge, threatened (1) alleging that Radius’s business as currently conducted infringes upon or constitutes an unauthorized use or violation of the proprietary rights of any Person, or (2) alleging that the Radius Intellectual Property is being infringed by any Person, or (3) challenging the ownership, validity or enforceability of the Radius Intellectual Property.

 

(e)           Radius has not entered into any consent agreement, indemnification agreement, forbearance to sue, settlement agreement or cross-licensing arrangement with any Person relating to the Radius Intellectual Property other than as part of the license agreements listed in Schedule 3.22(b) or set forth in Schedule 3.22(c).

 

(f)            Except as set forth in Schedule 3.22(f), Radius is not, nor will it be as a result of the execution and delivery of this Agreement or the performance of its obligations under this Agreement, in breach of any license, sublicense or other contract relating to the Radius Intellectual Property that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect on Radius or the Surviving Company.

 

3.23        Tax-Free Reorganization.  Neither Radius nor, to Radius’s Knowledge, any of its Affiliates has taken or agreed to take any action that would prevent the Merger from qualifying as a reorganization under Section 368(a) of the Code.

 

22

 

3.24        Vote Required.  The Requisite Radius Stockholder Vote is the only vote of the holders of any class or series of Radius capital stock necessary to approve the Merger.

 

3.25        Full Disclosure.  The representations and warranties of Radius contained in this Agreement (and in any schedule, exhibit, certificate or other instrument to be delivered under this Agreement) are true and correct in all material respects, and such representations and warranties do not omit any material fact necessary to make the statements contained therein, in light of the circumstances under which they were made, not misleading. There is no fact of which Radius has Knowledge that has not been disclosed to MPMAC pursuant to this Agreement, including the schedules hereto, all taken together as a whole, which has had or could reasonably be expected to have a Material Adverse Effect on Radius or the Surviving Company or materially adversely affect the ability of Radius to consummate in a timely manner the transactions contemplated hereby.

 

ARTICLE IV
 REPRESENTATIONS AND WARRANTIES OF MPMAC AND MERGER SUB

 

MPMAC and Merger Sub hereby represent and warrant to Radius as follows:

 

4.1          Organization and Qualification.  MPMAC and Merger Sub each are, and on the Effective Date will be, corporations duly organized, validly existing and in good standing under the laws of the State of Delaware, and each has, and on the Effective Date will have, the requisite corporate power to carry on their respective businesses as now conducted. The copies of the Certificate of Incorporation and Bylaws of MPMAC and Merger Sub that have been made available to Radius on or prior to the date of this Agreement are correct and complete copies of such documents as in effect as of the date hereof, and shall be in effect on the Effective Date. MPMAC and Merger Sub are, and on the Effective Date each will be, licensed or qualified to do business in every jurisdiction which the nature of their respective businesses or their respective ownership of properties require each to be licensed or qualified, except where the failure to be so licensed or qualified would not have a Material Adverse Effect on MPMAC or Merger Sub, respectively.

 

4.2          Authority Relative to this Agreement; Non-Contravention.  Each of MPMAC and Merger Sub has the requisite corporate power and authority to enter into this Agreement, and to carry out its obligations hereunder. The execution and delivery of this Agreement by MPMAC and Merger Sub, and the consummation by MPMAC and Merger Sub of the transactions contemplated hereby have been duly authorized by the Boards of Directors of MPMAC and Merger Sub. Subject only to the adoption of this Agreement by MPMAC as the sole stockholder of Merger Sub, with respect to which MPMAC will take appropriate action promptly following the date hereof, no further corporate proceedings on the part of MPMAC or Merger Sub are necessary to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby or will otherwise be sought by MPMAC. This Agreement has been duly executed and delivered by MPMAC and Merger Sub and, assuming it is a valid and binding obligation of Radius, constitutes a valid and binding obligation of MPMAC and Merger Sub enforceable in accordance with its terms except as enforcement may be limited by

 

23

 

general principles of equity whether applied in a court of law or a court of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally. Except for (x) approvals under applicable Blue Sky laws and the filing of Form D with the Securities and Exchange Commission and (y) the filing of the Certificate of Merger with the Delaware Secretary of State, no authorization, consent or approval of, or filing with, any public body, court or authority is necessary on the part of MPMAC or Merger Sub for the consummation by MPMAC or Merger Sub of the transactions contemplated by this Agreement, except for such authorizations, consents, approvals and filings as to which the failure to obtain or make the same would not, in the aggregate, reasonably be expected to have a Material Adverse Effect on MPMAC or Merger Sub, or adversely affect the consummation of the transactions contemplated hereby.

 

4.3          No Conflicts.  Neither MPMAC nor Merger Sub is subject to, or obligated under, any provision of (a) their respective Certificates of Incorporation or Bylaws, (b) any agreement, arrangement or understanding, (c) any license, franchise or permit, nor (d) subject to obtaining the approvals referred to in the next sentence, any law, regulation, order, judgment or decree, which would conflict with, be breached or violated, or in respect of which a right of termination or acceleration or any security interest, charge or encumbrance on any of their respective assets would be created, by the execution, delivery or performance of this Agreement or the consummation of the transactions contemplated hereby, other than any such conflicts, breaches, violations, rights of termination or acceleration or security interests, charges or encumbrances which, in the aggregate, could not reasonably be expected to have a Material Adverse Effect on MPMAC or Merger Sub.

 

4.4          Capitalization.

 

(a)           As of the date hereof, MPMAC is, and on the Effective Date will be, authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, of which 5,000,000 shares of common stock and no shares of preferred stock are currently issued and outstanding. The issued and outstanding shares of capital stock of MPMAC are, and on the Effective Date will be, duly authorized, validly issued, fully paid and nonassessable and not issued in violation of any preemptive rights and, to MPMAC’s Knowledge, free from any restrictions on transfer (other than restrictions under the Securities Act or state securities laws) or any option, lien, pledge, security interest, encumbrance or charge of any kind. MPMAC has, and on the Effective Date will have, no other equity securities or securities containing any equity features authorized, issued or outstanding. There are no agreements or other rights or arrangements existing which provide for the sale or issuance of capital stock by MPMAC and there are no rights, subscriptions, warrants, options, conversion rights or agreements of any kind outstanding to purchase or otherwise acquire from MPMAC any shares of capital stock or other securities of MPMAC of any kind, and there will not be any such agreements prior to or on the Effective Date.  Immediately prior to the execution of this Agreement, MPMAC and each person holding shares of MPMAC Common Stock on the date hereof (the “MPMAC Stockholders”) have entered into an agreement in the form attached hereto as Exhibit D (the “Redemption Agreement”) pursuant to which MPMAC will redeem all shares of MPMAC Common Stock held by the MPMAC Stockholders in exchange for aggregate consideration of $50,000.  The

 

24

 

redemption of such shares shall become effective concurrently with the Effective Time.  Other than the shares of MPMAC Common Stock and MPMAC Preferred Stock comprising the Merger Consideration, upon the consummation of such redemption, there will be no other shares of MPMAC Common Stock or MPMAC Preferred Stock outstanding.  There are, and on the Effective Date there will be, no agreements or other obligations (contingent or otherwise) which may require MPMAC to repurchase or otherwise acquire any shares of its capital stock other than the Redemption Agreement.

 

(b)           MPMAC is not a party to, and, to MPMAC’s Knowledge, there do not exist, any voting trusts, proxies, or other contracts with respect to the voting of shares of capital stock of MPMAC.

 

(c)           The authorized capital of Merger Sub consists of 1,000 shares of common stock, par value $0.0001 per share, all of which are, and on the Effective Date will be, issued and outstanding and held of record by MPMAC. The issued and outstanding shares of capital stock of Merger Sub are, and on the Effective Date will be, duly authorized, validly issued, fully paid and nonassessable and have not been issued in violation of any preemptive rights, and, to MPMAC’s Knowledge, free from any restrictions on transfer (other than restrictions under the Securities Act or state securities laws) or any option, lien, pledge, security interest, encumbrance or charge of any kind. There are no rights, subscriptions, warrants, options, conversion rights or agreements of any kind outstanding to purchase or otherwise acquire from Merger Sub any shares of capital stock or other securities of Merger Sub of any kind, and there will not be any such agreements prior to or on the Effective Date. There are, and on the Effective Date there will be, no agreements or other obligations (contingent or otherwise) which may require Merger Sub to repurchase or otherwise acquire any shares of its capital stock.

 

4.5          Exchange Act Reports; Financial Statements.

 

(a)           Since the filing of MPMAC’s Registration Statement on Form 10 on April 16, 2008 (the “MPMAC Form 10”), MPMAC has timely filed all reports, forms and documents that it was required to file with the SEC pursuant to Section 13(a), 14(a), 14(c) and 15(d) of the Exchange Act (together with the MPMAC Form 10, the “MPMAC Previous Filings”).  MPMAC shall notify Radius promptly of the filing of any additional forms, reports or documents with the SEC by MPMAC after the date hereof and prior to the Effective Time (together with the MPMAC Previous Filings, the “MPMAC SEC Filings”). As of their respective filing dates, each of the MPMAC SEC Filings (i) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and (ii) complied as to form in all material respects with the Exchange Act and the applicable rules and regulations of the SEC promulgated thereunder.

 

(b)           The financial statements (including footnotes thereto) included in or incorporated by reference into the MPMAC SEC Filings (the “MPMAC Financial Statements”) were complete and correct in all material respects as of their respective filing dates, complied as to form in all material respects with the Exchange Act and the applicable accounting requirements, rules and regulations of the SEC promulgated thereunder as of their respective

 

25

 

dates and have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as otherwise noted therein). The MPMAC Financial Statements fairly present the financial condition of MPMAC as of the dates thereof and results of operations for the periods referred to therein (subject, in the case of unaudited MPMAC Financial Statements, to normal recurring year-end adjustments).  There has been no change in MPMAC accounting policies except as described in the notes to the MPMAC Financial Statements.

 

4.6          Litigation.  There are no actions, suits, proceedings, orders or investigations pending or, to the Knowledge of MPMAC, threatened against MPMAC, Merger Sub, or MPMAC’s officers, directors or employees, individually or in the aggregate, at law or in equity, or before or by any federal, state or other governmental department, court, commission, board, bureau, agency or instrumentality, domestic or foreign, and to the Knowledge of MPMAC, there is no reasonable basis for any proceeding, claim, action or governmental investigation directly or indirectly involving MPMAC, Merger Sub, or MPMAC’s officers, directors, or employees, individually or in the aggregate. Neither MPMAC nor Merger Sub are a party to any order, judgment or decree issued by any federal, state or other governmental department, court, commission, board, bureau, agency or instrumentality, domestic or foreign.

 

4.7          Subsidiaries.  Merger Sub is MPMAC’s only subsidiary, direct or indirect. MPMAC owns all of the outstanding shares of capital stock of Merger Sub and all such shares are duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights or encumbrances.

 

4.8          No Brokers or Finders.  None of MPMAC or any of its officers, directors, employees or Affiliates has employed any broker, finder, investment banker or investment advisor or Person performing a similar function, or incurred any liability for brokerage commissions, finders’ fees, investment advisory fees or similar compensation in connection with the transactions contemplated by this Agreement.

 

4.9          Tax Matters.

 

(a)           (i) MPMAC has timely filed or sent (or has had timely filed or sent on its behalf) all returns, declarations, reports, estimates, information returns, and statements, including any schedules and amendments to such documents (“MPMAC Returns”), required to be filed or sent by it in respect of any Taxes or required to be filed or sent by it by any applicable Taxing authority; (ii) all such MPMAC Returns are complete and accurate in all material respects; (iii) MPMAC has timely paid (or has had timely paid on its behalf) all Taxes required to have been paid by it; (iv) MPMAC has established on the MPMAC Latest Balance Sheet, in accordance with GAAP, reserves that are adequate for the payment of any Taxes not yet paid; (v) MPMAC has complied with all applicable laws, rules, and regulations relating to the collection or withholding of Taxes from third parties (including without limitation employees) and the payment thereof (including, without limitation, withholding of Taxes under Sections 1441 and 1442 of the Code, or similar provisions under any foreign laws).

 

(b)           To MPMAC’s Knowledge, there are no liens for Taxes upon any assets of MPMAC, except liens for Taxes not yet due.

 

26

 

(c)           No deficiency for any Taxes has been asserted, assessed or, to MPMAC’s Knowledge, proposed against MPMAC that has not been finally resolved or that is not being contested in good faith. No waiver, extension or comparable consent given by MPMAC regarding the application of the statute of limitations with respect to any Taxes or MPMAC Returns is outstanding, nor is any request for any such waiver or consent pending. There has been no Tax audit or other administrative proceeding or court proceeding with regard to any Taxes or MPMAC Returns, nor is any such Tax audit or other proceeding pending, nor has there been any notice to MPMAC by any Taxing authority regarding any such Tax audit or other proceeding, or, to the Knowledge of MPMAC, is any such Tax audit or other proceeding threatened with regard to any Taxes or MPMAC Returns. MPMAC does not expect the assessment of any additional Taxes of MPMAC for any period prior to the date hereof and has no Knowledge of any unresolved questions, claims or disputes concerning the liability for Taxes of MPMAC which would exceed the estimated reserves established on its books and records.

 

(d)           MPMAC is not a party to any agreement, contract or arrangement that would result, separately or in the aggregate, in the payment of any “excess parachute payments” within the meaning of Section 280G of the Code and the consummation of the transactions contemplated by this Agreement will not be a factor causing payments to be made by MPMAC not to be deductible (in whole or in part) under Section 280G of the Code. MPMAC is not liable for Taxes of any other Person, and is not currently under any contractual obligation to indemnify any Person with respect to Taxes, or a party to any Tax sharing agreement or any other agreement providing for payments by MPMAC with respect to Taxes. MPMAC is not a party to any joint venture, partnership or other arrangement or contract which could be treated as a partnership for federal income Tax purposes. MPMAC has not agreed and is not required, as a result of a change in method of accounting or otherwise, to include any adjustment under Section 481 of the Code (or any corresponding provision of state, local or foreign law) in Taxable income. MPMAC will not be required to include any item of income in Taxable income for any Taxable period (or portion thereof) ending after the Closing Date as a result of any (i) prepaid amount received on or prior to the Closing Date, or (ii) “closing agreement” described in Section 7121 of the Code (or any similar or corresponding provision of any other Tax law). MPMAC has no property, sales or payroll in any state creating a Tax nexus. No claim has ever been made by a Taxing authority in a jurisdiction where MPMAC does not currently file MPMAC Returns that MPMAC is or may be subject to Tax imposed by that jurisdiction. There are no advance rulings in respect of any Tax pending or issued by any Taxing authority with respect to any Taxes of MPMAC. MPMAC has not entered into any gain recognition agreements under Section 367 of the Code and the regulations promulgated thereunder. MPMAC is not liable with respect to any indebtedness the interest of which is not deductible for applicable federal, foreign, state or local income Tax purposes.

 

(e)           MPMAC has been neither a “distributing corporation” nor a “controlled corporation” (within the meaning of Section 355 of the Code) in a distribution of stock qualifying for tax-free treatment under Section 355 of the Code.

 

(f)            MPMAC has not requested any extension of time within which to file any MPMAC Return, which return has not since been filed.

 

27

 

4.10        Contracts and Commitments.  Except as contemplated herein, MPMAC is not a party to any contract, agreement, arrangement or other understanding, whether written or oral, which are currently in effect, and which relate to MPMAC or its business.

 

4.11        Affiliate Transactions.  No officer, director or employee of MPMAC, or any member of the immediate family of any such officer, director or employee, or any entity in which any of such persons owns any beneficial interest (other than any publicly-held corporation whose stock is traded on a national securities exchange, the Nasdaq Stock Market, or in an over-the-counter market and less than one percent of the stock of which is beneficially owned by any of such persons) (collectively “MPMAC Insiders”), has any agreement with MPMAC or any interest in any property, real, personal or mixed, tangible or intangible, used in or pertaining to the business of MPMAC. MPMAC is not indebted to any MPMAC Insider (except for reimbursement of ordinary business expenses) and no MPMAC Insider is indebted to MPMAC (except for cash advances for ordinary business expenses). No MPMAC Insider has any direct or indirect interest in any competitor, supplier or customer of MPMAC or in any person, firm or entity from whom or to whom MPMAC leases any property, or in any other person, firm or entity with whom MPMAC transacts business of any nature. For purposes of this Section 4.11, the members of the immediate family of an officer, director or employee shall consist of the spouse, parents, children or siblings of such officer, director or employee. Affiliates of MPMAC are stockholders of Radius as indicated in Schedule 3.4(b).

 

4.12        Compliance with Laws; Permits.

 

(a)           Except for any noncompliance that would not reasonably be expected to have a Material Adverse Effect on MPMAC, MPMAC and its officers, directors, agents and employees have complied with all applicable laws, regulations and other requirements, including, but not limited to, federal, state, local and foreign laws, ordinances, rules, regulations and other requirements pertaining to equal employment opportunity, employee retirement, affirmative action and other hiring practices, occupational safety and health, workers’ compensation, unemployment and building and zoning codes, and no claims have been filed against MPMAC, and MPMAC has not received any notice, alleging a violation of any such laws, regulations or other requirements. MPMAC is not relying on any exemption from or deferral of any such applicable law, regulation or other requirement that would not be available to Radius after it acquires MPMAC’s properties, assets and business.

 

(b)           MPMAC has no licenses, permits and certificates from federal, state, local and foreign authorities (including, without limitation, federal and state agencies regulating occupational health and safety), and none are necessary and material to its operations and business.

 

4.13        Validity of the MPMAC Capital Stock.  The shares of MPMAC Common Stock and MPMAC Preferred Stock to be issued to holders of Radius Common Stock or Radius Preferred Stock, respectively, pursuant to this Agreement will be, when issued, duly authorized, validly issued, fully paid and nonassessable and free of preemptive rights and encumbrances.

 

28

 

4.14        Books and Records.  The books of account, minute books, stock record books, and other records of MPMAC, complete copies of which have been made available to Radius, have been properly kept and contain no inaccuracies except for inaccuracies that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on MPMAC. At the Closing, all of MPMAC’s records will be in the possession of MPMAC.

 

4.15        Real Property.  MPMAC does not own or lease any real property.

 

4.16        Insurance.  MPMAC does not own or maintain any insurance policies.

 

4.17        No Undisclosed Liabilities.  Except as reflected in the unaudited consolidated balance sheet of MPMAC at [December 31, 2010] included in MPMAC’s Annual Report on Form 10-K for the year ended as on such date (the “MPMAC Latest Balance Sheet”), MPMAC has no liabilities (whether accrued, absolute, contingent, unliquidated or otherwise) except liabilities which have arisen after the date of the MPMAC Latest Balance Sheet in the ordinary course of business (none of which is a material uninsured liability) and except for no more than $10,000 of MPMAC Professional Fees.

 

4.18        Environmental Matters.  None of the operations of MPMAC involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260-270 or any state, local or foreign equivalent.

 

4.19        Absence of Certain Developments.  Except as disclosed in the MPMAC SEC Filings or as otherwise contemplated by this Agreement, since the date of the MPMAC Latest Balance Sheet, MPMAC has conducted its business only in the ordinary course consistent with past practice and there has not occurred or been entered into, as the case may be: (i) any event having a Material Adverse Effect on MPMAC, (ii) any event that would reasonably be expected to prevent or materially delay the performance of MPMAC’s obligations pursuant to this Agreement, (iii) any material change by MPMAC in its accounting methods, principles or practices, (iv) any declaration, setting aside or payment of any dividend or distribution in respect of the shares of capital stock of MPMAC or any redemption, purchase or other acquisition of any of MPMAC’s securities, (v) any increase in the compensation or benefits or establishment of any bonus, insurance, severance, deferred compensation, pension, retirement, profit sharing, stock option (including, without limitation, the granting of stock options, stock appreciation rights, performance awards or restricted stock awards), stock purchase or other employee benefit plan of MPMAC, or any other increase in the compensation payable or to become payable to any employees, officers, consultants or directors of MPMAC, (vi) any issuance, grants or sale of any stock, options, warrants, notes, bonds or other securities, or entry into any agreement with respect thereto by MPMAC, (vii) any amendment to the Certificate of Incorporation or Bylaws of MPMAC, (viii) other than in the ordinary course of business consistent with past practice, any (w) capital expenditures by MPMAC, (x) purchase, sale, assignment or transfer of any material assets by MPMAC, (y) mortgage, pledge or existence of any lien, encumbrance or charge on any material assets or properties, tangible or intangible of MPMAC, except for liens for Taxes not yet due and such other liens, encumbrances or charges which do not, individually or in the aggregate, have a Material Adverse Effect on MPMAC, or (z) cancellation, compromise, release or waiver by MPMAC of any rights of material value or any material debts or claims, (ix) any

 

29

 

incurrence by MPMAC of any material liability (absolute or contingent), except for current liabilities and obligations incurred in the ordinary course of business consistent with past practice, (x) damage, destruction or similar loss, whether or not covered by insurance, materially affecting the business or properties of MPMAC, (xi) entry by MPMAC into any agreement, contract, lease or license other than in the ordinary course of business consistent with past practice, (xii) any acceleration, termination, modification or cancellation of any agreement, contract, lease or license to which MPMAC is a party or by which any of them is bound, (xiii) entry by MPMAC into any loan or other transaction with any officers, directors or employees of MPMAC, (xiv) any charitable or other capital contribution by MPMAC or pledge therefore, (xv) entry by MPMAC into any transaction of a material nature other than in the ordinary course of business consistent with past practice, or (xvi) any negotiation or agreement by MPMAC to do any of the things described in the preceding clauses (i) through (xv).

 

4.20        Employee Benefit Plans.

 

(a)           MPMAC does not have any (i) “employee benefit plans,” within the meaning of Section 3(3) of ERISA, (ii) bonus, stock option, stock purchase, stock appreciation right, incentive, deferred compensation, supplemental retirement, severance, and fringe benefit plans, programs, policies or arrangements, or (iii) employment or consulting agreements, for the benefit of, or relating to, any current or former employee (or any beneficiary thereof) of MPMAC, in the case of a plan described in (i) or (ii) above, that is currently maintained by MPMAC or with respect to which MPMAC has an obligation to contribute, and in the case of an agreement described in (iii) above, that is currently in effect.

 

(b)           No director, officer, or employee of MPMAC will become entitled to retirement, severance or similar benefits or to enhanced or accelerated benefits (including any acceleration of vesting or lapsing of restrictions with respect to equity-based awards) solely as a result of consummation of the transactions contemplated by this Agreement.

 

4.21        Employees.  Except as disclosed in the MPMAC SEC Filings, MPMAC has no employees.

 

4.22        Proprietary Information and Inventions.  No current MPMAC employee, consultant, and advisory board member is party to either a non-disclosure agreement or an alternative employment agreement with MPMAC containing comparable non-disclosure provisions.

 

4.23        Intellectual Property.

 

(a)           MPMAC does not own or license the right to use any (i) Patents, (ii) Copyrights, (iii) Trademarks, (iv) Know-How, or (v) software (collectively, the “MPMAC Intellectual Property”).

 

(b)           To MPMAC’s Knowledge, MPMAC is not infringing upon the proprietary rights of any Person. There are no claims pending or, to MPMAC’s Knowledge,

 

30

 

threatened alleging that MPMAC is currently infringing upon or using in an unauthorized manner or violating the proprietary rights of any Person.

 

(c)           MPMAC is not, nor will it be as a result of the execution and delivery of this Agreement or the performance of its obligations under this Agreement, in breach of any license, sublicense or other Contract relating to Intellectual Property that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect on MPMAC.

 

4.24        Tax Free Reorganization.  Neither MPMAC nor, to MPMAC’s Knowledge, any of its Affiliates has taken or agreed to take any action that would prevent the Merger from qualifying as a reorganization under Section 368(a) of the Code.

 

4.25        Full Disclosure.  The representations and warranties of MPMAC and Merger Sub contained in this Agreement (and in any schedule, exhibit, certificate or other instrument to be delivered under this Agreement) are true and correct in all material respects, and such representations and warranties do not omit any material fact necessary to make the statements contained therein, in light of the circumstances under which they were made, not misleading. There is no fact of which MPMAC or Merger Sub has Knowledge that has not been disclosed to Radius pursuant to this Agreement, including the schedules hereto, all taken together as a whole, which has had or could reasonably be expected to have a Material Adverse Effect on MPMAC or Merger Sub, or materially adversely affect the ability of MPMAC or Merger Sub to consummate in a timely manner the transactions contemplated hereby.

 

ARTICLE V
 CONDUCT OF BUSINESS PENDING THE MERGER

 

5.1          Conduct of Business by MPMAC and Merger Sub.  From the date of this Agreement to the Effective Date, unless Radius shall otherwise agree in writing or as otherwise expressly contemplated or permitted by other provisions of this Agreement, including but not limited to this Section 5.1, neither MPMAC nor Merger Sub shall, directly or indirectly, (a) amend its Certificate of Incorporation or Bylaws, (b) split, combine or reclassify any outstanding shares of capital stock of MPMAC, (c) declare, set aside, make or pay any dividend or distribution in cash, stock, property or otherwise with respect to the capital stock of MPMAC, (d) default in its obligations under any material debt, contract or commitment which default results in the acceleration of obligations due thereunder, except for such defaults arising out of MPMAC’s entry into this Agreement for which consents, waivers or modifications are required to be obtained, (e) conduct its business other than in the ordinary course on an arms-length basis and in accordance in all material respects with all applicable laws, rules and regulations and MPMAC’s past custom and practice, (f) issue or sell any additional shares of, or options, warrants, conversions, privileges or rights of any kind to acquire any shares of, any of its capital stock, except in connection with the exercise or conversion of MPMAC securities outstanding on the date of this Agreement or payment of stock dividends, (g) acquire (by merger, exchange, consolidation, acquisition of stock or assets or otherwise) any corporation, partnership, joint venture or other business organization or division or material assets thereof or (h) make or change any material Tax elections, settle or compromise any material Tax liability or file any amended MPMAC Returns.

 

31

 

5.2          Conduct of Business by Radius.  From the date of this Agreement to the Effective Date, unless MPMAC shall otherwise agree in writing or except as set forth in Schedule 5.2 or otherwise expressly contemplated or permitted by other provisions of this Agreement, including but not limited to this Section 5.2, Radius shall not, directly or indirectly, (a) amend its Certificate of Incorporation or Bylaws, (b) split, combine or reclassify any outstanding shares of capital stock of Radius, (c) declare, set aside, make or pay any dividend or distribution in cash, stock, property or otherwise with respect to the capital stock of Radius, (d) default in its obligations under any material debt, contract or commitment which default results in the acceleration of obligations due thereunder, except for such defaults arising out of Radius’s entry into this Agreement for which consents, waivers or modifications are required to be obtained, (e) conduct its business other than in the ordinary course on an arms-length basis and in accordance in all material respects with all applicable laws, rules and regulations and Radius’s past custom and practice, (f) issue or sell any additional shares of, or options, warrants, conversions, privileges or rights of any kind to acquire any shares of, any of its capital stock, except in connection with exercise or conversion of Radius options or warrants outstanding on the date of this Agreement or the issuance of options authorized under the Stock Option Plan on the date of this Agreement, (g) acquire (by merger, exchange, consolidation, acquisition of stock or assets or otherwise) any corporation, partnership, joint venture or other business organization or division or material assets thereof or (h) make or change any material Tax elections, settle or compromise any material Tax liability or file any amended Radius Return.

 

ARTICLE VI
 ADDITIONAL COVENANTS AND AGREEMENTS

 

6.1          Governmental Filings.  Subject to the terms and conditions herein provided, each party will use all reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective as promptly as practicable the transactions contemplated by this Agreement. Each party will use all reasonable efforts and will cooperate with the other party in the preparation and filing, as soon as practicable, of all filings, applications or other documents required under applicable laws, including, but not limited to, the Exchange Act, to consummate the transactions contemplated by this Agreement. Prior to submitting each filing, application, registration statement or other document with the applicable regulatory authority, each party will, to the extent practicable, provide the other party with an opportunity to review and comment on each such application, registration statement or other document to the extent permitted by applicable law. Each party will use all reasonable efforts and will cooperate with the other party in taking any other actions necessary to obtain such regulatory or other approvals and consents at the earliest practicable time, including participating in any required hearings or proceedings.

 

6.2          Expenses.  Except as otherwise provided in this Agreement, all reasonable and documented costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by Radius.

 

32

 

6.3          Due Diligence; Access to Information; Confidentiality.

 

(a)           Between the date hereof and the Closing Date, Radius and MPMAC shall afford to the other party and their authorized representatives the opportunity to conduct and complete a due diligence investigation of the other party as described herein. In light of the foregoing, each party shall permit the other party full access on reasonable notice and at reasonable hours to its properties and shall disclose and make available (together with the right to copy) to the other party and its officers, employees, attorneys, accountants and other representatives (hereinafter collectively referred to as “Representatives”), all books, papers, and records relating to the assets, stock, properties, operations, obligations and liabilities of such party and its subsidiaries, including, without limitation, all books of account (including, without limitation, the general ledger), Tax records, minute books of directors’ and stockholders’ meetings, organizational documents, bylaws, contracts and agreements, filings with any regulatory authority, accountants’ work papers, litigation files (including, without limitation, legal research memoranda), attorney’s audit response letters, documents relating to assets and title thereto (including, without limitation, abstracts, title insurance policies, surveys, environmental reports, opinions of title and other information relating to the real and personal property), plans affecting employees, securities transfer records and stockholder lists, and any books, papers and records (collectively referred to herein as “Evaluation Material”) relating to other assets or business activities in which such party may have a reasonable interest, and otherwise provide such assistance as is reasonably requested in order that each party may have a full opportunity to make such investigation and evaluation as it shall reasonably desire to make of the business and affairs of the other party; provided, however, that the foregoing rights granted to each party shall, whether or not and regardless of the extent to which the same are exercised, in no way affect the nature or scope of the representations, warranties and covenants of the respective party set forth herein. In addition, each party and its Representatives shall cooperate fully (including providing introductions, where necessary) with such other party to enable the party to contact third parties, including customers, prospective customers, specified agencies or others as the party deems reasonably necessary to complete its due diligence; provided that such party agrees not to initiate such contacts without the prior approval of the other party, which approval will not be unreasonably withheld.

 

(b)           Radius and MPMAC agree that each such party will not use the Evaluation Material for any purpose other than in connection with the Merger and the transactions contemplated hereunder. Each agrees not to disclose or allow disclosure to others of any Evaluation Material, except to such party’s Affiliates or Representatives, in each case, to the extent necessary to permit such Affiliate or Representative to assist such party in connection with the Merger and the transactions contemplated hereunder. Each agrees that it will, within ten (10) days of the other party’s request, re-deliver to such party all copies of that party’s Evaluation Material in its possession or that of its Affiliates or Representatives if the Merger does not close as contemplated herein.

 

(c)           In the event any party or anyone to whom Evaluation Material has been transmitted in accordance with the terms herein is requested in connection with any proceeding to disclose any Evaluation Material, or a party has determined that it is required under applicable law or regulation to disclose Evaluation Material, such party will give the other party prompt notice of such request or determination so that the other party may seek an appropriate protective

 

33

 

order or other remedy or waive compliance with this Agreement, and such party will cooperate with the other party to obtain such protective order. In the event such protective order is not obtained, the other party waives compliance with the relevant provisions of this Section, such party (or such person to whom such request is directed) will furnish only that portion of the Evaluation Material which is required to be disclosed. The parties acknowledge that, upon execution and delivery, this Agreement (but not the exhibits and schedules thereto) will be filed by MPMAC with the SEC under cover of Form 8-K.

 

(d)           Notwithstanding any of the foregoing, if prior to Closing, for any reason, the transactions contemplated by this Agreement are not consummated, neither MPMAC nor Radius nor any of their Representatives shall disclose to third parties or otherwise use any Evaluation Material or other confidential information received from the other party in the course of investigating, negotiating, and performing the transactions contemplated by this Agreement; provided, however, that nothing shall be deemed to be confidential information which:

 

(i)            is or becomes generally available to the public other than as a result of a disclosure by such party, its affiliates or Representatives;

 

(ii)           was available to such party on a non-confidential basis prior to its disclosure;

 

(iii)          becomes available to such party on a non-confidential basis from a source other than the other party or its agents, advisors or Representatives;

 

(iv)          developed by such party independently of any disclosure by the other party; or

 

(v)           is disclosed in compliance with Section 6.3(c).

 

Nothing in this Section 6.3 shall prohibit the disclosure of information required to be made under federal or state securities laws. If any disclosure is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all reasonable efforts, acting in good faith, to agree upon a text for such disclosure which is satisfactory to both parties.

 

(e)           MPMAC and Radius each agree that money damages would not be sufficient to remedy any breach by the other party of this Section, and that, in addition to all other remedies, each party against which a breach of this Section has been committed shall be entitled to specific performance and injunctive or other equitable relief as a remedy of such breach.

 

6.4          Tax Treatment.  It is intended by the parties hereto that the Merger shall constitute a reorganization within the meaning of Section 368(a) of the Code. Each of the parties hereto adopts this Agreement as a “plan of reorganization” within the meaning of Treasury Regulation § 1.368-2(g) and 1.368-3(a). Both prior to and after the Closing, each party’s books and records shall be maintained, and all federal, state and local income Tax returns and schedules

 

34

 

thereto shall be filed in a manner consistent with the Merger being qualified as a reorganization under Section 368(a) of the Code (and comparable provisions of any applicable state or local laws); except to the extent the Merger is determined in a final administrative or judicial decision not to qualify as such a reorganization within the meaning of Code Section 368(a). Each of Radius and MPMAC and their respective Affiliates agree to provide the customary representations, assumptions and qualifications regarding the treatment of the Merger and this Agreement as a reorganization within the meaning of Section 368(a) of the Code.

 

6.5          Press Releases.  Radius and MPMAC shall agree with each other as to the form and substance of any press release or public announcement related to this Agreement or the transactions contemplated hereby; provided, however, that nothing contained herein shall prohibit either party, following notification to the other party, from making any disclosure which is required by law or regulation. If any such press release or public announcement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all reasonable efforts, acting in good faith, to agree upon a text for such disclosure which is satisfactory to both parties.

 

6.6          Securities Reports.  MPMAC shall timely file with the SEC all reports and other documents required to be filed under the Securities Act or Exchange Act. All such reports and documents (i) shall not, as of the date of such filing, contain any untrue statement of material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (ii) shall comply as to form, in all material respects, with the applicable rules and regulations of the SEC. MPMAC agrees to provide to Radius copies of all reports and other documents filed under the Securities Act or Exchange Act with the SEC by it between the date hereof and the Effective Date within two (2) days after the date such reports or other documents are filed with the SEC.

 

6.7          Private Placement.  Each of Radius and MPMAC shall take all necessary action on its part such that the issuance of the Merger Consideration to Radius stockholders constitutes a valid “private placement” under the Securities Act. Without limiting the generality of the foregoing, Radius shall (1) provide each Radius stockholder with a stockholder qualification questionnaire in the form reasonably acceptable to both MPMAC and Radius (a “Stockholder Questionnaire”) and (2) use its commercially reasonably best efforts to cause each Radius stockholder to truthfully attest that (i) such stockholder is acquiring the Merger Consideration for his, her or its sole account, for investment and not with a view to the resale or distribution thereof and (ii) that stockholder either (A) is an “accredited investor” as defined in Regulation D of the Securities Act, (B) has such knowledge and experience in financial and business matters that the stockholder is capable of evaluating the merits and risks of receiving the Merger Consideration, or (C) has appointed an appropriate person reasonably acceptable to both MPMAC and Radius to act as the stockholder’s purchaser representative in connection with evaluating the merits and risks of receiving the Merger Consideration.

 

6.8          Radius Stockholders’ Meeting; Materials to Stockholders.

 

(a)           Radius shall, in accordance with Section 251 of the DGCL and its certificate of incorporation and by-laws, duly call, give notice of, convene and hold a special

 

35

 

meeting of Radius Stockholders (the “Radius Stockholder Meeting”) as promptly as practicable after the date hereof for the purpose of considering and taking action upon this Agreement and the Merger. Alternatively, Radius shall use its best efforts to obtain, in lieu of holding the Radius Stockholder Meeting, the written consent of the number of Radius stockholders necessary under its Certificate of Incorporation, Bylaws and the DGCL to approve this Agreement and the Merger.

 

(b)           Radius shall as promptly as practicable following the date of this Agreement prepare and mail to Radius stockholders all information as may required to comply with the DGCL, the Securities Act and the Exchange Act.

 

6.9          No Solicitation.

 

(a)           Unless and until this Agreement shall have been terminated pursuant to Section 8.1, neither MPMAC nor its officers, directors or agents shall, directly or indirectly, encourage, solicit or initiate discussions or negotiations with, or engage in negotiations or discussions with, or provide non-public information to, any Person or group of Persons concerning any merger, sale of capital stock, sale of substantial assets or other business combination; provided, however, that MPMAC may engage in such discussion and provide such non-public information (subject to obtaining confidentiality agreements) in response to an unsolicited proposal from an unrelated party if the Board of Directors of MPMAC determines, in good faith, after consultation with counsel, that the failure to engage in such discussions and provide such non-public information (subject to obtaining confidentiality agreements) may constitute a breach of the fiduciary or legal obligations of the Board of Directors of MPMAC. MPMAC will promptly advise Radius if it receives a proposal or inquiry with respect to the matters described above.

 

(b)           Unless and until this Agreement shall have been terminated pursuant to Section 8.1, neither Radius nor its officers, directors or agents shall, directly or indirectly, encourage, solicit or initiate discussions or negotiations with, or engage in negotiations or discussions with, or provide non-public information to, any Person or group of Persons concerning any merger, sale of capital stock, sale of substantial assets or other business combination; provided, however, that Radius may engage in such discussion in response to any unsolicited proposal from an unrelated party if the Board of Directors of Radius determines, in good faith, after consultation with counsel, that the failure to engage in such discussions and provide such non-public information (subject to obtaining confidentiality agreements) may constitute a breach of the fiduciary or legal obligations of the Board of Directors of Radius. Radius will promptly advise MPMAC if it receives a proposal or inquiry with respect to the matters described above.

 

6.10        Failure to Fulfill Conditions.  In the event that either of the parties hereto determines that a condition to its respective obligations to consummate the transactions contemplated hereby cannot be fulfilled on or prior to the termination of this Agreement, it will promptly notify the other party.

 

36

 

6.11        Notification of Certain Matters.  On or prior to the Effective Date, each party shall give prompt notice to the other party of (i) the occurrence or failure to occur of any event or the discovery of any information, which occurrence, failure or discovery would be likely to cause any representation or warranty on its part contained in this Agreement to be untrue, inaccurate or incomplete after the date hereof in any material respect or, in the case of any representation or warranty given as of a specific date, would be likely to cause any such representation or warranty on its part contained in this Agreement to be untrue, inaccurate or incomplete in any material respect as of such specific date, and (ii) any material failure of such party to comply with or satisfy any covenant or agreement to be complied with or satisfied by it hereunder.

 

6.12        Customary Representations, Assumptions and Qualifications.  MPMAC and its respective Affiliates agree to provide the customary representations, assumptions and qualifications with respect to registration of the shares of MPMAC Common Stock and MPMAC Preferred Stock to be issued in the Merger under the Securities Act.

 

ARTICLE VII
 CONDITIONS

 

7.1          Conditions to Obligations of Each Party.  The respective obligations of each party to effect the transactions contemplated hereby are subject to the fulfillment or waiver at or prior to the Effective Date of the following conditions:

 

(a)           No Prohibitive Change of Law. There shall have been no law, statute, rule or regulation, domestic or foreign, enacted or promulgated which would prohibit or make illegal the consummation of the transactions contemplated hereby.

 

(b)           Stockholder Approvals. This Agreement and the Merger shall have been approved by the Requisite Radius Stockholder Vote.

 

(c)           Section 14(f) Compliance. Ten days shall have elapsed since an information statement containing the information required by Section 14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder has been filed with the SEC and transmitted to the stockholders of MPMAC in accordance with said Rule 14f-1.

 

(d)           Adverse Proceedings. There shall not be threatened, instituted or pending any action or proceeding before any court or governmental authority or agency (i) challenging or seeking to make illegal, or to delay or otherwise directly or indirectly restrain or prohibit, the consummation of the transactions contemplated hereby or seeking to obtain material damages in connection with such transactions, (ii) seeking to prohibit direct or indirect ownership or operation by MPMAC or Merger Sub of all or a material portion of the business or assets of Radius, or to compel MPMAC or Merger Sub or Radius to dispose of or to hold separately all or a material portion of the business or assets of MPMAC or Merger Sub or of Radius, as a result of the transactions contemplated hereby; (iii) seeking to invalidate or render unenforceable any material provision of this Agreement or any of the other agreements attached as exhibits hereto or contemplated hereby, or (iv) otherwise relating to and materially adversely affecting the transactions contemplated hereby.

 

37

 

(e)           Governmental Action. There shall not be any action taken, or any statute, rule, regulation, judgment, order or injunction proposed, enacted, entered, enforced, promulgated, issued or deemed applicable to the transactions contemplated hereby, by any federal, state or other court, government or governmental authority or agency, that would reasonably be expected to result, directly or indirectly, in any of the consequences referred to in Section 7.1(d).

 

(f)            Market Condition. There shall not have occurred any general suspension of trading on the New York Stock Exchange, the Nasdaq Stock Market, or any general bank moratorium or closing or any war, national emergency or other event affecting the economy or securities trading markets in any of the foregoing cases generally that would make completion of the Merger impossible.

 

(g)                       Recapitalization of Radius.  The Recapitalization (as such term is defined in that certain Series A-1 Convertible Preferred Stock Purchase Agreement by and among Radius and the Investors party thereto dated the date hereof (the “Radius Series A-1 Purchase Agreement”)) and the Stage I Closing (as such term is defined in the Radius Series A-1 Purchase Agreement) shall have been consummated.

 

7.2          Additional Conditions to Obligation of MPMAC and Merger Sub.  The obligation of MPMAC and Merger Sub to consummate the transactions contemplated hereby in accordance with the terms of this Agreement is also subject to the fulfillment or waiver of the following conditions:

 

(a)           Representations and Compliance. The representations of Radius contained in this Agreement were accurate as of the date of this Agreement and are accurate as of the Closing Date, in all respects (in the case of any representation containing any materiality qualification) or in all material respects (in the case of any representation without any materiality qualification), except for representations and warranties made as of a specific date, which shall be accurate as of such date. Radius shall in all material respects have performed each obligation and agreement and complied with each covenant to be performed and complied with by it hereunder at or prior to the Closing Date.

 

(b)           Officers’ Certificate. Radius shall have furnished to MPMAC and Merger Sub a certificate of the Chief Executive Officer and the Treasurer of Radius, dated as of the Effective Date, in which such officers shall certify that, to their best Knowledge, the conditions set forth in Section 7.2(a) have been fulfilled.

 

(c)           Secretary’s Certificate. Radius shall have furnished to MPMAC (i) copies of the text of the resolutions by which the corporate action on the part of Radius necessary to approve this Agreement, the Certificate of Merger and the transactions contemplated hereby and thereby were taken, (ii) a certificate dated as of the Closing Date executed on behalf of Radius by its corporate secretary or one of its assistant corporate secretaries certifying to MPMAC that such copies are true, correct and complete copies of such resolutions and that such resolutions were duly adopted and have not been amended or rescinded, (iii) an incumbency

 

38

 

certificate dated as of the Closing Date executed on behalf of Radius by its corporate secretary or one of its assistant corporate secretaries certifying the signature and office of each officer of Radius executing this Agreement, the Certificate of Merger or any other agreement, certificate or other instrument executed pursuant hereto by Radius, (iv) a copy of the Certificate of Incorporation of Radius, certified by the Secretary of State of Delaware, and a certificate from the Secretary of State of Delaware evidencing the good standing of Radius in such jurisdiction as of a day within three business days prior to the Closing Date.

 

(d)           Consents and Approvals. Radius shall have obtained all consents and approvals necessary to consummate the transactions contemplated by this Agreement, in order that the transactions contemplated herein not constitute a breach or violation of, or result in a right of termination or acceleration of, or creation of any encumbrance on any of Radius’s assets pursuant to the provisions of, any agreement, arrangement or undertaking of or affecting Radius or any license, franchise or permit of or affecting Radius.

 

(e)           Merger Certificate. Radius shall have executed a copy of the Certificate of Merger.

 

(f)            Stockholder Questionnaire. Each of the Radius stockholders shall have executed and delivered to MPMAC a completed Stockholder Questionnaire that is accurate in all material respects and contains the attestations contemplated in clause (2) of Section 6.7.

 

(g)           Indemnification of MPMAC Officers and Directors.  Each of the Indemnity Agreements between MPMAC and each of its current and former officers and directors shall be in full force and effect.

 

(h)           Securities Law Opinion.  Bingham McCutchen LLP, as counsel to MPMAC, shall have issued an opinion, which opinion may be based on customary representations from Radius, MPMAC and their respective stockholders and Affiliates and subject to customary assumptions and qualifications, to the effect that it is not necessary to register the shares of MPMAC Common Stock and MPMAC Preferred Stock to be issued in the Merger under the Securities Act in connection with such issuance in the Merger.

 

7.3          Additional Conditions to Obligation of Radius.  The obligation of Radius to consummate the transactions contemplated hereby in accordance with the terms of this Agreement is also subject to the fulfillment or waiver of the following conditions:

 

(a)           Representations And Compliance. The representations of MPMAC and Merger Sub contained in this Agreement were accurate as of the date of this Agreement and are accurate as of the Effective Time, in all respects (in the case of any representation containing any materiality qualification) or in all material respects (in the case of any representation without any materiality qualification), except for representations and warranties made as of a specific date, which shall be accurate as of such date. MPMAC and Merger Sub, respectively, shall in all material respects have performed each obligation and agreement and complied with each covenant to be performed and complied with by them hereunder at or prior to the Effective Date.

 

39

 

(b)           Officers’ Certificate. MPMAC shall have furnished to Radius a certificate of the Chief Executive Officer and the Chief Financial Officer of MPMAC, dated as of the Effective Date, in which such officers shall certify that, to their best Knowledge, the conditions set forth in Section 7.3(a) have been fulfilled.

 

(c)           Secretary’s Certificate. MPMAC shall have furnished to Radius (i) copies of the text of the resolutions by which the corporate action on the part of MPMAC necessary to approve this Agreement and the Certificate of Merger, the election of the directors of MPMAC to serve following the Closing Date and the transactions contemplated hereby and thereby were taken, which shall be accompanied by a certificate of the corporate secretary or assistant corporation secretary of MPMAC dated as of the Closing Date certifying to Radius that such copies are true, correct and complete copies of such resolutions and that such resolutions were duly adopted and have not been amended or rescinded, (ii) an incumbency certificate dated as of the Closing Date executed on behalf of MPMAC by its corporate secretary or one of its assistant corporate secretaries certifying the signature and office of each officer of MPMAC executing this Agreement, the Certificate of Merger or any other agreement, certificate or other instrument executed pursuant hereto, and (iii) a copy of the Certificate of Incorporation of MPMAC, certified by the Secretary of State of Delaware, and certificates from the Secretary of State of Delaware evidencing the good standing of MPMAC in such jurisdiction as of a day within three business days prior to the Closing Date.

 

(d)           Consents and Approvals. MPMAC and Merger Sub shall have obtained all consents and approvals necessary to consummate the transactions contemplated by this Agreement in order that the transactions contemplated herein not constitute a breach or violation of, or result in a right of termination or acceleration of, or creation of any encumbrance on any of MPMAC’s or Merger Sub’s assets pursuant to the provisions of, any agreement, arrangement or undertaking of or affecting MPMAC or any license, franchise or permit of or affecting MPMAC.

 

(e)           MPMAC Certificate of Designation. MPMAC shall have filed the Certificate of Designations and such filing shall have been accepted by the Secretary of State of the State of Delaware.

 

(f)            Resignations. Each of the non-continuing officers and non-continuing directors of MPMAC immediately prior to the Effective Time shall deliver duly executed resignations from their positions with MPMAC effective immediately after the Effective Time.

 

(g)           MPMAC Liabilities. Except for MPMAC Professional Fees (which MPMAC Professional Fees shall not exceed $10,000), MPMAC shall have no liabilities.

 

(h)        Dissenters’ Rights. Holders of no more than [ten (10)] percent of the outstanding shares of Radius Common Stock and Radius Preferred Stock, respectively, shall have validly exercised, or remained entitled to exercise, their appraisal rights under Section 262 of the DGCL.

 

40

 

(j)            Indemnification of Radius Officers and Directors.  Each of the Indemnity Agreements between Radius and each of its current and former officers and directors shall be in full force and effect.

 

(k)           Tax Opinion. Bingham McCutchen LLP, counsel to Radius, shall have issued an opinion, which opinion may be based on customary representations from Radius, MPMAC and their respective Affiliates and subject to customary assumptions and qualifications, to the effect that for federal income tax purposes: (i) the Merger will qualify as a reorganization under Section 368(a) of the Code; and (ii) Radius, MPMAC and Merger Sub will each be a party to the reorganization within the meaning of Section 368(b) of the Code.

 

ARTICLE VIII
 TERMINATION

 

8.1          Termination.  This Agreement may be terminated prior to the Effective Date:

 

(a)           by mutual consent of Radius and MPMAC, if the Board of Directors of each so determines by vote of a majority of the members of its entire board;

 

(b)           by MPMAC, if any representation of Radius set forth in this Agreement was inaccurate when made or becomes inaccurate such that the condition set forth in Section 7.2(a) could not be satisfied;

 

(c)           by Radius, if any representation of MPMAC set forth in this Agreement was inaccurate when made or becomes inaccurate such that the condition set forth in Section 7.3(a) could not be satisfied;

 

(d)           by MPMAC, if Radius fails to perform or comply with any of the obligations that it is required to perform or to comply with under this Agreement such that the condition set forth in Section 7.2(a) could not be satisfied;

 

(e)           by Radius, if MPMAC fails to perform or comply with any of the obligations that it is required to perform or to comply with under this Agreement such that the condition set forth in Section 7.3(a) could not be satisfied;

 

(f)            by Radius, if, following a vote by the stockholders of Radius at the Radius Stockholder Meeting or following a solicitation for written consent of the stockholders of Radius in lieu of the Radius Stockholder Meeting, the Merger and this Agreement are not duly approved by the stockholders of Radius;

 

(g)           by either Radius or MPMAC if the Closing Date is not on or before September 30, 2011 or such later date as Radius and MPMAC may mutually agree (except that a party seeking to terminate this Agreement pursuant to this clause may not do so if the failure to consummate the Merger by such date shall be due to the action or failure to act of the party seeking to terminate this Agreement in breach of such party’s obligations under this Agreement);

 

41

 

(h)           by MPMAC if, after complying with Section 6.9(a) and affording Radius ten (10) business days notice of its proposal to enter into an agreement with a third party for a transaction of a nature specified in Section 6.9(a) (and, if Radius so elects, after good faith negotiations with Radius during such ten business day period, to attempt to make adjustments in the terms and conditions of this Agreement as would enable MPMAC to proceed with the Merger), the Board of Directors of MPMAC shall have concluded that such third party offer is superior to the provisions of this Agreement, after considering any revised offer made by Radius; and

 

(i)            by Radius if, after complying with Section 6.9(b) and affording MPMAC ten (10) business days notice of its proposal to enter into an agreement with a third party for a transaction of a nature specified in Section 6.9(b) (and, if MPMAC so elects, after good faith negotiations with MPMAC during such ten business day period to attempt to make adjustments in the terms and conditions of this Agreement as would enable Radius to proceed with the Merger), the Board of Directors of Radius shall have concluded that such third party offer is superior to the provisions of this Agreement, after considering any revised offer made by MPMAC.

 

8.2          Effect of Termination.  If this Agreement is terminated pursuant to Section 8.1 hereof, then (a) this Agreement shall become void and have no effect whatsoever, except that the provisions of Article I (“Definitions”), this Article VIII (“Termination”), Article IX (“General Provisions”) and Section 6.2 (“Expenses”) shall survive any such termination, (b) no party hereto shall have any liability hereunder arising from any breach by such party of any provision of this Agreement if such breach occurred prior to such termination, (c) each party will redeliver all documents, work papers and other material of the other party or parties relating to the transactions contemplated hereby including such memoranda, notes, lists, records or other documents compiled or derived from such material, whether so obtained before or after the execution hereof, to the party furnishing the same and (d) all information received by any party hereto with respect to the business of the other parties or their affiliated companies shall remain subject to the terms of Section 6.3(b) - (e) hereof.

 

ARTICLE IX
 GENERAL PROVISIONS

 

9.1          Notices.  All notices and other communications hereunder shall be in writing and shall be sufficiently given if made by hand delivery, by telecopier, by overnight delivery service for next business day delivery, or by registered or certified mail (return receipt requested), in each case with delivery charges prepaid, to the parties at the following addresses (or at such other address for a party as shall be specified by it by like notice):

 

	
If to Radius:
    	
 
    	
Radius   Health, Inc.
    
	
 
    	
 
    	
201   Broadway, 6th floor
    
	
 
    	
 
    	
Cambridge,   MA  02139
    
	
 
    	
 
    	
Attn:   Richard Lyttle
    

 

42

 

	
With copies to:
    	
 
    	
Bingham   McCutchen LLP
    
	
 
    	
 
    	
One   Federal Street
    
	
 
    	
 
    	
Boston,   MA 02110
    
	
 
    	
 
    	
Facsimile:   617-951-8736
    
	
 
    	
 
    	
Telephone:   617-951-8000
    
	
 
    	
 
    	
Attn:   Julio E. Vega, Esq. and Matthew J. Cushing, Esq.
    
	
 
    	
 
    	
 
    
	
If to MPMAC
    	
 
    	
MPM Acquisition Corp.
    
	
or Merger Sub:
    	
 
    	
MPM Asset Management LLC
    
	
 
    	
 
    	
300   Technology Square, Fifth Floor
    
	
 
    	
 
    	
Cambridge,   MA 02139
    
	
 
    	
 
    	
Facsimile:   617-551-4701
    
	
 
    	
 
    	
Telephone:   617-551-4700
    
	
 
    	
 
    	
Attn:   Nick Harvey
    

 

All such notices and other communications shall be deemed to have been duly given as follows: when delivered by hand, if personally delivered, when received; (i) if delivered by registered or certified mail (return receipt requested), when receipt acknowledged; or (ii) if telecopied, on the day of transmission or, if that day is not a business day, on the next business day; and the next business day delivery after being timely delivered to a recognized overnight delivery service.

 

9.2          No Survival.  The representations and warranties and obligations contained in this Agreement will terminate at the Effective Time or on termination of this Agreement in accordance with Section 8.1, except that, if the Effective Time occurs, the obligations contained in Article II and any other obligation contained in this Agreement requiring performance or compliance after the Effective Time (including without limitation Section 6.3(d)) will survive the Effective Time indefinitely.

 

9.3          Interpretation.  The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. References to Sections and Articles refer to Sections and Articles of this Agreement unless otherwise stated. Words such as “herein,” “hereinafter,” “hereof,” “hereto,” “hereby” and “hereunder,” and words of like import, unless the context requires otherwise, refer to this Agreement (including the Schedules hereto). As used in this Agreement, the masculine, feminine and neuter genders shall be deemed to include the others if the context requires.

 

9.4          Severability.  If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties shall negotiate in good faith to modify this Agreement and to preserve each party’s anticipated benefits under this Agreement.

 

43

 

9.5          Amendment.  This Agreement may not be amended or modified except by an instrument in writing approved by the parties to this Agreement and signed on behalf of each of the parties hereto.

 

9.6          Waiver.  At any time prior to the Effective Date, any party hereto may (a) extend the time for the performance of any of the obligations or other acts of the other party hereto or (b) waive compliance with any of the agreements of the other party or with any conditions to its own obligations, in each case only to the extent such obligations, agreements and conditions are intended for its benefit. Any such extension or waiver shall only be effective if made in writing and duly executed by the party giving such extension or waiver.

 

9.7          Miscellaneous.  This Agreement (together with all other documents and instruments referred to herein): (a) constitutes the entire agreement, and supersedes all other prior agreements and undertakings, both written and oral, among the parties, with respect to the subject matter hereof; and (b) shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, but shall not be assignable by either party hereto without the prior written consent of the other party hereto.

 

9.8          Counterparts.  This Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.

 

9.9          Third Party Beneficiaries.  Each party hereto intends that this Agreement, except as expressly provided herein, shall not benefit or create any right or cause of action in or on behalf of any person other than the parties hereto.

 

9.10        Governing Law.  This Agreement is governed by the internal laws of the State of Delaware without regard to such State’s principles of conflicts of laws that would defer to the substantive laws of another jurisdiction.

 

9.11        Jurisdiction; Service of Process.  Any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement must, to the extent such courts will accept such jurisdiction, be brought against any of the parties in the courts of the State of Delaware, or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware, and each of the parties consents to the jurisdiction of those courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein. Process in any such action or proceeding may be served by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section 9.1. Nothing in this Section 9.11, however, affects the right of any party to serve legal process in any other manner permitted by law.

 

9.12        Disclosure in Schedules.  For purposes of this Agreement, with respect to any matter that is clearly disclosed on any Schedule hereto with respect to any Section hereof in such a way as to make its relevance to the information called for by another Section hereof or any other Schedule, as the case may be, reasonably apparent, such matter shall be deemed to have been disclosed in response to such other Section or Schedule, notwithstanding the omission of

 

44

 

any appropriate cross-reference thereto; provided, however, that each of MPMAC and Radius hereby covenants to make a good faith diligent effort to make all appropriate cross-references within and to any and all Sections of this Agreement and Schedules hereto.

 

[Remainder of Page Left Intentionally Blank - Signature Page to Follow]

 

45

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed on the date first written above by their respective officers.

 

 

	
 
    	
RADIUS HEALTH, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   C. Richard Lyttle
    
	
 
    	
 
    	
Name:
    	
C.   Richard Lyttle
    
	
 
    	
 
    	
Title:
    	
President
    

 

 

	
 
    	
MPM ACQUISITION CORP.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   C. Richard Lyttle
    
	
 
    	
 
    	
Name:
    	
C.   Richard Lyttle
    
	
 
    	
 
    	
Title:
    	
President
    

 

 

	
 
    	
RHI MERGER CORP.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   C. Richard Lyttle
    
	
 
    	
 
    	
Name:
    	
C.   Richard Lyttle
    
	
 
    	
 
    	
Title:
    	
President
    

 

Signature Page to

Agreement and Plan of Merger

 

46

 

Exhibit A

 

 

CERTIFICATE OF MERGER

 

MERGING

 

RHI MERGER CORP.

(a Delaware corporation)

 

WITH AND INTO

 

RADIUS HEALTH, INC.

(a Delaware corporation)

 

Pursuant to Section 251 of the General Corporation Law of the State of Delaware, the undersigned corporation, which is organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that:

 

FIRST:  The name and state of incorporation of the constituent corporations are: (a) RHI Merger Corp., a corporation organized and existing under the laws of the State of Delaware (“Merger Sub”) and (b) Radius Health, Inc., a corporation organized and existing under the laws of the State of Delaware (together with Merger Sub, the “Constituent Corporations”).

 

SECOND:  An Agreement and Plan of Merger by and among MPM Acquisition Corp., a Delaware corporation (“MPMAC”), and the Constituent Corporations, dated as of April 25, 2011, (the “Merger Agreement”), has been approved, adopted, certified, executed and acknowledged by each of the Constituent Corporations in accordance with the requirements of Section 251(c) of the General Corporation Law of the State of Delaware.

 

THIRD:  The name of the surviving corporation is Radius Health, Inc. (the “Surviving Corporation”).

 

FOURTH:  The Certificate of Incorporation of the Surviving Corporation is amended and restated in its entirety to read as set forth in Exhibit A hereto.

 

FIFTH:  The executed Merger Agreement is on file at the principal place of business of the Surviving Corporation at  201 Broadway, 6th Floor, Cambridge, MA 02139.

 

SIXTH:  A copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of either Constituent Corporation.

 

SEVENTH:  The merger is to become effective on the date and time of filing of this Certificate of Merger.

 

[The remainder of this page is intentionally left blank.]

 

 

IN WITNESS WHEREOF, the undersigned has caused this Certificate of Merger to be executed as of the        day of May, 2011.

 

	
 
    	
 
    	
RADIUS HEALTH, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
RHI MERGER CORP.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
Title:
    	
 
    

 

 

Exhibit A

 

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

RADIUS HEALTH, INC.

 

FIRST:  The name of the corporation is:

 

Radius Health, Inc.

 

SECOND:  The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19808.  The name of its registered agent at such address is The Corporation Trust Company.

 

THIRD:  The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (the “DGCL”) and to possess and employ all powers and privileges now or hereafter granted or available under the laws of the State of Delaware to such corporations.

 

FOURTH:  The total number of shares of capital stock which the corporation shall have authority to issue is One Thousand (1,000), all of which shall be common stock, and the par value of each such share is $0.0001.

 

FIFTH:  The following provisions are inserted for the management of the business and for the conduct of the affairs of the corporation and for defining and regulating the powers of the corporation and its directors and stockholders and are in furtherance and not in limitation of the powers conferred upon the corporation by statute:

 

(a)                                  The election of directors need not be by written ballot, unless the by-laws of the corporation so provide.

 

(b)                                 The Board of Directors shall have the power and authority:

 

(1)                                  to adopt, amend or repeal by-laws of the corporation, subject only to such limitation, if any, as may be from time to time imposed by law or by the by-laws; and

 

(2)                                  to the full extent permitted or not prohibited by law, and without the consent of or other action by the stockholders, to authorize or create mortgages, pledges or other liens or encumbrances upon any or all of the assets, real, personal or mixed, and franchises of the corporation, including after-acquired property, and to exercise all of the powers of the corporation in connection therewith; and

 

(3)                                  subject to any provision of the by-laws, to determine whether, to what extent, at what times and places and under what conditions and regulations the accounts, books and papers of the corporation (other than the stock ledger), or any of them, shall be open to the inspection of the stockholders, and no stockholder shall have

 

A-1

 

any right to inspect any account, book or paper of the corporation except as conferred by statute or authorized by the by-laws or by the Board of Directors.

 

SIXTH:  The corporation is to have perpetual existence.

 

SEVENTH:  The corporation shall indemnify its officers, directors, employees and agents to the greatest extent permitted by the DGCL. No director of the corporation shall be personally liable to the corporation or to any of its stockholders for monetary damages for breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability; provided, however, that to the extent required from time to time by applicable law, this Article Seventh shall not eliminate or limit the liability of a director, to the extent such liability is provided by applicable law, (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of Title 8 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.  No amendment to or repeal of this Article Eighth shall apply to or have any effect on the liability or alleged liability of any director for or with respect to any acts or omissions of such director occurring prior to the effective date of such amendment or repeal.

 

EIGHTH: Meetings of the stockholders may be held within or without the State of Delaware, as the by-laws may provide. The books of the corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the by-laws of the corporation.

 

NINTH:  The corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.

 

A-2

 

Exhibit B

 

 

CERTIFICATE OF DESIGNATIONS

OF THE

SERIES A-1 CONVERTIBLE PREFERRED STOCK,

SERIES A-2 CONVERTIBLE PREFERRED STOCK,

SERIES A-3 CONVERTIBLE PREFERRED STOCK,

SERIES A-4 CONVERTIBLE PREFERRED STOCK,

SERIES A-5 CONVERTIBLE PREFERRED STOCK,

and

SERIES A-6 CONVERTIBLE PREFERRED STOCK

OF

MPM ACQUISITION CORP.

 

Pursuant to Section 151 of the General Corporation Law of the State of Delaware, the undersigned corporation submits the following statement for the purpose of establishing and designating several series of shares and fixing and determining the relative rights and preferences thereof:

 

1.             The name of the Corporation is MPM ACQUISITION CORP., a Delaware corporation (the “Corporation”).

 

2.             The Corporation’s Board of Directors (the “Board of Directors”) duly adopted the following resolution by Unanimous Written Consent of the Board of Directors dated May 16, 2011:

 

WHEREAS, the Corporation’s directors have reviewed and approved the Certificate of Designations (“Certificate of Designations”), attached hereto and incorporated herein by reference, delineating the number of shares, the voting powers, designations, preferences and relative, participating, optional, redemption, conversion, exchange, dividend or other special rights and qualifications, limitations or restrictions of several series of Preferred Stock to be issued by the Corporation and designated as Series A-1 Convertible Preferred Stock, par value $.0001 per share (the “Series A-1 Stock”), Series A-2 Convertible Preferred Stock, par value $.0001 per share (the “Series A-2 Stock”), Series A-3 Convertible Preferred Stock, par value $.0001 per share, (the “Series A-3 Stock” and together with the Series A-1 Stock and Series A-2 Stock, the “Participating Preferred Stock”), Series A-4 Convertible Preferred Stock, par value $.0001 per share (the “Series A-4 Stock”), Series A-5 Convertible Preferred Stock, par value $.0001 per share (the “Series A-5 Stock”) and Series A-6 Convertible Preferred Stock, par value $.0001 per share (the “Series A-6 Stock”, and together with the Series A-1 Stock, the Series A-2 Stock, the Series A-3 Stock, the Series A-4 Stock and the Series A-5 Stock, the “Preferred Stock”); now, therefore, be it

 

RESOLVED, that the President or any Vice President of the Corporation, individually or collectively, be, and such officers hereby are, authorized and directed to execute, acknowledge, attest, record and file with the Secretary of State of the State of Delaware the Certificate of Designation in accordance with the Delaware General Corporation Law and to take all other actions that such officers deem necessary to effectuate this Certificate of Designations.

 

2

 

1.     Designation and Amount.  The number of shares, powers, terms, conditions, designations, preferences and privileges, relative, participating, optional and other special rights, and qualifications, limitations and restrictions, if any, of the Corporation’s Preferred Stock shall be as set forth herein. The number of authorized shares of the Series A-1 Stock is One Million (1,000,000), the number of authorized shares of the Series A-2 Stock is Nine Hundred Eighty-three Thousand Two Hundred Thirteen (983,213), the number of authorized shares of the Series A-3 Stock is One Hundred Forty-two Thousand Two Hundred Thirty (142,230), the number of authorized shares of the Series A-4 Stock is Four Thousand (4,000), the number of authorized shares of the Series A-5 Stock is Seven Thousand (7,000) and the number of authorized shares of the Series A-6 Stock is Eight Hundred Thousand (800,000).

 

2.     Ranking.  As to dividends (other than with respect to the payment of the Series A-5 Accruing Dividend which shall rank senior in payment to any other dividends payable on any and all series of Preferred Stock) and upon Liquidation (as defined in Section 4(b) hereof) or an Event of Sale (as defined in Section 5 hereof), each share of Series A-1 Stock shall rank equally with each other share of Series A-1 Stock and senior to all shares of Series A-2 Stock, Series A-3 Stock, Series A-4 Stock, Series A-5 Stock and Series A-6 Stock and senior to all shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the Effective Time, except as otherwise approved by the affirmative vote or consent of the holders of shares of Series A-1 Stock, Series A-2 Stock and/or Series A-3 Stock representing at least 70% of the voting power of the shares of Series A-1 Stock, Series A-2 Stock and Series A-3 Stock then outstanding (the “Senior Majority”); each share of Series A-2 Stock shall rank equally with each other share of Series A-2 Stock and senior to all shares of Series A-3 Stock, Series A-4 Stock, Series A-5 Stock and Series A-6 Stock and senior to all shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the Effective Time, except as otherwise approved by the affirmative vote or consent of the Senior Majority; each share of Series A-3 Stock, Series A-5 Stock and Series A-6 Stock shall rank equally with each other share of Series A-3 Stock, Series A-5 and Series A-6 Stock and senior to all shares of Series A-4 Stock and shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the Effective Time, except as otherwise approved by the affirmative vote or consent of the Senior Majority. Each share of Series A-4 Stock, shall rank equally with each other share of Series A-4 Stock and senior to all shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the Effective Time, except as otherwise approved by the affirmative vote or consent of the Senior Majority.

 

3.     Dividend Provisions.

 

(a)       Series A-1 Stock.  The holders of shares of Series A-1 Stock shall be entitled to receive a per share dividend at the rate of 8% of the Series A-1 Original Purchase Price (as defined in Section 8 hereof) per annum, compounding annually (the “Series A-1 Accruing Dividend”), and which will accrue on a quarterly basis commencing on the date of issuance of such share of Series A-1 Stock. The holders of Series A-1 Stock shall be entitled to receive dividends prior in right to the payment of dividends and other distributions (whether in cash, property or securities of the Corporation, including subscription or other rights to acquire securities of the Corporation) on the Series A-2 Stock, Series A-3 Stock, Series A-4 Stock, Series A-5 Stock, Series A-6 Stock and Common Stock, but not with respect to the payment of the Series A-5

 

3

 

Special Accruing Dividend, as set forth in Section 3(d) below, which shall rank senior in payment to any dividends payable with respect to the Series A-1 Stock.  Any dividends with respect to the Series A-1 Stock shall be payable, at the sole discretion of the Board of Directors, in cash or the issuance of that number of shares of Common Stock equal to the quotient obtained by dividing (x) the amount of such accrued and unpaid dividends thereon by (y) the Current Market Price of a share of Common Stock, when as and if declared or paid by the Board of Directors and, as accrued, on any Liquidation (as defined in Section 4(b) hereof) or Event of Sale (as defined in Section 5 hereof). Dividends with respect to the Series A-1 Stock shall be payable in shares of Common Stock (calculated based upon the then effective Series A-1 Conversion Price), as accrued, upon the conversion of the Series A-1 Stock into Common Stock.  Whenever any dividend may be declared or paid on any share of Series A-1 Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each other share of the Series A-1 Stock then outstanding, so that all outstanding shares of Series A-1 Stock will participate equally with each other and ratably per share (calculated as provided in Section 3(f) hereof).  Whenever any dividend or other distribution, whether in cash or property or in securities of the Corporation (or subscription or other rights to purchase or acquire securities of the Corporation), may be declared or paid on: (i) any shares of the Common Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each share of the Series A-1 Stock then outstanding so that all outstanding shares of Series A-1 Stock will participate in such dividend ratably with such shares of Common Stock (calculated as provided in Section 3(e) hereof); or (ii) any shares of any other series of Preferred Stock (other than the Series A-2 Accruing Dividend, the Series A-3 Accruing Dividend, and the Series A-5 Special Accruing Dividend (as defined in Section 3(d) hereof)), the Board of Directors shall also declare and pay a dividend on the same terms, at the same or equivalent rate upon each share of the Series A-1 Stock then outstanding so that all outstanding shares of Series A-1 Stock will participate in such dividend ratably with such shares of such other series of Preferred Stock (based on the number of shares of Common Stock into which each share of Series A-1 Stock and each share of such other series of Preferred Stock is then convertible, if applicable, or, otherwise, the relative liquidation preference per share, of such other series of Preferred Stock as compared with the Series A-1 Stock then outstanding).

 

(b)       Series A-2 Stock.  The holders of shares of Series A-2 Stock shall be entitled to receive a per share dividend at the rate of 8% of the Series A-2 Original Purchase Price (as defined in Section 8 hereof) per annum, compounding annually (the “Series A-2 Accruing Dividend”), and which will accrue on a quarterly basis commencing on the date of issuance of such share of Series A-2 Stock. The holders of Series A-2 Stock shall be entitled to receive dividends prior in right to the payment of dividends and other distributions (whether in cash, property or securities of the Corporation, including subscription or other rights to acquire securities of the Corporation) on the Series A-3 Stock, Series A-4 Stock, Series A-5 Stock, Series A-6 Stock and Common Stock, but not with respect to the payment of the Series A-5 Special Accruing Dividend, as set forth below in Section 3(d) below, which shall rank senior in payment to any dividends payable with respect to the Series A-2 Stock.  Any dividends with respect to the Series A-2 Stock shall be payable, at the sole discretion of the Board of Directors, in cash or the issuance of that number of shares of Common Stock equal to the quotient obtained by dividing (x) the amount of such accrued and unpaid dividends thereon by (y) the then fair market value of a share of Common Stock, when as and if declared or paid by the Board of Directors and, as accrued, on any Liquidation or Event of Sale. Dividends with respect to the Series A-2 Stock shall be payable

 

4

 

in shares of Common Stock (calculated based upon the then effective Series A-2 Conversion Price), as accrued, upon the conversion of the Series A-2 Stock into Common Stock.  Whenever any dividend may be declared or paid on any share of Series A-2 Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each other share of the Series A-2 Stock then outstanding, so that all outstanding shares of Series A-2 Stock will participate equally with each other and ratably per share (calculated as provided in Section 3(f) hereof).  Whenever any dividend or other distribution, whether in cash or property or in securities of the Corporation (or subscription or other rights to purchase or acquire securities of the Corporation), may be declared or paid on: (i) any shares of the Common Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each share of the Series A-2 Stock then outstanding so that all outstanding shares of Series A-2 Stock will participate in such dividend ratably with such shares of Common Stock (calculated as provided in Section 3(d) hereof); or (ii) any shares of any other series of Preferred Stock (other than the Series A-1 Accruing Dividend, the Series A-3 Accruing Dividend and the Series A-5 Special Accruing Dividend), the Board of Directors shall also declare and pay a dividend on the same terms, at the same or equivalent rate upon each share of the Series A-2 Stock then outstanding so that all outstanding shares of Series A-2 Stock will participate in such dividend ratably with such shares of such other series of Preferred Stock (based on the number of shares of Common Stock into which each share of Series A-2 Stock and each share of such other series of Preferred Stock is then convertible, if applicable, or, otherwise, the relative liquidation preference per share, of such other series of Preferred Stock as compared with the Series A-2 Stock then outstanding).

 

(c)       Series A-3 Stock.  The holders of shares of Series A-3 Stock shall be entitled to receive a per share dividend at the rate of 8% of the Series A-3 Original Purchase Price (as defined in Section 8 hereof) per annum, compounding annually (the “Series A-3 Accruing Dividend”), and which will accrue on a quarterly basis commencing on the date of issuance of such share of Series A-3 Stock. The holders of Series A-3 Stock shall be entitled to receive dividends prior in right to the payment of dividends and other distributions (whether in cash, property or securities of the Corporation, including subscription or other rights to acquire securities of the Corporation) on the Series A-4 Stock, Series A-5 Stock, Series A-6 Stock and Common Stock, but not with respect to the payment of the Series A-5 Special Accruing Dividend as set forth below in Section 3(d) below, which shall rank senior in payment to any dividends payable with respect to the Series A-3 Stock.  Any dividends with respect to the Series A-3 Stock shall be payable, at the sole discretion of the Board of Directors, in cash or the issuance of that number of shares of Common Stock equal to the quotient obtained by dividing (x) amount of such accrued and unpaid dividends thereon by (y) the then fair market value of a share of Common Stock, when as and if declared or paid by the Board of Directors and, as accrued, on any Liquidation) or Event of Sale. Dividends with respect to the Series A-3 Stock shall be payable in shares of Common Stock (calculated based upon the then effective Series A-3 Conversion Price), as accrued, upon the conversion of the Series A-3 Stock into Common Stock.  Whenever any dividend may be declared or paid on any share of Series A-3 Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each other share of the Series A-3 Stock then outstanding, so that all outstanding shares of Series A-3 Stock will participate equally with each other and ratably per share (calculated as provided in Section 3(f) hereof).  Whenever any dividend or other distribution, whether in cash or property or in securities of the Corporation (or subscription or other rights to purchase or acquire securities of the Corporation),

 

5

 

may be declared or paid on: (i) any shares of the Common Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each share of the Series A-3 Stock then outstanding so that all outstanding shares of Series A-3 Stock will participate in such dividend ratably with such shares of Common Stock (calculated as provided in Section 3(f) hereof); or (ii) any shares of any other series of Preferred Stock (other than the Series A-1 Accruing Dividend, the Series A-2 Accruing Dividend and the Series A-5 Special Accruing Dividend), the Board of Directors shall also declare and pay a dividend on the same terms, at the same or equivalent rate upon each share of the Series A-3 Stock then outstanding so that all outstanding shares of Series A-3 Stock will participate in such dividend ratably with such shares of such other series of Preferred Stock (based on the number of shares of Common Stock into which each share of Series A-3 Stock and each share of such other series of Preferred Stock is then convertible, if applicable, or, otherwise, the relative liquidation preference per share, of such other series of Preferred Stock as compared with the Series A-3 Stock then outstanding).

 

(d)       Series A-5 Stock.  Without regard to the payment of the required dividends to the holders of Series A-1 Stock, Series A-2 Stock and Series A-3 Stock in accordance with Section 3(a), (b) and (c), respectively, above, the holders of shares of the Series A-5 Stock shall be entitled to receive a per share dividend (the “Series A-5 Special Accruing Dividend”) that shall accrue and be paid in the form of Series A-6 Stock or other securities subject to and in accordance with the provisions of that certain Stock Issuance Agreement to which the Corporation and Nordic Bioscience Clinical Development VII A/S are party dated March 29, 2011 (the “Stock Issuance Agreement”). Whenever any dividend may be declared or paid on any shares of Series A-5 Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each other share of the Series A-5 Stock then outstanding, so that all outstanding shares of Series A-5 Stock will participate equally with each other and ratably per share (calculated as provided in Section 3(f) hereof).  Whenever any dividend or other distribution, whether in cash or property or in securities of the Corporation (or subscription or other rights to purchase or acquire securities of the Corporation) may be declared or paid on (i) any shares of the Common Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each share of the Series A-5 Stock then outstanding so that all outstanding shares of Series A-5 Stock will participate in such dividend ratably with such shares of Common Stock (calculated as provided in Section 3(f) hereof); or (ii) any shares of any other series of Preferred Stock (other than the Series A-1 Accruing Dividend, the Series A-2 Accruing Dividend and the Series A-3 Accruing Dividend), the Board of Directors shall also declare and pay a dividend on the same terms, at the same or equivalent rate upon each share of the Series A-5 Stock then outstanding so that all outstanding shares of Series A-5 Stock will participate in such dividend ratably with such shares of such other series of Preferred Stock (based on the number of shares of Common Stock into which each share of Series A-5 Stock and each share of such other series of Preferred Stock is then convertible, if applicable, or, otherwise, the relative liquidation preference per share, of such other series of Preferred Stock as compared with the Series A-5 Stock then outstanding).

 

(e)       Series A-4 Stock and Series A-6 Stock.  Following payment in full of required dividends to the holders of Series A-1 Stock, Series A-2 Stock, Series A-3 and Series A-5 Stock or any other class or series of capital stock that is senior to or on parity with the any such series of Preferred Stock as to dividends, in accordance with Sections 3(a), (b), (c) or (d) above or any other section of this Certificate as in effect from time to time, the holders of shares of the

 

6

 

Series A-4 Stock and Series A-6 Stock shall be entitled to receive, when, if and as declared by the Board of Directors, dividends on any shares of Series A-4 Stock or Series A-6 Stock, as the case may be, out of funds legally available for that purpose, at a rate to be determined by the Board of Directors if and when they may so declare any dividend on the Series A-4 Stock or A-6 Stock, as the case may be.  Whenever any dividend may be declared or paid on any shares of Series A-4 Stock or Series A-6 Stock, as applicable, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each other share of the Series A-4 Stock or the Series A-6 Stock, as applicable, then outstanding, so that all outstanding shares of Series A-4 Stock or Series A-6 Stock, as applicable, will participate equally with each other and ratably per share (calculated as provided in Section 3(f) hereof).  Whenever any dividend or other distribution, whether in cash or property or in securities of the Corporation (or subscription or other rights to purchase or acquire securities of the Corporation), may be declared or paid on: (i) any shares of the Common Stock, the Board of Directors shall also declare and pay a dividend on the same terms, at the same rate and in like kind upon each share of the Series A-4 Stock and Series A-6 Stock then outstanding so that all outstanding shares of Series A-4 Stock and Series A-6 Stock will participate in such dividend ratably with such shares of Common Stock (calculated as provided in Section 3(f) hereof); or (ii) any shares of any other series of Preferred Stock (other than the Series A-1 Accruing Dividend, the Series A-2 Accruing Dividend, the Series A-3 Accruing Dividend and the Series A-5 Special Accruing Dividend), the Board of Directors shall also declare and pay a dividend on the same terms, at the same or equivalent rate upon each share of the Series A-4 Stock and Series A-6 Stock then outstanding so that all outstanding shares of Series A-4 Stock and Series A-6 Stock will participate in such dividend ratably with such shares of such other series of Preferred Stock (based on the number of shares of Common Stock into which each share of Series A-4 Stock and Series A-6 Stock and each share of such other series of Preferred Stock is then convertible, if applicable, or, otherwise, the relative liquidation preference per share, of such other series of Preferred Stock as compared with the Series A-4 Stock and Series A-6 Stock then outstanding).

 

(f)        In connection with any dividend declared or paid hereunder, each share of Preferred Stock shall be deemed to be that number of shares (including fractional shares) of Common Stock into which it is then convertible, rounded up to the nearest one-tenth of a share.  No fractional shares of capital stock shall be issued as a dividend hereunder. The Corporation shall pay a cash adjustment for any such fractional interest in an amount equal to the fair market value thereof on the last Business Day (as defined in Section 8 hereof) immediately preceding the date for payment of dividends as determined by the Board of Directors in good faith.

 

4.     Liquidation Rights.

 

(a)       As to rights upon any Liquidation (as defined in Section 4(b) hereof) or an Event of Sale (as defined in Section 5 hereof), each share of Series A-1 Stock shall rank equally with each other share of Series A-1 Stock and senior to all shares of Series A-2 Stock, Series A-3 Stock, Series A-4 Stock, Series A-5 Stock and Series A-6 Stock; each share of Series A-2 Stock shall rank equally with each other share of Series A-2 Stock and senior to all shares of Series A-3 Stock, Series A-4 Stock, Series A-5 Stock and Series A-6 Stock; each share of Series A-3 Stock, Series A-5 Stock and Series A-6 Stock shall rank equally with each other share of Series A-3 Stock, Series A-5 and Series A-6 Stock and senior to all shares of Series A-4 Stock and shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the

 

7

 

Effective Time, except as otherwise approved by the affirmative vote or consent of the Senior Majority. Each share of Series A-4 Stock, shall rank equally with each other share of Series A-4 Stock and senior to all shares of Common Stock and all other classes or series of stock not authorized by this Certificate as of the Effective Time, except as otherwise approved by the affirmative vote or consent of the Senior Majority.

 

(b)       In the event of any liquidation, dissolution or winding-up of the affairs of the Corporation (collectively, a “Liquidation”): (i) the holders of shares of Series A-1 Stock then outstanding (the “Series A-1 Stockholders”) shall be entitled to receive, ratably with each other, out of the assets of the Corporation legally available for distribution to its stockholders, whether from capital, surplus or earnings, before any payment shall be made to the holders of Series A-2 Stock then outstanding (the “Series A-2 Stockholders”), Series A-3 Stock then outstanding (the “Series A-3 Stockholders”), Series A-4 Stock then outstanding (the “Series A-4 Stockholders”), Series A-5 Stock then outstanding (the “Series A-5 Stockholders”)  or Series A-6 Stock then outstanding (the “Series A-6 Stockholders” and collectively with the Series A-1 Stockholders, Series A-2 Stockholders, Series A-3 Stockholders, Series A-4 Stockholders and the Series A-5 Stockholders, the “Preferred Stockholders”), or the holders of Common Stock or any other class or series of stock ranking on Liquidation junior to such Series A-1 Stock, an amount per share equal to the Series A-1 Original Purchase Price (as defined in Section 8 hereof), plus an amount equal to any declared or accrued but unpaid dividends thereon, calculated pursuant to Section 3(a) hereof; and (ii) after the distribution to the Series A-1 Stockholders, and any other class or series of capital stock that is senior to the Series A-2 Stock as to Liquidation, of the full amount to which they are entitled to receive pursuant to this Section 4(b) or any other section of this Certificate as in effect from time to time, the Series A-2 Stockholders, shall be entitled to receive, ratably with each other, out of the assets of the Corporation legally available for distribution to its stockholders, whether from capital, surplus or earnings, before any payment shall be made to the Series A-3 Stockholders, the Series A-4 Stockholders, the Series A-5 Stockholders or the Series A-6 Stockholders, or the holders of Common Stock or any other class or series of stock ranking on Liquidation junior to such Series A-2 Stock, an amount per share equal to the Series A-2 Original Purchase Price (as defined in Section 8 hereof), plus an amount equal to any declared or accrued but unpaid dividends thereon, calculated pursuant to Section 3(b) hereof; (iii) after the distribution to the Series A-1 Stockholders, the Series A-2 Stockholders and holders of any other class or series of capital stock that is senior to the Series A-3 Stock as to Liquidation, of the full amount to which they are entitled to receive pursuant to this Section 4(b) or any other section of this Certificate as in effect from time to time, the Series A-3 Stockholders, the Series A-5 Stockholders, and the Series A-6 Stockholders shall be entitled to receive out of the assets of the Corporation legally available for distribution to its stockholders, whether from capital, surplus or earnings, before any payment shall be made to the Series A-4 Stockholders or the holders of Common Stock or any other class or series of stock ranking on Liquidation junior to such Series A-3 Stock, Series A-5, or Series A-6 Stock an amount per share equal to the Series A-3 Original Purchase Price (as defined in Section 8 hereof), Series A-5 Original Purchase Price (as defined in Section 8 hereof) or Series A-6 Original Purchase Price (as defined in Section 8 hereof), respectively, plus an amount equal to any declared or accrued but unpaid dividends thereon, calculated pursuant to Section 3 hereof; and (iv) after the distribution to the Series A-1 Stockholders, the Series A-2 Stockholders, the Series A-3 Stockholders, the Series A-5 Stockholders, the Series A-6 Stockholders and holders of any other class or series of capital stock that is senior to the Series A-4 Stock as to Liquidation, of the full amount to which they are entitled to receive pursuant to this Section 4(b) or any other section of

 

8

 

this Certificate as in effect from time to time, the Series A-4 Stockholders shall be entitled to receive out of the assets of the Corporation legally available for distribution to its stockholders, whether from capital, surplus or earnings, before any payment shall be made to the holders of Common Stock or any other class or series of stock ranking on Liquidation junior to such Series A-4 Stock an amount per share equal to the Series A-4 Original Purchase Price (as defined in Section 8 hereof), plus an amount equal to any declared or accrued but unpaid dividends thereon, calculated pursuant to Section 3 hereof. Notwithstanding the foregoing or anything else expressed or implied herein, the transactions contemplated by that certain Agreement and Plan of Merger dated as of April 25, 2011 by and among the Corporation, Radius Health, Inc. and RHI Merger Corp. (the “Merger Agreement”) shall not be “Liquidation” for purposes of this Certificate of Designations.

 

(c)       If, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Series A-1 Stockholders the full amount to which each of them shall be entitled pursuant to Section 4(b) above, then the Series A-1 Stockholders shall share ratably in any distribution of assets according to the respective amounts which would be payable to them in respect of the shares of Series A-1 Stock held upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

(d)       If, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Series A-2 Stockholders the full amount to which each of them shall be entitled pursuant to Section 4(b) above and to pay to the holders of any other class or series of capital stock that is on a parity with the Series A-2 Stock upon Liquidation the full amount to which each of such holders shall be entitled pursuant to Section 4(b) or any other section of this Certificate as in effect from time to time, then the Series A-2 Stockholders and such holders shall share ratably in any distribution of assets according to the respective amounts which would be payable to them in respect of the shares of Series A-2 Stock and the shares of such other class or series of capital stock held upon such distribution if all amounts payable on or with respect to< all of> such shares were paid in full.

 

(e)       If, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Series A-3 Stockholders, the Series A-5 Stockholders and the Series A-6 Stockholders the full amount to which each of them shall be entitled pursuant to Section 4(b) above and to pay to the holders of any other class or series of capital stock that is on a parity with the Series A-3, Series A-5 Stock and the Series A-6 Stock upon Liquidation the full amount to which each of such holders shall be entitled pursuant to Section 4(b) or any other section of this Certificate as in effect from time to time, then the Series A-3 Stockholders, the Series A-5 Stockholders, the Series A-6 Stockholders and such holders shall share ratably in any distribution of assets according to the respective amounts which would be payable to them in respect of the shares of Series A-3 Stock, Series A-5 Stock and Series A-6 Stock and the shares of such other class or series of capital stock, as the case may be, held upon such distribution if all amounts payable on or with respect to all of such shares were paid in full.

 

(f)        If, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Series A-4 Stockholders the full amount to which each of them shall be entitled pursuant to Section 4(b) above and to pay to the holders of any other class or series of capital stock that is on a parity with the Series A-4 Stock

 

9

 

upon Liquidation the full amount to which each of such holders shall be entitled pursuant to Section B.4(b) or any other section of this Certificate as in effect from time to time, then the Series A-4 Stockholders and such holders shall share ratably in any distribution of assets according to the respective amounts which would be payable to them in respect of the shares of Series A-4 Stock and the shares of such other class or series of capital stock held upon such distribution if all amounts payable on or with respect to all of such shares were paid in full.

 

(g)       In the event of any Liquidation, after payment shall have been made to the Preferred Stockholders of the full amount to which they shall be entitled pursuant to Section 4(b) and to the holders of any class or series of capital stock that is senior to or on parity with the Preferred Stock, or any series, thereof, as in effect from time to time, the holders of each other class or series of capital stock (other than Common Stock) ranking on Liquidation junior to the Preferred Stock, but senior to the Common Stock, as a class, shall be entitled to receive an amount equal (and in like kind) to the aggregate preferential amount fixed for each such junior class or series of capital stock.  If, upon any Liquidation, after payment shall have been made to the Preferred Stockholders of the full amount to which they shall be entitled pursuant to Section 4(b), the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay a class or series of capital stock (other than the Common Stock) junior to the Preferred Stock the full amount to which they shall be entitled pursuant to the preceding sentence, the holders of such other class or series of capital stock shall share ratably, based upon the number of then outstanding shares of such other class or series of capital stock, in any remaining distribution of assets according to the respective preferential amounts fixed for such junior class or series of capital stock or which would be payable to them in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

(h)       In the event of any Liquidation, after payments shall have been made first to the Preferred Stockholders and to the holders of any class or series of capital stock that is senior to or on parity with the Preferred Stock, or any series thereof, as in effect from time to time, and to the holders of class or series of capital stock that is junior to or on parity with the Preferred Stock but senior to the Common Stock, of the full amount to which they each shall be entitled as aforesaid, the holders of Common Stock, as a class, shall be entitled to share ratably with the holders of Participating Preferred Stock as provided in the last sentence in this Section 4(h)) in all remaining assets of the Corporation legally available for distribution to its stockholders.  For purposes of calculating the amount of any payment to be paid upon any such Liquidation pursuant to the participation feature described in this Section 4(h), each share of such Participating Preferred Stock shall be deemed to be that number of shares (including fractional shares and any shares attributable to the payment of accrued and unpaid dividends upon conversion of such Participating Preferred Stock pursuant to Section 7(b)) of Common Stock into which it is then convertible, rounded to the nearest one-tenth of a share.

 

(i)        (i) In the event of and simultaneously with the closing of an Event of Sale, the Corporation shall, unless waived by the Senior Majority or otherwise prevented by law, redeem all of the shares of Preferred Stock then outstanding for a cash amount per share determined as set forth in Sections Section 4(a) through (h) hereof (the “Special Liquidation Price,” said redemption being referred to herein as a “Special Liquidation”).  In the event the Event of Sale involves consideration that does not consist of cash, then the Special Liquidation Price may be paid with such consideration having a value equal to the Special Liquidation Price.  To the extent there is

 

10

 

any cash consideration in connection with an Event of Sale, at the option of the Senior Majority, the cash consideration will first (i) be applied to satisfy the Special Liquidation Price payable to the Series A-1 Stockholders and to the holders of any other class or series of capital stock that is senior to or on parity with the Series A-1 Stock as to Liquidation; and then (ii) be applied to satisfy the Special Liquidation Price payable to the holders of Series A-2 Stock and to the holders of any other class or series of capital stock that is junior to the Series A-1 Stock but senior to or on parity with the Series A-2 Stock as to Liquidation; and then (iii) be applied to satisfy the Special Liquidation Price payable to holders of Series A-3 Stock, Series A-5 Stock, Series A-6 Stock and any other class or series of capital stock that is junior to the Series A-2 Stock but senior to or on parity with the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock as to Liquidation (in relative proportion to the full liquidation preference the Series A-3 Stockholders, Series A-5 Stockholders, Series A-6 Stockholders and the holders of such other class or series of capital stock would have received had there been sufficient cash consideration to have paid their liquidation preference in full) and then (iv) be applied to satisfy the Special Liquidation Price payable to the holders of Series A-4 Stock and to the holders of any other class or series of capital stock that is junior to the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock but senior to or on parity with the Series A-4 Stock, in all cases, prior to the payment thereof to any other stockholders of the Corporation.  For all purposes of this Section 4(i), the Special Liquidation Price shall be equal to that amount per share which would be received by each Preferred Stockholder if, in connection with an Event of Sale, all the consideration paid in exchange for the assets or the shares of capital stock (as the case may be) of the Corporation were actually paid to and received by the Corporation and the Corporation were immediately thereafter liquidated and its assets distributed pursuant to Sections 4(a) through (h) hereof.  To the extent that one or more redemptions (as described in Section 5 hereof) and/or Special Liquidations are occurring concurrently, the Special Liquidation under this Section 4(i) shall be deemed to occur first.  The date upon which the Special Liquidation shall occur is sometimes referred to herein as the “Special Liquidation Date”.

 

(ii)           In the absence of an applicable waiver pursuant to Section 4(i) above, at any time on or after the Special Liquidation Date, a Preferred Stockholder shall be entitled to receive the Special Liquidation Price for each such share of Preferred Stock owned by such holder.  Subject to the provisions of Section 4(i)(iii) hereof, payment of the Special Liquidation Price will be made to each such holder upon actual delivery to the Corporation or its transfer agent of the certificate of such holder representing such shares of Preferred Stock, as the case may be, or an affidavit of loss as to the same.

 

(iii)          If on the Special Liquidation Date less than all the shares of Preferred Stock then outstanding may be legally redeemed by the Corporation, the Special Liquidation shall be made first as to the Series A-1 Stock (and any other class or series of capital stock that is senior to or on parity with the Series A-1 Stock as to Liquidation), pro  rata with respect to such Series A-1 Stock  (or such other class or series of capital stock that is senior to or on parity with the Series A-1 Stock as to Liquidation) based upon the number of outstanding shares of Series A-1 Stock (or such other class or series of capital stock that is senior to or on parity with the Series A-1 Stock as to Liquidation) then owned by each such holder thereof until such holders are satisfied in full, and then to the Series A-2 Stock (and any other class or series of capital stock that is junior to the Series A-1 Stock but senior to or on parity with the Series A-2 Stock as to Liquidation), pro  rata with respect to such Series A-2 Stock  (or such other class or series of capital stock that is junior to the Series A-1 Stock but senior to or on parity with the

 

11

 

Series A-2 Stock as to Liquidation) based upon the number of outstanding shares of Series A-2 Stock (or such other class or series of capital stock that is junior to the Series A-1 Stock but senior to or on parity with the Series A-2 Stock as to Liquidation) then owned by each such holder thereof until such holders are satisfied in full, and then to the holders of the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock pro rata with respect to such Series A-3, Stock Series A-5 Stock and Series A-6 Stock (and any other class or series of capital stock that is junior to the Series A-2 Stock but senior to or on parity with the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock as to Liquidation), based upon the number of outstanding shares of Series A-3 Stock, Series A-5 Stock and Series A-6 Stock <(or such other class or series of capital stock that is junior to the Series A-2 Stock but senior to or on parity with the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock as to Liquidation) then owned by each holder thereof, and then to the Series A-4 Stock (and any other class or series of capital stock that is junior to the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock but senior to or on parity with the Series A-4 Stock as to Liquidation), pro rata with respect to such Series A-4 Stock  (or such other class or series of capital stock that is senior to or on parity with the Series A-4 Stock as to Liquidation) based upon the number of outstanding shares of Series A-4 Stock (or such other class or series of capital stock that is that is junior to the Series A-3 Stock, Series A-5 Stock and Series A-6 Stock but senior to or on parity with the Series A-4 Stock as to Liquidation) then owned by each such holder thereof until such holders are satisfied in full.

 

(iv)          On and after any Special Liquidation Date, all rights in respect of the shares of Preferred Stock to be redeemed shall cease and terminate except the right to receive the applicable Special Liquidation Price as provided herein, and such shares of Preferred Stock shall no longer be deemed to be outstanding, whether or not the certificates representing such shares of Preferred Stock have been received by the Corporation; provided, however, that, if the Corporation defaults in the payment of the Special Liquidation Price with respect to any Preferred Stock, the rights of the holder(s) thereof with respect to such shares of Preferred Stock shall continue until the Corporation cures such default.

 

(v)           Anything contained herein to the contrary notwithstanding, all or any of the provisions of this Section 4(i) may be waived by the Senior Majority, by delivery of written notice of waiver to the Corporation prior to the closing of any Event of Sale.

 

(vi)          Any notice required to be given to the holders of shares of Preferred Stock pursuant to Section 7(g) hereof in connection with an Event of Sale shall include a statement by the Corporation of (A) the Special Liquidation Price which each Preferred Stockholder shall be entitled to receive upon the occurrence of a Special Liquidation under this Section 4(i) and (B) the extent to which the Corporation will, if at all, be legally prohibited from paying each holder of Preferred Stock the Special Liquidation Price.

 

5.     Definition of “Event of Sale”.  For purposes of this Certificate of Designations, an “Event of Sale” shall mean: (A) the sale by the stockholders of voting control of the Corporation, (B) the merger, consolidation or reorganization with or into any other corporation, entity or person or any other corporate reorganization, in which (I) the capital stock of the Corporation immediately prior to such merger, consolidation or reorganization represents less than 50% of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such merger, consolidation or reorganization or (II) the surviving

 

12

 

entity (or, if the surviving entity is a wholly owned subsidiary, its parent) has a class of securities that is (or has been within 90 days prior to such transaction) tradeable on any public market or exchange or (C) the sale, exclusive license or other disposition of all or substantially all of the assets or intellectual property of the Corporation in a single transaction or series of related transactions. Notwithstanding the foregoing and for purposes of clarification, the term “Event of Sale” shall not include any transaction involving the Corporation and Radius Health, Inc., a Delaware corporation.

 

6.     Voting.

 

(a)       Subject to any separate voting rights provided for herein or otherwise required by law, the holders of Preferred Stock shall be entitled to vote, together with the holders of Common Stock as one class, on all matters as to which holders of Common Stock shall be entitled to vote, in the same manner and with the same effect as such holders of Common Stock.  In any such vote, each share of Preferred Stock shall entitle the holder thereof to the number of votes per share that equals the number of shares of Common Stock (including fractional shares) into which each such share of Preferred Stock is then convertible, rounded up to the nearest one-tenth of a share, but not including any shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock.

 

(b)       In addition to the rights specified in Section 6(a):

 

(i)            for so long as any shares of Series A-1 Stock are outstanding, the holders of a majority of the shares of Series A-1 Stock outstanding, voting as a separate class, shall have the right to elect two (2) members of the Board of Directors of the Corporation; and

 

(ii)           Oxford Bioscience Partners IV L.P. (including for this purpose, members of the Oxford/Saints Group (as defined in the Stockholders’ Agreement), HealthCare Ventures or Wellcome Trust (collectively, the “G3 Holders”) voting as a separate class shall have the right to elect one (1) member of the Board of Directors of the Corporation by majority vote of the shares of Series A-1 Stock held by them; provided, however, that in order to be eligible to vote or consent with respect to the election of such member of the Board of Directors, a G3 Holder together with members of such G3 Holders’ Group (as defined in the Stockholders’ Agreement) must hold greater than twenty percent (20%) of the shares of Series A-1 Stock purchased under the Series A-1 Stock Purchase Agreement by such G3 Holder and the members of such G3 Holders’ Group; and

 

(iii)          MPM Capital L.P., voting as a separate class, shall have the right to elect one (1) member of the Board of Directors of the Corporation by majority vote of the shares of Series A-1 Stock held by MPM Capital L.P.; provided that such member of the Board of Directors shall be an individual with particular expertise in the development of pharmaceutical products; and, provided, further, that in order to be eligible to vote or consent with respect to the election of such member of the Board of Directors, MPM Capital L.P. together with members of the MPM Group (as defined in the Stockholders’ Agreement) must hold greater than twenty percent (20%) of the shares of Series A-1 Stock purchased under the Series A-1 Stock Purchase Agreement by MPM Capital L.P. and the members of the MPM Group.

 

13

 

(iv)          The members of the Board of Directors elected by the Series A-1 Stockholders, the G3 Holders and MPM Capital L.P. pursuant to this Section 6(b) are referred to herein as the “Preferred Directors”.

 

(c)       In any election of Preferred Directors pursuant to Section 6(b), each holder of Preferred Stock eligible to participate in the election of Preferred Directors shall be entitled to one vote for each share of Common Stock (including fractional shares) into which each such share of Preferred Stock held by such holder is then convertible, rounded up to the nearest one-tenth of a share (determined as set forth in the second sentence of Section 6(a) hereof), and no holder of Preferred Stock shall be entitled to cumulate its votes by giving one candidate more than one vote per share.  The voting right of the Series A-1 Stockholders, the G3 Holders and the MPM Holder contained in Section 6(b), may be exercised at a special meeting of the applicable holders of Preferred Stock called as provided in accordance with the by-laws of the Corporation, at any annual or special meeting of the stockholders of the Corporation, or by written consent of such applicable holders of Preferred Stock in lieu of a meeting.  The Preferred Directors elected pursuant to Section 6(b) shall serve from the date of their election and qualification until their successors have been duly elected and qualified.  The number of directors constituting the entire membership of the Board of Directors of the Corporation shall be set by the Board of Directors pursuant to the By-Laws of the Corporation.

 

(d)       A vacancy in the directorships elected by the Series A-1 Stockholders, the G3 Holders or the MPM Holder pursuant to Section 6(b), may be filled by a vote at a meeting called in accordance with the by-laws of the Corporation or written consent in lieu of such meeting of the applicable holders of Preferred Stock, respectively, or by the remaining directors as provided in the Corporation’s By-Laws.

 

(e)       The holders of capital stock of the corporation, voting as a single class, shall elect the remaining member or members of the Board of Directors of the Corporation.  In any election of directors pursuant to this Section 6(e), each stockholder shall be entitled to one vote for each share of Common Stock held or, if Preferred Stock, into which each such share of Preferred Stock is then convertible (determined in accordance with Section 6(a) hereof), and no stockholder shall be entitled to cumulate its votes by giving one candidate more than one vote per share.  The voting right of the stockholders contained in this Section 6(e) may be exercised at a special meeting of the stockholders called as provided in accordance with the by-laws of the Corporation, at any annual or special meeting of the stockholders of the Corporation, or by written consent of the stockholder in lieu of a meeting.  The director or directors elected pursuant to this Section 6(e) shall serve from the date of their election and qualification until their successors have been duly elected and qualified.

 

(f)        A vacancy in the directorship or directorships elected by the stockholders pursuant to Section 6(e), may be filled by a vote at a meeting called in accordance with the by-laws of the Corporation or written consent in lieu of such meeting of the stockholders of the Corporation, or by the remaining directors as provided in the Corporation’s By-Laws.

 

(g)       Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative

 

14

 

approval of the Senior Majority acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each Series A-1 Stockholder, Series A-2 Stockholder and Series A-3 Stockholder, to do the following:

 

(i)            authorize, create, designate, issue or sell any class or series of capital stock (including any shares of treasury stock) or rights, options, warrants or other securities convertible into or exercisable or exchangeable for capital stock which by its terms is convertible into or exchangeable for any equity security, other than Excluded Stock, which, as to the payment of dividends or distribution of assets, including without limitation distributions to be made upon a Liquidation, is senior to or on a parity with the Series A-1 Stock; or

 

(ii)           amend, alter or repeal any provision of this Certificate; or

 

(iii)          permit, approve or agree to any Liquidation, Event of Sale, dissolution or winding up of the Corporation.

 

The foregoing approval shall be obtained in addition to any approval required by law.

 

(h)       Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-1 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-1 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-1 Stock in a manner that materially adversely affects the Series A-1 Stock and such amendment does not change or alter the comparable rights, preferences or privileges of any other series of New Preferred Stock in a manner that materially adversely affects such other series of New Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-1 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences or privileges senior to or on a parity with the Series A-1 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-1 Stock.

 

(i)        Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-2 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which

 

15

 

meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-2 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-2 Stock in a manner that materially adversely affects the Series A-2 Stock and such amendment does not change or alter the comparable rights, preferences or privileges of any other series of Preferred Stock in a manner that materially adversely affects such other series of Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-2 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences or privileges senior to or on a parity with the Series A-2 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-2 Stock.

 

(j)        Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-3 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-3 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-3 Stock in a manner that materially adversely affects the Series A-3 Stock and such amendment does not change or alter the comparable rights, preferences or privileges of any other series of Preferred Stock in a manner that materially adversely effects such other series of Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-3 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences or privileges senior to or on a parity with the Series A-3 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-3 Stock.

 

(k)       Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-4 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-4 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-4 Stock in a manner that materially adversely affects the Series A-4 Stock and such amendment does not change or alter the

 

16

 

comparable rights, preferences or privileges of any other series of Preferred Stock in a manner that materially adversely affects such other series of Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-4 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences or privileges senior to or on a parity with the Series A-4 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-4 Stock.

 

(l)        Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-5 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-5 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-5 Stock in a manner that materially adversely affects the Series A-5 Stock and such amendment does not change or alter the comparable rights, preferences or privileges of any other series of Preferred Stock in a manner that materially adversely affects such other series of Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-5 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences or privileges senior to or on a parity with the Series A-5 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-5 Stock.

 

(m)      Except as otherwise expressed, implied or contemplated in this Certificate, the Series A-1 Purchase Agreement or the Merger Agreement, the Corporation shall not, directly or indirectly, through a merger, consolidation, reorganization or otherwise, without the affirmative approval of holders of a majority of the then outstanding shares of Series A-6 Stock, acting separately from the holders of Common Stock or any other securities of the Corporation, given by written consent in lieu of a meeting or by vote at a meeting called for such purpose, for which meeting or approval by written consent timely and specific notice in the manner provided in the by-laws of the Corporation shall have been given to each holder of such Series A-6 Stock, amend, alter or repeal any provision of this Certificate if such amendment, alteration or repeal would (i) alter or change the rights, preferences or privileges of the Series A-6 Stock in a manner that materially adversely affects the Series A-6 Stock and such amendment does not change or alter the comparable rights, preferences or privileges of any other series of Preferred Stock in a manner that materially adversely affects such other series of Preferred Stock or (ii) increases or decreases the authorized number of shares of Series A-6 Stock. The foregoing approval shall be obtained in addition to any approval required by law. For purposes of clarification, the creation, authorization or issuance of any new class or series of capital stock of the Corporation having rights, preferences

 

17

 

or privileges senior to or on a parity with the Series A-6 Stock (and any amendment to the certificate of incorporation of the Company for purposes of creating or authorizing such new class or series of capital stock) shall not be deemed or treated as materially adversely affecting the Series A-6 Stock.

 

(n)       The Corporation shall obtain the consent of the Board of Directors before it may authorize or issue any additional shares of capital stock of the Corporation or any of its subsidiaries.

 

7.     Conversion.

 

(a)       Any Preferred Stockholder shall have the right, at any time or from time to time, to convert any or all of its shares of Preferred Stock into that number of fully paid and nonassessable shares of Common Stock for each share of Preferred Stock so converted equal to the quotient of the Series A-1 Original Purchase Price, Series A-2 Original Purchase Price, Series A-3 Original Purchase Price, Series A-4 Original Purchase Price, Series A-6 Original Purchase Price or Series A-6 Original Purchase Price, as applicable, for such share divided by the Series A-1 Conversion Price, the Series A-2 Conversion Price, Series A-3 Conversion Price, Series A-4 Conversion Price, Series A-5 Conversion Price or the Series A-6 Conversion Price (each as defined in Section 7(e)(i) hereof), as applicable, for such share of Preferred Stock, as last adjusted and then in effect, rounded up to the nearest one-tenth of a share; provided, however, that cash shall be paid in lieu of the issuance of fractional shares of Common Stock, as provided in Section 7(d) hereof.

 

(b)       (i) Any Preferred Stockholder who exercises the right to convert shares of Preferred Stock into shares of Common Stock pursuant to this Section 7 shall be entitled to payment of all accrued dividends, whether or not declared and all declared but unpaid dividends payable with respect to such Preferred Stock pursuant to  Section 3 herein, up to and including the Conversion Date (as defined in Section 7(b)(iii) hereof).

 

(ii)           Any Preferred Stockholder may exercise the right to convert such shares into Common Stock pursuant to this Section 7 by delivering to the Corporation during regular business hours, at the office of the Corporation or any transfer agent of the Corporation or at such other place as may be designated by the Corporation, the certificate or certificates for the shares to be converted (the “New Preferred Certificate”), duly endorsed or assigned in blank to the Corporation (if required by it) or an affidavit of loss as to the same.

 

(iii)          Each New Preferred Certificate shall be accompanied by written notice stating that such holder elects to convert such shares and stating the name or names (with address) in which the certificate or certificates for the shares of Common Stock (the “Common Certificate”) are to be issued.  Such conversion shall be deemed to have been effected on the date when such delivery is made, and such date is referred to herein as the “Conversion Date.”

 

(iv)          As promptly as practicable thereafter, the Corporation shall issue and deliver to or upon the written order of such holder, at the place designated by such holder, (A) a Common Certificate for the number of full shares of Common Stock to which such holder is entitled and (B) a check or cash in respect of any fractional interest in shares of Common

 

18

 

Stock to which such holder is entitled, as provided in Section 7(d) hereof, payable with respect to the shares so converted up to and including the Conversion Date.

 

(v)           The person in whose name the Common Certificate or Certificates are to be issued shall be deemed to have become a holder of record of Common Stock on the applicable Conversion Date, unless the transfer books of the Corporation are closed on such Conversion Date, in which event the holder shall be deemed to have become the stockholder of record on the next succeeding date on which the transfer books are open, provided that the Series A-1 Conversion Price, the Series A-2 Conversion Price, Series A-3 Conversion Price, Series A-4 Conversion Price, the Series A-5 Conversion Price or the Series A-6 Conversion Price, as applicable, upon which the conversion shall be executed shall be that in effect on the Conversion Date.

 

(vi)          Upon conversion of only a portion of the number of shares covered by a New Preferred Certificate, the Corporation shall issue and deliver to or upon the written order of the holder of such New Preferred Certificate, at the expense of the Corporation, a new certificate covering the number of shares of Preferred Stock representing the unconverted portion of the New Preferred Certificate, which new certificate shall entitle the holder thereof to all the rights, powers and privileges of a holder of such Preferred Stock.

 

(c)       If a Preferred Stockholder shall surrender more than one share of the same class of Preferred Stock for conversion at any one time, then the number of full shares of Common Stock issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Preferred Stock so surrendered.

 

(d)       No fractional shares of Common Stock shall be issued upon  conversion of Preferred Stock. The Corporation shall instead pay a cash adjustment for any such fractional interest in an amount equal to the Current Market Price thereof on the Conversion Date, as determined in accordance with Section 7(e)(vi) hereof.

 

(e)       For all purposes of this Certificate of Designations, the initial conversion price of the Series A-1 Stock shall be $8.142, the initial conversion price of the Series A-2 Stock shall be $8.142,  the initial conversion price of the Series A-3 Stock shall be $8.142, the initial conversion price of the Series A-4 Stock shall be $8.142, the initial conversion price of the Series A-5 Stock shall be $8.142, and the initial conversion price of the Series A-6 Stock shall be $8.142, in each case subject to adjustment from time to time as follows (the conversion price of any or each of the Series A-1 Stock, the Series A-2 Stock, the Series A-3 Stock, the Series A-4 Stock, the Series A-5 Stock and the Series A-6 Stock is sometimes referred to generically in this Section 7 as the “Conversion Price”):

 

(i)            Subject to Section 7(e)(ii) and 7(e)(x) below, if the Corporation shall, at any time or from time to time after the Series A-1 Original Issuance Date, issue or sell any shares of Common Stock (which term, for purposes of this Section 7(e)(i), including all subsections thereof, shall be deemed to include all other securities convertible into, or exchangeable or exercisable for, shares of Common Stock (including, but not limited to, Preferred Stock) or options to purchase or other rights to subscribe for such convertible or exchangeable securities, in each case other than Excluded Stock (as defined in Section 7(e)(ii)

 

19

 

below), for a consideration per share less than the Series A-1 Conversion Price in effect immediately prior to the issuance of such Common Stock or other securities (a “Dilutive Issuance”), then (X) the Conversion Price of the Series A-1 Stock (the “Series A-1 Conversion Price”) in effect immediately prior to each such Dilutive Issuance shall automatically be reduced to a price equal to the product obtained by multiplying such Series A-1 Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of Common Stock that the aggregate consideration received by the Corporation for the additional stock so issued would purchase at such Series A-1 Conversion Price as in effect immediately prior to such issuance, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of additional stock so issued, (Y) the Conversion Price for the Series A-2 Stock (the “Series A-2 Conversion Price”) in effect immediately prior to each such Dilutive Issuance shall automatically be reduced to a price equal to the product obtained by multiplying such Series A-2 Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of Common Stock that the aggregate consideration received by the Corporation for the additional stock so issued would purchase at such Series A-2 Conversion Price as in effect immediately prior to such issuance, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of additional stock so issued, and (Z) the Conversion Price for the Series A-3 Stock (the “Series A-3 Conversion Price”) in effect immediately prior to each such Dilutive Issuance shall automatically be reduced to a price equal to the product obtained by multiplying such Series A-3 Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of Common Stock that the aggregate consideration received by the Corporation for the additional stock so issued would purchase at such Series A-3 Conversion Price as in effect immediately prior to such issuance, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including, without limitation, shares of Common Stock issued or issuable upon conversion of the outstanding Preferred Stock, but excluding shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock) plus the number of shares of additional stock so issued.  For purposes of this Section 7(e)(i), the number of shares of Common Stock deemed issuable upon conversion of such outstanding shares of Existing Preferred Stock shall be determined without giving effect to

 

20

 

any adjustments to the applicable Conversion Price resulting from the Dilutive Issuance that is the subject of this calculation. For purposes of Part B of this Certificate, the term “Series A-4  Conversion  Price” shall mean the Conversion Price of the Series A-4 Stock, the term “Series A-5  Conversion  Price” shall mean the Conversion Price of the Series A-5 Stock and the term “Series A-6  Conversion  Price” shall mean the Conversion Price of the Series A-6 Stock. For the purposes of any adjustment of the Conversion Price pursuant to this Section 7(e)(i), the following provisions shall be applicable.

 

a.             In the case of the issuance of Common Stock in whole or in part for cash, the consideration shall be deemed to be the amount of cash paid therefor after deducting therefrom any discounts, commissions or other expenses allowed, paid or incurred by the Corporation for any underwriting or otherwise in connection with the issuance and sale thereof, plus the value of any property other than cash received by the Corporation, determined as provided in Section 7(e)(i)(b) hereof, plus the value of any other consideration received by the Corporation determined as set forth in Section 7(e)(i)(c) hereof.

 

b.             In the case of the issuance of Common Stock for a consideration in whole or in part in property other than cash, the value of such property other than cash shall be deemed to be the fair market value of such property as determined in good faith by the Board of Directors, irrespective of any accounting treatment; provided, however, that such fair market value of such property as determined by the Board of Directors shall not exceed the aggregate Current Market Price (as defined in Section 7(e)(viii) hereof) of the shares of Common Stock or such other securities being issued, less any cash consideration paid for such shares, determined as provided in Section 7(e)(i)(a) hereof and less any other consideration received by the Corporation for such shares, determined as set forth in Section 7(e)(i)(c) hereof.

 

c.             In the case of the issuance of Common Stock for consideration in whole or in part other than cash or property, the value of such other consideration shall be deemed to be the aggregate par value of such Common Stock (or the aggregate stated value if such Common Stock has no par value).

 

d.             In the case of the issuance of options or other rights to purchase or subscribe for Common Stock or the issuance of securities by their terms convertible into or exchangeable or exercisable for Common Stock or options to purchase or other rights to subscribe for such convertible or exchangeable or exercisable securities:

 

i.              the aggregate maximum number of shares of Common Stock deliverable upon exercise of such options to purchase or rights to subscribe for Common Stock shall be deemed to have been issued at the time such options or rights were issued and for a consideration equal to the consideration (determined in the manner provided in Sections 7(e)(i)(a), (b) and (c) hereof), if any, received by the Corporation upon the issuance of such options or rights plus the minimum purchase price provided in such options or rights for the Common Stock covered thereby (the consideration in each case to be determined in the manner provided in Sections 7(e)(i)(a), (b) and (c) hereof);

 

21

 

ii.             the aggregate maximum number of shares of Common Stock deliverable upon conversion of, or in exchange for, any such convertible or exchangeable securities or upon the exercise of options to purchase or rights to subscribe for such convertible or exchangeable securities and subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options or rights were issued and for a consideration equal to the consideration received by the Corporation for any such securities and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum additional consideration, if any, to be received by the Corporation upon the conversion or exchange of such securities or the exercise of any related options or rights (the consideration in each case to be determined in the manner provided in Sections 7(e)(i)(a), (b) and (c) hereof);

 

iii.            if there is any change (whether automatic pursuant to the terms contained therein or as a result of the amendment of such terms) in the exercise price of, or number of shares deliverable upon exercise of, any such options or rights or upon the conversion or exchange of any such convertible or exchangeable securities (other than a change resulting from the original antidilution provisions thereof in place at the time of issuance of such security), then the applicable Conversion Price shall automatically be readjusted in proportion to such change (notwithstanding the foregoing, no adjustment pursuant to this clause shall have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (i) the applicable Conversion Price on the original adjustment date, or (ii) the applicable Conversion Price that would have resulted from any Dilutive Issuances between the original adjustment date and such readjustment date);

 

iv.            upon the expiration of any such options or rights or the termination of any such rights to convert or exchange such convertible or exchangeable securities (or in the event that the change that precipitated an adjustment pursuant to Section 7(e)(i)(d)(iii) hereof is reversed or terminated, or expires), then the applicable Conversion Price shall be automatically readjusted to the applicable Conversion Price that would have been obtained had such options, rights or convertible or exchangeable securities not been issued; and

 

v.             if the terms of any option or convertible security (excluding options or convertible securities which, upon exercise, conversion or exchange thereof, would entitle the holder thereof to receive shares of Common Stock which are Excluded Stock), the issuance of which was not a Dilutive Issuance, are revised after the Series A-1 Original Issuance Date (either automatically pursuant the provisions contained therein or as a result of an amendment to such terms) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such option or convertible security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such option or convertible security, as so amended, and the shares of Common Stock subject thereto shall be deemed to have been issued effective upon such increase or decrease becoming effective.

 

(ii)           “Excluded Stock” shall mean:

 

22

 

a.             Common Stock issued upon conversion of any shares of Preferred Stock, including any shares of Common Stock issuable upon conversion of any dividends accrued on such Preferred Stock;

 

b.             Common Stock issued or issuable to officers, directors or employees of or consultants or independent contractors to the Corporation, pursuant to any written agreement, plan or arrangement to purchase, or rights to subscribe for, such Common Stock, including Common Stock issued under the Corporation’s 2003 Long-Term Incentive Plan, as amended, or other equity incentive plan or other agreements that have been approved in form and in substance by the Senior Majority, calculated in accordance with Section 6(a) (including, in such calculation, any outstanding restricted stock awards held by such holders), and which, as a condition precedent to the issuance of such shares, provide for the vesting of such shares and subject such shares to restrictions on transfer and rights of first offer in favor of the Corporation, and restricted stock grants to directors, employees or consultants as approved by the Board of Directors of the Corporation; provided, however, that the maximum number of shares of Common Stock heretofore or hereafter issuable pursuant to the Corporation’s 2003 Long-Term Incentive Plan, as amended, and all such agreements, plans and arrangements shall not exceed 2,015,666 shares of Common Stock;

 

c.             Common Stock issued as a stock dividend or distribution on the Preferred Stock payable in shares of Common Stock, or capital stock of any other class issuable upon any subdivision, recombination, split-up or reverse stock split of all the outstanding shares of such class of capital stock;

 

d.             Common Stock or other securities issued or issuable to banks, lenders or landlords, provided that each such issuance is approved by the Board of Directors , including, but not limited to, warrants to acquire Common Stock held by Silicon Valley Bank (or its affiliates, successors and assignees), warrants to purchase Preferred Stock issued or to be issued to GE Healthcare Financial Services, Inc. (“GEHFS”) and Oxford Finance Corporation (“OFC”) pursuant to a proposed debt financing approved by the Board of Directors (the “GE Financing”), shares of Preferred Stock issued or issuable to GE in connection with the GE Financing or upon exercise by GEHFS or OFC of warrants issued in the GE Financing and shares of common stock issuable upon conversion of any such shares of Preferred Stock issued to GEHFS or OFC pursuant to the GE Financing;

 

e.             Common Stock or other securities issued or issuable to third parties in connection with strategic partnerships or alliances, corporate partnerships, joint ventures or other licensing transactions, provided that each such transaction and related issuance is approved by the Board of Directors, , including, but not limited to, (A) any shares of Preferred Stock or Common Stock issued or issuable to Ipsen Pharma SAS (“Ipsen”), pursuant to the terms of that certain License Agreement, as amended and may be amended with the approval of the Board of Directors of the Corporation and in effect from time to time, by and between the Corporation and Ipsen as payment for milestones in lieu of cash payments and (B) hares of Series A-5 Stock issued or issuable pursuant to that certain Stock Issuance Agreement as of March 29, 2011 by and between the Corporation and Nordic Bioscience and the letter agreement as of March 29, 2011 by and between the Corporation and Nordic Bioscience, pursuant to which the Corporation will issue shares of the Corporation’s

 

23

 

Series A-5 Convertible Preferred Stock, $0.01 par value per share and the issuance of Series A-6 Stock issued or to be issued as dividends on such Series A-5 Stock, and shares of Common Stock issuable upon conversion of any such shares of Series A-5 Stock and Series A-6 Stock;

 

f.              Common Stock or other securities issued or issuable pursuant to the acquisition by the Corporation of any other corporation, partnership, joint venture, trust or other entity by any merger, stock acquisition, reorganization, or purchase of substantially all assets or otherwise in which the Corporation or its stockholders of record immediately prior to the effective date of such transaction, directly or indirectly, own at least a majority of the voting power of the acquired entity or the resulting entity after such transaction, in each case so long as approved by the Board of Directors;

 

g.             Common Stock or other securities, the issuance of which is approved by the Senior Majority, with such approval expressly waiving the application of the anti-dilution provisions of this Section 7 as a result of such issuance;

 

h.             Preferred Stock or Common Stock issued or issuable pursuant to any warrant outstanding as of the date hereof or any warrant and any shares of Preferred Stock or common stock, or common stock issued upon exercise of any Preferred Stock, issued in connection with the Qualified Financing, including, but not limited to a warrant for shares of Series A-1 Preferred Stock issued or issuable to Leerink Swan, any shares of Preferred Stock or Common Stock upon exercise thereof and any Common Stock issuable upon conversion of such Preferred Stock issued upon exercise thereof; and

 

i.              All shares of Preferred Stock and Common Stock issued in connection with the Qualified Financing as provided in this Certificate and the Series A-1 Purchase Agreement, and all shares of Common Stock issued or issuable upon conversion of any such shares of Preferred Stock.

 

(iii)          If the number of shares of Common Stock outstanding at any time after the Series A-1 Original Issuance Date (as defined in Section 8) is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up of shares of Common Stock, then, following the record date fixed for the determination of holders of Common Stock entitled to receive such stock dividend, subdivision or split-up, the applicable Conversion Price shall be appropriately decreased in the form of a Proportional Adjustment (as defined in Section 8) so that the number of shares of Common Stock issuable on conversion of each share of Preferred Stock shall be increased in proportion to such increase in outstanding shares.

 

(iv)          If the number of shares of Common Stock outstanding at any time after the Series A-1 Original Issuance Date is decreased by a combination of the outstanding shares of Common Stock (other than pursuant to the Reverse Split), then, following the record date for such combination, the applicable Conversion Price shall be appropriately increased in the form of a Proportional Adjustment so that the number of shares of Common Stock issuable on conversion of each share of Preferred Stock shall be decreased in proportion to such decrease in outstanding shares.

 

24

 

(v)           Except as otherwise contemplated in the Series A-1 Purchase Agreement, if at any time after the Series A-1 Original Issuance Date, the Corporation shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than shares of Common Stock) or in cash or other property, then and in each such event provision shall be made so that the holders of the Preferred Stock shall receive upon conversion thereof in addition to the number of shares of Common Stock receivable thereupon, the kind and amount of securities of the Corporation, cash or other property which they would have been entitled to receive had the Preferred Stock been converted into Common Stock on the date of such event and had they thereafter, during the period from the date of such event to and including the conversion date, retained such securities receivable by them as aforesaid during such period, giving application to all adjustments called for during such period under this paragraph with respect to the rights of the holders of the Preferred Stock; and provided further, however, that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of such securities, cash, or other property in an amount equal to the amount of such securities, cash, or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.

 

(vi)          Subject to the provisions of Section 4(i) above, in the event, at any time after the Series A-1 Original Issuance Date, of any capital reorganization, or any reclassification of the capital stock of the Corporation (other than pursuant to the Reverse Split, other than as contemplated under this Certificate and the Series A-1 Purchase Agreement and other than a change in par value or from par value to no par value or from no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Corporation with or into another person (other than pursuant to the Merger Agreement and other than a consolidation or merger in which the Corporation is the continuing corporation and which does not result in any change in the powers, designations, preferences and rights, or the qualifications, limitations or restrictions, if any, of the capital stock of the Corporation) or of the sale or other disposition of all or substantially all the properties and assets of the Corporation in their entirety to any other person (any such transaction, an “Extraordinary Transaction”), then the Corporation shall provide appropriate adjustment in the form of a Proportional Adjustment to the applicable Conversion Price with respect to each share of Preferred Stock outstanding after the effectiveness of such Extraordinary Transaction such that each share of Preferred Stock outstanding immediately prior to the effectiveness of the Extraordinary Transaction shall be convertible into the kind and number of shares of stock or other securities or property of the Corporation, or of the corporation resulting from or surviving such Extraordinary Transaction, that a holder of the number of shares of Common Stock deliverable (immediately prior to the effectiveness of the Extraordinary Transaction) upon conversion of such share of Preferred Stock would have been entitled to receive upon such Extraordinary Transaction. The provisions of this Section 7(e)(vi) shall similarly apply to successive Extraordinary Transactions.

 

(vii)         All calculations under this Section 7(e) shall be made to the nearest one-tenth of a cent ($.001) or to the nearest one-tenth of a share, as the case may be.

 

(viii)        For the purpose of any computation pursuant to Section 7(d), Section 3(a) hereof or this Section 7(e), the “Current Market Price” at any date of one share of Common

 

25

 

Stock shall be defined as the average of the daily closing prices for the 20 consecutive Business Days ending on the fifth (5th) Business Day before the day in question (as adjusted for any stock dividend, split-up, combination or reclassification that took effect during such 20 Business Day period), determined as follows:

 

a.             If the Common Stock is listed or admitted for trading on a national securities exchange, then the closing price for each day shall be the last reported sales price regular way or, in case no such reported sales took place on such day, the average of the last reported bid and asked prices regular way, in either case on the principal national securities exchange on which the Common Stock is listed or admitted to trading.

 

b.             If the Common Stock is not at the time listed or admitted for trading on any such exchange, then such price shall be equal to the last reported bid and asked prices on such day as reported by the NASD OTCBB or the National Quotation Bureau, Inc., or any similar reputable quotation and reporting service if such quotation is not reported by the NASD OTCBB or the National Quotation Bureau, Inc.

 

c.             If the Common Stock is not traded in such manner that the quotations referred to in this Section 7(e)(viii) are available for the period required hereunder, then the Current Market Price shall be the fair market value of such share, as determined in good faith by a majority of the entire Board of Directors.

 

(ix)           In any case in which the provisions of this Section 7(e) shall require that an adjustment shall become effective immediately after a record date for an event, the Corporation may defer until the occurrence of such event (A) issuing to the holder of any shares of Preferred Stock converted after such record date and before the occurrence of such event the additional shares of capital stock issuable upon such conversion by reason of the adjustment required by such event over and above the shares of capital stock issuable upon such conversion before giving effect to such adjustment, and (B) paying to such holder any cash amounts in lieu of fractional shares pursuant to Section 7(d) hereof; provided, however, that the Corporation shall deliver to such holder a due bill or other appropriate instrument evidencing such holder’s right to receive such additional shares and such cash upon the occurrence of the event requiring such adjustment.

 

(x)            If a state of facts shall occur that, without being specifically controlled by the provisions of this Section 7, would not fairly protect the conversion rights of the holders of the Preferred Stock in accordance with the essential intent and principles of such provisions, then the Board of Directors shall make an adjustment in the application of such provisions, in accordance with such essential intent and principles, so as to protect such conversion rights.

 

(f)        Whenever the applicable Conversion Price shall be adjusted as provided in Section 7(e) hereof, the Corporation shall forthwith file and keep on record at the office of the Secretary of the Corporation and at the office of its transfer agent or at such other place as may be designated by the Corporation, a statement, signed by both its President or Chief Executive Officer and its Treasurer or Chief Financial Officer, showing in detail the facts requiring such adjustment and the applicable Conversion Price that shall be in effect after such adjustment. The Corporation shall also cause a copy of such statement to be sent by first-class, certified mail, return receipt

 

26

 

requested, postage prepaid, to each Preferred Stockholder at such holder’s address appearing on the Corporation’s records. Where appropriate, such copy shall be given in advance of any such adjustment and shall be included as part of a notice required to be mailed under the provisions of Section 7(g) hereof.

 

(g)       In the event the Corporation shall propose to take any action of the types described in Section 7(e)(i), (iii), (iv) or (v) hereof, or any other Event of Sale, other then the transactions contemplated by the Series A-1 Purchase Agreement and the Merger Agreement, the Corporation shall give notice to each Preferred Stockholder in the manner set forth in Section 7(f) hereof, which notice shall specify the record date, if any, with respect to any such action and the date on which such action is to take place. Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action (to the extent such effect may be known at the date of such notice) on the applicable Conversion Price with respect to the Preferred Stock, and the number, kind or class of shares or other securities or property which shall be deliverable or purchasable upon each conversion of Preferred Stock. In the case of any action (other than any action contemplated or required by the Series A-1 Purchase Agreement or Merger Agreement) that would require the fixing of a record date, such notice shall be given at least 20 days prior to the record date so fixed, and in the case of any other action, such notice shall be given at least 30 days prior to the taking of such proposed action.

 

(h)       The Corporation shall pay all documentary, stamp or other transactional taxes attributable to the issuance or delivery of shares of capital stock of the Corporation upon conversion of any shares of Preferred Stock; provided, however, that the Corporation shall not be required to pay any taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificate for such shares in a name other than that of the Preferred Stockholder in respect of which such shares of Preferred Stock are being issued.

 

(i)        The Corporation shall reserve out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the Preferred Stock, sufficient shares of Common Stock to provide for the conversion of all outstanding shares of Preferred Stock.

 

(j)        All shares of Common Stock which may be issued in connection with the conversion provisions set forth herein will, upon issuance by the Corporation, be validly issued, fully paid and nonassessable, not subject to any preemptive or similar rights, and free from all taxes, liens or charges with respect thereto created or imposed by the Corporation.

 

8.     Definitions.  As used in this Certificate of Designations, the following terms shall have the corresponding meanings:

 

“Business Day” shall mean any day other than a Saturday, Sunday or day on which banks are closed in the city and state where the principal executive office of the Corporation is located.

 

“Series A-1 Original Issuance Date” shall mean the date of issuance by the Corporation of the first share of Series A-1 Stock to be issued by the Corporation.

 

27

 

“Series A-1 Original Purchase Price” shall mean, with respect to the Series A-1 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Series A-2 Original Purchase Price” shall mean, with respect to the Series A-2 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Series A-3 Original Purchase Price” shall mean, with respect to the Series A-3 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Series A-4 Original Purchase Price” shall mean, with respect to the Series A-4 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Series A-5 Original Purchase Price” shall mean, with respect to the Series A-5 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Series A-6 Original Purchase Price” shall mean, with respect to the Series A-6 Stock, $81.42 per share, subject, for all purposes other than Section 7 hereof (which provisions shall be applied in accordance with their own terms), to Proportional Adjustment.

 

“Proportional Adjustment” shall mean an adjustment made to the price of the Preferred Stock upon the occurrence of a stock split, reverse stock split, stock dividend, stock combination reclassification or other similar change with respect to such security, such that the price of one share of the Preferred Stock before the occurrence of any such change shall equal the aggregate price of the share (or shares or fractional share) of such security (or any other security) received by the holder of the Preferred Stock with respect thereto upon the effectiveness of such change.

 

“Qualified Financing” shall mean the transaction involving the issuance of shares of Series A-1 Stock pursuant to the terms of the Series A-1 Purchase Agreement.

 

“Series A-1 Purchase Agreement” shall mean that certain Series A-1 Convertible Preferred Stock Purchase Agreement dated as of April 25, 2011 by and among the Radius Health, Inc., a Delaware corporation and the “Investors” party thereto.

 

28

 

9.     Forced Conversion and Forfeiture Upon Failure to Perform Future Funding Obligations Pursuant to the Series A-1 Purchase Agreement.

 

(a)       Trigger Event.  In the event that an Investor (as defined in the Series A-1 Purchase Agreement) does not timely and completely fulfill his, her or its Future Funding Obligations (as defined in the Series A-1 Purchase Agreement) in the Qualified Financing pursuant to the terms of the Series A-1 Purchase Agreement, then (i) all shares of Preferred Stock then held by such Investor shall automatically, and without any further action on the part of such Investor, be converted into shares of Common Stock at a rate of 1 share of Common Stock for every 10 shares of Preferred Stock to be so converted and (ii) the Corporation shall have the right to repurchase and each such holders shall be required to sell all shares of Common Stock issued upon conversion (either pursuant to the foregoing clause (i) or otherwise) of all of the Additional A-1 Preferred Stock (as defined in the Series A-1 Purchase Agreement), all Series A-2 Stock, all Series A-3 Stock and all Series A-4 Stock issued to such Stockholder pursuant to the Automatic Reclassification (as defined in the Series A-1 Purchase Agreement) (the “Repurchased Shares”) for a per share purchase price equal to the par value of such Repurchased Shares and all such Repurchased Shares shall thereafter be cancelled by the Corporation and no longer be issued and outstanding shares of capital stock of the Corporation in accordance with Section 4(e) of the Series A-1 Purchase Agreement and Section 9(b) below. The conversion and repurchase of shares of the Corporation set forth in this Section 9(a) is referred to as a “Subsequent Closing Adjustment.”

 

(b)       Procedural Requirements.  Upon a Subsequent Closing Adjustment, each holder of shares of Preferred Stock converted pursuant to Section 9(a) shall be sent written notice of such Subsequent Closing Adjustment and the place designated for mandatory conversion of all such shares of Preferred Stock and the repurchase of all Repurchased Shares.  Upon receipt of such notice, each holder of such shares of Preferred Stock and Repurchased Shares shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, certificates surrendered for conversion or repurchase shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.  All rights with respect to the Preferred Stock so converted or such Repurchased Shares to be repurchased, including the rights, if any, to receive notices and vote (other than as a holder of shares of Common Stock that are not Repurchased Shares), will terminate at the time of the failure to fulfill the obligations of any Closing (as defined in the Series A-1 Purchase Agreement) (notwithstanding the failure of the holder or holders thereof to surrender the certificates for such shares at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates therefor (or lost certificate affidavit and agreement), to receive the items provided for in the next sentence of this Section 9(b).  As soon as practicable after the the surrender of the certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock so converted that is not included among the Repurchased Shares, the Corporation shall issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in Section 7(d) in lieu of any fraction of a share of Common Stock otherwise issuable

 

29

 

upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted.  Such converted Preferred Stock, together with all Repurchased Shares repurchased pursuant to Section 9(a)(ii) and/or (iii) shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock and Common Stock accordingly.

 

10.       Special Mandatory Conversion.

 

(a)       Trigger Events.  Each share of Preferred Stock shall be automatically converted into fully paid and non-assessable shares of Common Stock at the then-effective applicable Conversion Price in the event that (i) the Senior Majority shall have elected to convert all shares of Preferred Stock or (2) the Common Stock of the Corporation becomes listed for trading on a national securities exchange. Each of the conversions set forth in this Section 10(a) is referred to as a “Special Mandatory Conversion.”  All accrued but unpaid dividends on shares Preferred Stock shall be paid, in cash or additional shares at the discretion of the Board of Directors, in connection with any Special Mandatory Conversion.

 

(b)       Procedural Requirements.  Upon a Special Mandatory Conversion, each holder of shares of Preferred Stock converted pursuant to Section 10(a) shall be sent written notice of such Special Mandatory Conversion and the place designated for mandatory conversion of all shares of Preferred Stock.  Upon receipt of such notice, each holder of such shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.  All rights with respect to the Preferred Stock so converted, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the time of the Special Mandatory Conversion (notwithstanding the failure of the holder or holders thereof to surrender the certificates for such shares at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates therefor (or lost certificate affidavit and agreement), to receive the items provided for in the next sentence of this Section 10(b).  As soon as practicable after the Special Mandatory Conversion and the surrender of the certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock so converted, the Corporation shall issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in Section 7(d) in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted, and a new certificate for the number of shares, if any, of Preferred Stock represented by such surrendered certificate and not converted pursuant to Section 10(a).  Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may

 

30

 

thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

 

(c)       Duration of Section. This Section 10  and the rights and obligations of the parties hereunder shall automatically terminate on the consummation of a Liquidation or an Event of Sale.

 

3.             The undersigned further certifies that the authorized number of shares of Preferred Stock is Ten Million (10,000,000) and that the authorized number of shares of the Series A-1 Stock, none of which has been issued, is One Million (1,000,000), that the authorized number of shares of the Series A-2 Stock, none of which has been issued, is Nine Hundred Eighty-three Thousand Two Hundred Thirteen (983,213), that the authorized number of shares of the Series A-3 Stock, none of which has been issued, is One Hundred Forty-two Thousand Two Hundred Thirty (142,230), that the authorized number of shares of the Series A-4 Stock, none of which has been issued, is Four Thousand (4,000), that the authorized number of shares of the Series A-5 Stock, none of which has been issued, is Seven Thousand (7,000), and that the authorized number of shares of the Series A-6 Stock, none of which has been issued, is Eight Hundred Thousand (800,000).

 

4.             The resolution set forth above has been duly adopted by all necessary action on the part of the Corporation.

 

[signature page follows]

 

31

 

IN WITNESS WHEREOF, MPM ACQUISITION CORP. has caused this Certificate to be executed by                                  , its                               , this 17 day of May, 2011.

 

	
 
    	
MPM   ACQUISITION CORP.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

32

 

Exhibit C

 

 

LETTER OF TRANSMITTAL

 

For Delivery of Shares of Common Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, 
 Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5 Preferred Stock and Series A-6 Preferred Stock

of

RADIUS HEALTH, INC.

 

Pursuant to the Agreement and Plan of Merger by and among

MPM ACQUISITION CORP.

 and

RHI MERGER CORP.

 

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ON THE LAST PAGE HEREOF WILL NOT CONSTITUTE A VALID DELIVERY TO MPM ACQUISITION CORP.

 

THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ

CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED.

 

NOTE:  SIGNATURES MUST BE PROVIDED BELOW

 

Reference is hereby made to that certain Agreement and Plan of Merger (the “Merger Agreement”) entered into on or about April 22, 2011 by and among (i) MPM ACQUISITION CORP., a Delaware corporation (the “Parent”), (ii) RHI MERGER CORP., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”),  and  (iii) RADIUS HEALTH, INC., a Delaware corporation, (the “Company”).  Capitalized terms used herein without definition shall have the meanings specified in the Merger Agreement.

 

Pursuant to the Merger Agreement, Merger Sub merged with and into the Company on or about May 17, 2011 (the “Merger”).  At the Effective Time of the Merger, subject to certain exceptions, each outstanding share of Company Preferred Stock and Company Common Stock (each a “Share” and collectively, the “Shares”), other than any “Dissenting Shares” as referenced in the Merger Agreement, was converted into the right to receive, as set forth in the Merger Agreement, a portion of the consideration payable by Parent in the Merger through the issuance of shares of Parent Preferred Stock and Company Common Stock, respectively, in each case without interest.  The shares of Parent Preferred Stock and Parent Common Stock and cash in lieu of fractional shares to be received upon delivery of the Shares pursuant to the terms of the Merger Agreement are referred to herein as the “Merger  Consideration.”

 

In order to receive the Merger Consideration for your Shares, you must deliver the following documents and items to the Parent, at the address provided in the Instructions and Terms set forth below:

 

·                  a completed and signed Letter of Transmittal;

 

·                  a completed and signed Substitute Form W-9 (if you are a U.S. resident) or a completed and signed Form W-8BEN (if you are a non-U.S. resident); and

 

·                  your original stock certificate(s) representing your Shares.

 

Parent will issue checks with respect to any cash in lieu of fractional shares.

 

PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY

 

 

Letter of Transmittal

 

RADIUS HEALTH, INC.

RHI MERGER CORP.

MPM ACQUISITION CORP.

 

Re:          Merger of Radius Health, Inc. and RHI Merger Corp.

 

Ladies and Gentlemen:

 

The undersigned hereby delivers to MPM ACQUISITION CORP. (the “Parent”) the below-described Shares of RADIUS HEALTH, INC. (the “Company”), upon the terms and subject to the conditions set forth in that certain Agreement and Plan of Merger entered into on or about April 22, 2011 (the “Merger Agreement”), among the Parent, RHI Merger Corp. and the Company, and this Letter of Transmittal, receipt of which is hereby acknowledged.  Capitalized terms used herein without definition shall have the meanings specified in the Merger Agreement.

 

The undersigned represents and warrants that the undersigned is the sole record and beneficial owner of the Shares (as defined in this Letter of Transmittal) described below and is entitled to receive the entire Merger Consideration (as defined in this Letter of Transmittal) payable with respect to such Shares.  The undersigned hereby waives all dissenters’ appraisal rights or similar rights or remedies to which he, she or it may be entitled, available under Section 262 of the Delaware General Corporation Law, or any other applicable law, in connection with the Merger and the transactions contemplated by the Merger Agreement.

 

The undersigned hereby acknowledges that failure to provide a properly completed and signed Substitute Form W-9 (if the undersigned is a U.S. resident) or a properly completed and signed Form W-8BEN (if the undersigned is not a U.S. resident), may result in backup withholding of 28% under U.S. tax laws of any Merger Consideration payments made to the undersigned, and may result in a penalty imposed by the U.S. Internal Revenue Service.

 

The undersigned represents and warrants that the undersigned has full power and authority to execute and deliver this Letter of Transmittal and to deliver and transfer the certificates representing the undersigned’s Shares (the “Certificates”).  In addition, the undersigned shall promptly remit and transfer to the Parent any and all distributions, rights or other securities issued or issuable in respect of such Shares after the date hereof, other than the Merger Consideration (collectively, “Distributions”), in respect of the Shares delivered hereby, accompanied by appropriate documentation of transfer and, pending such remittance or appropriate assurance thereof, the Parent shall be, subject to applicable law, entitled to all rights and privileges as owner of any such Distributions and may withhold the entire Merger Consideration or deduct from the Merger Consideration the amount or value thereof, as determined by the Parent in its sole discretion.

 

The undersigned hereby represents and warrants that the mailing address set forth below is the true, correct and complete mailing address for the undersigned and the undersigned hereby agrees to indemnify and hold harmless Parent, the Company and their respective agents and representatives from any claims by any person, including the undersigned, relating to the delivery of any Merger Consideration to be paid to the undersigned to such address.

 

Please issue all certificates representing shares of Parent Preferred Stock and Parent Common Stock, as the case may be, issuable to the undersigned in the Merger and all checks for cash in lieu of fractional shares to the undersigned. It is the obligation of the undersigned to notify the Parent of any change in the addresses set forth herein.

 

The undersigned acknowledges and agrees that the delivery will be effected, and the risk of loss and title to the certificates representing the outstanding shares of Company Preferred Stock or Company Common Stock, as the case may be, will pass only upon delivery of such certificates to Parent or an affidavit of lost security and indemnity agreement (see instruction 4).

 

The undersigned agrees and acknowledges that its right to receive the Merger Consideration is subject to the provisions of the Merger Agreement and agrees to be bound by all of the provisions of the Merger Agreement to the same extent as if the undersigned were a party to the Merger Agreement. The undersigned acknowledges that Parent will not deliver a closing payment to the undersigned unless the undersigned delivers to Parent Certificates representing the Shares covered by this Letter of Transmittal (or an affidavit of lost security and indemnity agreement (see instruction 4)), this Letter of Transmittal executed by the undersigned and the Form W-9.  The undersigned also acknowledges that Parent or Company may withhold certain amounts from the closing payment that may be required to be withheld by applicable law.

 

The undersigned acknowledges that no interest will accrue with respect to the Merger Consideration.

 

The undersigned agrees to release and forever discharge Company, Parent, Merger Sub and their respective affiliates, stockholders, agents, directors, officers, assigns, predecessors and successors (collectively, the “Released Parties”) from any and all legal, equitable or other claims with respect to ownership of any equity interest in the Company, including, without limitation, (a)

 

 

breach of duty, tort, contract (express or implied), or relief or rights under any federal, state or local law, statute or regulation or pursuant to any organizational documents of Company, (b) at law or in equity, or (c) based in any other way upon any act or omission on the part of the Released Parties and derivative rights that the undersigned had or now have, or that may hereafter have against any released party by reason of any event, transaction, conduct, occurrence, relationship or cause whatsoever occurring on or prior to the date of this Letter of Transmittal; provided, however, that the undersigned is not releasing the undersigned’s rights, if any, (1) under the Merger Agreement and the related documents executed in connection therewith; (2) under that Series A-1 Convertible Preferred Stock Purchase Agreement, dated on our about April 22, 2011 (the “Stock Purchase Agreement”) and the related documents executed in connection therewith, each of which was assumed by Parent in the Merger; (3) if the undersigned is a director or officer of the Company, under (i) the indemnification provisions contained in the Certificate of Incorporation or Bylaws of the Company or any of its subsidiaries and (ii) any directors and officers insurance policy (or any “tail” policy thereof) of the Company or any of its subsidiaries against which the undersigned is entitled to make a claim; (4) if the undersigned is an employee of the Company, with respect to salaries, bonuses and expenses in the aggregate that have accrued in the ordinary course of business; (5) if the undersigned is any employee of the Company, to accrued vacation and vested benefits in the aggregate under the Company’s employee benefit plans, other than with respect to options to acquire capital stock of the Company granted to the undersigned by the Company; and (6) with respect to claims against Parent that relate to or arise out of agreements, events, matters, causes, things, acts, omissions or conduct to the extent unrelated to the Company, the Merger Agreement, the Stock Purchase Agreement and the transactions contemplated thereby.

 

No authority herein conferred or agreed to be conferred shall be affected by, and all such authority shall survive, the death or incapacity of the undersigned.  All obligations of the undersigned hereunder shall be binding upon the heirs, executors, administrators, legal representatives, successors and assigns of the undersigned. Nothing herein is intended to or will confer any rights or remedies on any person other than the undersigned or the parties to the Merger Agreement.

 

PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY.

 

Complete the following with respect to all Shares being delivered with this letter of transmittal:

 

DESCRIPTION OF SHARES DELIVERED

 

	
 
    	
 
    	
 
    	
 
    	
Share Certificate(s) and Shares Delivered
   (Attach additional list, if necessary)
    	
 
    
	
NAME(S) and ADDRESS(ES) of
   the Registered Holder(s) (please
   fill in exactly as name appears
   on Share Certificate)
    	
 
    	
Class of Security
   (Company Preferred Stock
   and Company Common Stock)
    	
 
    	
Share
   Certificate
   Number(s)
    	
 
    	
Total Number
   of Shares
   Represented by
   Certificate(s)
   (Pre-Reverse Split)
    	
 
    	
Total Number
   of Shares
   Represented by
   Certificate(s)
   (Post-Reverse Split)
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
Total Shares:
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

o    Check here if any of the Certificates representing Shares that you own have been lost or destroyed and see Instruction 4.

 

Number of Shares represented by lost or destroyed Certificates:

 

 

IMPORTANT

HOLDER(S) SIGN HERE

 (Please also complete Substitute Form W-9 if you are a U.S. resident or

a Form W-8BEN if you are not a U.S. resident)

By signing below, you agree to be bound by the Instructions and Terms of the Letter of Transmittal.

 

	
Signature   of holder(s):
    	
 
    
	
 
    	
 
    
	
 
    	
 
    

 

Date:                                    , 2011

 

(Must be signed by registered holder(s) exactly as name(s) appear(s) on the Certificate(s) for the Shares or on a security position listing or by person(s) authorized to become registered holder(s) by Certificates and documents transmitted herewith. If signature is by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, please provide the following information.)

 

	
Name(s):
    	
 
    	
 
    
	
(Please Print)
    

 

	
Capacity   (Full Title):
    	
 
    	
 
    

 

	
Address:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    

(Include Zip Code)

 

	
(Daytime   Area Code and Telephone No.)
    	
 
    
	
 
    	
 
    
	
(Tax   Identification or Social Security No.)
    	
 
    

 

 

INSTRUCTIONS AND TERMS

 

1. Delivery of Letter of Transmittal and Certificates. This Letter of Transmittal is to be used if Certificates are to be forwarded herewith.  Certificates evidencing all physically delivered Shares, as well as this Letter of Transmittal (or copy thereof), properly completed and duly executed and all other documents required by this Letter of Transmittal must be received by Parent at its address(es) set forth herein before payment for such Shares will be made.  If Certificates are forwarded to Parent in multiple deliveries, a properly completed and duly executed Letter of Transmittal (or copy thereof) must accompany each such delivery.

 

The method of delivery of this Letter of Transmittal, Certificates and all other required documents is at the option and risk of the delivering holder of Certificates, and the delivery will be deemed made only when actually received by Parent.  If delivery is by mail, registered mail with return receipt requested, properly insured, is recommended.  In all cases, sufficient time should be allowed to ensure timely delivery.

 

2. Inadequate Space. If the space provided under “Description of Shares Delivered” is inadequate, the description of the Shares delivered hereby should be listed on a separate signed schedule and attached hereto.

 

3. Signatures on Letter of Transmittal; Stock Powers and Endorsements. If this Letter of Transmittal is signed by the registered holder(s) of the Shares delivered hereby, the signature(s) must correspond with the name(s) as written on the face of the Certificate(s) without alteration, enlargement or any change whatsoever.

 

If any of the Shares delivered hereby are owned of record by two or more joint owners, all such owners must sign this Letter of Transmittal.

 

If any of the delivered Shares are registered in different names on several Certificates, it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of the Shares.

 

If this Letter of Transmittal or any Certificate or stock power is signed by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, such person should so indicate when signing, and proper evidence satisfactory to Parent and the Purchaser of such person’s authority so to act must be submitted.

 

If this Letter of Transmittal is signed by the registered Holder(s) of the Shares transmitted hereby, no endorsements of Certificate(s) or separate stock powers are required.

 

4. Lost, Mutilated or Destroyed Certificates.  If any Certificates have been lost, mutilated or destroyed, the Holder should promptly notify the Parent by checking the box immediately preceding the special payment/special delivery instructions and indicating the number of Shares lost. The Holder will then be instructed as to the procedure to be followed (which may include satisfactory indemnification and an affidavit of loss) in order to replace the relevant Certificates. This Letter of Transmittal and related documents cannot be processed until the procedures for replacing lost, mutilated or destroyed Certificates have been followed.

 

If you have any questions regarding this Letter of Transmittal, please contact:

 

Nicholas Harvey

Chief Financial Officer

Radius Health, Inc.

617-444-1834

 

 

IMPORTANT TAX INFORMATION

 

Circular 230 Disclosure:  The statements contained herein were not intended or written to be used, and cannot be used, for the purpose of avoiding any federal tax penalties.  Because the statements in this document might be viewed as a “marketed opinion” under the “Circular 230” rules set forth in applicable Treasury Regulations, holders are hereby informed that such statements were written to support the “promotion or marketing” of the matters described herein.  Holders should seek advice from their independent tax advisers regarding the tax consequences of these matters based on their particular circumstances.

 

Under United States federal income tax law, a holder may be subject to backup withholding of 28% of the gross proceeds received by such holder from the Parent.  In order to avoid such backup withholding, a U.S. holder must provide the Parent with such holder’s correct taxpayer identification number (“TIN”) and certify that such holder is not subject to such backup withholding by completing the Substitute Form W-9 provided herewith.  If such holder is an individual, the TIN is his or her social security number. Failure to provide a holder’s TIN on the Substitute Form W-9, if applicable, may subject the holder (or other payee) to a $50 penalty imposed by the Internal Revenue Service (“IRS”). More serious penalties may be imposed for providing false information which, if willfully done, may result in fines and/or imprisonment.  The depositary may withhold 28% on all payment of the Merger Consideration if the TIN is not certified on its records. In order for a foreign holder to qualify as an exempt recipient, that holder should submit an appropriate Form W-8 (generally, an IRS Form W-8BEN), signed under penalties of perjury, attesting to that holder’s exempt status.  An IRS form W-8BEN has been included as part of these materials.  Failure to provide the information on the appropriate form may subject holders to 28% United States federal income tax withholding on the payment of the Merger Consideration. Backup withholding is not an additional tax. Rather, the tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund may be obtained by timely filing a tax return with the IRS. The Parent cannot refund amounts withheld by reason of backup withholding.

 

 

 

TO BE COMPLETED BY ALL SHAREHOLDERS

THAT ARE RESIDENTS OF THE UNITED STATES OF AMERICA

 

PAYER’S NAME: [PARENT]

 

	
SUBSTITUTE

 

FORM W-9

 

Department of the Treasury

Internal Revenue Service
    	
Part 1—PLEASE   PROVIDE YOUR TIN IN THE BOX AT RIGHT AND CERTIFY BY SIGNING AND DATING BELOW.
    	
Social Security Number or   Employer

Identification Number

 

                                                              
    
	
 
    	
Part 2—If you are   exempt from backup withholding, please check the box:  o
    	
Part 3—If you are awaiting a   TIN, check box:  o 
    
	
 
    	
 
    	
 
    
	
Payer’s Request for Taxpayer

Identification Number (“TIN”)   and Certification
    	
Part 4—CERTIFICATION  Under penalties of perjury, I certify   that:

 

(1)         the   number shown on this form is my correct TIN (or I am waiting for a number to   be issued to me);

 

(2)         I am   not subject to backup withholding because (a) I am exempt from backup   withholding, or (b) I have not been notified by the Internal Revenue   Service (“IRS”) that I am subject to backup withholding as a result of a   failure to report all interest or dividends, or (c) the IRS has notified   me that I am no longer subject to backup withholding; and

 

(3)         I am   a U.S. Citizen or other U.S. person (including U.S. resident alien)

 

Certification Instructions  You must cross out item 2 above if you have   been notified by the IRS that you are subject to backup withholding because   you have failed to report all interest and dividends on your tax   returns.  However, if after being   notified by the IRS that you were subject to backup withholding you received   another notification from the IRS stating that you are no longer subject to   backup withholding, do not cross out item (2).  The IRS does not require   your consent to any provision of this document other than the certifications   to avoid backup withholding.
    
	
 
    	
 
    	
 
    
	
 
    	
SIGNATURE
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
DATED
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
NAME
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
BUSINESS NAME, IF DIFFERENT FROM ABOVE
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
TYPE OF ENTITY
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
ADDRESS
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
CITY, STATE AND ZIP CODE
    	
 
    	
 
    
											

 

NOTE:                     FAILURE TO COMPLETE AND RETURN THIS SUBSTITUTE FORM W-9 MAY RESULT IN BACKUP WITHHOLDING OF 28% OF ANY PAYMENTS MADE TO YOU OF MERGER CONSIDERATION. IN ADDITION, FAILURE TO PROVIDE SUCH INFORMATION MAY RESULT IN A PENALTY IMPOSED BY THE IRS.  PLEASE REVIEW THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 FOR ADDITIONAL DETAILS.

 

NOTE:                     YOU MUST COMPLETE THE FOLLOWING CERTIFICATE IF YOU CHECKED THE BOX IN PART 3 OF THE  SUBSTITUTE FORM W-9.

 

CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER

 

I certify under penalties of perjury that a TIN has not been issued to me, and either (1) I have mailed or delivered an application to receive a TIN to the appropriate IRS Center or Social Security Administration office or (2) I intend to mail or deliver an application in the near future. I understand that if I do not provide a TIN by the time of payment, a percentage (currently 28%) of all reportable payments made to me thereafter will be withheld until I provide a TIN, and that such retained amounts will be remitted to the IRS as backup withholding.

 

	
Signature
    	
 
    	
 
    	
Dated                  ,   2011
    

 

 

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER SUBSTITUTE FORM W-9

 

Guidelines for Determining the Proper Identification Number of the Payee (You) to Give the Payer. – Social security numbers have nine digits separated by two hyphens: i.e., 000-00-0000.  Employer identification numbers have nine digits separated by only one hyphen: i.e., 00-0000000.  The table below will help determine the number to give the payer.  All “Section” references are to the Internal Revenue Code of 1986, as amended.  “IRS” is the Internal Revenue Service.

 

	
For this type of account:
    	
 
    	
Give the social security number of –
    
	
 
    	
 
    	
 
    
	
1.               Individual
    	
 
    	
The Individual
    
	
 
    	
 
    	
 
    
	
2.               Two or more individuals   (joint account)
    	
 
    	
The actual owner of the account or, if combined funds, the first   individual on the account(1)
    
	
 
    	
 
    	
 
    
	
3.               Custodian account of a   minor (Uniform Gift to Minors Act)
    	
 
    	
The minor(2)
    
	
 
    	
 
    	
 
    
	
4.               a.  The usual revocable savings trust account   (grantor is also trustee)

 
    	
 
    	
The grantor-trustee(1)
    
	
                        b.  So-called trust account that is not a legal   or valid trust under state law
    	
 
    	
The actual owner(1)
    
	
 
    	
 
    	
 
    
	
5.               Sole proprietorship or   disregarded entity owned by an individual
    	
 
    	
The owner(3)
    

 

	
For this type of account:
    	
 
    	
Give the employer identification number
   of –
    
	
 
    	
 
    	
 
    
	
6.               Disregarded entity not   owned by an individual
    	
 
    	
The owner
    
	
 
    	
 
    	
 
    
	
7.               A valid trust, estate, or   pension trust
    	
 
    	
The legal entity(4)
    
	
 
    	
 
    	
 
    
	
8.               Corporation or LLC   electing corporate status on Form 8832
    	
 
    	
The corporation
    
	
 
    	
 
    	
 
    
	
9.               Association, club, religious,   charitable, educational, or other tax-exempt organization
    	
 
    	
The organization
    
	
 
    	
 
    	
 
    
	
10.         Partnership or   multi-member LLC
    	
 
    	
The partnership
    
	
 
    	
 
    	
 
    
	
11.         A broker or registered   nominee
    	
 
    	
The broker or nominee
    
	
 
    	
 
    	
 
    
	
12.         Account with the   Department of Agriculture in the name of a public entity (such as a state or   local government, school district, or prison) that receives agricultural   program payments
    	
 
    	
The public entity
    

 

(1)          List first and circle the name of the person whose number you furnish.  If only one person on a joint account has a social security number, that person’s number must be furnished.

(2)          Circle the minor’s name and furnish the minor’s social security number.

(3)          You must show your individual name, but you may also enter your business or “doing business as” name.  You may use either your social security number or your employer identification number (if you have one), but the IRS encourages you to use your SSN..

(4)          List first and circle the name of the trust, estate, or pension trust.  (Do not furnish the taxpayer identification number of the personal representative or trustee unless the legal entity itself is not designated in the account title.)

 

NOTE:  If no name is circled when there is more than one name, the number will be considered to be that of the first name listed.

 

Obtaining a Number

 

If you don’t have a taxpayer identification number or your don’t know your number, obtain Form SS-5, Application for a Social Security Card, at the local Social Administration office or online at www.ssa.gov, or Form SS-4, Application for Employer Identification Number, by calling 1 (800) TAX-FORM or online at www.irs.gov, and apply for a number.

 

Payees Exempt from Back up Withholding

 

The following payees are exempt from backup withholding:

 

·                  An organization exempt from tax under Section 501(a), an individual retirement account (IRA), or a custodial account under Section 403(b)(7), if the account satisfies the requirements of Section 401(f)(2).

·                  The United States or any of its agencies or instrumentalities.

·                  A state, the District of Columbia, a possession of the United States, or any of their political subdivisions or instrumentalities.

·                  An international organization or any of its agencies or instrumentalities.

·                  A foreign government or any of its political subdivisions, agencies or instrumentalities.

 

Other payees that may be exempt from backup withholding:

 

·                  A corporation.

·                  A foreign central bank of issue.

·                  A dealer in securities or commodities required to register in the United States, the District of Columbia, or a possession of the United States.

·                  A futures commission merchant registered with the Commodity Futures Trading Commission.

·                  A real estate investment trust.

·                  An entity registered at all times during the tax year under the Investment Company Act of 1940.

·                  A common trust fund operated by a bank under Section 584(a).

·                  A financial institution.

·                  A middleman known in the investment community as a nominee or custodian.

·                  A trust exempt from tax under Section 664 or described in Section 4947.

 

Dividends and patronage dividends that are generally exempt from backup withholding include:

 

·                  Payments to nonresident aliens subject to withholding under Section 1441.

·                  Payments to partnerships not engaged in a trade or business in the United States and that have at least one nonresident alien partner.

·                  Payments of patronage dividends not paid in money.

·                  Payments made by certain foreign organizations.

·                  Section 404(k) distributions made by an ESOP.

 

Interest payments that are generally exempt from backup withholding include:

 

·                  Payments of interest on obligations issued by individuals.  However, you may be subject to backup withholding if this interest is $600 or more and you have not provided your correct taxpayer identification number to the payer.

·                  Payment of tax-exempt interest (including exempt-interest dividends under Section 852).

·                  Payments described in Section 6049(b)(5) to nonresident aliens.

·                  Payments on tax-free covenant bonds under Section 1451.

·                  Payments made by certain foreign organizations.

·                  Mortgage or student loan interest paid to you.

 

Certain payments, other than payments of interest, dividends, and patronage dividends, that are exempt from information reporting are also exempt from backup withholding.  For details, see Sections 6041, 6041A, 6042, 6044, 6045, 6049, 6050A and 6050N, and the regulations thereunder.

 

Exempt payees described above should file Form W-9 or a substitute Form W-9 to avoid possible erroneous backup withholding.  IF YOU ARE EXEMPT FROM BACKUP WITHHOLDING, ENTER YOUR NAME, FURNISH YOUR TAXPAYER IDENTIFICATION NUMBER, CHECK THE BOX IN PART 2 OF THE FORM, SIGN AND DATE THE FORM, AND RETURN IT TO THE PAYER.

 

Privacy Act Notice. – Section 6109 of the Internal Revenue Code requires you to provide your correct TIN to persons who must file information returns with the IRS to report interest, dividends, and certain other income paid to you, mortgage interest you paid, the acquisition or abandonment of secured property, cancellation of debt, or contributions you made to an IRA, or Archer MSA or HSA. The IRS uses the numbers for identification purposes and to help verify the accuracy of your tax return. The IRS may also provide this information to the Department of Justice for civil and criminal litigation, and to cities, states, the District of Columbia, and U.S. possessions to carry out their tax laws. The IRS may also disclose this information to other countries under a tax treaty, to federal and state agencies to enforce federal nontax criminal laws, or to federal law enforcement and intelligence agencies to combat terrorism.  You must provide your TIN whether or not you are required to file a tax return. Payers must generally withhold 28% of taxable interest, dividend, and certain other payments to a payee who does not give a TIN to a payer. Certain penalties may also apply.

 

Penalties

 

(1)  Failure to Furnish Taxpayer Identification Number. – If you fail to furnish your taxpayer identification number to a payer, you are subject to a penalty of $50 for each such failure unless your failure is due to reasonable cause and not to willful neglect.

 

(2)  Civil Penalty for False Information With Respect to Withholding. – If you make a false statement with no reasonable basis that results in no backup withholding, you are subject to a $500 penalty.

 

(3)  Criminal Penalty for Falsifying Information. – Willfully falsifying certifications or affirmations may subject you to criminal penalties including fines and/or imprisonment.

 

FOR ADDITIONAL INFORMATION CONTACT YOUR TAX CONSULTANT OR THE INTERNAL REVENUE SERVICE

 

 

THE FOLLOWING W-8BEN

TO BE COMPLETED BY SHAREHOLDERS

THAT ARE NOT RESIDENTS OF THE UNITED STATES OF AMERICA

 

 

	
      Form W-8BEN

 

(Rev.   February 2006)

Department of the   Treasury Internal Revenue Service
    	
Certificate of Foreign   Status of Beneficial Owner

for United States Tax Withholding

·  Section references   are to the Internal Revenue Code. ·  See   separate instructions.

·  Give this form   to the withholding agent or payer. Do not send to the IRS.
    	
OMB No. 1545-1621
    
	
 
    	
 
    
	
Do not use this form for:
    	
Instead, use Form:
    
	
·
    	
A U.S. citizen or   other U.S. person, including a resident alien individual
    	
W-9
    
	
·
    	
A person claiming   that income is effectively connected with the conduct of a trade or business   in the United States
    	
W-8ECI
    
	
·
    	
A foreign   partnership, a foreign simple trust, or a foreign grantor trust (see   instructions for exceptions)
    	
W-8ECI or   W-8IMY
    
	
·
    	
A foreign government,   international organization, foreign central bank of issue, foreign tax-exempt   organization, foreign private foundation, or government of a U.S. possession   that received effectively connected income or that is claiming the   applicability of section(s) 115(2), 501(c), 892, 895, or   1443(b) (see instructions)
    	
W-8ECI or   W-8EXP
    
	
Note:   These entities should use Form W-8BEN if they are claiming   treaty benefits or are providing the form only to claim they are a foreign   person exempt from backup withholding.
    	
 
    
	
·
    	
A person acting as an intermediary
    	
W-8IMY Note: See   instructions for additional exceptions.
    
	
 
    	
 
    	
 
    
	
Part I
    	
Identification   of Beneficial Owner (See instructions.)
    
	
1
    	
Name of individual or organization that is the beneficial owner
    	
2  Country of incorporation or organization
    
	
 
    	
 
    	
 
    	
 
    
	
3
    	
Type of beneficial   owner:
    	
o Individual
    	
o Corporation
    	
o Disregarded entity
    	
o Partnership
    	
o Simple trust
    
	
 
    	
o Grantor trust
    	
o Complex trust
    	
o Estate
    	
o Government
    	
o International organization
    
	
 
    	
o Central bank of issue
    	
o Tax-exempt organization
    	
o Private foundation
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
4
    	
Permanent residence   address (street, apt. or suite no., or rural route). Do not use a P.O. box or in-care-of address.
    
	
 
    	
 
    	
 
    
	
 
    	
City or town, state   or province. Include postal code where appropriate.
    	
Country (do   not abbreviate)
    
	
 
    	
 
    	
 
    
	
5
    	
Mailing address (if   different from above)
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
City or town, state   or province. Include postal code where appropriate.
    	
Country (do   not abbreviate)
    
	
 
    	
 
    	
 
    
	
6
    	
U.S. taxpayer   identification number, if required (see instructions)

o SSN or ITIN    o EIN
    	
7  Foreign tax identifying number, if any   (optional)
    
	
 
    
	
8
    	
Reference   number(s) (see instructions)
    	
 
    
	
 
    
	
Part II
    	
Claim   of Tax Treaty Benefits (if applicable)
    
	
9 I certify that (check all that apply):
    
	
a
    	
o
    	
The beneficial owner is a resident of                             within   the meaning of the income tax treaty between the United States and that   country.
    
	
b
    	
o
    	
If required, the U.S.   taxpayer identification number is stated on line 6 (see instructions).
    
	
c
    	
o
    	
The beneficial owner is not an individual, derives the item (or items) of   income for which the treaty benefits are claimed, and, if applicable, meets   the requirements of the treaty provision dealing with limitation on benefits   (see instructions).
    
	
d
    	
o
    	
The beneficial owner is not an individual, is claiming treaty benefits   for dividends received from a foreign corporation or interest from a U.S.   trade or business of a foreign corporation, and meets qualified resident   status (see instructions).
    
	
e
    	
o
    	
The beneficial owner is related to the person obligated to pay the income   within the meaning of section 267(b) or 707(b), and will file   Form 8833 if the amount subject to withholding received during a   calendar year exceeds, in the aggregate, $500,000.
    
	
 
    	
 
    	
 
    
	
10 Special rates and conditions (if applicable—see instructions): The   beneficial owner is claiming the provisions of Article                   of the treaty identified on line 9a above to claim a                       % rate of withholding on (specify type of income):                            Explain the reasons the beneficial owner meets the terms of the treaty   article:                              
    
	
 
    
	
Part III
    	
Notional Principal Contracts
    
	
 
    	
o
    	
I have   provided or will provide a statement that identifies those notional principal   contracts from which the income is not effectively   connected with the conduct of a trade or business in the United States. I   agree to updatethis statement as required.
    
	
 
    	
 
    	
 
    
	
Part IV
    	
Certification
    
																		

Under penalties of perjury, I declare that I have examined the information on this form and to the best of my knowledge and belief it is true, correct, and complete. I further certify under penalties of perjury that:

1 I am the beneficial owner (or am authorized to sign for the beneficial owner) of all the income to which this form relates,

2 The beneficial owner is not a U.S. person,

3 The income to which this form relates is (a) not effectively connected with the conduct of a trade or business in the United States, (b) effectively connected but is not subject to tax under an income tax treaty, or (c) the partner’s share of a partnership’s effectively connected income, and

4 For broker transactions or barter exchanges, the beneficial owner is an exempt foreign person as defined in the instructions.

Furthermore, I authorize this form to be provided to any withholding agent that has control, receipt, or custody of the income of which I am the beneficial owner or any withholding agent that can disburse or make payments of the income of which I am the beneficial owner.

 

	
 
    	
 
    	
 
    	
 
    
	
Sign Here
    	
Signature of beneficial owner (or individual   authorized to sign for beneficial owner)
    	
Date (MM-DD-YYYY)
    	
Capacity in which acting
    

 

 

	
Form W-8IMY

(Rev.   February 2006)

 

Department of the   Treasury Internal Revenue Service
    	
Certificate of Foreign Intermediary,   
   Foreign Flow-Through Entity, or Certain U.S.
   Branches for United States Tax Withholding

·  Section references are to   the Internal Revenue Code. ·  See separate instructions.

·  Give this form to the withholding   agent or payer. Do not send to the IRS.
    	
OMB No. 1545-1621
    
	
 
    	
 
    	
 
    
	
Do not use this form for:
    	
Instead, use Form:
    
	
·
    	
A beneficial owner   solely claiming foreign status or treaty benefits
    	
W-8BEN
    
	
·
    	
A hybrid entity   claiming treaty benefits on its own behalf
    	
W-8BEN
    
	
·
    	
A person claiming   that income is effectively connected with the conduct of a trade or business   in the United States
    	
W-8ECI
    
	
·
    	
A disregarded entity.   Instead, the single foreign owner should use
    	
W-8BEN or   W-8ECI
    
	
·
    	
A foreign government,   international organization, foreign central bank of issue, foreign tax-exempt   organization, foreign private foundation, or government of a U.S. possession   claiming the applicability of section(s) 115(2), 501(c), 892, 895, or   1443(b)
    	
W-8EXP
    
					

 

	
Part I
    	
Identification   of Entity
    
	
1
    	
 
    	
Name of individual or organization that is acting as intermediary
    	
2    Country of incorporation or organization
    
	
 
    	
 
    	
 
    	
 
    
	
3
    	
 
    	
Type of entity—check   the appropriate box:
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
o Withholding foreign trust. Complete   Part V.
    
	
 
    	
 
    	
o    Qualified intermediary. Complete Part II.
    	
 
    	
o Nonwithholding foreign partnership. Complete   Part VI.
    
	
 
    	
 
    	
o    Nonqualified intermediary. Complete Part III.
    	
 
    	
o Nonwithholding foreign simple trust.   Complete Part VI.
    
	
 
    	
 
    	
o  U.S.   branch. Complete Part IV.
    	
 
    	
o Nonwithholding foreign grantor trust.   Complete Part VI.
    
	
 
    	
 
    	
o    Withholding foreign partnership. Complete Part V.
    	
 
    	
 
    
	
 
    	
 
    	
Permanent residence   address (street, apt. or suite no., or rural route). Do not use P.O. box.
    
	
 
    	
 
    	
 
    
	
City or town,   state or province. Include postal code where appropriate.
    	
Country (do   not abbreviate)
    
	
 
    	
 
    
	
5
    	
 
    	
Mailing address (if   different from above)  
    
	
 
    	
 
    	
 
    
	
City or town,   state or province. Include postal code where appropriate.
    	
Country (do   not abbreviate)
    
	
 
    	
 
    
	
 
    	
U.S. taxpayer   identification number (if required, see instructions) 110:
    	
7    Foreign tax identifying number, if any   (optional)
    
	
 
    	
o  SSN or ITIN
    	
o  EIN
    	
o  QI-EIN
    	
o
    	
 
    
	
8
    	
Reference   number(s) (see instructions)
    
	
 
    	
 
    
	
Part II
    	
Qualified   Intermediary
    
	
9a
    	
o
    	
(All qualified intermediaries check here) I certify that the entity   identified in Part I:
    
	
 
    	
 
    	
·      Is a qualified intermediary and is not acting   for its own account with respect to the account(s) identified on line 8   or in a withholding statement associated with this form and

·      Has provided or will provide a   withholding statement, as required.
    
	
 
    	
 
    	
 
    
	
  b
    	
o
    	
(If applicable) I certify that the entity identified in Part I has   assumed primary withholding responsibility under Chapter 3 of the Code with   respect to the account(s) identified on this line 9b or in a withholding   statement associated with this form ·
    
	
 
    	
 
    	
 
    
	
  c
    	
o
    	
(If applicable) I certify that the entity identified in Part I has   assumed primary Form 1099 reporting and backup withholding   responsibility as authorized in its withholding agreement with the IRS with   respect to the account(s) identified on this line 9c or in a withholding   statement associated with this form ·
    
	
 
    	
 
    	
 
    
	
Part III
    	
Nonqualified   Intermediary
    
	
10a
    	
o
    	
(All nonqualified intermediaries check here) I certify that the entity   identified in Part I is not a qualified intermediary and is not acting   for its own account.
    
	
 
    	
 
    	
 
    
	
   b
    	
o
    	
(If applicable) I certify that the entity identified in Part I is   using this form to transmit withholding certificates and/or other documentary   evidence and has provided or will provide a withholding statement, as required.
    
											

 

 

	
 
    	
Part IV  Certain United States Branches
    

Note: You may use this Part if the entity identified in Part l is a U.S. branch of a foreign bank or insurance company and is subject to certain regulatory requirements (see instructions).

	
 
    	
 
    	
  o  I certify that the entity identified in   Part I is a U.S. branch and that the payments are not effectively   connected with the conduct of a trade or business in the United States.
    
	
Check   box 12 or box 13, whichever applies:
    
	
12
    	
o
    	
I certify that the entity identified in Part I is using this form as   evidence of its agreement with the withholding agent to be treated as a U.S.   person with respect to any payments associated with this certificate.
    
	
13
    	
o
    	
I certify that the entity identified in Part I:
    
	
 
    	
 
    	
·      Is using this form to transmit withholding   certificates or other documentary evidence for the persons for whom the   branch receives a payment and

·      Has   provided or will provide a withholding statement, as required.
    
	
 
    	
 
    	
 
    
	
Part V
    	
Withholding   Foreign Partnership or Withholding Foreign Trust
    
	
14
    	
o
    	
I certify that the entity identified in Part I:
    
	
 
    	
 
    	
·      Is a withholding foreign partnership or a   withhholding foreign trust and

·      Has provided or will provide a   withholding statement, as required.
    
	
 
    	
 
    	
 
    
	
Part VI
    	
Nonwithholding   Foreign Partnership, Simple Trust, or Grantor Trust
    
	
15
    	
o
    	
I certify that the entity identified in Part I:
    
	
 
    	
 
    	
·      Is a nonwithholding foreign partnership, a   nonwithholding foreign simple trust, or a nonwithholding foreign grantor   trust and that the payments to which this certificate relates are not   effectively connected, or are not treated as effectively connected, with the   conduct of a trade or business in the United States and

·      Is   using this form to transmit withholding certificates and/or other documentary   evidence and has provided or will provide a withholding statement, as   required.
    
	
 
    	
 
    	
 
    
	
Part VII
    	
Certification
    
				

 

Under penalties of perjury, I declare that I have examined the information on this form and to the best of my knowledge and belief it is true, correct, and complete. Furthermore, I authorize this form to be provided to any withholding agent that has control, receipt, or custody of the income for which I am providing this form or any withholding agent that can disburse or make payments of the income for which I am providing this form.

 

	
Sign Here
    	
Signature of authorized official
    	
Date (MM-DD-YYYY)
    

 

2

 

LETTER OF TRANSMITTAL DELIVERY INSTRUCTIONS

 

By mail, Hand or Overnight Carrier, to:

 

Kathryn Ostman, Esq.

Bingham McCutchen LLP

One Federal Street

Boston, MA 02110

617-951-8637

 

With a copy to:

 

Nicholas Harvey

Chief Financial Officer

Radius Health, Inc.

201 Broadway

Sixth Floor

Cambridge, MA 02139

 

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE PARENT.

 

 

 

Exhibit D

 

1

 

REDEMPTION AGREEMENT

 

This Agreement (the “Agreement”) is made as of April 25, 2011, by and between MPM Acquisition Corp., a Delaware corporation (the “Issuer”), and MPM Asset Management LLC, a Delaware limited liability company (the “Seller”).

 

W I T N E S S E T H:

 

WHEREAS, the Seller is the owner of five million (5,000,000) shares of the Issuer’s common stock, par value $0.0001 per share (“Common Stock”), and

 

WHEREAS, the Seller desires to sell to the Issuer, and the Issuer desires to re-purchase from the Seller, five million (5,000,000) shares of Common Stock (the “Shares”), on and subject to the terms of this Agreement;

 

WHEREFORE, the parties hereto hereby agree as follows:

 

1.               Sale of the Shares. Subject to the terms and conditions of this Agreement, and in reliance upon the representations, warranties, covenants and agreements contained in this Agreement, the Seller shall sell the Shares to the Issuer, and the Issuer shall re-purchase the Shares from the Seller, for a purchase price equal to an aggregate sum of fifty thousand dollars ($50,000) (the “Purchase Price”).

 

2.               Closing.

 

(a)           The purchase and sale of the Shares shall take place at a closing (the “Closing”), to occur concurrently with the completion of the merger transaction (the “Merger”) contemplated by that certain Agreement and Plan of Merger of even date herewith (the “Merger Agreement”) among the Issuer, Radius Health, Inc. and RHI Merger Corp. The parties hereto shall have no obligation to complete the Closing in the event the Merger is not consummated.

 

(b)             At the Closing:

 

(i) The Seller shall deliver to the Issuer certificates representing the Shares, duly endorsed in form for transfer to the Issuer.

 

(ii) The Issuer shall pay to the Seller the Purchase Price for the Shares.

 

(iii)  At, and at any time after, the Closing, the parties shall duly execute, acknowledge and deliver all such further assignments, conveyances, instruments and documents, and shall take such other action consistent with the terms of this Agreement to carry out the transactions contemplated by this Agreement.

 

3.               Representations and Warranties of the Issuer. The Issuer hereby makes the following representations and warranties to the Seller:

 

2

 

(a)             The Issuer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Issuer has the corporate power to own its properties and to carry on its business as now being conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the failure to be so qualified and in good standing would have a material adverse effect on the Issuer. The Issuer is not in violation of any of the provisions of its certificate of incorporation or by-laws. No consent, approval or agreement of any individual or entity is required to be obtained by the Issuer in connection with the execution and performance by the Issuer of this Agreement or the execution and performance by the Issuer of any agreements, instruments or other obligations entered into in connection with this Agreement.

 

(b)             The Issuer has authorized capital stock consisting of 100,000,000 shares of Issuer Common Stock, and 10,000,000 shares of preferred stock, par value $0.0001 per share (the “Preferred Stock”), of which 5,000,000 shares of Common Stock, consisting of the Shares, and no shares of Preferred Stock, are the only shares presently issued and outstanding.

 

(c)             There is no private or governmental action, suit, proceeding, claim, arbitration or investigation pending before any agency, court or tribunal, foreign or domestic, or, to the Issuer’s knowledge, threatened against the Issuer or any of its properties or any of its officers or directors (in their capacities as such). There is no judgment, decree or order against the Issuer that could prevent, enjoin, alter or delay any of the transactions contemplated by this Agreement. The term “Issuer’s knowledge” shall mean and include actual knowledge of the Seller or of any member, director or officer of the Issuer.

 

(d)             There are no material claims, actions, suits, proceedings, inquiries, labor disputes or investigations (whether or not purportedly on behalf of the Issuer) pending or, to the Issuer’s knowledge, threatened against the Issuer or any of its assets, at law or in equity or by or before any governmental entity or in arbitration or mediation. No bankruptcy, receivership or debtor relief proceedings are pending or, to the best of the Issuer’s knowledge, threatened against the Issuer.

 

(e)             The Issuer has complied with, is not in violation of, and has not received any notices of violation with respect to, any federal, state, local or foreign Law, judgment, decree, injunction or order, applicable to it, the conduct of its business, or the ownership or operation of its business. References in this Agreement to “Laws” shall refer to any laws, rules or regulations of any federal, state or local government or any governmental or quasi-governmental agency, bureau, commission, instrumentality or judicial body (including, without limitation, any federal or state securities law, regulation, rule or administrative order).

 

(f)              The Issuer has properly filed all tax returns required to be filed and has paid all taxes shown thereon to be due. To the Issuer’s knowledge, all tax returns previously filed are true and correct in all material respects.

 

3

 

(g)             The Issuer has no outstanding liabilities or obligations to any party except as reflected on the Issuer’s Form 10-K for the year ended December 31, 2010, other than charges since such date similar to those incurred in past periods and consistent with past practice, all of which will be discharged prior to or at the Closing so that, at the Closing, the Issuer will have no direct, contingent or other obligations of any kind or any commitment or contractual obligations of any kind and description.

 

(h)             All of the business and financial transactions of the Issuer have been fully and properly reflected in the books and records of the Issuer in all material respects and in accordance with generally accepted accounting principles consistently applied.

 

(i)              The Issuer is current with its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). None of the Issuer’s filings made pursuant to the Exchange Act (collectively, the “Issuer SEC Documents”) contain any misstatements of material fact or omit to state a material fact necessary to make the statements made therein not misleading. The Issuer SEC Documents, as of their respective dates, complied in all material respects with the requirements of the Exchange Act, and the rules and regulations of the Commission thereunder, and are available on the Commission’s EDGAR system. There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Issuer, from that set forth in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2010.

 

(j)              As of the Closing, the Issuer will have assets sufficient to satisfy its payment obligations set forth in Section 1 hereof and the redemption contemplated hereby shall be permitted by the Delaware General Corporation Law. The execution and delivery of this Agreement by the Issuer and the Seller and the consummation of the transactions contemplated by this Agreement will not result in any violation of the Issuer’s certificate of incorporation or by-laws or any applicable Law, including without limitation, the Delaware General Corporation Law.

 

(k)             All representations, covenants and warranties of the Issuer contained in this Agreement shall be true and correct on and as of the Closing Date with the same effect as though the same had been made on and as of such date.

 

4.               Representations and Warranties of the Seller. The Seller hereby makes the following representations and warranties to the Issuer:

 

(a)             The Seller is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware. The Seller has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and otherwise to carry out its obligations hereunder. The Seller is not in violation of any of the provisions of its constitutive or governing documents. No consent, approval or agreement of any individual or entity is required to be obtained by the Seller in connection with the execution and performance by the Seller

 

4

 

of this Agreement or the execution and performance by the Issuer of any agreements, instruments or other obligations entered into in connection with this Agreement.

 

(b)             The Seller owns the Shares free and clear of all any and all liens, claims, encumbrances, preemptive rights, right of first refusal and adverse interests of any kind.

 

(c)             There is no private or governmental action, suit, proceeding, claim, arbitration or investigation pending before any agency, court or tribunal, foreign or domestic, or, to the Seller’s knowledge, threatened against the Seller or any of its properties or any of its officers or directors (in their capacities as such). There is no judgment, decree or order against the Seller that could prevent, enjoin, alter or delay any of the transactions contemplated by this Agreement. The term “Seller’s knowledge” shall mean and include actual knowledge of the Seller or of any director or officer of the Seller.

 

(d)             No bankruptcy, receivership or debtor relief proceedings are pending or, to the best of the Seller’s knowledge, threatened against the Seller.

 

(e)             All representations, covenants and warranties of the Seller contained in this Agreement shall be true and correct on and as of the Closing Date with the same effect as though the same had been made on and as of such date.

 

5.               Termination by Mutual Agreement. This Agreement may be terminated at any time by mutual consent of the parties hereto, provided that such consent to terminate is in writing and is signed by each of the parties hereto.

 

6.               Miscellaneous.

 

(a)             Entire Agreement. This Agreement constitutes the entire agreement of the parties, superseding and terminating any and all prior or contemporaneous oral and written agreements, understandings or letters of intent between or among the parties with respect to the subject matter of this Agreement. No part of this Agreement may be modified or amended, nor may any right be waived, except by a written instrument which expressly refers to this Agreement, states that it is a modification or amendment of this Agreement and is signed by the parties to this Agreement, or, in the case of waiver, by the party granting the waiver. No course of conduct or dealing or trade usage or custom and no course of performance shall be relied on or referred to by any party to contradict, explain or supplement any provision of this Agreement, it being acknowledged by the parties to this Agreement that this Agreement is intended to be, and is, the complete and exclusive statement of the agreement with respect to its subject matter. Any waiver shall be limited to the express terms thereof and shall not be construed as a waiver of any other provisions or the same provisions at any other time or under any other circumstances.

 

5

 

(b)             Severability. If any section, term or provision of this Agreement shall to any extent be held or determined to be invalid or unenforceable, the remaining sections, terms and provisions shall nevertheless continue in full force and effect.

 

(c)             Notices. All notices provided for in this Agreement shall be in writing signed by the party giving such notice, and delivered personally or sent by overnight courier, mail or messenger against receipt thereof or sent by registered or certified mail, return receipt requested, or by facsimile transmission or similar means of communication if receipt is confirmed or if transmission of such notice is confirmed by mail as provided in this Section 5(c). Notices shall be deemed to have been received on the date of personal delivery or telecopy or attempted delivery. Notice shall be delivered to the parties at the following addresses:

 

	
If   to the Issuer:
    	
 
    	
c/o MPM Acquisition Corp.
    
	
 
    	
 
    	
200   Clarendon Street, 54th Floor
    
	
 
    	
 
    	
Boston,   Massachusetts 02116
    
	
 
    	
 
    	
Facsimile:   (617) 425-9201
    
	
 
    	
 
    	
Attn:   C. Richard Lyttle, Ph.D.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
If   to Seller:
    	
 
    	
MPM   Asset Management LLC
    
	
 
    	
 
    	
200   Clarendon Street, 54th Floor
    
	
 
    	
 
    	
Boston,   Massachusetts 02116
    
	
 
    	
 
    	
Facsimile:   (617) 425-9201
    
	
 
    	
 
    	
Attn:   Dr. Ansbert Gadicke
    

 

Either party may, by like notice, change the address, person or telecopier number to which notice shall be sent.

 

(d)             Governing Law. This Agreement shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts applicable to agreements executed and to be performed wholly within such Commonwealth, without regard to any principles of conflicts of law. Each of the parties hereby irrevocably consents and agrees that any legal or equitable action or proceeding arising under or in connection with this Agreement shall be brought in the federal or state courts located in the County of Suffolk in the Commonwealth of Massachusetts, by execution and delivery of this Agreement, irrevocably submits to and accepts the jurisdiction of said courts, (iii) waives any defense that such court is not a convenient forum, and (iv) consent to any service of process made either (x) in the manner set forth in Section 6(c) of this Agreement (other than by telecopier), or (y) any other method of service permitted by law.

 

(e)             Waiver of Jury Trial. EACH PARTY HEREBY EXPRESSLY WAIVES ANY RIGHT TO A TRIAL BY JURY IN THE EVENT OF ANY SUIT, ACTION OR PROCEEDING TO ENFORCE THIS AGREEMENT OR ANY OTHER ACTION OR PROCEEDING WHICH MAY ARISE OUT OF OR IN ANY WAY BE CONNECTED WITH THIS AGREEMENT OR ANY OF THE OTHER DOCUMENTS.

 

6

 

(f)              Successors. This Agreement shall be binding upon the parties and their respective heirs, executors, administrators, legal representatives, successors and assigns; provided, however, that neither party may assign this Agreement or any of its rights under this Agreement without the prior written consent of the other party.

 

(g)             Further Assurances. Each party to this Agreement agrees, without cost or expense to any other party, to deliver or cause to be delivered such other documents and instruments as may be reasonably requested by any other party to this Agreement in order to carry out more fully the provisions of, and to consummate the transaction contemplated by, this Agreement.

 

(h)             Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

(i)              Headings. The headings in the Sections of this Agreement are inserted for convenience only and shall not constitute a part of this Agreement.

 

[Remainder of this page intentionally left blank.]

 

7

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	
 
    	
MPM   ACQUISITION CORP.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
C.   Richard Lyttle, Ph.D.
    
	
 
    	
Title:
    	
President   and Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
 
    	
MPM   ASSET MANAGEMENT LLC
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
MPM   Capital LP, its sole Member and Manager
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
Medical   Portfolio Management, LLC, its general partner
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    	
Name:   Dr. Ansbert Gadicke
    
	
 
    	
 
    	
 
    	
Title:
    

 

8

 

 

Exhibit E

 

 

INDEMNIFICATION AGREEMENT

 

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of May       , 2011 between Radius Health, Inc., a Delaware corporation (the “Company”), and                                (“Indemnitee”).

 

WITNESSETH THAT:

 

WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.  Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions.  At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself.  The Bylaws and Certificate of Incorporation of the Company require indemnification of the officers and directors of the Company.  Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (“DGCL”).  The Bylaws, Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the Bylaws and Certificate of Incorporation of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee

 

 

thereunder; and

 

WHEREAS, Indemnitee does not regard the protection available under the Company’s Bylaws and Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as a director without adequate protection, and the Company desires Indemnitee to serve in such capacity.  Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and

 

NOW, THEREFORE, in consideration of Indemnitee’s agreement to serve as a director from and after the date hereof, the parties hereto agree as follows:

 

1.             Indemnity of Indemnitee.  The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time.  In furtherance of the foregoing indemnification, and without limiting the generality thereof:

 

(a)           Proceedings Other Than Proceedings by or in the Right of the Company.  Indemnitee shall be entitled to the rights of indemnification provided in this Section l(a) if, by reason of his Corporate Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company.  Pursuant to this Section 1(a), Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him, or on his behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful.

 

(b)           Proceedings by or in the Right of the Company.  Indemnitee shall be entitled to the rights of indemnification provided in this Section 1(b) if, by reason of his Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company.  Pursuant to this Section 1(b), Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee’s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of Chancery of the State of Delaware shall determine that such indemnification may be made.

 

(c)           Indemnification for Expenses of a Party Who is Wholly or Partly Successful.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than

 

 

all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter.  For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

2.             Additional Indemnity.  In addition to, and without regard to any limitations on, the indemnification provided for in Section 1 of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf if, by reason of his Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee.  The only limitation that shall exist upon the Company’s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Sections 6 and 7 hereof) to be unlawful.

 

3.             Contribution.

 

(a)           Whether or not the indemnification provided in Sections 1 and 2 hereof is available, in respect of any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.  The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.

 

(b)           Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction from which such action, suit or proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which the Law may require to be considered.  The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who

 

 

are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.

 

(c)           The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.

 

(d)           To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

4.             Indemnification for Expenses of a Witness.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness, or is made (or asked to) respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

5.             Advancement of Expenses.  Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding.  Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.  Any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest free.

 

6.             Procedures and Presumptions for Determination of Entitlement to Indemnification.  It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the DGCL and public policy of the State of Delaware.  Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement:

 

(a)           To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine

 

 

whether and to what extent Indemnitee is entitled to indemnification.  The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.  Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.

 

(b)           Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 6(a) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the board:  (1) by a majority vote of the disinterested directors, even though less than a quorum, (2) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum, (3) if there are no disinterested directors or if the disinterested directors so direct, by independent legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee, or (4) if so directed by the Board of Directors, by the stockholders of the Company.  For purposes hereof, disinterested directors are those members of the board of directors of the Company who are not parties to the action, suit or proceeding in respect of which indemnification is sought by Indemnitee.

 

(c)           If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this Section 6(c).  The Independent Counsel shall be selected by the Board of Directors.  Indemnitee may, within 10 days after such written notice of selection shall have been given, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 13 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.  If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 6(b) hereof.  The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 6(b) hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 6(c), regardless of the manner in which such Independent Counsel was selected or appointed.

 

(d)           In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement.  Anyone seeking to

 

 

overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.  Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(e)           Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise (as hereinafter defined) in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise.  In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.  Whether or not the foregoing provisions of this Section 6(e) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

(f)            If the person, persons or entity empowered or selected under Section 6 to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 6(f) shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 6(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board of Directors or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.

 

(g)           Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and

 

 

which is reasonably available to Indemnitee and reasonably necessary to such determination.  Any Independent Counsel, member of the Board of Directors or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the Indemnitee’s entitlement to indemnification under this Agreement.  Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

(h)           The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.  In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

(i)            The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

7.             Remedies of Indemnitee.

 

(a)           In the event that (i) a determination is made pursuant to Section 6 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 5 of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to Section 6(b) of this Agreement within 90 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of Indemnitee’s entitlement to such indemnification.  Indemnitee shall commence such proceeding seeking an adjudication within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 7(a).  The Company shall not oppose Indemnitee’s right to seek any such adjudication.

 

(b)           In the event that a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 7 shall be conducted in all respects as a de novo

 

 

trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under Section 6(b).

 

(c)           If a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this Section 7, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s misstatement not materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)           In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of his rights under, or to recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types described in the definition of Expenses in Section 13 of this Agreement) actually and reasonably incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery.

 

(e)           The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement.  The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.

 

(f)            Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.

 

8.             Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation.

 

(a)           The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution of directors or otherwise, of the Company.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal.  To the extent that a change in the DGCL, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Certificate of Incorporation, Bylaws and this Agreement, it is the

 

 

 

intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

(b)           To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies.  If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 

(c)           In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

(d)           Except as provided in paragraph (c) above, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)           Except as provided in paragraph (c) above, the Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

9.             Exception to Right of Indemnification. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

(a)           for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)           for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 

 

 

16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or

 

(c)           in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board of Directors of the Company authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

10.           Duration of Agreement.  All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under Section 7 hereof) by reason of his Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.  This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.

 

11.           Security.  To the extent requested by Indemnitee and approved by the Board of Directors of the Company, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.  Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.

 

12.           Enforcement.

 

(a)           The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company.

 

(b)           This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

13.           Definitions.  For purposes of this Agreement:

 

(a)           “Corporate Status” describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company.

 

 

(b)           “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(c)           “Enterprise” shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.

 

(d)           “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.  Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(e)           “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent:  (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.  The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

(f)            “Proceeding” includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of the fact that Indemnitee is or was an officer or director of the Company, by reason of any action taken by him or of any inaction on his part while acting as an officer or director of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise; in each case whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding 

 

 

one initiated by an Indemnitee pursuant to Section 7 of this Agreement to enforce his rights under this Agreement.

 

14.           Severability.  The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.  Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws.  In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.

 

15.           Modification and Waiver.  No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

 

16.           Notice By Indemnitee.  Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder.  The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.

 

17.           Notices.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given:  (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent:

 

(a)                                  To Indemnitee at the address set forth below Indemnitee signature hereto.

 

(b)                                 To the Company at:

 

Radius Health, Inc.
 201 Broadway, 6th Floor

Cambridge,  Massachusetts 02139

Attention: Chief Executive Officer

 

or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

 

18.           Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.  This Agreement may also be executed and delivered by facsimile 

 

 

signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

19.           Headings.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

20.           Governing Law and Consent to Jurisdiction.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

 

SIGNATURE PAGE TO FOLLOW

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and year first above written.

 

 

	
 
    	
RADIUS HEALTH, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:   
    	
C.   Richard Edmund Lyttle
    
	
 
    	
 
    	
Title:
    	
Chief   Executive Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
INDEMNITEE
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:
    
	
 
    	
 
    	
 
    
	
 
    	
Address:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
					

 

 

Disclosure Schedules

 

 

RADIUS HEALTH, INC.

 

Schedule to the Agreement and Plan of Merger, dated April 25, 2011 (the “Merger  Agreement”).

 

                The following Schedules are delivered by Radius Health, Inc., a Delaware corporation (the “Corporation”) in connection with the closing of the transactions contemplated by the Merger Agreement (the “Closing”).

 

Schedule 2.2(f)

 

Effect on Radius Capital Stock and Merger Sub Capital Stock

 

1.               The Corporation has entered into Stock Option Agreements with the following individuals:

 

	
Option
   Number
    	
 
    	
Name
    	
 
    	
Grant Date
    	
 
    	
Options Outstanding
    	
 
    
	
04-051
    	
 
    	
Ho,   Sam
    	
 
    	
5/4/2004
    	
 
    	
—
    	
 
    
	
03-002
    	
 
    	
Lane,   Ben
    	
 
    	
12/16/2003
    	
 
    	
—
    	
 
    
	
03-003
    	
 
    	
Henderson,   Bart
    	
 
    	
12/16/2003
    	
 
    	
—
    	
 
    
	
03-001
    	
 
    	
Hattersley,   Gary
    	
 
    	
12/16/2003
    	
 
    	
162,500
    	
 
    
	
03-005
    	
 
    	
Manolagas,   Stavros
    	
 
    	
11/14/2003
    	
 
    	
—
    	
 
    
	
03-008
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
11/14/2003
    	
 
    	
—
    	
 
    
	
03-007
    	
 
    	
Potts,   John Thomas
    	
 
    	
11/14/2003
    	
 
    	
—
    	
 
    
	
03-006
    	
 
    	
Katsenellenbogen,   John
    	
 
    	
11/14/2003
    	
 
    	
—
    	
 
    
	
03-004
    	
 
    	
Pitzele,   Barnett
    	
 
    	
12/16/2003
    	
 
    	
—
    	
 
    
	
04-072
    	
 
    	
Glass,   Chris
    	
 
    	
8/12/2004
    	
 
    	
10,000
    	
 
    
	
04-052
    	
 
    	
Estabrook,   Edith
    	
 
    	
5/4/2004
    	
 
    	
24,000
    	
 
    
	
04-071
    	
 
    	
Colbourn,   Kelly
    	
 
    	
8/12/2004
    	
 
    	
—
    	
 
    
	
04-103
    	
 
    	
Lyttle,   Richard
    	
 
    	
10/28/2004
    	
 
    	
1,625,000
    	
 
    
	
04-101
    	
 
    	
Guy,   Keisha
    	
 
    	
10/28/2004
    	
 
    	
—
    	
 
    
	
04-102
    	
 
    	
McIntyre,   Dotty
    	
 
    	
10/28/2004
    	
 
    	
—
    	
 
    
	
04-100
    	
 
    	
Shomali,   Maysoun
    	
 
    	
12/28/2004
    	
 
    	
—
    	
 
    
	
05-01
    	
 
    	
Glass,   Chris
    	
 
    	
12/6/2005
    	
 
    	
10,000
    	
 
    
	
06-02
    	
 
    	
Hattersley,   Gary
    	
 
    	
2/15/2006
    	
 
    	
81,250
    	
 
    
	
06-04
    	
 
    	
Guy,   Keisha
    	
 
    	
2/15/2006
    	
 
    	
—
    	
 
    
	
06-05
    	
 
    	
McIntyre,   Dotty
    	
 
    	
2/15/2006
    	
 
    	
—
    	
 
    
	
06-06
    	
 
    	
Shomali,   Maysoun
    	
 
    	
2/15/2006
    	
 
    	
—
    	
 
    
	
06-01
    	
 
    	
Ho,   Sam
    	
 
    	
2/15/2006
    	
 
    	
—
    	
 
    
	
06-03
    	
 
    	
Colbourn,   Kelly
    	
 
    	
2/15/2006
    	
 
    	
—
    	
 
    
	
06-07
    	
 
    	
O’Dea,   Louis
    	
 
    	
2/15/2006
    	
 
    	
339,625
    	
 
    
	
07-01
    	
 
    	
McIntyre,   Dotty
    	
 
    	
7/12/2007
    	
 
    	
—
    	
 
    
	
07-08
    	
 
    	
Lyttle,   Richard
    	
 
    	
7/12/2007
    	
 
    	
2,377,688
    	
 
    
	
07-07
    	
 
    	
O’Dea,   Louis
    	
 
    	
7/12/2007
    	
 
    	
623,206
    	
 
    
	
07-09
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
7/12/2007
    	
 
    	
1,250,840
    	
 
    
	
07-06
    	
 
    	
Hattersley,   Gary
    	
 
    	
7/12/2007
    	
 
    	
356,653
    	
 
    
	
07-10
    	
 
    	
Miller,   Chris
    	
 
    	
7/12/2007
    	
 
    	
500,336
    	
 
    
	
07-11
    	
 
    	
Katsenellenbogen,   John
    	
 
    	
7/12/2007
    	
 
    	
100,000
    	
 
    

 

1

 

	
07-12
    	
 
    	
Potts,   John Thomas
    	
 
    	
7/12/2007
    	
 
    	
540,790
    	
 
    
	
07-13
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
7/12/2007
    	
 
    	
412,805
    	
 
    
	
07-02
    	
 
    	
Shomali,   Maysoun
    	
 
    	
7/12/2007
    	
 
    	
—
    	
 
    
	
07-03
    	
 
    	
Estabrook,   Edith
    	
 
    	
7/12/2007
    	
 
    	
16,000
    	
 
    
	
07-05
    	
 
    	
Lumpkins,   Mary
    	
 
    	
7/12/2007
    	
 
    	
3,000
    	
 
    
	
07-04
    	
 
    	
Guerriero,   Jonathan
    	
 
    	
7/12/2007
    	
 
    	
62,500
    	
 
    
	
07-14
    	
 
    	
Grunwald,   Maria
    	
 
    	
12/6/2007
    	
 
    	
137,500
    	
 
    
	
07-15
    	
 
    	
Herendeen,   Hillary
    	
 
    	
12/6/2007
    	
 
    	
—
    	
 
    
	
07-16
    	
 
    	
Downall,   Julie
    	
 
    	
12/6/2007
    	
 
    	
—
    	
 
    
	
08-01
    	
 
    	
Welch,   Kathy
    	
 
    	
2/7/2008
    	
 
    	
60,000
    	
 
    
	
08-09
    	
 
    	
Lyttle,   Richard
    	
 
    	
5/8/2008
    	
 
    	
3,040,081
    	
 
    
	
08-05
    	
 
    	
O’Dea,   Louis
    	
 
    	
5/8/2008
    	
 
    	
1,064,028
    	
 
    
	
08-06
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
5/8/2008
    	
 
    	
950,025
    	
 
    
	
08-08
    	
 
    	
Hattersley,   Gary
    	
 
    	
5/8/2008
    	
 
    	
456,012
    	
 
    
	
08-07
    	
 
    	
Miller,   Chris
    	
 
    	
5/8/2008
    	
 
    	
356,259
    	
 
    
	
08-02
    	
 
    	
McCarthy,   Daniel F.
    	
 
    	
5/8/2008
    	
 
    	
30,000
    	
 
    
	
08-03
    	
 
    	
Zielstorff,   Mark
    	
 
    	
5/8/2008
    	
 
    	
—
    	
 
    
	
08-04
    	
 
    	
Gallacher,   Kyla
    	
 
    	
5/8/2008
    	
 
    	
—
    	
 
    
	
08-14
    	
 
    	
Lyttle,   Richard
    	
 
    	
12/3/2008
    	
 
    	
1,295,640
    	
 
    
	
08-10
    	
 
    	
O’Dea,   Louis
    	
 
    	
12/3/2008
    	
 
    	
453,474
    	
 
    
	
08-11
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
12/3/2008
    	
 
    	
404,888
    	
 
    
	
08-13
    	
 
    	
Hattersley,   Gary
    	
 
    	
12/3/2008
    	
 
    	
194,346
    	
 
    
	
08-12
    	
 
    	
Miller,   Chris
    	
 
    	
12/3/2008
    	
 
    	
101,221
    	
 
    
	
08-26
    	
 
    	
Potts,   John Thomas
    	
 
    	
12/3/2008
    	
 
    	
167,891
    	
 
    
	
08-25
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
12/3/2008
    	
 
    	
204,715
    	
 
    
	
08-16
    	
 
    	
Grunwald,   Maria
    	
 
    	
12/3/2008
    	
 
    	
82,500
    	
 
    
	
08-15
    	
 
    	
Guerriero,   Jonathan
    	
 
    	
12/3/2008
    	
 
    	
120,000
    	
 
    
	
08-17
    	
 
    	
Shomali,   Maysoun
    	
 
    	
12/3/2008
    	
 
    	
—
    	
 
    
	
08-18
    	
 
    	
Welch,   Kathy
    	
 
    	
12/3/2008
    	
 
    	
36,000
    	
 
    
	
08-19
    	
 
    	
Estabrook,   Edie
    	
 
    	
12/3/2008
    	
 
    	
24,000
    	
 
    
	
08-20
    	
 
    	
McCarthy,   Daniel F.
    	
 
    	
12/3/2008
    	
 
    	
18,000
    	
 
    
	
08-21
    	
 
    	
Gallacher,   Kyla
    	
 
    	
12/3/2008
    	
 
    	
—
    	
 
    
	
08-22
    	
 
    	
Zielstorff,   Mark
    	
 
    	
12/3/2008
    	
 
    	
—
    	
 
    
	
08-23
    	
 
    	
Downall,   Julie
    	
 
    	
12/3/2008
    	
 
    	
—
    	
 
    
	
08-24
    	
 
    	
Lumpkins,   Mary
    	
 
    	
12/3/2008
    	
 
    	
3,000
    	
 
    
	
09-01
    	
 
    	
Sullivan,   Kelly
    	
 
    	
4/9/2009
    	
 
    	
25,000
    	
 
    
	
09-02
    	
 
    	
McKay,   Kathleen
    	
 
    	
4/9/2009
    	
 
    	
—
    	
 
    
	
09-03
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
4/9/2009
    	
 
    	
75,000
    	
 
    
	
09-04
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
12/2/2009
    	
 
    	
75,000
    	
 
    
	
10-01
    	
 
    	
Auerbach,   Alan
    	
 
    	
10/12/2010
    	
 
    	
2,084,602
    	
 
    
	
10-02
    	
 
    	
Auerbach,   Alan
    	
 
    	
10/12/2010
    	
 
    	
1,765,398
    	
 
    
	
10-03
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
11/30/2010
    	
 
    	
25,000
    	
 
    

 

2

 

Schedule 2.2(g)

 

Effect on Radius Capital Stock and Merger Sub Capital Stock

 

[Please see Schedule 3.4(a)]

 

3

 

Disclosure Schedule to the Merger Agreement

 

This Schedule sets forth exceptions to the representations and warranties of the Corporation to be given at the Closing (which exceptions shall be deemed to be representations and warranties as if made under the Purchase Agreement).  The information in this Schedule is provided as of the Closing Date.

 

The disclosure of any item or information in this Schedule shall not be construed as an admission that such item or information is material to the Corporation, and any inclusion in the Schedule shall expressly not be deemed to constitute an admission, or otherwise imply, that any such item or information is material or creates measures of materiality for the purposes of the Merger Agreement.  Nothing in this Schedule constitutes an admission of any liability or obligation of the Corporation to any third party, nor an admission to any third party against the Corporation’s interests.

 

With respect to any matter that is clearly disclosed in any Section of this Schedule in such a way as to make its relevance to the information called for by another Section of this Schedule readily apparent, such matter shall be deemed to have been included in the Schedule in response to such other Section, notwithstanding the omission of any appropriate cross-reference thereto. The Section numbers referred to in this Schedule correspond to the Section numbers in the Merger Agreement.  Capitalized terms not otherwise defined in this Schedule shall have the meanings set forth in the Merger Agreement.

 

4

 

Schedule 3.4(a)

 

Capitalization

 

1.               Capitalization of the Corporation as of the date of the Merger Agreement:

 

RADIUS CAPITALIZATION

 

	
 
    	
 
    	
Before A-1 Financing and Merger, post reverse split
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A
    	
 
    	
Series B 
    	
 
    	
Series C
    	
 
    	
Series A
   Warrants
    	
 
    	
Common 
    	
 
    	
Options
    	
 
    	
Shares Out
    	
 
    	
Shares Out %
    	
 
    	
Fully Diluted
   Shares
    	
 
    	
Fully Diluted
   %
    	
 
    
	
Preferred
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MPM Bioventures III, L.P.
    	
 
    	
 
    	
 
    	
29,850
    	
 
    	
121,944
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
151,794
    	
 
    	
1.24
    	
%
    	
151,794
    	
 
    	
1.09
    	
%
    
	
MPM Bioventures III-QP,   L.P.
    	
 
    	
 
    	
 
    	
443,959
    	
 
    	
1,813,643
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,257,602
    	
 
    	
18.41
    	
%
    	
2,257,602
    	
 
    	
16.24
    	
%
    
	
MPM Bioventures III GMBH   & Co. Beteiligungs KG
    	
 
    	
 
    	
 
    	
37,520
    	
 
    	
153,275
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
190,795
    	
 
    	
1.56
    	
%
    	
190,795
    	
 
    	
1.37
    	
%
    
	
MPM Bioventures III   Parallel Fund, L.P.
    	
 
    	
 
    	
 
    	
13,408
    	
 
    	
54,773
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
68,181
    	
 
    	
0.56
    	
%
    	
68,181
    	
 
    	
0.49
    	
%
    
	
MPM Asset Management   Investors 2003 BVIII LLC
    	
 
    	
 
    	
 
    	
8,595
    	
 
    	
35,114
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
43,709
    	
 
    	
0.36
    	
%
    	
43,709
    	
 
    	
0.31
    	
%
    
	
MPM Bio IV NVS Strategic   Fund
    	
 
    	
 
    	
 
    	
—
    	
 
    	
1,842,426
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,842,426
    	
 
    	
15.03
    	
%
    	
1,842,426
    	
 
    	
13.26
    	
%
    
	
Wellcome Trust
    	
 
    	
 
    	
 
    	
—
    	
 
    	
2,103,250
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,103,250
    	
 
    	
17.15
    	
%
    	
2,103,250
    	
 
    	
15.13
    	
%
    
	
HealthCare Ventures VII
    	
 
    	
 
    	
 
    	
800,000
    	
 
    	
1,234,986
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,034,986
    	
 
    	
16.60
    	
%
    	
2,034,986
    	
 
    	
14.64
    	
%
    
	
Oxford Bioscience Partners   IV
    	
 
    	
 
    	
 
    	
264,017
    	
 
    	
1,147,967
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,411,984
    	
 
    	
11.52
    	
%
    	
1,411,984
    	
 
    	
10.16
    	
%
    
	
mRNA Fund II
    	
 
    	
 
    	
 
    	
2,648
    	
 
    	
11,517
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
14,165
    	
 
    	
0.12
    	
%
    	
14,165
    	
 
    	
0.10
    	
%
    
	
BB Biotech Ventures II
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,051,625
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,051,625
    	
 
    	
8.58
    	
%
    	
1,051,625
    	
 
    	
7.57
    	
%
    
	
Scottish Widows
    	
 
    	
 
    	
 
    	
 
    	
 
    	
560,866
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
560,866
    	
 
    	
4.57
    	
%
    	
560,866
    	
 
    	
4.04
    	
%
    
	
Dr. Raymond F. Schinazi
    	
 
    	
4,142
    	
 
    	
 
    	
 
    	
15,243
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
19,385
    	
 
    	
0.16
    	
%
    	
19,385
    	
 
    	
0.14
    	
%
    
	
David E. Thompson   Revocable Trust
    	
 
    	
16,190
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
16,190
    	
 
    	
0.13
    	
%
    	
16,190
    	
 
    	
0.12
    	
%
    
	
Hostetler Family Trust UTD   3/18/92 Karl Y. Hostetler, Trustee
    	
 
    	
15,357
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
15,357
    	
 
    	
0.13
    	
%
    	
15,357
    	
 
    	
0.11
    	
%
    
	
H.Watt Gregory, III
    	
 
    	
10,957
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10,957
    	
 
    	
0.09
    	
%
    	
10,957
    	
 
    	
0.08
    	
%
    
	
The Richman Trust dated   2/6/83 Douglas D. Richman, Co-Trustee
    	
 
    	
5,357
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5,357
    	
 
    	
0.04
    	
%
    	
5,357
    	
 
    	
0.04
    	
%
    
	
Breining Family Trust
    	
 
    	
3,357
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
3,357
    	
 
    	
0.03
    	
%
    	
3,357
    	
 
    	
0.02
    	
%
    
	
Dr. Dennis A. Carson
    	
 
    	
2,666
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,666
    	
 
    	
0.02
    	
%
    	
2,666
    	
 
    	
0.02
    	
%
    
	
B Van Wyck
    	
 
    	
1,819
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,819
    	
 
    	
0.01
    	
%
    	
1,819
    	
 
    	
0.01
    	
%
    
	
Jonnie K. Westbrook
    	
 
    	
1,819
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,819
    	
 
    	
0.01
    	
%
    	
1,819
    	
 
    	
0.01
    	
%
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Common
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Alan Auerbach
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
256,666
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
256,666
    	
 
    	
1.85
    	
%
    
	
Stavros C. Manolagas
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
91,040
    	
 
    	
 
    	
 
    	
91,040
    	
 
    	
0.74
    	
%
    	
91,040
    	
 
    	
0.66
    	
%
    
	
Michael Rosenblatt
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
46,664
    	
 
    	
41,168
    	
 
    	
46,664
    	
 
    	
0.38
    	
%
    	
87,832
    	
 
    	
0.63
    	
%
    
	
John Thomas Potts Trust
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
20,291
    	
 
    	
—
    	
 
    	
20,291
    	
 
    	
0.17
    	
%
    	
20,291
    	
 
    	
0.15
    	
%
    
	
John Thomas Potts, Jr.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
4,496
    	
 
    	
47,245
    	
 
    	
4,496
    	
 
    	
0.04
    	
%
    	
51,741
    	
 
    	
0.37
    	
%
    
	
John Katzenellenbogen   Trust
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
40,438
    	
 
    	
—
    	
 
    	
40,438
    	
 
    	
0.33
    	
%
    	
40,438
    	
 
    	
0.29
    	
%
    
	
John Katzenellenbogen
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
8,961
    	
 
    	
6,666
    	
 
    	
8,961
    	
 
    	
0.07
    	
%
    	
15,627
    	
 
    	
0.11
    	
%
    
	
Bart Henderson
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
30,468
    	
 
    	
—
    	
 
    	
30,468
    	
 
    	
0.25
    	
%
    	
30,468
    	
 
    	
0.22
    	
%
    

 

5

 

RADIUS CAPITALIZATION

 

	
 
    	
 
    	
Before A-1 Financing and Merger, post reverse split
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A
    	
 
    	
Series B
    	
 
    	
Series C
    	
 
    	
Series A
   Warrants
    	
 
    	
Common
    	
 
    	
Options
    	
 
    	
Shares Out
    	
 
    	
Shares Out %
    	
 
    	
Fully Diluted
   Shares
    	
 
    	
Fully Diluted
   %
    	
 
    
	
Board of Trustees of the Uni of Arkansas
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
17,333
    	
 
    	
 
    	
 
    	
17,333
    	
 
    	
0.14
    	
%
    	
17,333
    	
 
    	
0.12
    	
%
    
	
Sillicon Valley Bank
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,333
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
1,333
    	
 
    	
0.01
    	
%
    
	
Ben Lane
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
8,125
    	
 
    	
 
    	
 
    	
8,125
    	
 
    	
0.07
    	
%
    	
8,125
    	
 
    	
0.06
    	
%
    
	
Ruff Trust, F. Bronson Van Wyck, Trustee
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
0.04
    	
%
    	
5,124
    	
 
    	
0.04
    	
%
    
	
H2 Enterprises, LLC
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
0.04
    	
%
    	
5,124
    	
 
    	
0.04
    	
%
    
	
Dr. Karl Y. Hostetler
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
 
    	
 
    	
5,124
    	
 
    	
0.04
    	
%
    	
5,124
    	
 
    	
0.04
    	
%
    
	
Czerepak, Elizabeth
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
11,666
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
11,666
    	
 
    	
0.08
    	
%
    
	
Stavroula Kousteni, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
421
    	
 
    	
—
    	
 
    	
421
    	
 
    	
0.00
    	
%
    	
421
    	
 
    	
0.00
    	
%
    
	
Robert L. Jilka, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
572
    	
 
    	
—
    	
 
    	
572
    	
 
    	
0.00
    	
%
    	
572
    	
 
    	
0.00
    	
%
    
	
Robert S. Weinstein, M.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
421
    	
 
    	
—
    	
 
    	
421
    	
 
    	
0.00
    	
%
    	
421
    	
 
    	
0.00
    	
%
    
	
Teresita M.   Bellido, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
234
    	
 
    	
—
    	
 
    	
234
    	
 
    	
0.00
    	
%
    	
234
    	
 
    	
0.00
    	
%
    
	
Chris Glass
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,333
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
1,333
    	
 
    	
0.01
    	
%
    
	
Dotty McIntyre, RA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
891
    	
 
    	
—
    	
 
    	
891
    	
 
    	
0.01
    	
%
    	
891
    	
 
    	
0.01
    	
%
    
	
Thomas E. Sparks, Jr.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
883
    	
 
    	
 
    	
 
    	
883
    	
 
    	
0.01
    	
%
    	
883
    	
 
    	
0.01
    	
%
    
	
Sam Ho
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
833
    	
 
    	
—
    	
 
    	
833
    	
 
    	
0.01
    	
%
    	
833
    	
 
    	
0.01
    	
%
    
	
Charles O’Brien, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
140
    	
 
    	
—
    	
 
    	
140
    	
 
    	
0.00
    	
%
    	
140
    	
 
    	
0.00
    	
%
    
	
Alwyn Michael Parfitt, M.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
280
    	
 
    	
 
    	
 
    	
280
    	
 
    	
0.00
    	
%
    	
280
    	
 
    	
0.00
    	
%
    
	
Barry Pitzele
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
266
    	
 
    	
—
    	
 
    	
266
    	
 
    	
0.00
    	
%
    	
266
    	
 
    	
0.00
    	
%
    
	
Benita S. Katzenellenbogen, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
187
    	
 
    	
 
    	
 
    	
187
    	
 
    	
0.00
    	
%
    	
187
    	
 
    	
0.00
    	
%
    
	
Kelly Colbourn
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
102
    	
 
    	
—
    	
 
    	
102
    	
 
    	
0.00
    	
%
    	
102
    	
 
    	
0.00
    	
%
    
	
Julie Glowacki, Ph.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
93
    	
 
    	
 
    	
 
    	
93
    	
 
    	
0.00
    	
%
    	
93
    	
 
    	
0.00
    	
%
    
	
Socrates E.   Papapoulos, M.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
93
    	
 
    	
 
    	
 
    	
93
    	
 
    	
0.00
    	
%
    	
93
    	
 
    	
0.00
    	
%
    
	
Tonya D. Smith
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
66
    	
 
    	
 
    	
 
    	
66
    	
 
    	
0.00
    	
%
    	
66
    	
 
    	
0.00
    	
%
    
	
Kent Westbrook, M.D.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
46
    	
 
    	
 
    	
 
    	
46
    	
 
    	
0.00
    	
%
    	
46
    	
 
    	
0.00
    	
%
    
	
Edie Estabrook
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
4,266
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
4,266
    	
 
    	
0.03
    	
%
    
	
Maysoun Shomali, Sr. RA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,383
    	
 
    	
 
    	
 
    	
2,383
    	
 
    	
0.02
    	
%
    	
2,383
    	
 
    	
0.02
    	
%
    
	
Lumpkins, Mary
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
400
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
400
    	
 
    	
0.00
    	
%
    
	
Guerriero, Jonathan
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,500
    	
 
    	
12,166
    	
 
    	
2,500
    	
 
    	
0.02
    	
%
    	
14,666
    	
 
    	
0.11
    	
%
    
	
Grunwald, Maria
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
14,666
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
14,666
    	
 
    	
0.11
    	
%
    
	
McCarthy, Daniel F.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
3,200
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
3,200
    	
 
    	
0.02
    	
%
    
	
Sullivan, Kelly
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1,666
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
1,666
    	
 
    	
0.01
    	
%
    
	
Welch, Kathy
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6,400
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
6,400
    	
 
    	
0.05
    	
%
    
	
Richard Lyttle
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
66,666
    	
 
    	
489,227
    	
 
    	
66,666
    	
 
    	
0.54
    	
%
    	
555,893
    	
 
    	
4.00
    	
%
    
	
Louis O’Dea
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
29,207
    	
 
    	
165,355
    	
 
    	
29,207
    	
 
    	
0.24
    	
%
    	
194,562
    	
 
    	
1.40
    	
%
    
	
Nick Harvey
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
30,000
    	
 
    	
143,716
    	
 
    	
30,000
    	
 
    	
0.24
    	
%
    	
173,716
    	
 
    	
1.25
    	
%
    
	
Gary Hattersley
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
83,384
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
83,384
    	
 
    	
0.60
    	
%
    
	
Chris Miller
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
33,355
    	
 
    	
30,498
    	
 
    	
33,355
    	
 
    	
0.27
    	
%
    	
63,853
    	
 
    	
0.46
    	
%
    
	
ESOP Remaining
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
315,172
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
315,172
    	
 
    	
2.27
    	
%
    
	
Additions to Option Plan
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    	
 
    	
0.00
    	
%
    	
—
    	
 
    	
0.00
    	
%
    
	
Total
    	
 
    	
61,664.00
    	
 
    	
1,599,997.00
    	
 
    	
10,146,629.00
    	
 
    	
1,333.00
    	
 
    	
452,827.00
    	
 
    	
1,634,860.00
    	
 
    	
12,261,117.00
    	
 
    	
100.00
    	
%
    	
13,897,310.00
    	
 
    	
100.00
    	
%
    
	
%Total Fully Diluted
    	
 
    	
0.4
    	
%
    	
11.5
    	
%
    	
73.0
    	
%
    	
0.0
    	
%
    	
3.3
    	
%
    	
11.8
    	
%
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Share   Price
    	
 
    	
$
    	
15.00
    	
 
    	
$
    	
8.14
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
$
    	
8.14
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Amount
    	
 
    	
$
    	
23,999,955
    	
 
    	
$
    	
82,613,853
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
$
    	
113,151,898
    	
 
    	
 
    	
 
    

 

6

 

2.               In connection with that certain Loan and Security Agreement, dated as of August 6, 2004, by and between the Corporation and Silicon Valley Bank (“SVB”), as amended, the Corporation issued to SVB a warrant exercisable for the purchase of an aggregate of up to 20,000 shares of Series A Junior Convertible Preferred Stock at $1.00 per share.  The warrant, which expires in August 2014, will be amended and restated as of the Stage I Closing Date to purchase shares of the Corporation’s common stock.  The warrant was 100% vested as of the grant date.

 

3.               Series A Convertible Redeemable Preferred Stock Purchase Agreement, dated November 14, 2003, by and among the Corporation and the stockholders listed on the schedules thereto.

 

4.               Series B Convertible Redeemable Preferred Stock Purchase Agreement, dated November 14, 2003, by and among the Corporation and the stockholders listed on the schedules thereto.

 

5.               Series C Convertible Redeemable Preferred Stock Purchase Agreement, dated December 15, 2006, by and among the Corporation and the Investors referenced therein, as amended by Amendment No. 1 thereto, dated February 12, 2007, Amendment No. 2 thereto, dated February 22, 2007, Amendment No. 3 thereto, dated August 17, 2007, and Amendment No. 4 thereto, dated November 14, 2008.

 

6.               Fourth Amended and Restated Certificate of Incorporation of the Corporation filed with the Secretary of State of the State of Delaware on May 17, 2011.

 

7.               Growth Capital Loan Proposal Letter by and among the Corporation, GE Healthcare Financial Services, Inc., and Oxford Finance Corporation, dated December 21, 2010.  The proposed loan documents would include an obligation of the Corporation to issue a warrant to purchase Series A-1 Convertible Preferred Stock for 4% of the principal as drawn, equaling $1,000,000 (4% of $25 million).

 

8.               In connection with that certain Letter Agreement by and between the Corporation and Leerink Swann LLC (“Leerink”), dated September 24, 2010, the Corporation is obligated to issue a warrant to purchase Series A-1 Convertible Preferred Stock of the Corporation (the “Leerink Warrant”).

 

9.               Stock Issuance Agreement by and between the Corporation and Nordic Bioscience Clinical Development VII A/S (“Nordic”), dated March 29, 2011.

 

10.         In connection with that certain License Agreement, dated September 27, 2005, by and between SCRAS S.A.S., a French corporation, with its principal office at 42, Rue du Docteur Blanche, 75016 Paris, France, on behalf of itself and its Affiliates (collectively, “Ipsen”), and the Corporation, as amended on September 12, 2007, and assigned by SCRAS S.A.S. to successor Ipsen Pharma SAS on January 1, 2009 (the “Ipsen License Agreement”), the Corporation is currently in discussions with Ipsen to make its payment milestones to Ipsen pursuant to the Ipsen License Agreement with shares of Series A-1 Preferred Stock at $8.142 per share.

 

11.         2007 Amended and Restated Management and Employee Bonus Plan approved at a meeting of the Board of Directors of the Corporation held on October 1, 2009 and approved by the Stockholders by written consent on November 11, 2009, which shall be terminated by written agreement of the participants effective upon the Closing.

 

7

 

Schedule 3.4(b)

 

Capitalization

 

[Please see Schedule 3.4(a)]

 

8

 

Schedule 3.8

 

Tax Matters

 

None.

 

9

 

Schedule 3.9

 

Contracts and Commitments

 

A.           Loan Agreements

 

1.               Growth Capital Loan Proposal Letter by and among the Corporation, GE Healthcare Financial Services, Inc., and Oxford Finance Corporation, dated December 21, 2010.

 

2.               Demand Promissory Note issued by MPM Acquisition Corp. to the Corporation, dated November 22, 2010.

 

B.             License Agreements

 

1.               Ipsen License Agreement.

 

2.               Pharmaceutical Development Agreement by and between the Corporation and Ipsen, dated January 2, 2006, as amended by Amendment No. 1, dated January 1, 2007, Amendment No. 2, dated January 1, 2009, and Amendment No. 3, dated June 16, 2010.

 

3.               License Agreement, dated June 29, 2006, by and between Eisai Co. and the Corporation.

 

C.             Research, Development and/or Service Agreements

 

1.                           Development and Clinical Supplies Agreement by and between the Corporation, 3M Company and 3M Innovative Properties (3M Company and 3M Innovative Properties, collectively, “3M”), dated June 19, 2009, as amended on each of May 5, 2009, December 31, 2009, March 3, 2010, September 16, 2010, September 29, 2010, February 4, 2011, and March 2, 2011.

 

2.                           Letter of Payment Authorization for Study No. 670364 by and between the Corporation and Charles River Laboratories (“CRL”), dated November 20, 2010.

 

3.                           Letter of Payment Authorization for Dawley Rat - Rat Bone Quality Study by and between the Corporation and CRL, dated February 7, 2011.

 

4.                           Work Order No. 2 by and between the Corporation and LONZA Sales Ltd. (“Lonza”), dated January 15, 2010, as amended April 27, 2010, and as further amended December 15, 2010.

 

5.                           Letter Agreement by and between the Corporation and Leerink , dated February 4, 2010.

 

6.                           Letter Agreement by and between the Corporation and Leerink, dated September 24, 2010.

 

7.                           Stock Issuance Agreement by and between the Corporation and Nordic, dated March 29, 2011.

 

8.                           Amendment Letter by and between the Corporation and Nordic, dated February 1, 2011.

 

10

 

9.                           Clinical Trial Services Agreement and Work Statement NB-1 by and between the Corporation and Nordic, dated March 29, 2011.

 

10.                     Side Letter by and between the Corporation and Nordic, dated March 29, 2011.

 

11.                     Engagement Letter by and between the Corporation and Ernst & Young LLP, dated October 5, 2010.

 

12.                     Master Clinical Services Agreement by and between the Corporation and Celerion, Inc., dated November 2, 2010, as amended by Work Order No. 1, dated November 3, 2010.

 

13.                     Change Order No. 2 to Statement of Work by and between the Corporation and INC Research, Inc., dated September 3, 2010.

 

14.                     Letter of Payment Authorization for Chronic Dermal Toxicity Study by and between the Corporation and CRL, dated April 29, 2011.

 

D.            Real Property

 

1.               Sublease by and between the Corporation and Sonos, Inc., dated January 14, 2011, for the property located at 201 Broadway, Cambridge, Massachusetts.

 

E.              Other Agreements

 

1.               Radius Health, Inc. 401(k) Plan

 

2.               Radius Health, Inc. Flexible Spending Account Plan

 

F.              Stock Option Plans

 

1.               2003 Long Term Incentive Plan

 

2.               2007 Management and Employee Bonus Plan approved at a meeting of the Board of Directors of the Corporation held on December 6, 2007 and approved by the Stockholders by written consent on February 14, 2008, which shall be terminated by written agreement of the participants effective upon the Closing.

 

11

 

G.             Stock Option Agreements

 

The Corporation has entered into Stock Option Agreements with the following individuals:

 

	
Option
   Number
    	
 
    	
Name
    	
 
    	
# Options
    	
 
    	
Grant Date
    	
 
    	
Options
   Canceled
    	
 
    	
Options
   Outstanding
    	
 
    
	
04-051
    	
 
    	
Ho,   Sam
    	
 
    	
10,000
    	
 
    	
5/4/2004
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
03-002
    	
 
    	
Lane,   Ben
    	
 
    	
325,000
    	
 
    	
12/16/2003
    	
 
    	
203,125
    	
 
    	
—
    	
 
    
	
03-003
    	
 
    	
Henderson,   Bart
    	
 
    	
650,000
    	
 
    	
12/16/2003
    	
 
    	
192,969
    	
 
    	
—
    	
 
    
	
03-001
    	
 
    	
Hattersley,   Gary
    	
 
    	
162,500
    	
 
    	
12/16/2003
    	
 
    	
 
    	
 
    	
162,500
    	
 
    
	
04-003
    	
 
    	
O’Brien,   Charles
    	
 
    	
8,000
    	
 
    	
2/5/2004
    	
 
    	
 
    	
 
    	
8,000
    	
 
    
	
04-005
    	
 
    	
Kousteni,   Stavroula
    	
 
    	
30,000
    	
 
    	
2/5/2004
    	
 
    	
 
    	
 
    	
30,000
    	
 
    
	
03-005
    	
 
    	
Manolagas,   Stavros
    	
 
    	
1,108,812
    	
 
    	
11/14/2003
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
03-008
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
370,241
    	
 
    	
11/14/2003
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
03-007
    	
 
    	
Potts,   John Thomas
    	
 
    	
304,374
    	
 
    	
11/14/2003
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
03-006
    	
 
    	
Katsenellenbogen,   John
    	
 
    	
606,573
    	
 
    	
11/14/2003
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
03-004
    	
 
    	
Pitzele,   Barnett
    	
 
    	
5,000
    	
 
    	
12/16/2003
    	
 
    	
1,000
    	
 
    	
—
    	
 
    
	
04-001
    	
 
    	
Bellido,   Teresita
    	
 
    	
17,000
    	
 
    	
2/4/2004
    	
 
    	
 
    	
 
    	
17,000
    	
 
    
	
04-002
    	
 
    	
Jilka,   Robert
    	
 
    	
28,000
    	
 
    	
2/4/2004
    	
 
    	
 
    	
 
    	
25,725
    	
 
    
	
04-004
    	
 
    	
Weinstien,   Robert
    	
 
    	
17,000
    	
 
    	
2/4/2004
    	
 
    	
 
    	
 
    	
17,000
    	
 
    
	
04-072
    	
 
    	
Glass,   Chris
    	
 
    	
10,000
    	
 
    	
8/12/2004
    	
 
    	
 
    	
 
    	
10,000
    	
 
    
	
04-052
    	
 
    	
Estabrook,   Edith
    	
 
    	
24,000
    	
 
    	
5/4/2004
    	
 
    	
 
    	
 
    	
24,000
    	
 
    
	
04-071
    	
 
    	
Colbourn,   Kelly
    	
 
    	
1,000
    	
 
    	
8/12/2004
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
04-103
    	
 
    	
Lyttle,   Richard
    	
 
    	
1,625,000
    	
 
    	
10/28/2004
    	
 
    	
 
    	
 
    	
1,625,000
    	
 
    
	
04-101
    	
 
    	
Guy,   Keisha
    	
 
    	
8,000
    	
 
    	
10/28/2004
    	
 
    	
8,000
    	
 
    	
—
    	
 
    
	
04-102
    	
 
    	
McIntyre,   Dotty
    	
 
    	
8,000
    	
 
    	
10/28/2004
    	
 
    	
2,000
    	
 
    	
—
    	
 
    
	
04-100
    	
 
    	
Shomali,   Maysoun
    	
 
    	
15,000
    	
 
    	
12/28/2004
    	
 
    	
15,000
    	
 
    	
—
    	
 
    
	
05-01
    	
 
    	
Glass,   Chris
    	
 
    	
10,000
    	
 
    	
12/6/2005
    	
 
    	
 
    	
 
    	
10,000
    	
 
    
	
06-02
    	
 
    	
Hattersley,   Gary
    	
 
    	
81,250
    	
 
    	
2/15/2006
    	
 
    	
 
    	
 
    	
81,250
    	
 
    
	
06-04
    	
 
    	
Guy,   Keisha
    	
 
    	
8,000
    	
 
    	
2/15/2006
    	
 
    	
8,000
    	
 
    	
—
    	
 
    
	
06-05
    	
 
    	
McIntyre,   Dotty
    	
 
    	
8,000
    	
 
    	
2/15/2006
    	
 
    	
4,000
    	
 
    	
—
    	
 
    
	
06-06
    	
 
    	
Shomali,   Maysoun
    	
 
    	
15,000
    	
 
    	
2/15/2006
    	
 
    	
15,000
    	
 
    	
—
    	
 
    
	
06-01
    	
 
    	
Ho,   Sam
    	
 
    	
10,000
    	
 
    	
2/15/2006
    	
 
    	
7,500
    	
 
    	
—
    	
 
    
	
06-03
    	
 
    	
Colbourn,   Kelly
    	
 
    	
3,000
    	
 
    	
2/15/2006
    	
 
    	
2,469
    	
 
    	
—
    	
 
    
	
06-07
    	
 
    	
O’Dea,   Louis
    	
 
    	
570,000
    	
 
    	
2/15/2006
    	
 
    	
 
    	
 
    	
339,625
    	
 
    
	
07-01
    	
 
    	
McIntyre,   Dotty
    	
 
    	
27,000
    	
 
    	
7/12/2007
    	
 
    	
23,625
    	
 
    	
—
    	
 
    
	
07-08
    	
 
    	
Lyttle,   Richard
    	
 
    	
2,377,688
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
2,377,688
    	
 
    
	
07-07
    	
 
    	
O’Dea,   Louis
    	
 
    	
830,941
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
623,206
    	
 
    
	
07-09
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
1,250,840
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
1,250,840
    	
 
    
	
07-06
    	
 
    	
Hattersley,   Gary
    	
 
    	
356,653
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
356,653
    	
 
    
	
07-10
    	
 
    	
Miller,   Chris
    	
 
    	
500,336
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
—
    	
 
    
	
07-11
    	
 
    	
Katsenellenbogen,   John
    	
 
    	
100,000
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
100,000
    	
 
    
	
07-12
    	
 
    	
Potts,   John Thomas
    	
 
    	
540,790
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
540,790
    	
 
    
	
07-13
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
660,491
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
412,805
    	
 
    
	
07-02
    	
 
    	
Shomali,   Maysoun
    	
 
    	
44,000
    	
 
    	
7/12/2007
    	
 
    	
8,250
    	
 
    	
—
    	
 
    
	
07-03
    	
 
    	
Estabrook,   Edith
    	
 
    	
16,000
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
16,000
    	
 
    
	
07-05
    	
 
    	
Lumpkins,   Mary
    	
 
    	
3,000
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
3,000
    	
 
    
	
07-04
    	
 
    	
Guerriero,   Jonathan
    	
 
    	
100,000
    	
 
    	
7/12/2007
    	
 
    	
 
    	
 
    	
62,500
    	
 
    
	
07-14
    	
 
    	
Grunwald,   Maria
    	
 
    	
137,500
    	
 
    	
12/6/2007
    	
 
    	
 
    	
 
    	
137,500
    	
 
    

 

12

 

	
07-15
    	
 
    	
Herendeen,   Hillary
    	
 
    	
8,000
    	
 
    	
12/6/2007
    	
 
    	
8,000
    	
 
    	
—
    	
 
    
	
07-16
    	
 
    	
Downall,   Julie
    	
 
    	
8,000
    	
 
    	
12/6/2007
    	
 
    	
8,000
    	
 
    	
—
    	
 
    
	
08-01
    	
 
    	
Welch,   Kathy
    	
 
    	
60,000
    	
 
    	
2/7/2008
    	
 
    	
 
    	
 
    	
60,000
    	
 
    
	
08-09
    	
 
    	
Lyttle,   Richard
    	
 
    	
3,040,081
    	
 
    	
5/8/2008
    	
 
    	
 
    	
 
    	
3,040,081
    	
 
    
	
08-05
    	
 
    	
O’Dea,   Louis
    	
 
    	
1,064,028
    	
 
    	
5/8/2008
    	
 
    	
 
    	
 
    	
1,064,028
    	
 
    
	
08-06
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
950,025
    	
 
    	
5/8/2008
    	
 
    	
 
    	
 
    	
950,025
    	
 
    
	
08-08
    	
 
    	
Hattersley,   Gary
    	
 
    	
456,012
    	
 
    	
5/8/2008
    	
 
    	
 
    	
 
    	
456,012
    	
 
    
	
08-07
    	
 
    	
Miller,   Chris
    	
 
    	
380,010
    	
 
    	
5/8/2008
    	
 
    	
23,751
    	
 
    	
356,259
    	
 
    
	
08-02
    	
 
    	
McCarthy,   Daniel F.
    	
 
    	
30,000
    	
 
    	
5/8/2008
    	
 
    	
 
    	
 
    	
30,000
    	
 
    
	
08-03
    	
 
    	
Zielstorff,   Mark
    	
 
    	
10,000
    	
 
    	
5/8/2008
    	
 
    	
10,000
    	
 
    	
—
    	
 
    
	
08-04
    	
 
    	
Gallacher,   Kyla
    	
 
    	
10,000
    	
 
    	
5/8/2008
    	
 
    	
10,000
    	
 
    	
—
    	
 
    
	
08-14
    	
 
    	
Lyttle,   Richard
    	
 
    	
1,295,640
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
1,295,640
    	
 
    
	
08-10
    	
 
    	
O’Dea,   Louis
    	
 
    	
453,474
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
453,474
    	
 
    
	
08-11
    	
 
    	
Harvey,   B. Nicholas
    	
 
    	
404,888
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
404,888
    	
 
    
	
08-13
    	
 
    	
Hattersley,   Gary
    	
 
    	
194,346
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
194,346
    	
 
    
	
08-12
    	
 
    	
Miller,   Chris
    	
 
    	
161,955
    	
 
    	
12/3/2008
    	
 
    	
60,734
    	
 
    	
101,221
    	
 
    
	
08-26
    	
 
    	
Potts,   John Thomas
    	
 
    	
167,891
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
167,891
    	
 
    
	
08-25
    	
 
    	
Rosenblatt,   Michael
    	
 
    	
204,715
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
204,715
    	
 
    
	
08-16
    	
 
    	
Grunwald,   Maria
    	
 
    	
82,500
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
82,500
    	
 
    
	
08-15
    	
 
    	
Guerriero,   Jonathan
    	
 
    	
120,000
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
120,000
    	
 
    
	
08-17
    	
 
    	
Shomali,   Maysoun
    	
 
    	
50,000
    	
 
    	
12/3/2008
    	
 
    	
50,000
    	
 
    	
—
    	
 
    
	
08-18
    	
 
    	
Welch,   Kathy
    	
 
    	
36,000
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
36,000
    	
 
    
	
08-19
    	
 
    	
Estabrook,   Edie
    	
 
    	
24,000
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
24,000
    	
 
    
	
08-20
    	
 
    	
McCarthy,   Daniel F.
    	
 
    	
18,000
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
18,000
    	
 
    
	
08-21
    	
 
    	
Gallacher,   Kyla
    	
 
    	
6,000
    	
 
    	
12/3/2008
    	
 
    	
6,000
    	
 
    	
—
    	
 
    
	
08-22
    	
 
    	
Zielstorff,   Mark
    	
 
    	
6,000
    	
 
    	
12/3/2008
    	
 
    	
6,000
    	
 
    	
—
    	
 
    
	
08-23
    	
 
    	
Downall,   Julie
    	
 
    	
4,800
    	
 
    	
12/3/2008
    	
 
    	
4,800
    	
 
    	
—
    	
 
    
	
08-24
    	
 
    	
Lumpkins,   Mary
    	
 
    	
3,000
    	
 
    	
12/3/2008
    	
 
    	
 
    	
 
    	
3,000
    	
 
    
	
09-01
    	
 
    	
Sullivan,   Kelly
    	
 
    	
25,000
    	
 
    	
4/9/2009
    	
 
    	
 
    	
 
    	
25,000
    	
 
    
	
09-02
    	
 
    	
McKay,   Kathleen
    	
 
    	
45,000
    	
 
    	
4/9/2009
    	
 
    	
45,000
    	
 
    	
—
    	
 
    
	
09-03
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
75,000
    	
 
    	
4/9/2009
    	
 
    	
 
    	
 
    	
75,000
    	
 
    
	
09-04
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
75,000
    	
 
    	
12/2/2009
    	
 
    	
 
    	
 
    	
75,000
    	
 
    
	
10-01
    	
 
    	
Auerbach,   Alan
    	
 
    	
2,084,602
    	
 
    	
10/12/2010
    	
 
    	
 
    	
 
    	
2,084,602
    	
 
    
	
10-02
    	
 
    	
Auerbach,   Alan
    	
 
    	
1,765,398
    	
 
    	
10/12/2010
    	
 
    	
 
    	
 
    	
1,765,398
    	
 
    
	
10-03
    	
 
    	
Czerepak,   Elizabeth
    	
 
    	
25,000
    	
 
    	
11/30/2010
    	
 
    	
 
    	
 
    	
25,000
    	
 
    

 

13

 

H.            Consulting Agreements

 

The Corporation has entered into consulting agreements with the following parties:

 

	
Party
    	
 
    	
Effective Date
    
	
1.               Dr. John Bilezidian
    	
 
    	
9/14/2005
    
	
2.               Dr. David Archer
    	
 
    	
10/24/2005
    
	
3.               Beckloff   Associates, Inc
    	
 
    	
6/18/2004
    
	
4.               Terisita Bellido
    	
 
    	
6/24/2004
    
	
5.               Dr. M. Shalender   Bashin
    	
 
    	
1/3/2006
    
	
6.               IntaPro LLC
    	
 
    	
3/22/2005
    
	
7.               Access BIO, LC
    	
 
    	
7/8/2005
    
	
8.               Dr. John C. Chabala
    	
 
    	
5/3/2004
    
	
9.               SVC Associates, Inc
    	
 
    	
10/25/2005
    
	
10.         Burton G Christensen
    	
 
    	
7/23/2004
    
	
11.         Dr. Mitchell Creinin
    	
 
    	
10/17/2005
    
	
12.         Frame and Spence   Consulting LLP
    	
 
    	
7/21/2005
    
	
13.         Dr. Christopher Glass
    	
 
    	
9/1/2004
    
	
14.         Dr. Frances J. Hayes
    	
 
    	
4/21/2005
    
	
15.         TLG Consulting Inc
    	
 
    	
7/1/2005
    
	
16.         Robert A. Jassmond
    	
 
    	
4/18/2006
    
	
17.         Robert Jilka
    	
 
    	
6/24/2004
    
	
18.         Dr. John   Katzenellenbogen
    	
 
    	
11/14/2003
    
	
19.         Cathy Kerzner
    	
 
    	
11/18/2005
    
	
20.         Stavroula Kousteni
    	
 
    	
6/24/2004
    
	
21.         Richard Labaudiniere
    	
 
    	
1/1/2004
    
	
22.         Robert Lindsay
    	
 
    	
07/26/2004
    
	
23.         Willis Maddrey
    	
 
    	
07/23/2004
    
	
24.         Dr. Stavros C.   Manolagas
    	
 
    	
11/14/2003
    
	
25.         Dr. Stavros C.   Manolagas
    	
 
    	
12/14/2005
    
	
26.         Musso and Associates LLC
    	
 
    	
06/24/2005
    
	
27.         Musso and Associates LLC
    	
 
    	
03/08/2006
    
	
28.         Robert M. Neer
    	
 
    	
11/22/2005
    
	
29.         Anthony Norman
    	
 
    	
6/4/2004
    
	
30.         Charles O’Brien
    	
 
    	
06/24/2004
    
	
31.         Skokie Valley Consulting   Agrmt
    	
 
    	
12/01/2003
    
	
32.         PK Noonan &   Associates LLC
    	
 
    	
07/08/2005
    
	
33.         Dr. John Thomas   Potts, Jr
    	
 
    	
11/14/2003
    
	
34.         Dr. Cliff Rosen
    	
 
    	
07/22/2005
    
	
35.         Dr. Michael   Rosenblatt
    	
 
    	
11/14/2003
    
	
36.         Joseph S. Simon
    	
 
    	
07/08/2005
    
	
37.         Ian Smith
    	
 
    	
07/13/2004
    
	
38.         Gilbert Stork
    	
 
    	
07/13/2004
    
	
39.         KellySci Consulting Inc.
    	
 
    	
11/16/2007
    
	
40.         Robert J. Szot
    	
 
    	
06/22/2005
    
	
41.         Robert Weinstein
    	
 
    	
06/24/2004
    
	
42.         ChanTest Inc
    	
 
    	
11/08/2005
    
	
43.         Diamond BioPharm Ltd
    	
 
    	
10/26/2007
    
	
44.         Diamond BioPharm Ltd
    	
 
    	
8/15/2007
    

 

14

 

	
45.         Diamond BioPharm Ltd
    	
 
    	
8/15/2007
    
	
46.         Team Consulting Ltd
    	
 
    	
8/18/2007
    
	
47.         Joel Morganroth
    	
 
    	
10/23/2007
    
	
48.         Joel Morganroth
    	
 
    	
10/10/2006
    
	
49.         INTAPRO LLC
    	
 
    	
3/22/2005
    
	
50.         Roy Swaringen
    	
 
    	
3/6/2008
    
	
51.         Skokie Valley Consulting   Corp.
    	
 
    	
12/1/2003
    
	
52.         Target Health Inc.
    	
 
    	
4/14/2006
    
	
53.         LGL Consulting LLC
    	
 
    	
4/28/2008
    
	
54.         David Archer
    	
 
    	
3/26/2008
    
	
55.         Osheroff Consulting   Services LLC
    	
 
    	
8/15/2008
    
	
56.         Dylan J. Callahan a.k.a.   d/b/a Organized Minds
    	
 
    	
6/1/2008
    
	
57.         PK Noonan &   Associates LLC
    	
 
    	
9/15/2008
    
	
58.         Matrix BioAnalytical   Laboratories Inc
    	
 
    	
4/11/2008
    
	
59.         Prof David Handelsman
    	
 
    	
2/9/2009
    
	
60.         David Goltzman
    	
 
    	
3/4/2009
    
	
61.         Professor Dennis Black
    	
 
    	
4/14/2009
    
	
62.         Dr. Radha Iyengar
    	
 
    	
7/20/2009
    
	
63.         Frame and Spence   Consulting LLP
    	
 
    	
5/5/2009
    
	
64.         Access Bio LC
    	
 
    	
8/20/2009
    
	
65.         David Archer, MD
    	
 
    	
3/27/2009
    
	
66.         Jean-Francois Sibi
    	
 
    	
11/2/2009
    
	
67.         Diamond Biopharm Ltd
    	
 
    	
11/9/2009
    
	
68.         Harry Genant, MD
    	
 
    	
12/12/2009
    
	
69.         Radha Iyengar
    	
 
    	
1/19/2010
    
	
70.         Safety Partners, Inc.
    	
 
    	
06/03/2004
    
	
71.         Joel Morganroth
    	
 
    	
10/10/2006
    
	
72.         Joel Morganroth
    	
 
    	
10/23/2007
    
	
73.         Robert Schenken
    	
 
    	
07/24/2004
    
	
74.         Kathleen Banks
    	
 
    	
11/13/2009
    
	
75.         Goldmann Consulting LLC
    	
 
    	
7/5/2010
    
	
76.         Duck Flats Pharma LLC
    	
 
    	
8/2/2010
    
	
77.         Dennis Black
    	
 
    	
11/29/2010
    
	
78.         Welsh Consulting
    	
 
    	
1/20/2011
    
	
79.         Michael Gross
    	
 
    	
5/3/2011
    

 

I.                 Employment Agreements

 

1.               Letter Agreement by and between the Corporation and C. Richard Edmund Lyttle, dated July 2, 2004.

 

2.               Letter Agreement by and between the Corporation and B. Nicholas Harvey, dated November 15, 2006.

 

3.               Letter Agreement by and between the Corporation and Louis St. Laurence O’Dea, dated January 30, 2006, as amended by Letter Agreement dated July 21, 2008.

 

4.               Letter Agreement by and between the Corporation and Gary Hattersley, dated November 21, 2003, as amended by Letter Agreement dated July 21, 2008.

 

15

 

5.               See also Attachment A to this Schedule 3.9 for the Form of Letter Agreement entered into by and between the Corporation and its at-will employees.

 

J.                Contracts Relating to Election of Directors

 

1.               The Corporation has agreed pursuant to that certain Term Sheet dated March 31, 2011, to allocate four of the seven seats on the Board of Directors to certain of the Investors listed in Schedule I to the Purchase Agreement.

 

2.               The Corporation has agreed, in Article III, Section A.6(b) of its Fourth Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on May 17, 2011, to allocate four of the seven seats on the Board of Directors to certain of the Investors listed in Schedule I to the Purchase Agreement.

 

16

 

Attachment A to

Schedule 3.9

 

Form of Employee Letter Agreement

 

,2007

 

Dear               :

 

It is my pleasure to offer you the position of                                            at Radius Health, Inc. (the “Company”).  As you know, I am excited about the contributions that I expect you will make to the success of the Company.  Accordingly, if you accept this offer, I would like us to agree that you could start at Radius on or before                                (the “Start Date”).  This offer may be accepted by you by countersigning where indicated at the end of this letter.

 

DUTIES AND EXTENT OF SERVICE

 

As                                           , you will report to                                            and you will have responsibility for performing those duties as are customary for, and are consistent with, such position, as well as those duties that may be designated to you from time to time.  As you know, your employment will be contingent upon your agreeing to abide by the rules, regulations, instructions, personnel practices, and policies of the Company and any changes therein that the Company may adopt from time to time, and your execution of the Company’s standard Nondisclosure, Developments, and Non-Competition Agreement.

 

COMPENSATION AND BENEFITS

 

Your salary will be $                       per semi-monthly pay period, minus applicable taxes and withholdings.  Such salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Company.

 

You will be entitled to three weeks paid vacation annually.  You will also be entitled to participate in such employee benefit plans and fringe benefits as may be offered or made available by the Company to its employees.

 

STOCK OPTIONS

 

At the first meeting of the Company’s Board of Directors following your Start Date, it is my intention that the Company will recommend to the Board of Directors that you receive a common stock option grant of                shares.  This offer is contingent upon approval by the Board of Directors of your option grant specifically.  Promptly after the Grant Date, the Company and you will execute and deliver to each other the Company’s then standard form of stock option agreement, evidencing the Option and the terms thereof.  As you know, the Option shall be subject to, and governed by, the terms and provisions of the Plan and your stock option agreement.

 

NONDISCLOSURE, DEVELOPMENTS AND NON-COMPETITION

 

As you know, prior to commencing, and as a condition to your employment with the Company, all employees are required to agree to sign a copy of the Company’s standard Nondisclosure, Developments,

 

17

 

and Non-Competition Agreement.  The Company will ask you to sign this agreement after you have signed and returned this letter and prior to or on your Start Date.

 

At-Will Employment

 

This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company’s policy of employment at-will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, with or without notice.  Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.   In addition, nothing in any documents published by the Company shall in any way modify the above terms and these terms cannot be modified in any way by any oral or written representations made by anyone employed by the Company, except by written document signed by C. Richard Lyttle.

 

NO CONFLICTING OBLIGATION AND OBLIGATIONS

 

You represent and warrant that the performance by you of any or all of the terms of this letter agreement and the performance by you of your duties as an employee of the Company do not and will not breach or contravene (i) any agreement or contract (including, without limitation, any employment or consulting agreement, any agreement not to compete or any confidentiality or nondisclosure agreement) to which you are or may become a party on or at an time after the Start Date or (ii) any obligation you may otherwise have under applicable law to any former employer or to any person to whom you have provided, provide or will provide consulting services.

 

I am pleased on behalf of Radius to extend this offer to have you join us.  This is an exciting time for Radius and we would be delighted to have you as part of our organization.

 

Please acknowledge your acceptance of this offer and the terms of this letter agreement by signing below and returning a copy to me.

 

Sincerely,

 

 

I hereby acknowledge that I have had a full and adequate opportunity to read, understand and discuss the terms and conditions contained in this letter agreement prior to signing hereunder.

 

Date this          day of                             , 20

 

18

 

Schedule 3.10

 

Affiliate Transactions

 

1.               Indemnification Agreement, dated November 14, 2003, by and between the Corporation and Michael Rosenblatt, M.D.

 

2.               Indemnification Agreement, dated November 14, 2003, by and between the Corporation and Christopher Mirabelli.

 

3.               Indemnification Agreement, dated November 14, 2003, by and between the Corporation and Augustine Lawlor.

 

4.               Indemnification Agreement, dated November 14, 2003, by and between the Corporation and Ansbert K. Gadicke.

 

5.               Indemnification Agreement, dated November 14, 2003, by and between the Corporation and Edward Mascioli, M.D.

 

6.               Indemnification Agreement, dated October 12, 2010, by and between the Corporation and Alan Auerbach.

 

19

 

Schedule 3.14

 

Real Property

 

1.               Sublease by and between the Corporation and Sonos, Inc., dated January 14, 2011, for the property located at 201 Broadway, Cambridge, Massachusetts

 

20

 

Schedule 3.18

 

Absence of Certain Developments

 

None.

 

21

 

Schedule 3.19(a)

 

Employee Benefit Plans

 

1.               Radius Health, Inc. 401(k) Plan

 

2.               Radius Health, Inc. Flexible Spending Account Plan

 

3.               See also Schedule 3.9.

 

22

 

Schedule 3.19(f)

 

Employee Benefit Plans

 

None.

 

23

 

Schedule 3.20

 

Employees

 

	
Name
    	
 
    	
Job Title
    	
 
    	
Annual Base
   Salary or
   Annualized
   Wages
    	
 
    	
Bonus Compensation
   earned in
   2009
    	
 
    	
Bonus Compensation
   earned in
   2010
    	
 
    
	
1.     Jonathan Guerriero
    	
 
    	
Director,   Product Development
    	
 
    	
155,646
    	
 
    	
19,263
    	
 
    	
26,445
    	
 
    
	
2.     Edie Estabrook
    	
 
    	
Office   Manager (Part-time)
    	
 
    	
44,582
    	
 
    	
1,919
    	
 
    	
1,962
    	
 
    
	
3.     Mary Lumpkins
    	
 
    	
Administrative   Assistant
    	
 
    	
73,501
    	
 
    	
2,785
    	
 
    	
2,861
    	
 
    
	
4.     Maria Grunwald
    	
 
    	
Director,   Business Development
    	
 
    	
152,226
    	
 
    	
14,560
    	
 
    	
14,888
    	
 
    
	
5.     Dan McCarthy
    	
 
    	
Assistant   Director, Clinical Affairs
    	
 
    	
125,043
    	
 
    	
7,176
    	
 
    	
7,337
    	
 
    
	
6.     Kelly Sullivan
    	
 
    	
Associate,   Clinical
    	
 
    	
73,903
    	
 
    	
3,952
    	
 
    	
5,394
    	
 
    
	
7.     Kathy Welch
    	
 
    	
Controller
    	
 
    	
89,792
    	
 
    	
6,379
    	
 
    	
6,554
    	
 
    
	
8.     Gary Hattersley
    	
 
    	
VP,   Biology
    	
 
    	
223,860
    	
 
    	
27,300
    	
 
    	
0
    	
 
    
	
9.     Louis O’Dea
    	
 
    	
CMO
    	
 
    	
319,363
    	
 
    	
51,410
    	
 
    	
0
    	
 
    
	
10.   Rich Lyttle
    	
 
    	
CEO
    	
 
    	
378,622
    	
 
    	
73,877
    	
 
    	
0
    	
 
    
	
11.   Nick Harvey
    	
 
    	
CFO
    	
 
    	
278,492
    	
 
    	
40,755
    	
 
    	
0
    	
 
    

 

24

 

Schedule 3.21

 

Proprietary Information and Inventions

 

See attached Form of Confidentiality and Non-Competition Agreement.

 

25

 

Confidentiality and Non-Competition Agreement

 

In consideration for the agreement of Radius Health Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”) to employ me as an employee or consultant and my receipt of the compensation now and hereafter paid to me by the Company, I agree as follows:

 

1.     Definition of Confidential Information.  I acknowledge that I may be furnished or have access to confidential, proprietary or trade secret information relating to the Company’s past, present or future (i) products, processes, formulas, patterns, compositions, compounds, projects, specifications, know how, research data, clinical data, personnel data, compilations, programs, devices, methods, techniques, inventions, software, and improvements thereto; (ii) research and development activities, (iii) designs and technical data; (iv) marketing or business development activities, including without limitation prospective or actual bids or proposals, pricing information and financial information; (v) customers or suppliers; or (vi) other administrative, management, planning, financial, marketing, purchasing or manufacturing activities.  All of this type of information, whether it belongs to the Company or was provided to the Company by a third party with the understanding that it be kept confidential, and any documents, diskettes or other storage media, or other materials or items containing this type of information, are proprietary and confidential to the Company (“Confidential Information”).

 

2.     Obligations.  I agree to preserve and protect the confidentiality of Confidential Information both during and after my employment with the Company.  In addition, I agree not to, at any time during the term of this Agreement or thereafter, (i) disclose or disseminate Confidential Information to any third party, including without limitation employees or consultants of the Company without a legitimate business need to know; (ii) remove Confidential Information from the Company’s premises or make copies of Confidential Information, except as required to perform my job; or (iii) use Confidential Information for my own benefit or for the benefit of any third party.  I also agree to take all actions necessary to avoid unauthorized disclosure and otherwise to maintain the confidential or proprietary nature of such Confidential Information.  If I am not certain whether or not information is confidential, I will treat that information as Confidential Information until I have verification from the Company’s Personnel Officer that the information is not Confidential Information.

 

3.     Exceptions.  The Company agrees that the obligations in Section 2 do not apply to any information that I can establish (i) has become publicly known without a breach of this Agreement by me or a third party’s breach of an agreement to maintain the confidentiality of the information; or (ii) was developed by me prior to the date this Agreement is signed, and prior to the date any earlier Confidentiality Agreement of the Company was signed, if the date of development can be established by documentary evidence.

 

4.     Former Employer Information.  I agree that I will not, during my employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former or current employer or any other person or entity and that I will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.

 

5.     Inventions and Works Retained and Licensed.  I have attached hereto, as Exhibit A, a list describing all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me prior to my employment with the Company (collectively referred to as “Prior Works or Inventions”), which belong to me, which relate to the Company’s business, products, or research and development, and which are not assigned to the Company hereunder, or, if no such list is attached, I represent that there are no such Prior Works or Inventions.  If, in the course of my employment with the Company, I incorporate into a Company product, process or machine a Prior Work or Invention owned by

 

26

 

me or in which I have an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free, assignable, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Work or Invention as part of or in connection with such product, process or machine.

 

6.     Ownership of Works.  I agree that the Company owns all right, title and interest in, including without limitation all trade secrets, patents and copyrights, in the following works that I create, make, conceive or reduce to practice, solely or jointly:  (i) works that are created using the Company’s facilities, supplies, information, trade secrets or time, (ii) works that relate directly or indirectly to or arise out of the actual or proposed business of the Company, including, without limitation the research and development activities of the Company, (iii) works that relate directly or indirectly to or arise out of any task assigned to me or work I perform  for the Company  or (iv) works that are based on Confidential Information (collectively “Works”).  Because these Works will inevitably be based upon or somehow involve the Company’s business, products, services or methodologies, I agree that the Works will belong to the Company even if I create, make, conceive or reduce them to practice on my own time, using my own equipment, on the Company’s premises or elsewhere or after termination of my employment with the Company.  The Works belonging to the Company, include, without limitation program code and documentation.  I will promptly provide full written disclosure to an officer of the Company of any Works I create, make, conceive or reduce to practice, solely or jointly.  To the extent that the Works do not qualify as works made for hire under U.S. copyright law, I irrevocably assign to the Company the ownership of, and all rights of copyright in, the Works.  The Company will have the right to hold in its own name all rights in the Works, including without limitation all rights of copyright, trade secrets and trademark.  I also waive all claims to moral rights in any Works.  I acknowledge and agree that any and all patents, patent applications or other intellectual property rights relating to the Works are to be the exclusive property of the Company.

 

7.     Ownership of Inventions.  (a)  I irrevocably assign to the Company my entire right, title and interest in any invention, modification, design, program code, software, documentation, formula, data, know how, technique, process, method, device, discovery, improvement, developments, or works of authorship and all related patents, patent applications, copyrights and copyright applications whether patentable or not, created, made, conceived or reduced to practice, solely or jointly by me  whether or not during normal working hours or on my own time, using my own equipment, on the premises of the Company or elsewhere, or after termination of my employment with the Company that (i) is created using the Company’s facilities, supplies, information, trade secrets or time; (ii) relates directly or indirectly to or arises out of the actual or proposed business, including without limitation the research and development activities, of the Company; (iii) relates directly or indirectly to or arises out of any task assigned to me or work I perform for the Company or (iv) is based on Confidential Information (collectively “Inventions”).   I will promptly make full written disclosure to an officer of the Company of any Inventions I create, make, conceive or reduce to practice, solely or jointly.  I also waive all claims to moral rights in any Inventions.  I acknowledge and agree that any and all patents, patent applications or other intellectual property rights relating to the Inventions are to be the exclusive property of the Company.

 

(b)  I agree to cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Works and/or Inventions.  I agree to execute and deliver all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable to protect its rights and interests in any Works and/or Inventions.  I further agree that if the Company is unable, after reasonable effort, to secure my signature on any such papers, any executive officer of the Company shall be entitled to execute any such papers as my agent and attorney-in-fact, and I hereby irrevocably designate and appoint each executive officer of the Company as my agent and attorney-in-fact to execute any such papers on my

 

27

 

behalf, and to take any and all actions as the Company may deem necessary or desirable to protect its rights and interests in any Works and/or Inventions, under the conditions described in this sentence.

 

8.     Maintenance of Records.  I agree to keep and maintain adequate and current written records of all Works and Inventions made by me (solely or jointly with others) during the term of my employment with the Company.  The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company.  The records will be available to and remain the sole property of the Company at all times.

 

9.     Return of Confidential Information.  I agree to return to the Company all Confidential Information in my possession, custody or control immediately upon my termination from the Company, or earlier if the Company requests.

 

10.   Notification of New Employer.  In the event I leave the employ of the Company, I hereby grant consent to notification by the Company to my new employer about my rights and obligations under this Agreement.

 

11.   Noncompetition; Nonsolicitation of Employees.  I acknowledge and agree that

 

(i)  While I am employed at the Company and for a period of one (1) year after termination of such employment (for any reason whatsoever, whether voluntary or involuntarily), I agree that I will not, whether alone or as a partner, officer, director, consultant, agent, employee or stockholder of any company or their commercial enterprise, directly or indirectly engage in any business or other activity anywhere in the world which is competitive with or render services to any firm or business organization which competes with the Company in business of research, discovery and/or development of human therapeutics and vaccines for infectious diseases that are being actively researched, discovered or developed by the Company at the time of termination of such employment.  The foregoing prohibition shall not prevent my employment or engagement after termination if such employment or engagement, in any capacity, does not involve work or matters related to the business of research, discovery and/or development of human therapeutics and vaccines for infectious diseases that are being actively researched, discovered or developed by the Company at the time of termination of my employment.  I shall be permitted to own securities of a public company not in excess of five (5%) of any class of such securities and to own stock partnership interests or other securities of any entity not in excess of five (5%) of any class of such securities and such ownership shall not be considered to be competition with the Company; and

 

(ii)  during and for one (1) year after termination of my employment for any reason I shall not, directly or indirectly solicit, recruit or hire any employee of the Company to work for a third party other than the Company or engage in any activity that would cause any employee to violate any agreement with the Company.

 

12.   Representations and Warranties.  I represent and warrant that (i) I am able to perform the duties of my position and that my ability to work for the Company is not limited or restricted by any agreements or understandings between me and other persons or companies; (ii) I will not disclose to the Company, its employees, consultants, clients, teaming partners or suppliers, or induce any of them to use or disclose, any confidential information or material belonging to others, except with the written permission of the owner of the information or material; and (iii) any information, material or product I create or develop for, or any advice I provide to, the Company, its employees, consultants, clients, teaming partners or suppliers, will not rely or be based on confidential information or trade secrets I obtained or derived from a source other than the Company.  I agree to indemnify and hold the Company harmless from damages, claims, costs and expenses based on or arising from the breach of any agreement or

 

28

 

understanding between me and another person or company or from my use or disclosure of any confidential information or trade secrets I obtained from sources other than the Company.

 

13.   Damages and Injunctive Relief.  I acknowledge and agree that:

 

(i)    My obligations under this Agreement have a unique and substantial value to the Company and I remain obligated even if I voluntarily or involuntarily leave the Company’s employment.  I understand that if I violate this Agreement during or after my employment, the Company may be able to recover monetary damages from me and/or the other relief described below.

 

(ii)   A violation or even a threatened violation of this Agreement is likely to result in irreparable harm to the Company and monetary damages alone would not completely compensate the Company for the harm.  Accordingly, the Company may obtain an injunction prohibiting me from violating this Agreement, an order requiring me to render specific performance of the Agreement, and/or other appropriate equitable remedies.

 

(iii)  If a court determines that I have breached or attempted or threatened to breach this Agreement, I consent to the granting of an injunction restraining me from further breaches or attempted or threatened breaches of this Agreement, compelling me to comply with this Agreement, and/or prescribing other equitable remedies.

 

14.   Miscellaneous Provisions.

 

(i)    No failure to act by the Company will waive any right contained in this Agreement.  Any waiver by the Company must be in writing and signed by an officer of the Company to be effective.

 

(ii)   The provisions of this Agreement are applicable to Confidential Information, Works and Inventions disclosed, created, developed or proprietary before or after I sign this Agreement.

 

(iii)  This Agreement is to be construed according to its fair meaning and not strictly for or against either party.

 

(iv)  This Agreement will be governed by the law of the State of Delaware without regard to its conflicts of laws provisions.  Suit to enforce any provision of this Agreement or to obtain any remedy with respect hereto may be brought in a court of the Commonwealth of Massachusetts and for this purpose I expressly consent to the jurisdiction of said courts.

 

(v)   If any provision of this Agreement conflicts with the law of the State of Delaware or if any provision is held invalid by a court with jurisdiction over the parties to this Agreement, the provision will be deemed to be restated to reflect as nearly as possible the parties’ original intentions in accordance with applicable law, and the remainder of the Agreement will remain in full force and effect.  If it is not possible to restate the provision in a legal and valid manner, then the provision will be deemed not to be a part of the Agreement and the remaining provisions will remain in full force and effect.

 

(vi)  This document constitutes the entire agreement between the Company and me concerning the matters addressed in this Agreement and it supersedes any prior agreement concerning those matters.  This Agreement may not be changed in any respect except by a written agreement signed by both parties.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

 

29

 

(vii) All remedies provided in this Agreement are cumulative and in addition to all other remedies which may be available at law or in equity.

 

 

	
Signature:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Print   Name:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Address:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
THE   COMPANY
    	
RADIUS   HEALTH, INC.
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
 
    	
 
    

 

 

NWK3: 779588.05

 

30

 

Schedule 3.22(a)

 

Intellectual Property

 

None.

 

31

 

Schedule 3.22(b)

 

Intellectual Property

 

1.               The Corporation has filed for registration of its trademark rights in the following marks:

 

·                  N (Design), Application No. 78/391,239, Filing Date: 26-Mar-2004

 

·                  RADIUS, Application No. 78/707,397, Filing Date: 06-Sep-2005

 

·                  RADIUS, Application No. 78/707,419, Filing Date: 06-Sep-2005

 

·                  RADIUS (& Design), Application No. 78/797,031, Filing Date: 23-Jan-2006

 

·                  RADIUS (& Design), Application No. 78/797,016), Filing Date: 23-Jan-2006

 

2.               Domain name:  www.radiuspharm.com

 

3.               See also Attachment A to this Schedule 3.22(b).

 

32

 

Attachment A to

Schedule 3.22(b)

 

RADIUS PATENT AND PATENT APPLICATION SUMMARY

 

RAD-1901

 

A.            Owned by Radius

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Title
    
	
3803.1016-000
   (US)
    	
 
    	
61/127,025
   (5/09/08)
    	
 
    	
Richard C.   Lyttle,
   Gary Hattersley, Louis O’Dea
    	
 
    	
Expired
    	
 
    	
Pharmaceutical   Combinations and Methods of Using Same
    
	
3803.1016-001
   (PCT)
    	
 
    	
PCT/US2009/002885
   (5/07/09)
    	
 
    	
Richard C.   Lyttle,
   Gary Hattersley, Louis O’Dea
    	
 
    	
Pending
    	
 
    	
Pharmaceutical   Combinations and Methods of Using Same
    
	
3803.1016-002
   (US)
    	
 
    	
12/991,791
   (5/7/09)
    	
 
    	
Richard C.   Lyttle,
   Gary Hattersley, Louis O’Dea
    	
 
    	
Pending
    	
 
    	
Pharmaceutical   Combinations and Methods of Using Same
    
	
3803.1022-000
   (US)
    	
 
    	
61/334,095
   (5/12/10)
    	
 
    	
Richard C.   Lyttle,
   Gary Hattersley, Louis O’Dea
    	
 
    	
Pending (Provisional)
    	
 
    	
Therapeutic Regimens
    

 

B.            Jointly Owned by Radius and Eisai

 

	
HBSR Docket No.
    	
 
    	
Application Number
   (Pub. Number-Date)
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Title
    
	
3803.1001-000
   (US)
    	
 
    	
60/816,191
   (6/23/06)
    	
 
    	
Richard C. Lyttle, Bart Henderson, Gary Hattersley
    	
 
    	
U.S. Provisional;
   (Expired 06/23/07)
    	
 
    	
Treatment   of Vasomotor Symptoms With Selective Estrogen Receptor Modulators
    
	
3803.1001-002
   (PCT)
    	
 
    	
PCT/US2007/014598
   (WO2008/002490-1/3/08)
   6/22/07
    	
 
    	
Richard C. Lyttle, Bart Henderson, Gary Hattersley
    	
 
    	
Expired
    	
 
    	
Treatment   of Vasomotor Symptoms With Selective Estrogen Receptor Modulators
    

 

33

 

C.            Solely Owned by Radius

 

	
HBSR Docket No.
    	
 
    	
Application Number
   (Pub. Number-Date)
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1001-003
   (US)
    	
 
    	
12/308,640
  (6/22/07)

 

(US 2010/0105733 A1-4/29/2010)
    	
 
    	
Richard C. Lyttle, Bart Henderson, Gary Hattersley
    	
 
    	
U.S. National Stage of PCT
   Pending
    	
 
    	
Treatment   of Vasomotor Symptoms With Selective Estrogen Receptor Modulators
    
	
3803.1001-004
   (Europe)
    	
 
    	
07796378.3
   (6/22/07)

 

(EP2037905-3/25/09)
    	
 
    	
Richard C. Lyttle, Bart Henderson, Gary Hattersley
    	
 
    	
EP Regional Phase
   Pending
    	
 
    	
Treatment   of Vasomotor Symptoms With Selective Estrogen Receptor Modulators
    
	
3803.1001-005
   (Canada)
    	
 
    	
2656067
  (6/22/07)
    	
 
    	
Richard C. Lyttle, Bart Henderson, Gary Hattersley
    	
 
    	
Canadian National Stage of PCT
   Pending
    	
 
    	
Treatment   of Vasomotor Symptoms With Selective Estrogen Receptor Modulators
    

 

D.            Licensed to Radius by Eisai

 

	
HBSR Reference
   No.
    	
 
    	
Country
    	
 
    	
App.and/or Patent Number
   (Pub. Number-Date) and
   Filing Date
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.0020-003
    	
 
    	
Australia
    	
 
    	
2003292625 B2
   (2003292625 A1-7/22/2004)
   12/25/03

    	
 
    	
Granted
   11/6/2008
   Australian National Stage of PCT
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-004
    	
 
    	
Canada
    	
 
    	
2512000
   12/25/03
    	
 
    	
Pending
   Canadian National Stage of PCT
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-002
    	
 
    	
Europe
    	
 
    	
EP 2003782904
  (1577288 A1-9/21/05)
   12/25/03
    	
 
    	
Pending
   European Regional Stage of PCT
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-001
    	
 
    	
USA
    	
 
    	
US. Patent No. 7,612,114
   11/158,245
   (2006/0116364-6/1/06)
   6/22/05

    	
 
    	
Granted
   Continuation-in-Part of U.S. Designation of PCT
    	
 
    	
Selective   Estrogen Receptor Modulators
    

 

34

 

	
HBSR Reference
   No.
    	
 
    	
Country
    	
 
    	
App.and/or Patent Number
   (Pub. Number-Date) and
   Filing Date
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.0020-000
    	
 
    	
PCT
    	
 
    	
PCT/JP2003/016808
   (12/25/03)
   Publication No. WO 2004/058682
   (7/15/04)
    	
 
    	
Expired
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-005
    	
 
    	
India
    	
 
    	
2829/DELNP/2005
   (12/25/2003)

    	
 
    	
Pending
   Indian National Stage of PCT
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-006
    	
 
    	
Australia
    	
 
    	
Div. of 2003292625 B2

    	
 
    	
Pending
    	
 
    	
Selective   Estrogen Receptor Modulators
    
	
3803.0020-007
    	
 
    	
United   States
    	
 
    	
Application No. 12/544,965
   8/20/2009
   Publication No. US2009/0325930
   12/31/2009

    	
 
    	
Pending
    	
 
    	
Selective   Estrogen Receptor Modulators
    

 

SARMS

 

A.            Owned by Radius

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1015-000
   (US)
    	
 
    	
61/066,697
   (02/22/08)
    	
 
    	
Chris P. Miller

    	
 
    	
Expired

    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-001
   (US)
    	
 
    	
61/132,353
   (6/18/08)
    	
 
    	
Chris P. Miller
    	
 
    	
Expired
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-002
   (US)
    	
 
    	
61/205,727
   (1/21/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Expired
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-003
   (PCT)
    	
 
    	
PCT/US2009/001035
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Expired
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-004
   (US)
    	
 
    	
12/378,812
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-005
   (US)
    	
 
    	
12/541,489
   (8/14/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    

 

35

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1015-006
   (US)
    	
 
    	
12/806,636
   (8/17/10)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-007
   (Australia)
    	
 
    	
2009215843
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-008
   (Brazil)
    	
 
    	
PI09078444
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-009
   (Canada)
    	
 
    	
2716320
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-010
   (Europe)
    	
 
    	
09712082.8
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-011
   (India)
    	
 
    	
6324DELNP2010
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-012
   (Japan)
    	
 
    	
2010547633
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1015-013
   (Mexico)
    	
 
    	
MXA2010009162
   (2/19/09)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1019-000
   (US)
    	
 
    	
61/212,399
   (4/10/99)
    	
 
    	
Chris P. Miller

    	
 
    	
Expired
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1019-001
   (PCT)
    	
 
    	
PCT/US2010/030480 (4/9/10)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending

 

Published as
   WO2010/118287 (10/14/10)
    	
 
    	
Selective   Androgen Receptor Modulators
    

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1021-000
   (US)
    	
 
    	
61/301,492
   (2/4/10)
    	
 
    	
Chris P. Miller

    	
 
    	
Expired
    	
 
    	
Selective   Androgen Receptor Modulators
    
	
3803.1021-001
   (PCT)
    	
 
    	
PCT/US2011/023768 (2/4/11)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending

    	
 
    	
Selective   Androgen Receptor Modulators
    

 

36

 

	
HBSR Docket No.
    	
 
    	
Application
   Number and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1023-000
   (US)
    	
 
    	
61/361,168
   (7/2/10)
    	
 
    	
Chris P. Miller

    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    

 

	
HBSR Docket No.
    	
 
    	
Application
   Number and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1024-000
   (US)
    	
 
    	
61/387,440
   (9/28/10)
    	
 
    	
Chris P. Miller
    	
 
    	
Pending
    	
 
    	
Selective   Androgen Receptor Modulators
    

 

BaO58

 

A.            Jointly Owned by Radius and Ipsen

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1004-000
   (US)
    	
 
    	
60/848,960
   (10/3/06)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Expired
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-002
   (PCT)
    	
 
    	
PCT/US2007/021216
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Expired
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-003
   (US)
    	
 
    	
12/151,975
   (5/9/08)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Granted
   US Patent No. 7,803,770
   (9/28/10)
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-004
   (Australia)
    	
 
    	
2007322334
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    

 

37

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1004-005
   (Brazil)
    	
 
    	
PU07198213
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-006
   (Canada)
    	
 
    	
2664734
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-007
   (China)
    	
 
    	
200780037021.9
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-008
   (Europe)
    	
 
    	
07870768.4
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-009
   (India)
    	
 
    	
2340DELNP2009
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-010
   (Israel)
    	
 
    	
197926
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-011
   (Japan)
    	
 
    	
2009531434
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-012
   (Korea)
    	
 
    	
1020097008736
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-013
   (Mexico)
    	
 
    	
MXA2009003569
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    

 

38

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1004-014
   (New Zealand)
    	
 
    	
576682
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-015
   (Norway)
    	
 
    	
20091545
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-016
   (Russian Federation)
    	
 
    	
2009116531
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-017
   (Singapore)
    	
 
    	
2009922401
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-018
   (Ukraine)
    	
 
    	
200904264
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-019
   (US)
    	
 
    	
12/311,418
   (10/3/07)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-020
   (PCT)
    	
 
    	
PCT/US2009/002868
   (5/8/09)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Abandoned
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-021
   (Hong Kong)
    	
 
    	
09109160.6
   (10/2/09)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    
	
3803.1004-022
   (US)
    	
 
    	
12/855,458
   (8/12/10)
    	
 
    	
Michael J. Dey, Nathalie Mondoly, Benedice Rigaud, Bart Henderson and
   Richard C. Lyttle
    	
 
    	
Pending
    	
 
    	
PTHrP   Formulation
    

 

39

 

B.            Licensed to Radius by Ipsen (BaO58)

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US
    	
 
    	
USA
    	
 
    	
08/626,186
   (03/29/96)
    	
 
    	
U.S. Patent 5,723,577
   (03/03/98)
   Expires 03/29/16
    	
 
    	
Analogs   of PTH
    
	
038/US2
    	
 
    	
USA
    	
 
    	
08/779,768
   (01/07/97)
    	
 
    	
U.S. Patent 5,969,095 (10/19/99)
   Expires 3/29/16
    	
 
    	
Claims   BA058
    
	
038/US/PCT2
    	
 
    	
PCT
    	
 
    	
PCT/US96/11292
   (07/03/96)
    	
 
    	
Expired
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/EP
    	
 
    	
Europe
    	
 
    	
96924355.9
   (01/30/98)

 

Regional Phase entry of
   PCT/US96/11292

    	
 
    	
European Patent 0 847 278
   (09/24/03)
   Expires 07/03/16
   Activation in AT, BE, CH, DE, DK, ES, FI, FR, Gb, GR, IE, IT, LI, LU, MC, NL,   PT, SE; Ext: AL, LT, LV, SI
   Now Abandoned in AL, LT, LU, MC, SI, LV
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/EP-A
    	
 
    	
Europe
    	
 
    	
03077383.2
   (07/30/03)

 

Divisional of
   96924355.9
    	
 
    	
European Patent No.:1405861
   Expires 7/3/2016

 

Activation in AT, BE, CH, DE, DK, ES, FI, FR, Gb, GR, IE, IT, LI, LU,   MC, NL, PT, SE
    	
 
    	
Analogs   of PTH
    
	
038-EP-EPD[3]
    	
 
    	
Europe
    	
 
    	
10156965.5
   (3/18/2010)
    	
 
    	
Pending

    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/JP
    	
 
    	
Japan
    	
 
    	
9-505897
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Pending
   Published 8/17/1999

    	
 
    	
Analogs   of PTH
    

 

40

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US/PCT2/JP-A
    	
 
    	
Japan
    	
 
    	
008027/03
   (01/16/03)
   Divisional of 9-505897
    	
 
    	
Patent No. 4008825
   Granted 08/23/07
   Expires 7/3/2016
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/AU
    	
 
    	
Australia
    	
 
    	
64834/96
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 707094
   (07/01/99)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CA
    	
 
    	
Canada
    	
 
    	
2,226,177
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No.:2,226,177

 

Expires 7/3/2016
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CN
    	
 
    	
China
    	
 
    	
96196926.1
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. ZL96 196926.1
   (2/25/06)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CN-A
    	
 
    	
China
    	
 
    	
200410005427.2
   (07/03/96)

 

Divisional of
   96196926.1
    	
 
    	
Patent No.. ZL200410005427.7
   (8/20/02)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CN-C
    	
 
    	
China
    	
 
    	
2006 10100113.4
   (7/21/06)

 

Divisional of
   2004 10005427.7
    	
 
    	
Patent No.: ZL200610100113

 

Expires 7/3/2016
    	
 
    	
Analogs   of PTH
    
	
038-CN-DIV[4]
    	
 
    	
China
    	
 
    	
20100150544.8
    	
 
    	
Pending
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CN-HK
    	
 
    	
Hong Kong
    	
 
    	
99100132.1
   (01/13/99)
   Registration in Hong Kong of 961 96926.1
    	
 
    	
Patent No. 1 014 876
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    

 

41

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US/PCT2/HU
    	
 
    	
Hungary
    	
 
    	
P9901718
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No.: 226935

 

Expires 7/3/2016
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/IL
    	
 
    	
Israel
    	
 
    	
122837
   (07/03/96

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 122837
   (02/11/03)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/KR
    	
 
    	
Korea
    	
 
    	
1998-0700249
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 0500853
   (07/04/05)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/KR-A
    	
 
    	
Korea
    	
 
    	
2004-706338
   (04/28/04)
   Divisional of 1998-0700249
    	
 
    	
Patent No. 0563600
   (3/16/06)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/KR-B
    	
 
    	
Korea
    	
 
    	
2004-706339
   (04/28/04)
   Divisional of 1998-0700249
    	
 
    	
Patent No. 0563601
   (3/16/06)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/KR-C
    	
 
    	
Korea
    	
 
    	
2004-706340
   (04/28/04)
   Divisional of 1998-0700249
    	
 
    	
Patent No. 0563602
   (3/16/06)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/KR-D
    	
 
    	
Korea
    	
 
    	
2004-706341
   (04/28/04)
   Divisional of 1998-0700249
    	
 
    	
Patent No. 0563112
   (3/15/06)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/MX
    	
 
    	
Mexico
    	
 
    	
PA/a/1998/000418
   (07/03/96)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 222317
   (08/26/04)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    

 

42

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US/PCT2/NZ
    	
 
    	
New Zealand
    	
 
    	
312899
   (01/20/98)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 312899
   (02/08/00)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/PL
    	
 
    	
Poland
    	
 
    	
P.325905
   (01/12/98)

 

Regional Phase entry of
   PCT/US96/11292
    	
 
    	
Patent No. 186710
   (08/07/03)
   Expires 07/03/16
    	
 
    	
Analogs   of PTH
    
	
*038/US/PCT2/RU
    	
 
    	
Russia
    	
 
    	
98/102406
   (7/3/96)
    	
 
    	
Patent No. 2,157,699
   (10/20/00)
    	
 
    	
Analogs   of PTH
    
	
*038/US/PCT2/SG
    	
 
    	
Singapore
    	
 
    	
9706046.1
   (7/3/96)
    	
 
    	
Patent No. P-51260
   (10/16/01)
    	
 
    	
Analogs   of PTH
    
	
*038/US/TW
    	
 
    	
Taiwan
    	
 
    	
85108390
   (07/11/96)
    	
 
    	
Patent No. 153897
   (08/07/02)
    	
 
    	
Analogs   of PTH
    
	
038/US3
    	
 
    	
USA
    	
 
    	
08/813,534
   (03/07/97)
    	
 
    	
Patent No. 5,955,574
   (09/21/99)
   Expires 03/29/16
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2
    	
 
    	
PCT
    	
 
    	
PCT/US97/22498
   (12/08/97)
    	
 
    	
Expired
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/US2
    	
 
    	
USA
    	
 
    	
09/399,499
   (09/20/99)
    	
 
    	
Patent No. 6,544,949
   (04/08/03)
   Expires 03/29/16
    	
 
    	
Claims   a method of treating osteoporosis with BA058 and a pharmaceutical composition   including BA058
    
	
038/US3/PCT2/US2-A
    	
 
    	
USA
    	
 
    	
10/289,519
   (11/06/02)
    	
 
    	
Patent No. 6,921,750
   (07/26/05)
   Expires 03/29/16
    Reissue Application filed 9/16/06
   Application No. 11/523,812
    	
 
    	
Analogs   of PTH
    

 

43

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US3/PCT2/US2-B
    	
 
    	
USA
    	
 
    	
11/094,662
   (03/30/05)
    	
 
    	
Patent No. 7632811

 

Expires 9/6/2019
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/EP
    	
 
    	
Europe
    	
 
    	
97951595.4
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. EP0948541
   (03/29/06)
   Expires 12/08/17

 

Activation in: AT, BE, CH, LI, DE, DK, ES, FI, FR, GB, GR, IE, IT,   LU, MC, NL, PT, SE;
   Extension States: AL, LT, LV, MK, RO and SI
   Now Abandoned in AL, LT, LU, MK, MC, RO, SI
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/EP-A
    	
 
    	
Europe
    	
 
    	
05026436.5
   (12/12/05)

 

Divisional of EP 97951595.4
    	
 
    	
European Patent No. 1645566

 

Expires 12/8/2017

 

Activation in: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, NL,   PT, SE
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/JP
    	
 
    	
Japan
    	
 
    	
10-530865
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 3963482
   06/01/07
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/AU
    	
 
    	
Australia
    	
 
    	
55199/98
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 741584
   (03/21/02)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/CA
    	
 
    	
Canada
    	
 
    	
2,276,614
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 2,276,614
   (06/11/02)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    

 

44

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US3/PCT2/CN
    	
 
    	
China
    	
 
    	
97181915.7
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. ZL97181915.7
   (02/11/04)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/CN-HK
    	
 
    	
Hong Kong
    	
 
    	
00105467.3
   (12/08/00)
   Registration of 97181915.7
    	
 
    	
1026215
   (07/09/04)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/CZ
    	
 
    	
Czech Republic
    	
 
    	
PV 1999-2398
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No.298937
   (02/06/08)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/CZ-A
    	
 
    	
Czech Republic
    	
 
    	
PV2005-594
   (9/16/05)

 

Divisional of
   PV 2398-99
    	
 
    	
Pending
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/HU
    	
 
    	
Hungary
    	
 
    	
P9904596
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Pending
   Published
   6/28/2000
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/HU-A
    	
 
    	
Hungary
    	
 
    	
P0600009
   (1/11/06)

 

Divisional of
   HU P 99 04596
    	
 
    	
Pending
   Published 01/26/2006
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/IL
    	
 
    	
Israel
    	
 
    	
130794
   (12/08/07)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No.130794
   (07/03/06)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    

 

45

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US3/PCT2/IN
    	
 
    	
India
    	
 
    	
7/MAS/98
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 228906

 

Expires 1/1/2018
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/IN-A
    	
 
    	
India
    	
 
    	
63/CHE/2008
  (01/08/08)
   Divisional of 7/MAS/98
    	
 
    	
Pending
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/IN-B
    	
 
    	
India
    	
 
    	
456/CHE/2008
   (02/22/08)
   Divisional of 7/MAS/98
    	
 
    	
Pending
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/KR
    	
 
    	
Korea
    	
 
    	
1999-7006165
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 0497709
   (06/17/05)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/KR-A
    	
 
    	
Korea
    	
 
    	
2005-7003295
   (2/25/05)

 

Divisional of
   KR 1999-7006165
    	
 
    	
Patent No. 0699422
   (3/19/07)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/MX
    	
 
    	
Mexico
    	
 
    	
Pa/a/1999/006387
   (12/08/97)
    	
 
    	
Patent No. 222316
   (08/26/04)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/NZ
    	
 
    	
New Zealand
    	
 
    	
336610
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 336610
   (11/09/01)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/PL
    	
 
    	
Poland
    	
 
    	
P-334438
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 191898
   (2/15/06)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    

 

46

 

	
Ipsen Reference No.
    	
 
    	
Country
    	
 
    	
Application Number
   Filing Date and
   Priority
    	
 
    	
Status
    	
 
    	
Short Description
    
	
038/US3/PCT2/PL-A
    	
 
    	
Poland
    	
 
    	
P.370525
   (10/04/04)
   Divisional of P.33438
    	
 
    	
Patent No. 191239
   (09/03/07)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/RU
    	
 
    	
Russia
    	
 
    	
99117145
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 2,198,182
   (02/10/03)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/SG
    	
 
    	
Singapore
    	
 
    	
9903165.0
   (12/08/97)
   National Stage of PCT/US97/22498
   (12/08/97)
    	
 
    	
Patent No. 66567
   (07/18/00)
   Expires 12/08/17
    	
 
    	
Analogs   of PTH
    
	
038/US2/US3/TW
    	
 
    	
Taiwan
    	
 
    	
87100028
   (01/02/98)
    	
 
    	
Patent No. 156542
   (06/01/02)
   Expires 01/02/18
    	
 
    	
Analogs   of PTH
    
	
038/US/PCT2/CN-C/HK
    	
 
    	
HK
    	
 
    	
Filing 07103960.3
   4/16/2007
    	
 
    	
Patent No. HK1096976
   Expires 7/3/2016
    	
 
    	
Analogs   of PTH
    
	
038/US3/PCT2/US2-C
    	
 
    	
US
    	
 
    	
Filing 11/684,383
   3/09/2007
    	
 
    	
Patent No. 7,410,948
   (8/12/08)
   Expires 03/29/16
    	
 
    	
Analogs   of PTH
    

 

B.            Jointly Owned by Radius and 3M

 

	
HBSR Docket No.
    	
 
    	
Application Number
   and
   Filing Date
    	
 
    	
Inventors
    	
 
    	
Status
    	
 
    	
Short Description
    
	
3803.1025-000
   (US)
    	
 
    	
61/478,466
   (4/22/2011)
    	
 
    	
Gary Hattersley, Kris J. Hansen, Amy S. Determan
    	
 
    	
Pending
    	
 
    	
Method   of drug delivery for PTH, PTHrP, and related peptides.
    

 

47

 

Schedule 3.22(c)

 

Intellectual Property

 

1.               See items listed as “Jointly Owned” or “Licensed to Radius” in Item 3 of Schedule 3.22(b).

 

2.               Certain rights licensed to the Corporation pursuant to that certain Development and Clinical Supplies Agreement, by and between the Corporation and 3M, dated June 19, 2009.

 

48

 

Schedule 3.22(d)

 

Intellectual Property

 

None.

 

49

 

Schedule 3.22(f)

 

Intellectual Property

 

None.

 

50

 

Schedule 5.2

 

Conduct of Business by Radius

 

1.               The filing of the Fourth Amended and Restated Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware.

 

2.               The Corporation shall effectuate a reverse split of the Corporation’s outstanding capital stock such that each share of each class or series of capital stock of the Corporation that is issued and outstanding or held as treasury shares immediately prior to the effective date of the filing of the Fourth Amended and Restated Certificate of Incorporation of the Corporation shall automatically without any action on the part of the holder thereof, be reclassified and changed into 0.06666667 of one share of such class or series of capital stock of the Corporation effective immediately upon filing of the Fourth Amended and Restated Certificate of Incorporation of Radius.

 

3.               The Corporation shall enter into a Series A-1 Convertible Preferred Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which, among other things, the Corporation will offer, issue and sell to the investors listed therein up to an aggregate of 9,394,709 shares of Series A-1 Convertible Preferred Stock, par value $.01 per share (“Series A-1 Stock”), to be completed in three closings (the initial closing, the “Stage I Closing”, the second closing, the “Stage II Closing” and the final closing, the “Stage III Closing”) (collectively, the “Series A-1 Financing”).

 

4.               Pursuant to the terms of that certain Stock Issuance Agreement as of March 29, 2011 by and between the Corporation and Nordic Bioscience (the “Nordic Stock Issuance Agreement”) and the letter agreement as of March 29, 2011 by and between the Corporation and Nordic Bioscience (the “Nordic Letter Agreement”), pursuant to which the Corporation will issue shares of the Corporation’s Series A-5 Convertible Preferred Stock, $0.01 par value per share (“Series A-5 Stock”), to Nordic Bioscience, which entitle Nordic Bioscience to receive certain stock dividends payable in shares of the Corporation’s Series A-6 Convertible Preferred Stock, $0.01 par value per share (“Series A-6 Stock”).

 

5.               The Corporation shall effectuate a recapitalization such that (i) in the event that a holder of shares of any series of preferred stock, $0.01 par value per share, of the Corporation (“Preferred Stock”) that are issued and outstanding immediately prior to the Stage I Closing does not participate in the Series A-1 Financing at least at the level of such holder’s Pro Rata Share (as defined in the Purchase Agreement), then a portion of the shares of each series of Preferred Stock then held by such holder that is equal to such holder’s Applicable Portion (as defined in the Restated Certificate) shall automatically convert into shares of the Corporation’s common stock, $0.01 par value per share (“Common Stock”), at a rate of 1 share of Common Stock for every 5 shares of such series of Preferred Stock subject to such automatic conversion, effective immediately prior to the consummation of the Stage I Closing (such automatic conversion being hereinafter referred to as the “Forced Conversion”), (ii) each share of the Corporation’s Series C Convertible Preferred Stock, $0.01 par value per share (the “Series C Stock”) remaining outstanding after the Forced Conversion shall, immediately following the Forced Conversion, be reclassified and converted into one share of the Corporation’s Series A-2 Convertible Preferred Stock, $0.01 par value per share (the “Series A-2 Stock”), (iii) each share of the Corporation’s Series B Convertible Preferred Stock, $0.01 par value per share (the “Series B Stock”) remaining outstanding after the Forced Conversion shall, immediately following the Forced Conversion, be reclassified and converted into one share of the Corporation’s Series A-3 Convertible Preferred Stock, $0.01 par value per share (the “Series A-3 Stock”), and (iii) each share of the

 

 

51

 

Corporation’s Series A Convertible Preferred Stock, $0.01 par value per share (the “Series A Stock”) remaining outstanding after the Forced Conversion shall, immediately following the Forced Conversion, be reclassified and converted into one share of the Corporation’s Series A-4 Convertible Preferred Stock, $0.01 par value per share (the “Series A-4 Stock”).

 

6.               Pursuant to the terms of that certain License Agreement by and between the Corporation and Ipsen Pharma SAS (“Ipsen”), as amended, the Corporation may issue shares of Series A-1 Preferred Stock to Ipsen as payment milestones, in lieu of cash payments, at $8.142 per share.

 

7.               On December 21, 2010, the Corporation Accepted and Agreed to a Proposal from GE Healthcare Financial Services, Inc. (“GEHFS”) and Oxford Finance Corporation (“Oxford Finance”) which forth the terms on which GEHFS and Oxford Finance Corporation would provide debt financing to the Corporation in an aggregate amount of $25m in three tranched term loans.  As part of the Proposal, the Corporation would be required to issue to GEHFS and Oxford Finance warrants to purchase, in the aggregate, 122,820 shares of Series A-1 Convertible Preferred Stock and to grant to GEHFS the right to purchase up to an additional 122,820 shares on terms substantially the same as those on which MPM is making their investment in the Corporation in the Series A-1 Financing. It is expected that operative documents pertaining to such debt financing will be finalized on or about the Stage I Closing Date.

 

8.               In connection with that certain Loan and Security Agreement, dated as of August 6, 2004, by and between the Corporation and Silicon Valley Bank (“SVB”), as amended, the Corporation issued to SVB a warrant exercisable for the purchase of an aggregate of up to 20,000 shares of Series A Junior Convertible Preferred Stock at $1.00 per share (as amended, the “SVB Warrant”).  The warrant, which expires in August 2014, will be amended and restated as of the Stage I Closing Date to purchase 266 shares of the Corporation’s common stock.  The warrant was 100% vested as of the grant date.

 

9.               Pursuant to an engagement with Leerink Swann LLC (“Leerink”) for services in connection with the Series A-1 Financing, the Corporation has agreed to issue to Leerink a Warrant to purchase 24,564 shares of Series A-1 Convertible Preferred Stock at the Stage I Closing.

 

52Exhibit 10.5

 

Execution Copy

 

AMENDED AND RESTATED STOCK ISSUANCE AGREEMENT

 

This Amended and Restated Stock Issuance Agreement (this “Agreement”) is entered into as of May 16, 2011 (“Effective Date”) by and between RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”).

 

Background

 

Radius and NB are parties to that certain Clinical Trial Services Agreement dated as of March 29, 2011 (the “CTS Agreement”) and a certain Work Statement NB-1 under the CTS Agreement. Pursuant to Work Statement NB-1, NB has agreed to perform certain services relating to a Phase III clinical study of a Radius drug candidate known as BA058. Radius, in consideration of the activities of NB pursuant to the CTS Agreement and Work Statement NB-1 has authorized the sale to NB of shares of Series A-5 Convertible Preferred Stock, par value $0.01 per share (the “Series A-5 Preferred Stock”) of Radius having a value of €371,864, which shares entitle the holder to receive stock dividends payable in shares of Series A-6 Preferred Stock or (in the event that the Series A-5 Preferred Stock is converted and stock dividends are no longer payable) to receive payment in shares of another class or series of capital stock of Radius or any other Person having an aggregate value of up to an additional €36,814,531 as calculated on the date that such stock dividends or other payments accrue. Radius and NB entered into that certain Stock Issuance Agreement as of March 29, 2011 and now wish to enter into this Amended and Restated Stock Issuance Agreement to reflect additional detail not available on March 29, 2011 concerning the Series A-1 Financing and the capitalization of Radius immediately before and following the initial closing of the Series A-1 Financing.

 

NOW THEREFORE, in consideration of the premises and mutual covenants set forth herein, the parties hereby agree as follows:

 

1.  DEFINITIONS

 

1.1  Defined Terms. Capitalized terms used in this Agreement and not otherwise defined herein shall have the meaning set forth below.

 

“Affiliate” means with respect to either party, any Person that, directly or indirectly, is controlled by, controls or is under common control with such party. For purposes of this definition only, “control” means, with respect to any Person, the direct or indirect ownership of more than fifty percent (50%) of the voting or income interest in such Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person.

 

“Applicable Quarterly Amount” means, with respect to each calendar quarter commencing with the calendar quarter in which the first subject is enrolled in the clinical study that is the subject of Work Statement NB-1, the portion of the Bonus Equity Payment Amount that NB is due with respect to such calendar quarter as determined in accordance with Section 3.1(a).

 

“Bonus Equity Payment Amount” means €36,814,531, which represents the maximum portion of the fees and expenses payable to NB in connection with all services rendered by, or on behalf of NB, pursuant to the CTS Agreement and Work Statement NB-1 under the CTS Agreement that NB has agreed Radius may satisfy by issuing the Bonus Shares pursuant to, and in accordance with, the provisions of this Agreement.

 

“Bonus Shares” means, collectively, (a) the number of shares of Series A-6 Preferred Stock that accrue as a stock dividend with respect to all issued and outstanding shares of Series A-5 Preferred Stock pursuant to, and in accordance with, this Agreement; and (b) the number of shares of preferred stock or common stock of Radius or any other Person that accrue pursuant to, and in accordance with, the provisions of the second paragraph of Section 3.1(k) or the provisions of Section 3.1(l). The meaning of the term Bonus Shares shall be subject to change in accordance with the provisions of Section 3.1(m).

 

1

 

“Business Day” means any day other than a Saturday or Sunday that is not a national holiday in the U.S..

 

“Event of Sale” means (a) the sale by the stockholders of Radius in a single transaction or a series of related transactions, of issued and outstanding shares of capital stock of Radius that represent a majority of the voting power of Radius to one or more third parties that are not Affiliates of such stockholders, provided that this clause (a) shall not be applicable to Radius from and after the earlier  of (i) the closing of the initial public offering of Radius and (ii) the date on which any preferred stock or common stock of Radius is otherwise publicly traded or registered under the Securities Exchange Act of 1934, as amended; (b) the merger, consolidation or reorganization with or into any other corporation, entity or Person or any other corporate reorganization, in which the holders of the capital stock of Radius immediately prior to such merger, consolidation or reorganization, together with such holder’s Affiliates, do not hold shares of capital stock of the surviving entity that represent more than 50% of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such merger, consolidation or reorganization; or (c) the sale, exclusive license or other disposition of all or substantially all of the assets or intellectual property of Radius, in a single transaction or series of related transactions, to one or more third parties that are not Affiliates of Radius. For purposes of clarification, Event of Sale shall not include any transaction involving Radius and the Shell Company Successor that is described in clause (iii) of the Shell Company Successor definition.

 

“Fair Market Value” means, with respect to each Accrual Date, the greater  of (i) the Series A-5 Purchase Price Per Share (as such price per share may be adjusted for any stock splits, stock dividends, reverse stock splits, recapitalizations, mergers and other similar events affecting such Series A-5 Preferred Stock), (ii) the price per share of the preferred stock or common stock sold by Radius in the most recent equity financing closed by Radius prior to such Accrual Date (as such price per share may be adjusted for any stock splits, stock dividends, reverse stock splits, recapitalizations, mergers and other similar events affecting such preferred stock or common stock, as applicable); and (iii) the average of the closing prices of any preferred stock or the common stock (whichever has the higher trading price as of such Accrual Date) of Radius on a securities exchange (if such preferred stock or common stock, as applicable, is traded on an exchange) or the average of the closing sale prices or secondarily the closing bid prices of any preferred stock or the common stock (whichever has the higher trading price as of such Accrual Date) of Radius (if such preferred stock or common stock, as applicable, is regularly traded over-the-counter) over the twenty (20) calendar day period ending two (2) calendar days prior to such Accrual Date (as such closing prices, closing sale prices or closing bid prices, as applicable, may be adjusted for any stock splits, stock dividends, reverse stock splits, recapitalizations, mergers and other similar events affecting such preferred stock or common stock, as applicable).

 

“Person” means any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization, other than Radius or NB.

 

“Project Committee” has the meaning ascribed to it under the CTS Agreement.

 

“Shell Company Successor” means a shell company that (i) has securities registered under the Securities Exchange Act of 1934, as amended, (ii) has nominal operations and nominal assets (prior to any of the transactions described in the next clause) and (iii) directly or indirectly through one or more direct or indirect subsidiaries acquires Radius and/or all or substantially all of its assets or business (whether pursuant to a stock purchase, an asset purchase, a merger or any other similar transaction). and in consideration for such acquisition issues to the former stockholders of Radius shares of capital stock of such shell company.

 

1.2  Other Defined Terms. The following terms shall have the meanings set forth in the section appearing opposite such term:

 

	
“Accrual Date”
    	
 
    	
Section 3.1(a)
    
	
“Agreement”
    	
 
    	
Recitals
    
	
“Arbitration”
    	
 
    	
Section 3.1(d)
    
	
“Arbitrator”
    	
 
    	
Section 3.1(f)
    

 

2

 

	
“Bonus Shares Report”
    	
 
    	
Section 3.1(c)
    
	
“Closing”
    	
 
    	
Section 2.1(b)
    
	
“Conversion Shares”
    	
 
    	
Section 2.2
    
	
“Common Stock”
    	
 
    	
Section 4.4
    
	
“CTS Agreement”
    	
 
    	
Recitals
    
	
“Dispute Notice”
    	
 
    	
Section 3.1(d)
    
	
“Effective Date”
    	
 
    	
Recitals
    
	
“Independent Accounting Firm”
    	
 
    	
Section 3.1(e)
    
	
“NB”
    	
 
    	
Recitals
    
	
“Preferred Stock”
    	
 
    	
Section 4.4
    
	
“Radius”
    	
 
    	
Recitals
    
	
“Restated Certificate”
    	
 
    	
Section 2.2
    
	
“Rules”
    	
 
    	
Section 3.1(f)
    
	
“Securities Act”
    	
 
    	
Section 4.4
    
	
“Series A-1 Financing”
    	
 
    	
Section 6.6
    
	
“Series A-5 Preferred Stock”
    	
 
    	
Recitals
    
	
“Series A-5 Purchase Price Per Share”
    	
 
    	
Section 2.1(a)
    
	
“Series A-5 Shares”
    	
 
    	
Section 2.1(a)
    
	
“Series A-6 Preferred Stock”
    	
 
    	
Section 2.2
    
	
“Stage I Closing”
    	
 
    	
Section 6.6
    
	
“Stockholders Agreement”
    	
 
    	
Section 4.1
    
	
“Transaction Documents”
    	
 
    	
Section 4.1.
    

 

2.  ISSUANCE OF SERIES A-5 PREFERRED STOCK

 

2.1  Purchase and Sale of Series A-5 Preferred Stock. (a)  On May 17, 2011, NB will purchase and Radius will sell and issue to NB 64,430 shares of Radius Series A-5 Preferred Stock (the “Series A-5 Shares”), representing the quotient (rounded to the nearest whole number) obtained by dividing  (x) the U.S. Dollar equivalent (determined in accordance with the provisions of the next sentence) of €371,864 by  (y) US$8.142 per share (the “Series A-5 Purchase Price Per Share”). Radius shall determine the U.S. Dollar equivalent of such €371,864 using the exchange rate for buying U.S. Dollars with EUROS set forth in The Wall Street Journal(Online Edition) Market Data Center at http://online.wsj.com/mdc/public/page/marketsdata.html on the Business Day that is two (2) Business Days preceding the date of the Closing. The aggregate purchase price payable by NB for the Series A-5 Shares shall be €371,864.

 

(b)  The purchase and sale of the Series A-5 Shares to be purchased and sold pursuant to Section 2.1(a) shall take place at the offices of Bingham McCutchen LLP, One Federal Street, Boston, Massachusetts, at 10:00 a.m. local time on May 17, 2011 (which time and place are referred to as the “Closing”).

 

(c)  At the Closing, Radius will deliver to NB a certificate registered in NB’s name representing the Series A-5 Shares, against payment of the purchase price therefor by wire transfer in accordance with Radius’s instructions;.

 

2.2  Reservation of Series A-5 Preferred Stock and Series A-6 Preferred Stock. Radius will, prior to the Closing, authorize: (a) the sale and issuance of the Series A-5 Shares; (b) the accrual and issuance of all of the shares of Series A-6 Convertible Preferred Stock, par value $0.01 per share (the “Series A-6 Preferred Stock”), of Radius in accordance with the provisions of this Agreement; and (c) the reservation of shares of Common Stock, par value $0.01 per share for issuance upon conversion of the Series A-5 Preferred Stock and the Series A-6 Preferred Stock (the “Conversion Shares”). The Series A-5 Preferred Stock, the Series A-6 Preferred Stock and the Common Stock have the rights, privileges, preferences and restrictions set forth in the Fourth Amended and Restated Certificate of Incorporation of Radius, including those summarized in the Term Sheet in the form attached hereto as Attachment A, with such changes and additional provisions as may be made by Radius after the date hereof in connection with the negotiation by Radius of the closing documents for the Series A-1 Financing with prospective investors in the Series A-1 Financing (the “Restated Certificate”). The Series A-5 Preferred Stock and the Series A-6 Preferred Stock shall have the same right, privileges, preferences and restrictions except that the Series A-6 Preferred Stock shall not be entitled to accrue any shares of capital stock of Radius, whether as a stock dividend or otherwise, pursuant to, and in accordance with, the terms and conditions of this Agreement.

 

3

 

3.  BONUS SHARES

 

3.1  Calculation of Bonus Shares; Issuance of Bonus Shares. (a)  Subject to the terms and conditions of this Agreement (including the limitations set forth in Section 3.4), the holders of shares of Series A-5 Preferred Stock shall be entitled to receive stock dividends, payable in shares of Series A-6 Preferred Stock in accordance with the provisions of this Section 3.1, having an aggregate value (determined as provided in this Section 3.1) of up €36,814,531 as calculated on the date that such stock dividends accrue in accordance with this Section 3.1. Subject to the terms and conditions of this Agreement (including the limitations set forth in Section 3.4), on the last Business Day of each calendar quarter (each, an “Accrual Date”), beginning with the calendar quarter during which the first subject is enrolled in the clinical study that is the subject of Work Statement NB-1, each outstanding share of Series A-5 Preferred Stock shall accrue, as a stock dividend, a number of shares of Series A-6 Preferred Stock having a value (determined as provided further below in this Section 3.1) equal to (x) €36,814,531 minus the aggregate value of any prior stock dividends that accrue pursuant to this Section 3.1(a) (with such aggregate value of such prior stock dividends being determined as of the applicable prior Accrual Date) divided by  (y) the number of calendar quarters the Project Committee has determined it will take to complete the clinical study that is the subject of Work Statement NB-1 and lock the study database and transfer the study database to Radius in its then most recent determination delivered in accordance with Section 3.1(b).

 

(b)  When calculating the aggregate number of Bonus Shares accruing in each calendar quarter, Radius shall convert the portion of €36,814,531 to accrue in such calendar quarter into U.S. Dollars using the simple average of the exchange rate for buying U.S. Dollars with EUROS set forth in The Wall Street Journal(Online Edition) Market Data Center at http://online.wsj.com/mdc/public/page/marketsdata.html for all Mondays’ in such calendar quarter. Radius shall then calculate the aggregate number of Bonus Shares accrued in such calendar quarter by dividing (x) the U.S. Dollar equivalent (determined in accordance with the provisions set forth in the preceding sentence) of the Applicable Quarterly Amount, by (y) the Fair Market Value as of the applicable Accrual Date, and rounding down the resulting quotient to the nearest whole number. In the event that the Bonus Shares that accrue in any calendar quarter are in the form of stock dividends accruing on the shares of Series A-5 Preferred Stock that are outstanding on the Accrual Date applicable to such calendar quarter, the number of Bonus Shares accruing in such calendar quarter with respect to each share of Series A-5 Preferred Stock outstanding on the applicable Accrual Date shall be equal to the quotient (rounded down to the nearest whole number) obtained by dividing (i) the number of Bonus Shares that accrue on such applicable Accrual Date by (ii) the total number of shares of Series A-5 Preferred Stock issued and outstanding as of such applicable Accrual Date.

 

(c)  Radius and NB, acting through the Project Committee in accordance with Section 3 of the CTS Agreement, will evaluate the study timeline and update the completion date for the clinical study that is the subject of Work Statement NB-1 set forth in Work Statement NB-1 to account for delays or accelerations in the performance of the clinical study that is the subject of Work Statement NB-1. Not later than five (5) calendar days before the end of each calendar quarter, the Project Committee will provide Radius with a written update detailing the number of calendar quarters that the Project Committee determines it will take to complete the clinical study that is the subject of Work Statement NB-1 and lock the study database and transfer the study database to Radius. Based upon such written update provided by the Project Committee, Radius shall calculate, on the applicable Accrual Date, the number of Bonus Shares that accrue on such applicable Accrual Date in accordance with the provisions of Section 3.1(a). Within thirty (30) days following the end of each calendar quarter, Radius shall provide NB with a written report (each, a “Bonus Shares Report”) setting forth the calculation of the number of Bonus Shares that accrued in such calendar quarter in accordance with Section 3.1(a) and the aggregate Bonus Shares accrued as of the end of such calendar quarter. Such Bonus Shares Report shall be certified by the Chief Financial Officer (or equivalent financial and accounting officer) of Radius to be correct to the best of Radius’ knowledge and information.

 

(d)  The Bonus Shares Report as prepared by Radius shall be conclusive and binding on NB unless NB shall notify Radius in writing within thirty (30) days after receipt thereof that, in the opinion of NB, the number of Bonus Shares set forth on the Bonus Shares Report has not been calculated correctly. Such notice (the “Dispute Notice”) shall set forth in reasonable detail each item and amount with which NB disagrees and the basis for such disagreement. Radius and NB shall attempt to resolve such dispute and agree in writing upon the final content of the Bonus Shares Report and the final calculation of the number of Bonus Shares accrued in the period. If the

 

4

 

parties cannot so agree within ten (10) Business Days after the delivery by NB to Radius of the Dispute Notice, then either Radius or NB may submit such dispute to an independent arbitrator for determination (an “Arbitration”) in accordance with the terms set forth in Section 3.1(e)-(g).

 

(e)  Any request for Arbitration shall be made in writing to an independent accounting firm of recognized national standing to be mutually selected by Radius and NB, which firm shall not be an auditing firm for either party and shall not have provided material services to either party during the two (2) year period prior to the date of Arbitration initiation. The firm to which such request is made shall, upon agreeing in writing to determine the number of Bonus Shares that have accrued in such quarterly period in accordance with the terms of this Section 3.1, be the “Independent Accounting Firm”, as that term is used in this Section 3.1. If the parties are not able to agree within five (5) Business Days after the receipt by a party of the arbitration request, the New York Office of the American Arbitration Association shall be responsible for selecting an Independent Accounting Firm within ten (10) Business Days of being approached by a party.

 

(f)  The Arbitration shall be conducted under the auspices of the Independent Accounting Firm and shall be conducted in accordance with the then current expedited procedures applicable to the then current Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes (“Rules”) of the American Arbitration Association, as such Rules and procedures may be modified by this Section 3.1(f). The Independent Accounting Firm shall, within five (5) Business Days of its agreement to determine the number of Bonus Shares that have accrued in such quarterly period, provide to Radius and NB the name of its partner who will serve as the individual responsible for conducting the Arbitration (the “Arbitrator”). Within five (5) Business Days after the designation of the Arbitrator, the parties shall each simultaneously submit to the Arbitrator and one another a written statement of their respective positions on such disagreement. Each party shall have ten (10) Business Days from receipt of the other party’s submission to submit to the Arbitrator and the other party a written response thereto. The Arbitrator shall have the right to meet with the parties, either alone or together, as necessary to make a determination. The Arbitrator shall conduct an Arbitration to determine the number of Bonus Shares that have accrued in such quarterly period. The Arbitrator shall make such determination subsequent to conducting the Arbitration and shall set forth such determination in a written ruling, which ruling shall be rendered within forty-five (45) days of the selection date of the Arbitrator and shall be delivered to Radius and NB.

 

(g)  The locale of all hearings conducted by the Arbitrator in connection with the Arbitration shall be the New York office of the Independent Accounting Firm. The ruling of the Arbitrator shall be final, binding, and conclusive on Radius and NB; shall have the legal effect of an arbitral award; and shall be subject only to the judicial review permitted by the Federal Arbitration Act. Judgment on the ruling of the Arbitrator may be entered and enforced in any court having jurisdiction over the parties or their assets. The fees and disbursements of the Independent Accounting Firm shall be allocated and payable between Radius on the one hand and NB on the other hand in the same proportion that (i) the additional number of Bonus Shares that have been determined by the Arbitrator to have accrued in such period bears to (ii) the additional number of Bonus Shares that NB initially claimed in its Dispute Notice accrued in such period. If a party fails to proceed with Arbitration, unsuccessfully challenges the arbitration award, or fails to comply with the arbitration award, the other party is entitled to costs, including reasonable attorneys’ fees, for having to compel arbitration or defend or enforce the award. Except as otherwise required by law, the parties and the Arbitrator and Independent Accounting Firm will maintain as confidential all information or documents obtained during the arbitration process, including the resolution of the dispute. The parties knowingly and voluntarily waive their rights to have their dispute tried and adjudicated by a judge and jury; provided that nothing in this Section 3.1(g) will prevent a party from resorting to judicial proceedings if: (1) interim relief from a court is necessary to prevent serious and irreparable injury to such party; or (2) litigation is required to be filed prior to the running of the applicable statute of limitations. The use of any alternative dispute resolution procedure will not be construed under the doctrine of latches, waiver or estoppel to affect adversely the rights of either party. The parties shall use the procedure set forth in Section 3.1(e)-(g) for any dispute concerning calculation of Bonus Shares; any other disputes concerning this Agreement and the transactions contemplated hereby shall be resolved in accordance with Section 8.12.

 

5

 

(h)  Bonus Shares that accrue pursuant to Section 3.1(a) shall be subject to proportionate and equitable adjustment upon any stock splits, stock dividends, reverse stock splits, recapitalizations, mergers and other similar events involving or affecting the Series A-5 Preferred Stock.

 

(i)  Bonus Shares that accrue pursuant to Section 3.1(a) shall be payable, when, as and if declared or paid by the Board of Directors of Radius. The Board of Directors of Radius shall be required to declare and pay such Bonus Shares accrued pursuant to Section 3.1(a) hereof: (i) upon the request of the holder(s) of a majority of the shares of common stock or other capital stock issued or issuable in respect of Series A-5 Preferred Stock or (ii) on any Event of Sale.

 

(j)  The stock dividend feature of Section 3.1(a), as well as all other forms of accrual of Bonus Shares under this Agreement (including, without limitation, any contractual accrual of Bonus Shares pursuant to the second paragraph of Section 3.1(k) below or pursuant to Section 3.1(l) below) shall terminate upon an Event of Sale. Upon an Event of Sale, the Person that becomes the successor of Radius as a result of such Event of Sale shall, in lieu of accruing Bonus Shares pursuant to this Agreement, make cash payments to NB for the services to be rendered pursuant to Work Statement NB-1.

 

(k)  The stock dividend feature of Section 3.1(a) hereof shall also terminate upon the occurrence of any event that is not an Event of Sale if such event causes all outstanding shares of Series A-5 Preferred Stock of Radius to convert into, or be exchanged for, common stock of Radius or any other Person (including a Shell Company Successor) or any other class or series of capital stock of Radius or any other Person (including a Shell Company Successor); provided, however, that such stock dividend feature shall not terminate if such event that is not an Event of Sale consists of an acquisition of Radius, directly or indirectly, by such Shell Company Successor pursuant to which all shares of each of Series A-5 Preferred Stock and Series A-6 Preferred Stock of Radius shall convert into, or be exchanged for, shares of a series of preferred stock of the Shell Company Successor that has adopted and incorporated substantially the same terms provided under this Agreement with respect to the Series A-5 Preferred Stock or the Series A-6 Preferred Stock, as the case may be, of Radius, in which case such stock dividend feature shall be applicable to such series of preferred stock of the Shell Company Successor.

 

Upon termination of the stock dividend feature pursuant to this Section 3.1(k) in connection with an event that is not an Event of Sale: (1) all accrued Bonus Shares not yet issued or paid shall automatically convert into the right to receive a distribution of that number of accrued but not yet issued or paid shares of such common stock or such other class or series of capital stock that a holder of such accrued but not yet issued Bonus Shares would have been entitled to receive with respect to such Bonus Shares if such holder had claimed such Bonus Shares using the procedure described in Section 3.1(i)(i) and been the holder of record of such Bonus Shares immediately prior to the occurrence of such event; and (2) all Bonus Shares, if any, that would have accrued pursuant to Section 3.1(a) at any time after the occurrence of such event if such event had not occurred, shall accrue pursuant to this clause (2) on the same terms and conditions as if such accrual had been under Section 3.1(a) hereof and be payable in shares of such common stock of Radius or any other Person (including a Shell Company Successor), as the case may be, or such other class or series of capital stock of Radius or any other Person (including a Shell Company Successor), as the case may be, in accordance with the terms of this Agreement as if such accrual had been pursuant to Section 3.1(a). For purposes of clarification, any accrual of Bonus Shares pursuant to clause (2) of this paragraph shall be a contractual accrual and not an accrued stock dividend.

 

(l)  The stock dividend feature of Section 3.1(a) shall also terminate upon the transfer by NB of any or all of the Series A-5 Shares to any Person. Upon termination of the stock dividend feature pursuant to this Section 3.1(m), all Bonus Shares, if any, that would have accrued pursuant to Section 3.1(a) at any time after the occurrence of such transfer of Series A-5 Shares by NB if such transfer had not occurred, shall accrue pursuant to this Section 3.1(m) for the exclusive benefit of NB (and not the Person to whom such Series A-5 Shares were transferred) on the same terms and conditions as if such accrual had been under Section 3.1(a) hereof and be payable in shares of Series A-6 Preferred Stock subject to, and in accordance with, the terms of this Agreement as if such accrual had been pursuant to Section 3.1(a). For purposes of clarification, any accrual of Bonus Shares pursuant to this Section 3.1(l) shall be a contractual accrual and not an accrued stock dividend.

 

(m)  Notwithstanding anything express or implied in this Agreement to the contrary, in the event of any transaction involving Radius and a Shell Company Successor pursuant to which such Shell Company Successor,

 

6

 

directly or indirectly, acquires Radius or all or substantially all of its assets, then (1) such transaction shall not be treated as an Event of Sale, (2) such Shell Company Successor shall succeed to all of the rights and obligations of Radius under this Agreement and (3) if the stock dividend feature of Section 3.1(a) hereof does not terminate pursuant to the first paragraph of Section 3.1(k), all references in this Agreement to the terms Series A-5 Preferred Stock and Series A-6 Preferred Stock shall be deemed and treated as if they were references to the applicable series of preferred stock of such Shell Company Successor into which, or for which, such Series A-5 Preferred Stock and such Series A-6 Preferred Stock was converted or exchanged, as applicable.

 

3.2  Bonus Shares to be Duly Authorized and Issued, Fully Paid and Non-Assessable. Radius covenants and agrees that it will take all such action as may be necessary to ensure that all Bonus Shares issued pursuant to this Agreement shall, at the time of delivery of the certificates for such Bonus Shares, be duly and validly authorized and issued and fully paid and non-assessable shares.

 

3.3  Stock Record Date. No Person shall be deemed to have become the holder of record of any Bonus Shares until the date that the Board of Directors declare such accrued Bonus Shares payable in accordance with Section 3.1(i) and any certificate for such accrued Bonus Shares shall be dated as of such date. Prior to such date, no Person shall be entitled to any rights of a stockholder of Radius with respect to the Bonus Shares which may be issuable pursuant to this Agreement including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights and shall not be entitled to receive any notice of any proceedings of Radius, except as provided herein.

 

3.4  Limitation. (a)  Subject to Section 3.4(b), notwithstanding anything to the contrary expressed or implied in this Agreement, in the event that, at any time after Radius is acquired, directly or indirectly, by a Shell Company Successor, any accrual of Bonus Shares in accordance with the provisions of this Agreement would cause the cumulative number of Bonus Shares (calculated on an as converted to Common Stock basis) accrued pursuant to this Agreement from and after the effective date of such acquisition (whether or not such accrued Bonus Shares have been or are issued) to exceed 19.9% of the issued and outstanding shares of capital stock of such Shell Company Successor as of such effective date and as of each Accrual Date after such effective date (calculated on an as converted to Common Stock basis and after giving effect to appropriate and equitable adjustments upon any stock splits, stock dividends, reverse stock splits, recapitalizations, mergers and other similar events), then no such accrual shall be made pursuant to this Agreement, and Radius shall, in lieu of such accrual, make payment of any Applicable Quarterly Amount in cash.

 

(b)  The limitation imposed by Section 3.4(a) may be waived by Radius in its sole and absolute discretion at any time and from time to time. Any such waiver by Radius of such limitation in any particular instance shall not constitute a waiver of such limitation in any other instance.

 

4.  REPRESENTATIONS AND WARRANTIES OF RADIUS.

 

Radius hereby represents and warrants to NB as follows, as of the Closing:

 

4.1  Organization and Standing; Power and Authority. Radius is a corporation duly organized and validly existing under the laws of the State of Delaware and has the requisite corporate power and authority to (a) own and operate its properties and assets, (b) conduct its business as currently conducted, (c) execute and deliver this Agreement and the Amended and Restated Stockholders’ Agreement among Radius and the other parties thereto including those summarized in the Term Sheet in the form attached as Attachment A, with such changes and additional provisions as may be made by Radius after the date hereof in connection with the negotiation by Radius of the closing documents for the Series A-1 Financing with prospective investors in the Series A-1 Financing (the “Stockholders’ Agreement” and collectively with this Agreement the “Transaction Documents”), (d) issue and sell the Series A-5 Preferred Stock, and (e) perform its obligations pursuant to the Transaction Documents and the Restated Certificate.

 

4.2  Execution; Enforceability. All corporate action on the part of Radius, its stockholders and its directors necessary for the authorization, execution and delivery of the Transaction Documents by Radius, the authorization, sale, issuance and delivery of the Series A-5 Preferred Stock, the Bonus Shares and the Conversion Shares, and the performance of all of Radius’ obligations under the Transaction Documents to be performed as of the Closing has

 

7

 

been taken or will be taken prior to the Closing. All action on the part of the officers of Radius necessary for the execution and delivery of the Transaction Documents, the performance of all obligations of Radius under the Transaction Documents to be performed as of the Closing, and the issuance and delivery of the Series A-5 Preferred Stock has been taken or will be taken prior to the Closing. The Transaction Documents, when executed and delivered by Radius, shall constitute valid and binding obligations of Radius, enforceable in accordance with their terms, except (a) to the extent that the indemnification provisions contained in the Stockholders’ Agreement may be limited by applicable laws and principles of public policy; (b) as limited by bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; and (c) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity.

 

4.3  Authority. The execution of, and performance of, the transactions contemplated by the Transaction Documents and compliance with the provisions of the Transaction Documents by Radius will not, to the best of its knowledge, violate any provision of law and, if applicable, will not conflict with or result in any material breach of any of the terms, conditions or provisions of, or constitute a material default under, or require a consent or waiver under, its Restated Certificate or By-laws (each as amended to date and as in effect as of the date the Series A-5 Preferred Stock or the Bonus Shares are issued to NB) or any material indenture, lease, agreement or other instrument to which Radius is a party or by which it or any of its properties (whether tangible or intangible) is bound.

 

4.4  Capitalization. (a)  Radius shall have a total authorized capitalization immediately prior to the Stage I Closing consisting of: (i) 34,859,964 shares of Common Stock, $.01 par value per share (the “Common Stock”), of which (1) 522,506 shares shall be validly issued and outstanding, fully paid and nonassessable (including 266 shares issuable upon exercise of warrants to purchase Common Stock); (2) 29,364,436 shares shall have been duly reserved for issuance upon conversion of the Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5 Preferred Stock and Series A-6 Preferred Stock (including 147,384 shares of Series A-1 Preferred Stock issuable upon exercise of warrants to purchase Series A-1 Preferred Stock); and (3) 2,015,666 shares shall have been duly reserved for issuance under Radius’ 2003 Long-Term Incentive Plan, as amended (the “2003 Plan Option Shares”); and (ii) 29,364,436 shares of Preferred Stock, $.01 par value per share (the “Preferred Stock”), (1) of which 63,000 shares shall have been designated as Series A[ Preferred] Stock, 61,664 of which shall be issued and outstanding, fully paid and nonassessable; (2) of which 1,600,000 shares shall have been designated as Series B [Preferred ]Stock, 1,599,997 of which shall be issued and outstanding, fully paid and nonassessable; (3) of which 10,146629 shares shall have been designated as Series C Preferred Stock, all of which shall be issued and outstanding, fully paid and nonassessable; (4) of which 10,000,000 shares shall have been designated as Series A-1 Preferred Stock, none of which shall be issued and outstanding; (5) of which 9,832,133 shall have been designated the Series A-2 Preferred Stock, none of which shall be issued and outstanding; (6) of which 1,422,300 shall have been designated the Series A-3 Preferred Stock, none of which shall be issued and outstanding; (7) of which 40,003 shall have been designated the Series A-4 Preferred Stock, none of which shall be issued and outstanding; (8) of which 70,000 shall have been designated the Series A-5 Preferred Stock, none of which shall be issued and outstanding; and (9) of which 8,000,000 shall have been designated the Series A-6 Preferred Stock, none of which shall be issued and outstanding.

 

(b)  Radius shall have a total authorized capitalization immediately following the Stage I Closing, assuming compliance by all parties with the provisions of the Series A-1 Financing documents by each of the investors thereunder, consisting of: (i) 34,859,964 shares of Common Stock, of which: (1) 522,506 shall be validly issued and outstanding, fully paid and nonassessable (including 266 shares issuable upon exercise of warrants to purchase Common Stock); (2) 29,364,436 shares shall have been duly reserved for issuance upon conversion of the Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5 Preferred Stock and Series A-6 Preferred Stock (including 147,384 shares of Series A-1 Preferred Stock issuable upon exercise of warrants to purchase Series A-1 Preferred Stock); and (3) 2,015,666 shares shall have been duly reserved for issuance in connection with options available under the Corporation’s 2003 Long-Term Incentive Plan, as amended; (ii) 29,364,436 shares of Preferred Stock of which: (1) 63,000 shall have been designated the Series A Preferred Stock, none of which shall be issued and outstanding; (2) 1,600,000 shall have been designated the Series B Preferred Stock, none of which shall be issued and outstanding; (3) 10,146,629 shall have been designated the Series C Preferred Stock, none of which shall be issued and outstanding; (4) 10,000,000 shall have been designated the Series A-1 Preferred Stock, of which 4,136,912 shall be validly issued and outstanding, fully paid and nonassessable; (5) 9,832,133 shall have been designated the

 

8

 

Series A-2 Preferred Stock, all of which shall be validly issued and outstanding, fully paid and nonassessable; (6) 1,422,300 shall have been designated the Series A-3 Preferred Stock, all of which shall be validly issued and outstanding, fully paid and nonassessable; (7) 40,003 shall have been designated the Series A-4 Preferred Stock, all of which shall be validly issued and outstanding, fully paid and nonassessable; (8) 70,000 shall have been designated the Series A-5 Preferred Stock, of which 66,028 shall be validly issued and outstanding, fully paid and nonassessable; and (9) 8,000,000 shall have been designated the Series A-6 Preferred Stock, none of which shall be issued and outstanding.

 

(c)  All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and nonassessable, and were issued in accordance with the registration or qualification provisions of the Securities Act of 1933, as amended (the “Securities Act”) and any relevant state securities laws, or pursuant to valid exemptions therefrom. All shares of capital stock issuable upon exercise of outstanding options have been duly authorized and reserved and, when issued in accordance with the terms of such options, will be validly issued, fully paid and nonassessable. All shares of capital stock issuable upon exercise of outstanding warrants have been duly authorized and reserved, and the shares of Common Stock or Preferred Stock when issued in accordance with the terms of such warrants will be validly issued, fully paid and nonassessable.

 

(d)  The Series A-5 Preferred Stock, when issued, delivered and paid for in compliance with the provisions of this Agreement and the Bonus Shares when issued and delivered in compliance with this Agreement, will be validly issued, fully paid and nonassessable. The Conversion Shares have been duly and validly reserved and, when issued in compliance with the provisions of this Agreement, the Restated Certificate and applicable law, will be validly issued, fully paid and nonassessable. The Series A-5 Preferred Stock, the Bonus Shares and the Conversion Shares will be free of any liens or encumbrances, other than any liens or encumbrances created by NB; provided, however, that the Series A-5 Preferred stock, the Bonus Shares and the Conversion Shares are subject to restrictions on transfer under U.S. state and/or federal securities laws and as set forth herein and in the Stockholders’ Agreement.

 

4.5  Issuance of Shares. The issuance, sale and delivery of the Series A-5 Preferred Stock in accordance with this Agreement, and the issuance and delivery of the Conversion Shares upon conversion of the Series A-5 Preferred Stock, have been duly authorized by all necessary corporate action on the part of Radius, and all such shares have been duly reserved for issuance. The shares of Series A-5 Preferred Stock when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement, and the Conversion Shares, if and when issued upon such conversion, will be duly and validly issued, fully paid and non-assessable. The Bonus Shares when issued and delivered in accordance with the provisions of Section 3.1(i), and any shares of common stock if and when issued on conversion of such Bonus Shares (if applicable) will be duly and validly issued, fully paid and non-assessable.

 

4.6  Offering. Subject to the accuracy of the NB’s representations and warranties in Section 5, the offer, sale and issuance of the Series A-5 Preferred Stock to be issued in conformity with the terms of this Agreement and the issuance of the Conversion Shares and the issuance of the Bonus Shares to be issued in accordance with the terms of this Agreement, as applicable, constitute transactions exempt from the registration requirements of Section 5 of the Securities Act and from the registration or qualification requirements of applicable state securities laws, and neither Radius nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption.

 

4.7  Brokers. Radius has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement and neither NB nor any investor in Radius has, nor will, incur, directly or indirectly, as a result of any action taken by the Radius, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Transaction Documents.

 

4.8  Consents. All consents, approvals, orders and authorizations required on the part of Radius in connection with the execution, delivery or performance of the Transaction Documents and the consummation of the transactions contemplated thereby have been obtained.

 

5.  REPRESENTATIONS AND WARRANTIES OF NB.

 

NB represents and warrants to Radius as follows:

 

9

 

5.1  Accredited Investor. NB is an “accredited investor” within the meaning of Rule 501(a) under the Securities Act, and understands that Radius has relied upon its being an accredited investor in deciding to proceed with the transactions contemplated hereby, and in ascertaining the requirements of law applicable to the issuance and sale of the Shares and the Bonus Shares. NB’s financial condition is such that it is able to bear all economic risks of investment in the Series A-5 Preferred Stock or the Bonus Shares, including a complete loss of NB’s investment therein. NB acknowledges that Radius has provided it with adequate access to financial and other information concerning Radius as requested and that it has had the opportunity to ask questions of and receive answers from Radius concerning the transactions contemplated under this Agreement and the Stockholders’ Agreement and to obtain therefrom any additional information necessary to make an informed decision regarding an investment in Radius.

 

5.2  Investment. NB is acquiring the Series A-5 Preferred Stock and the Bonus Shares, for its own account for investment, not as a nominee or agent, and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and, except as contemplated by this Agreement and the Stockholders’ Agreement, NB has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof.

 

5.3  Not Registered. NB understands that the Series A-5 Preferred Stock, the Conversion Shares and the Bonus Shares have not been registered under the Securities Act, and must be held indefinitely until such time as they are subsequently registered under the Securities Act or an exemption from such registration is available. NB has been independently advised or is aware of the provisions of Rule 144 promulgated under the Securities Act that afford exemptions from registration depend on the satisfaction of various conditions, including, among other things: the availability of certain current public information about Radius, the resale occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being through an unsolicited “broker’s transaction” or in transactions directly with a market maker (as such term is defined under the Securities Exchange Act of 1934, as amended) and the number of shares being sold during any three-month period not exceeding specified limitations. NB also acknowledges that Radius is not under any obligation to register or to cause any Person to register any securities under the Securities Act.

 

5.4  Principal Place of Business. The address of the principal place of business, and the office in which NB’s investment decision was made, is located at Herlev Hovedgade 207, 2730 Herlev, Denmark.

 

5.5  Authority. NB has full power and authority to enter into and to perform this Agreement and the Stockholders’ Agreement in accordance with their respective terms. NB represents that it has not been organized, reorganized or recapitalized specifically for the purpose of investing in Radius. This Agreement has been duly executed and delivered by NB and constitutes a valid and binding obligation of NB enforceable against it in accordance with its terms. The execution of, and performance of, the transactions contemplated by the Transaction Documents and compliance with the provisions of the Transaction Documents by NB will not, to the best of its knowledge, violate any provision of law and, if applicable, will not conflict with or result in any material breach of any of the terms, conditions or provisions of, or constitute a material default under, or require a consent or waiver under, its organizational documents (if any, and each as amended to date and as in effect as of the date the Series A-5 Preferred Stock or the Bonus Shares are issued to NB) or any material indenture, lease, agreement or other instrument to which NB is a party or by which it or any of its properties (whether tangible or intangible) is bound.

 

5.6  Brokers. NB has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement and neither Radius nor any investor in Radius has, nor will, incur, directly or indirectly, as a result of any action taken by the NB, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Transaction Documents.

 

5.7  Consents. All consents, approvals, orders and authorizations required on the part of NB in connection with the execution, delivery or performance of this Agreement and the consummation of the transactions contemplated herein have been obtained and are effective.

 

5.8  Non-United States Person Consents. NB hereby represents that NB is satisfied as to the full observance of the laws of NB’s jurisdiction in connection with any invitation to subscribe for the Series A-5 Preferred Stock or any use of the Transaction Documents, including (a) the legal requirements within NB’s jurisdiction for the purchase of

 

10

 

Series A-5 Preferred Stock, (b) any foreign exchange restrictions applicable to such purchase, (c) any governmental or other consents that may need to be obtained and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of such securities. NB’s subscription and payment for, and NB’s continued beneficial ownership of, the Series A-5 Preferred Stock, will not violate any applicable securities or other laws of such NB’s jurisdiction.

 

6.  CLOSING CONDITIONS OF NB

 

NB’s obligation to purchase the Series A-5 Preferred Stock at the Closing is subject to the fulfillment on or before the Closing of each of the following conditions, unless waived by NB:

 

6.1  Representations and Warranties. The representations and warranties made by Radius in Section 4 shall be true and correct in all material respects as of the date of the Closing.

 

6.2  Covenants. All covenants, agreements and conditions contained in the Transaction Documents to be performed by Radius on or prior to the date of the Closing shall have been performed or complied with in all material respects as of the date of the Closing.

 

6.3  Restated Certificate. Prior to the Closing, the Restated Certificate shall have been duly authorized, executed and filed by Radius with and accepted by the Secretary of State of the State of Delaware.

 

6.4  Certificates and Documents. Radius shall deliver to NB a Certificate of the Secretary or an Assistant Secretary of Radius, dated as of the Closing, certifying that attached thereto: (a) is a true and complete copy of the Restated Certificate; (b) is a true and complete copy of the Radius By-Laws; and (c) is a true and complete copy of the resolutions of the Board of Directors and the stockholders of Radius authorizing and approving all matters in connection with this Agreement and the transactions contemplated hereby.

 

6.5  Compliance Certificate. Radius shall have delivered to NB a certificate executed by the Chief Executive Officer of Radius on behalf of Radius, certifying the satisfaction of the conditions to the Closing listed in Sections 6.1 and 6.2.

 

6.6  Series A-1 Financing. Radius shall have consummated an equity financing pursuant to which it shall have issued and sold shares of its Series A-1 Convertible Preferred Stock, par value $0.01 per share, to existing and/or new investors resulting in aggregate gross proceeds being received by Radius in an amount equal to approximately twenty million U.S. Dollars (US$20,000,000) (the “Stage I Closing”) and Radius and such investors shall have committed themselves to the issuance of two additional US$20,000,000 tranches of financing for the purchase of shares of Series A-1 Convertible Preferred Stock for aggregate gross proceeds being received by Radius from all three tranches in an amount equal to approximately sixty million U.S. Dollars (US$60,000,000) (the “Series A-1 Financing”).

 

7.  CLOSING CONDITIONS OF RADIUS

 

Radius’ obligation to sell and issue the Series A-5 Preferred Stock at the Closing is subject to the fulfillment on or before the Closing of the following conditions, unless waived by Radius:

 

7.1  Representations and Warranties. The representations and warranties made by NB in Section 5 shall be true and correct in all material respects as of the date of the Closing.

 

7.2  Covenants. All covenants, agreements and conditions contained in the Transaction Documents to be performed by NB on or prior to the date of the Closing shall have been performed or complied with in all material respects as of the date of the Closing.

 

7.3  Restated Certificate. Prior to the Closing, the Restated Certificate shall have been duly authorized, executed and filed by Radius with and accepted by the Secretary of State of the State of Delaware.

 

7.4  Stockholders’ Agreement. Prior to the Closing, NB shall have executed and delivered a counterpart to the Stockholders’ Agreement.

 

11

 

7.5  Securities Laws. Prior to the Closing, Radius shall be satisfied that the offer and sale of the Series A-5 Preferred Stock, the Conversion Shares and the Bonus Shares shall be qualified or exempt from registration or qualification under all applicable federal and state securities laws (including receipt by Radius of all necessary blue sky law permits and qualifications required by any state, if any).

 

7.6  Series A-1 Financing. Radius shall have consummated the Series A-1 Financing.

 

8.  GENERAL.

 

8.1  Notices. Unless otherwise provided herein, any notice, report, payment or document to be given by one party to another shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid (such mailed notice to be effective on the date which is three (3) Business Days after the date of mailing), or sent by nationally recognized overnight courier (such notice sent by courier to be effective one (1) Business Day after it is deposited with such courier), or sent by telefax (such notice sent by telefax to be effective when sent, if confirmed by certified or registered mail or overnight courier as aforesaid) to the address set forth on the signature page to this Agreement or to such other place as a party may designate as to itself by written notice to the other party. With respect to any notice given by Radius under any provision of the Delaware General Corporation Law or Radius’ charter or bylaws, NB agrees that such notice may be given by facsimile or by electronic mail. Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when delivered if delivered personally, or, if sent by air mail, at the earlier of its receipt or 48 hours after the same has been deposited in a regularly maintained receptacle for the deposit of the U.S. mail, addressed and mailed as aforesaid or, if sent by facsimile, upon confirmation of facsimile transfer or, if sent by electronic mail, upon confirmation of delivery when directed to the electronic mail address set forth below.

 

8.2  Applicable Law. This Agreement shall be governed by, subject to, and construed in accordance with the substantive laws of Massachusetts without regard for any choice or conflict of laws rule or provision that would result in the application of the substantive law of any other jurisdiction.

 

8.3  Waivers; Amendments. (a)  The waiver by a party of a breach or default under any provision under this Agreement or the failure of such party to exercise its rights under this Agreement in any instance shall not operate or be construed as a continuing waiver or a waiver of any subsequent breach or default No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar).

 

(b)  No agreement or understanding extending this Agreement or varying its terms shall be binding upon either party unless it is in a writing specifically referring to this Agreement and signed by a duly authorized representative of the applicable party. Any such amendment effected in accordance with this Section 8.3(b) shall be binding upon each holder of any securities issued pursuant to this Agreement at the time outstanding (including securities into which such securities have been converted or exchanged or for which such securities have been exercised) and each future holder of all such securities.

 

8.4  Integration. The terms and provisions contained in this Agreement (including the Attachments) and the CTS Agreement (including Work Statement NB-1) constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby and supersede all previous communications, representations, agreements and understandings relating to the subject matter hereof. No representations, inducements, promises or agreements, whether oral or otherwise, between the parties not contained in this Agreement and the CTS Agreement (including Work Statement NB-1) shall be of any force or effect.

 

8.5  Severability. In the event that any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement and such invalid or unenforceable provision shall be construed by limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, applicable law.

 

12

 

8.6  Binding Effect, Benefits. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by NB without the prior written consent of Radius. Any attempt by NB without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement shall be void. Subject to the foregoing, this Agreement shall inure to the benefit of and be binding upon the parties and their respective successors and assigns; nothing in this Agreement, expressed or implied, is intended to confer on any Person other than the parties hereto or, as applicable, their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

8.7  Headings. The Section headings are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement

 

8.8  Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be accepted as original signatures, orders may be transmitted electronically and any document created pursuant to this Agreement may be maintained in an electronic document storage and retrieval system, a copy of which shall be considered an original.

 

8.9  Further Assurances. Each party covenants and agrees that, subsequent to the execution and delivery of this Agreement and without any additional consideration, it will execute and deliver any further legal instruments and perform any acts that are or may become reasonably necessary to effectuate the purposes of this Agreement.

 

8.10  Rules of Construction. The parties agree that they have participated equally in the formation of this Agreement and that the language and terms of this Agreement shall not be construed against a party by reason of the extent to which such party or its professional advisors participated in the preparation of this Agreement.

 

8.11  Word Meanings. Words such as herein, hereinafter, hereof and hereunder refer to this Agreement as a whole and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires.

 

8.12  Dispute Resolution. Except as otherwise provided in Section 3.1(e)-(g) with respect to disputes concerning the accuracy of the calculation of Bonus Shares set forth on a Bonus Shares Report, any dispute among the parties concerning this Agreement and the transactions contemplated hereby shall be resolved using the procedures set forth in Section 10.1 and Section 10.2(a)-(b) of the CTS Agreement.

 

[remainder of this page intentionally left blank - signature page follows]

 

13

 

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on their behalf by their duly authorized representatives as of the Effective Date.

 

 

	
RADIUS   HEALTH, INC.
    	
 
    	
NORDIC   BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
    
	
 
    	
 
    	
 
    
	
/s/   C. Richard Lyttle
    	
 
    	
/s/   Claus Christiansen
    
	
By:   Cecil Richard Lyttle
    	
 
    	
By:   Clause Christiansen
    
	
Title:   President and Chief Executive Officer
    	
 
    	
Title:   Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
Notice   Address
    	
 
    	
Notice   Address
    
	
Radius   Health, Inc.
    	
 
    	
Nordic   Bioscience Clinical Development VII A/S
    
	
201   Broadway, 6th Floor
    	
 
    	
Herlev   Hovedgade 207
    
	
Cambridge,   MA 02139
    	
 
    	
2730   Herlev
    
	
USA
    	
 
    	
Denmark
    
	
Attn:   President
    	
 
    	
Attn:   Clinical Trial Leader & Medical Advisor / Clinical Studies
    
	
Phone:   01.617.444.1834
    	
 
    	
Phone:   45.4452.5251
    
	
Fax:   01.617.551.4701
    	
 
    	
Fax:   45.4452.5251
    

 

Attachment  A Term Sheet for Series A-1 Financing

 

14

 

Attachment A

 

Term Sheet for Series A-1 Financing
 [attached]

 

A-1

 

Radius Health Inc.

 

Project Fishbone

 

Key Terms of Series A-1 Preferred Stock Investment, 
 Strategic Alliance and Proposed Reverse Merger

 

THESE KEY TERMS ARE FOR DISCUSSION PURPOSES ONLY AND ARE NON-BINDING.

 

SERIES A-1 PREFERRED STOCK INVESTMENT (the “Series A-1 Offering”):

 

	
Issuer:
    	
 
    	
Radius Health   Inc, a Delaware corporation (“Radius” or the “Company”)
    
	
 
    	
 
    	
 
    
	
Type of   security:
    	
 
    	
Series A-1   Convertible Preferred Stock, par value $.01 per share (the “Series A-1   Stock”)
    
	
 
    	
 
    	
 
    
	
Investors:
    	
 
    	
Existing   Preferred Stock Investors in the Company (the “Lead Investors”) other   investors acceptable to the Lead Investors (collectively the “Investors”)
    
	
 
    	
 
    	
 
    
	
Investor   Amounts:
    	
 
    	
 
    

 

	
 
    	
 
    	
Pro Rata Portion
    	
 
    	
Super Pro Rata
   Amount
    	
 
    	
Total Series A-1
   Offering Investment
    	
 
    
	
MPM Bioventures III Funds
    	
 
    	
$
    	
8,038,666
    	
 
    	
$
    	
6,961,334
    	
 
    	
$
    	
15,000,000
    	
 
    
	
MPM Bio IV NVS Strategic Fund
    	
 
    	
$
    	
5,460,982
    	
 
    	
$
    	
1,932,348
    	
 
    	
$
    	
7,393,329
    	
 
    
	
Wellcome Trust
    	
 
    	
$
    	
6,234,069
    	
 
    	
—
    	
 
    	
$
    	
6,234,069
    	
 
    
	
HealthCare Ventures VII
    	
 
    	
$
    	
6,031,732
    	
 
    	
—
    	
 
    	
$
    	
4,800,000
    	
 
    
	
OB Partners IV or Saints Capital
    	
 
    	
$
    	
4,185,146
    	
 
    	
—
    	
 
    	
$
    	
3,958,011
    	
 
    
	
mRNA Fund II
    	
 
    	
$
    	
41,989
    	
 
    	
—
    	
 
    	
$
    	
41,989
    	
 
    
	
BB Biotech Ventures II
    	
 
    	
$
    	
3,117,035
    	
 
    	
$
    	
1,882,965
    	
 
    	
$
    	
5,000,000
    	
 
    
	
Scottish Widows
    	
 
    	
$
    	
1,662,418
    	
 
    	
—
    	
 
    	
$
    	
1,662,418
    	
 
    
	
Dr. Raymond F. Schinazi
    	
 
    	
$
    	
57,462
    	
 
    	
—
    	
 
    	
$
    	
57,462
    	
 
    
	
Other Series A
    	
 
    	
$
    	
170,501
    	
 
    	
—
    	
 
    	
$
    	
0
    	
 
    
	
Total
    	
 
    	
$
    	
35,000,000
    	
 
    	
$
    	
10,776,647
    	
 
    	
$
    	
44,147,279
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Brookside
    	
 
    	
 
    	
 
    	
$
    	
10,000,000
    	
 
    
	
 
    	
 
    	
BB Biotech AG
    	
 
    	
 
    	
 
    	
$
    	
5,000,000
    	
 
    
	
 
    	
 
    	
Potential Second   Closing
    	
 
    	
 
    	
 
    	
$
    	
852,721
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Equity Raise
    	
 
    	
 
    	
 
    	
$
    	
60,000,000
    	
 
    
	
 
    	
 
    	
Venture Debt
    	
 
    	
 
    	
 
    	
$
    	
25,000,000
    	
 
    
	
 
    	
 
    	
Total Financing
    	
 
    	
 
    	
 
    	
$
    	
85,000,000
    	
 
    

 

	
Aggregate Amount  of Financing:
    	
 
    	
Approximately   Sixty Million Dollars ($60,000,000) in three equal installments. First   installment to be issued by Radius. Second and
    

 

2

 

	
 
    	
 
    	
Third   installment to be issued by Surviving Corporation (See “Proposed Reverse   Merger” below). For all purposes of this term sheet, the term Pro Rata   Portion (as defined below) shall be based on $35,000,000 only and not the   full $60,000,000 of gross proceeds to be raised in connection with the   Series A-1 Offering. See Attachment. The term “Series A-1 Offering   Existing Investor Available Amount” shall mean such $35,000,000 portion   of such $60,000,000 in gross proceeds to be raised pursuant to the   Series A-1 Offering.
    
	
 
    	
 
    	
 
    
	
Reverse Stock   Split:
    	
 
    	
At any time   prior to the closing of the first installment of the Series A-1 Offering   (including immediately prior to such closing) the Company shall effect a 15:1   reverse stock split of all of its capital stock (the “Reverse Stock Split”).   Any fractional shares resulting from computations made in connection with the   Reverse Stock Split will be paid out in cash at such closing.
    
	
 
    	
 
    	
 
    
	
Series A-1   Original  Purchase   Price Per Share:
    	
 
    	
$8.142 (which   price reflects the consummation of the Reverse Stock Split)
    
	
 
    	
 
    	
 
    
	
Rights Offering:
    	
 
    	
Each holder of   the Company’s existing Series A Junior Convertible Preferred Stock, par   value $.01 per share (the “Existing A Preferred”), Series B   Convertible Redeemable Preferred Stock, par value $.01 per share (the “Existing   B Preferred”), and Series C Convertible Preferred Stock, par value   $.01 per share (the “Existing C Preferred” and together with the   Existing A Preferred and the Existing B Preferred, the “Existing Preferred”),   if such holder is an accredited investor under applicable United States   securities laws, shall be given the opportunity to purchase such holder’s Pro   Rata Portion (as defined below) of the Series A-1 Offering Existing   Investor Available Amount.
    
	
 
    	
 
    	
 
    
	
Pro Rata   Portion:
    	
 
    	
For purposes of   the Series A-1 Offering, the term “Pro Rata Portion” shall mean, with   respect to any holder of Existing Preferred, that percentage figure which   expresses the ratio that (a) the number of shares of issued and   outstanding Common Stock then owned by such holder of Existing Preferred   bears to (b) the aggregate number of shares of issued and outstanding   Common Stock then owned by all holders of Existing Preferred. For purposes of   the computation set forth in clauses (a) and (b) above, all issued   and outstanding securities held by holders of Existing Preferred that are   convertible into or exercisable or exchangeable for shares of Common Stock   (including any issued and issuable shares of Existing Preferred Stock) or for   any such convertible, exercisable or exchangeable securities, shall be   treated as having been so converted, exercised or exchanged at the rate or   price at which such securities are convertible, exercisable or exchangeable   for shares of Common Stock in effect at the time in question, whether or not   such securities are at such time immediately convertible, exercisable or   exchangeable.
    
	
 
    	
 
    	
 
    
	
Participation by   Existing  Preferred   Stockholders:
    	
 
    	
Any holder of   Existing Preferred that does not purchase its full Pro Rata Portion of the   Series A-1 Offering Existing Investor Available
    

 

3

 

	
 
    	
 
    	
Amount shall be   forced to convert the Applicable Portion (as defined below) of such holder’s   shares of Existing Preferred into shares of Common Stock, par value $.01 per   share, of the Company on a 5-for-1 basis and shall forfeit any and all   accrued dividends on the Applicable Portion of such holder’s Existing   Preferred being converted into Common Stock. The term “Applicable Portion”   means that percentage of such holder’s Pro Rata Portion not purchased by such   holder in the Series A-1 Offering.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Each holder of   Existing C Preferred that participates in the Series A-1 Offering shall,   subject to the “Super Pro Rata Participation” provisions set forth below,   (a) exchange each remaining share of Existing C Preferred of such holder   (after giving effect to the forced conversion provisions of the immediately   preceding paragraph) for one share of Series A-2 Convertible Preferred   Stock, par value $.01 per share (the “Series A-2 Stock”), and   (b) forfeit any and all accrued dividends on such holder’s Existing C   Preferred.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Each holder of   Existing B Preferred that participates in the Series A-1 Offering shall,   subject to the “Super Pro Rata Participation” provisions set forth below,   (a) exchange each remaining share of Existing B Preferred of such holder   (after giving effect to the forced conversion provisions of the immediately   preceding paragraph) for one share of Series A-3 Convertible Preferred   Stock, par value $.01 per share (the “Series A-3 Stock”), and   (b) forfeit any and all accrued dividends on such holder’s Existing B   Preferred.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Each holder of   Existing A Preferred that participates in the Series A-1 Offering shall   exchange each remaining share of Existing A Preferred of such holder (after   giving effect to the forced conversion provisions of the immediately preceding   paragraph) for one share of Series A-4 Convertible Preferred Stock, par   value $.01 per share (the “Series A-4 Stock”).
    
	
 
    	
 
    	
 
    
	
Super Pro Rata   Participation:
    	
 
    	
Notwithstanding   the foregoing, any holder of Existing B Preferred or Existing C Preferred that   purchases more than its full Pro Rata Portion of the Series A-1 Offering   Existing Investor Available Amount shall, in connection with such holder’s   exchange of shares of Existing Preferred Stock for shares of Series A-2   Stock or Series A-3 Stock, as applicable, in accordance with the   provisions set forth above in this term sheet, not forfeit that amount of   accrued dividends on such holder’s Existing Preferred equal to the dollar   amount invested in the Series A-1 Offering by such holder that is in excess   of its Pro Rata Portion of the Series A-1 Offering Existing Investor   Available Amount (the “Super Pro Rata Amount”), but rather shall only   forfeit accrued dividends in excess of the Super Pro Rata Amount and shall   exchange the right to receive accrued dividends in an amount equal to the   Super Pro Rata Amount for that number of additional shares of Series A-1   Stock obtained by dividing (a) such holder’s Super Pro Rata Amount by   (b) the Series A-1 Original Purchase Price Per Share.
    

 

4

 

	
Going Forward   Pay-to-Play:
    	
 
    	
Other than the   potential forced conversion of shares of Existing Preferred into shares of   Common Stock on a 5-for-1 basis as described under “Participation by Existing   Preferred Stockholders” above, following the issuance of the Series A-1   Stock there will never be any pay-to-play provisions made applicable to, or   implemented against, the New Preferred Stock (as defined below).
    
	
 
    	
 
    	
 
    
	
Conditions:
    	
 
    	
The closing of   the Series A-1 Offering shall be conditioned upon (1) the prior or   simultaneous execution and delivery of definitive documentation relating to   the strategic alliance with, and related equity issuance to, Nordic (as   defined below) and (2) the immediately subsequent closing of the Merger   (as defined below).
    
	
 
    	
 
    	
 
    
	
Required Merger   Approval:
    	
 
    	
In the   definitive documentation for the purchase of shares of Series A-1 Stock,   each investor will be required to (1) approve and adopt the Merger, as   well as authorize the officers of the Company to execute and deliver such   agreements, instruments and documents, for and in the name and on behalf of   the Company, as such officer or officers may deem necessary, advisable or   appropriate in order to effectuate the Merger, and (2) waive all rights,   if any, under Section 262 of the Delaware General Corporation Law to   seek an appraisal of any shares New Preferred Stock (as defined below) or   Common Stock held by or acquired by such investor.
    
	
 
    	
 
    	
 
    
	
STRATEGIC ALLIANCE
    
	
 
    	
 
    	
 
    
	
Description:
    	
 
    	
Radius and   Nordic Bioscience (“Nordic”) intend to enter into a strategic alliance   under which Nordic will initially provide all services necessary and   appropriate for the Phase 3 clinical trial for the subcutaneous formulation   of BA058 (“Fracture Study”) (a detailed description of services will   be included in the final strategic alliance agreement). The strategic   alliance with Nordic may be extended to other BA058 clinical studies,   including extension studies and transdermal formulation studies on terms to   be agreed by the parties. In consideration for the services to be provided by   Nordic, Radius will issue to Nordic the number of shares of Radius’   Series A-5 Convertible Preferred Stock, par value $.01 per share (the “Series A-5   Stock” and together with the Series A-1 Stock, the Series A-2   Stock, the Series A3 Stock, the Series A-4 Stock and the   Series A-6 Stock described below, the “New Preferred Stock”) upon   the execution of definitive documentation relating to the transaction (the “Initial   Nordic Shares”) equal to the quotient (rounded to the nearest whole   number) obtained by dividing (x) the United States Dollar equivalent of   €371,864 by (y) the Series A-5 Purchase Price Per Share. The   Initial Nordic Shares shall accrue quarterly dividends to be paid in the form   of shares of Series A-6 Convertible Preferred Stock, par value $.01 per   share (the “Series A-6 Stock”) as these services are delivered, as more   fully described below.
    

 

5

 

	
PROPOSED REVERSE MERGER
    
	
 
    	
 
    	
 
    
	
Description:
    	
 
    	
Prior to the   closing of the Series A-1 Offering, Radius shall have entered into an   Agreement and Plan of Merger pursuant to which the Company would complete a   reverse merger with a Form 10 Shell. The reverse merger would take place   in two steps: First, the Form 10 Shell would form a wholly-owned   subsidiary that would merge with and into the Company (the “Merger”)   resulting in the Company becoming a wholly-owned subsidiary of the   Form 10 Shell; and Second, the Company would be merged up and into the   Form 10 Shell pursuant to Section 253 of the Delaware General   Corporation Law in a “short-form merger” (the resulting corporation being   hereinafter referred to as the “Surviving Corporation”).
    
	
 
    	
 
    	
 
    
	
Consideration:
    	
 
    	
As consideration   for the Merger, the Stockholders of the Radius will receive, in exchange for   their shares of New Preferred Stock or Common Stock of Radius, shares of   preferred stock and common stock, as the case may be, in the Surviving   Corporation with terms, rights and preferences substantially similar (subject   to the conversion rights/ratio of the preferred stock described below) to   those of the shares of equity of Radius held by such stockholder prior to the   closing of the Merger. Upon the consummation of the Merger, shares of Common   Stock of Radius will be exchanged for shares of common stock of the Surviving   Corporation at a ratio of 1:1. Due to the number of shares of preferred stock   that the Surviving Corporation currently has authorized, and to avoid having   to file a proxy statement with the SEC in connection with increasing such   number of authorized shares, upon the consummation of the Merger, shares of   New Preferred Stock will be exchanged for shares of preferred stock of the   Surviving Corporation at a 10:1 ratio (i.e., 10 shares of New Preferred Stock   will be exchanged for one share of corresponding preferred stock of the   Surviving Corporation). Any fractional shares resulting from computations   made in connection with such exchange will be paid out in cash. Each share of   preferred stock of the Surviving Corporation will have the voting power   equivalent of ten shares of common stock of the Surviving Corporation. To   maintain as-converted ownership percentages, following the Merger, shares of   preferred stock of the Surviving Corporation will be convertible into shares   of common stock of the Surviving Corporation at a ratio of 1:10 (i.e., 1   share of preferred stock will convert into 10 shares of common stock).
    
	
 
    	
 
    	
 
    
	
TERMS OF THE NEW PREFERRED STOCK
    
	
 
    	
 
    	
 
    
	
Series A-1   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    
	
 
    	
 
    	
 
    
	
Series A-2   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    
	
 
    	
 
    	
 
    
	
Series A-3   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    

 

6

 

	
Series A-4   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    
	
 
    	
 
    	
 
    
	
Series A-5   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    
	
 
    	
 
    	
 
    
	
Series A-6   Original  Purchase   Price Per Share:
    	
 
    	
$8.142
    
	
 
    	
 
    	
 
    
	
Ranking:
    	
 
    	
As to   liquidation and dividends (other than with respect to the quarterly payment   of the Series A-5 Accruing Dividend), each share of Series A1 Stock   shall rank equally with each other share of Series A-1 Stock and senior   to all shares of Series A-2 Stock, Series A-3 Stock,   Series A-4 Stock, Series A-5 Stock and Series A-6 Stock. As to   liquidation and dividends (other than with respect to the quarterly payment   of the Series A-5 Accruing Dividend), each share of Series A-2   Stock shall rank equally with each other share of Series A-2 Stock and   senior to all shares of Series A-3 Stock, Series A-4 Stock,   Series A-5 Stock and Series A-6 Stock. As to liquidation and   dividends (other than with respect to the quarterly payment of the Series A-5   Accruing Dividend) each share of Series A-3 Stock, Series A-5 Stock   and Series A-6 Stock shall rank equally with each other share of   Series A-3 Stock, Series A5 and Series A-6 Stock and senior to   all shares of Series A-4 Stock. Each share of Series A-4 Stock,   shall rank equally with each other share of Series A-4 Stock.
    
	
 
    	
 
    	
 
    
	
Accruing   Dividends:
    	
 
    	
Series A-1   Stock Accruing Dividend: 8% per annum compounding annually and payable only   upon liquidation, dissolution or winding up of the Company. Accrued dividends   shall be paid upon conversion of the Series A-1 Preferred Stock to   Common Stock in either, at the sole discretion of the Company, the payment of   cash or the issuance of that number of shares of Common Stock equal to the   quotient obtained by dividing (x) amount of such accrued and unpaid   dividends thereon by (y) the then fair market value of a share of Common   Stock.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A-2   Stock Accruing Dividend: 8% per annum compounding annually and payable only   upon liquidation, dissolution or winding up of the Company. Accrued dividends   shall be paid upon conversion of the Series A-2 Preferred Stock to   Common Stock in either, at the sole discretion of the Company, the payment of   cash or the issuance of that number of shares of Common Stock equal to the   quotient obtained by dividing (x) amount of such accrued and unpaid   dividends thereon by (y) the then fair market value of a share of Common   Stock.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A-3   Stock Accruing Dividend: 8% per annum compounding annually and payable only   upon liquidation, dissolution or winding up of the Company. Accrued dividends   shall be paid upon conversion of the Series A-3 Preferred Stock to   Common Stock in either, at the sole discretion of the Company, the payment of   cash or the issuance of that number of shares of Common Stock equal to the quotient   obtained by
    

 

7

 

	
 
    	
 
    	
dividing   (x) amount of such accrued and unpaid dividends thereon by (y) the   then fair market value of a share of Common Stock.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A-5   Stock Accruing Dividend: Accruing dividend payable in shares of   Series A-6 Stock, representing up to an aggregate €36,814,531 in value   for the Fracture Study (such stock dividend shares, the “Bonus Shares”).   The number of Bonus Shares that Nordic shall be entitled to receive in the   aggregate shall accrue on a calendar quarterly basis starting with the   calendar quarter in which the first subject is enrolled in the Phase III   clinical trial to be conducted by Nordic. The quarterly amounts of such Bonus   Shares shall be calculated based upon the estimated time that will be   required to complete the clinical study (following enrollment of the first   study subject), lock the study database, transfer the study database to   Radius and for Radius to accept the Final Tables Listings and Figures for the   clinical study based on the study database. The parties, acting through a   Project Committee, will evaluate the study timeline and adjust the pro rata   amount to account for delays or accelerations in the performance of such   Fracture Study. The amount of each quarterly dividend shall be determined by   dividing the portion of €36,814,531 to be accrued in such quarter by the Fair   Market Value (as defined below) on the date the dividend accrues. “Fair   Market Value” for purposes of this calculation will equal the greater    of (i) the Series A-5 Purchase Price Per Share (as such price   per share may be adjusted for any stock splits, stock dividends, reverse   stock splits, recapitalizations, mergers and other similar events affecting   such Series A-5 Stock), (ii) the price per share of the preferred   stock or common stock sold by Radius or a Shell Company Successor (as defined   below) in the then most recent equity financing closed by Radius or the Shell   Company Successor prior to the applicable accrual date; and (iii) the   average of the closing prices of the common stock of Radius or a Shell   Company Successor, as the case may be, on a securities exchange (if such   common stock is traded on an exchange) or the average of the closing sale   prices or secondarily the closing bid prices of such common stock (if such   common stock is regularly traded over-the-counter) over the twenty (20)   calendar day period ending two (2) calendar days prior to the date the   stock dividend accrues. “Shell Company Successor” means a shell   company that (i) has securities registered under the Securities Exchange   Act of 1934, as amended, (ii) has nominal operations and nominal assets   (prior to any of the transactions described in clause (iii)) and   (iii) directly or indirectly through one or more direct or indirect   subsidiaries acquires Radius and/or all or substantially all of its assets or   business (whether pursuant to a stock purchase, an asset purchase, a merger   or any other similar transaction) and in consideration for such acquisition   issues to the former stockholders of Radius shares of capital stock of such   shell company. Upon any conversion of the Series A-5 Stock, the Bonus   Shares will continue to be paid but shall be paid in shares of Common Stock.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Series A-4   Stock and Series A-6. There shall be no accruing dividends   with respect to shares of Series A-4 Stock or Series A-6 Stock.
    

 

8

 

	
Liquidation   preference:
    	
 
    	
In the event of   any liquidation, dissolution or winding up of the Company,
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(a) the   holders of Series A-1 Stock shall be entitled to receive, on a   preferential basis with the liquidation preference payable to Series A-2   Stock, Series A-3 Stock, Series A-4 Stock, Series A-5 Stock   and Series A-6 Stock, an amount per share equal to the Series A-1   Original Purchase Price Per Share, plus any accrued but unpaid dividends on   such shares of Series A-1 Stock, and
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(b) the   holders of Series A-2 Stock shall be entitled to receive, on a   preferential basis with the liquidation preference payable to Series A-3   Stock, Series A-4 Stock, Series A-5 Stock and Series A-6   Stock, an amount per share equal to the Series A-2 Original Purchase   Price Per Share, plus any accrued but unpaid dividends on such shares of   Series A-2 Stock, and
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(c) the   holders of Series A-3 Stock, Series A-5 Stock and Series A-6   Stock shall be entitled to receive, on a pari passu basis with the   liquidation preference payable to the holders of all other shares of   Series A-3 Stock, Series A-5 Stock and Series A-6 Stock but in   preference to the liquidation preference payable to the holders of   Series A-4 Stock and Common Stock, an amount per share equal to the   applicable Original Purchase Price Per share, plus any accrued but unpaid   dividends on such Shares of Series A-3 Stock, Series A-5 Stock and   Series A-6 Stock, if any; and
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(d) the   holders of Series A-4 Stock shall be entitled to receive, on a pari   passu basis with the liquidation preference payable to the holders of all   other shares of Series A-4 Stock but in preference to the liquidation   preference payable to the holders of Common Stock, an amount per share equal   to the Series A-4 Original Purchase Price Per share, plus any declared   but unpaid dividends on such Shares of Series A-2 Stock; and
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
(e) after   the payment of the liquidation preference of all outstanding shares of New   Preferred Stock, all remaining proceeds shall be distributed among the   holders of Series A-1 Stock, Series A-2 Stock, Series A-3   Stock and Common Stock on an as-converted basis.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
A sale of the   Company shall be deemed to be a liquidation unless waived by a vote of the   holders of not less than the Required Investor Majority (as defined below).
    
	
 
    	
 
    	
 
    
	
Conversion:
    	
 
    	
Voluntary   Conversion. Each holder of New Preferred Stock shall have the right to convert   their shares New Preferred Stock, at any time, into shares of Common Stock.   The initial conversion rate for each series of New Preferred Stock shall be   1:1, subject to any adjustment for any stock splits, stock dividends, reverse   splits and similar events.
    

 

9

 

	
 
    	
 
    	
Mandatory   Conversion. Each share of New Preferred Stock will be subject to automatic   conversion, at the then applicable conversion price, into Common Stock upon:   (1) an election to convert made by holders of the Required Investor   Majority, or (2) completion of listing of the Common Stock on a national   securities exchange.
    
	
 
    	
 
    	
 
    
	
Voting Rights:
    	
 
    	
Generally. All of the New Preferred Stock will   vote together as a single class with the Common Stock, except as outlined   below in the sections entitled “Directors” and “Protective Provisions”.
    
	
 
    	
 
    	
 
    
	
Directors:
    	
 
    	
The Company’s   charter and by-laws shall allow for up to seven (7) members on the   Company’s Board of Directors. The size of the Board of Directors shall be   initially set at seven (7). Holders of Series A-1 Stock shall have the   right to elect two (2) directors (the “A-1 Directors”), who will   initially be Martin Muenchbach and Ansbert Gadicke. Oxford Biosciences,   HealthCare Ventures and Wellcome Trust, by majority vote, voting together,   shall have the right to elect one (1) director (the “G3 Director”),   who initially shall be Jonathan Fleming. One (1) member of the Board of   Directors shall be the Company’s CEO. MPM Capital shall have the right to   elect one (1) director who shall be an individual with particular expertise   in the development of pharmaceutical products (the “Industry Expert   Director”) and who initially shall be Elizabeth Stoner. The remaining two   (2) directors will be designated “independent directors” and be   nominated by a majority of the Board of Directors including a majority of the   A-1 Directors, the G3 Director and the Industry Expert Director, acting   together, and shall be elected by the holders of New Preferred Stock and   Common Stock voting together as a single class. Such “independent directors” shall   initially be Alan Auerbach and Kurt Graves. Until such time as shares of the   Company’s capital stock are traded on a national securities exchange and all   shares of the New Preferred Stock are converted into Common Stock, HealthCare   Ventures shall have the right to have one (1) observer present at all   meetings of the Board of Directors.
    
	
 
    	
 
    	
 
    
	
Protective   Provisions:
    	
 
    	
Existing   fundamental corporate transactions shall require the prior written approval   or consent of holders of at least 70% of the outstanding shares of   Series A-1 Stock, Series A-2 Stock and Series A-3 stock,   voting together as a single class (the “Required Investor Majority”).
    
	
 
    	
 
    	
 
    
	
Registration   Rights:
    	
 
    	
As soon as   practicable, but not later than 60 days following the closing of the Merger,   the Surviving Corporation shall file a registration statement with the SEC on   the appropriate form to allow the resale of all shares of Common Stock of the   Surviving Corporation outstanding as well as all shares of Common Stock   issuable upon conversion of the shares of Preferred Stock of the Surviving   Corporation issued in consideration of the Merger to the Preferred   Stockholders. Following the closing of the Series A-1 Offering until the   date on which the Common Stock becomes listed on a national securities   exchange, the holders of New Preferred Stock shall have piggyback   registration
    

 

10

 

	
 
    	
 
    	
rights on terms   substantially similar to the piggyback registration rights held by the   holders of Existing Preferred.
    
	
 
    	
 
    	
 
    
	
No Redemption:
    	
 
    	
None of the New   Preferred Stock shall be redeemable.
    
	
 
    	
 
    	
 
    
	
Anti-dilution   Protection:
    	
 
    	
All shares of   Series A-1 Stock, Series A-2 and Series A-3 Stock shall have   weighted-average anti-dilution protection (based on the applicable Original Purchase   Price Per Share of such share of New Preferred Stock) and anti-dilution   protection upon the occurrence of any subdivision or combination of the   Common Stock, stock dividend and other distribution, reorganization,   reclassification or similar event affecting the Common Stock, all on terms   substantially similar to the anti-dilution protection afforded the Existing   Preferred. Shares of Series A-4 Stock, Series A-5 Stock and   Series A-6 Stock shall have no anti-dilution protection other than   anti-dilution protection upon the occurrence of any subdivision or   combination of the Common Stock, stock dividend and other distribution,   reorganization, reclassification or similar event affecting the Common Stock   on terms substantially similar to the anti-dilution protection afforded the   Existing Series A Preferred.
    
	
 
    	
 
    	
 
    
	
Pre-emptive   Rights:
    	
 
    	
Each holder of   shares of Series A-1 Stock, Series A-2 and Series A-3 Stock   shall have pre-emptive rights on terms substantially similar to the   pre-emptive rights held by the holders of Existing Preferred.
    
	
 
    	
 
    	
 
    
	
Lock-Up:
    	
 
    	
Each Investor   shall agree to a lock-up agreement as part of the final definitive investment   documentation pursuant to which shares of Company capital stock will be   subject to restrictions on transfer in certain circumstances.
    

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]